

BRITISH SOCIETY FOR IMMUNOLOGY

England & Wales · Charity number 1043255

Details

Other names	B S I
Status	Registered
Legal form	Charitable company
Company number	03005933
Registered	1995-01-12
Register	View on the Charity Commission register

Contact

Address	9 Appold Street London EC2A 2AP
Phone	02030195901
Email	bsi@immunology.org
Website	www.immunology.org

Activities

Objects: TO ADVANCE THE SCIENCE OF IMMUNOLOGY FOR THE BENEFIT OF THE PUBLIC

Activities: Running innovative events in research, public engagement & educationPromoting & disseminating research, good practice in Immunology, translational medicine and vaccinationWorking with its members to develop the benefits of membership & the relevance of the societyProviding bursaries & grantsEnhancing public awareness of ImmunologyWorking with other societies

Classification

- **How:** Makes Grants To Individuals, Makes Grants To Organisations, Provides Advocacy/advice/information, Acts As An Umbrella Or Resource Body
- **What:** Education/training, The Advancement Of Health Or Saving Of Lives
- **Who:** Other Defined Groups, The General Public/mankind

Geography

- Northern Ireland
- Scotland
- Throughout England And Wales

Finances

Period end	Income	Expenditure	Assets	Employees
2025-06-30	£1,778,000	£2,353,000	£3,109,000	19
2024-06-30	£2,331,000	£2,830,000	£3,738,000	18
2023-06-30	£2,447,000	£2,853,000	£3,897,000	18
2022-06-30	£2,211,000	£2,540,000	£4,310,000	19
2021-06-30	£2,186,000	£1,827,000	£4,944,000	20

Trustees

Name	Role	Appointed
Dr Carolyn Bower-Nielsen		2024-07-01
Dr Divya Shah		2023-07-01
Dr Jessica Strid		2023-07-01
Dr Sinisa Savic		2022-07-01
James Lowe		2019-07-05
Lee Booty		2025-01-01
Nicholas Hartigan		2025-01-01
Prof James Brewer		2022-12-06
Prof Teresa Lambe		2022-12-06
Prof Tracy Hussell		2022-12-06
Professor Deborah Kay Dunn-Walters		2019-07-01
Professor Lucy Catherine Garner		2026-06-01
Professor Lucy Sarah Kate Walker		2026-07-01
Professor Siobhan Burns		2025-07-01

Accounts



Annual Report 2025

Trustees' Report

For the year ended 30 June 2025

What we do and why it matters

The British Society for Immunology is the UK membership organisation working with scientists and clinicians to forward immunology research and application around the world. Our ambitious and collaborative community consists of over 5,000 immunologists, giving us a powerful voice to advocate on immunological science and health for the benefit of society.

The Society supports its members, students and the wider public to learn more about immunology through disseminating research and providing resources, activities and grants to aid education in this field.

Immunological science underpins many aspects of human and animal health and disease, from communicable disease and vaccination to the management and treatment of many chronic conditions. Through enhancing our knowledge of how the immune system functions for the public benefit, the British Society for Immunology can play a key role in advancing Society's ability to prevent and treat disease.

Our mission

The British Society for Immunology's mission is to support our immunology community in driving scientific discovery and making a positive impact on health.

We accomplish this by:

- Connected community: providing the immunology community with support to establish more connections and enhance collaboration, both within the field, and with other related scientific disciplines and between sectors.
- Championing careers: providing sector leading support to attract and retain talent in immunology.
- Catalysing change: influencing and improving the external environment to enable immunology to thrive and deliver positive outcomes for health.

The Trustees confirm they have referred to the Charity Commission's guidance on public benefit when reviewing the Society's aims and objectives, planning future activities and setting the annual operating plan.

Our strategic objectives

The British Society for Immunology strategy sets our direction and priorities for 2021-2025.

Building on the strong foundations of our past work and guided by our updated vision and mission statements and set of values, this ambitious strategy lays out how we will work with our membership to deliver for the immunology and wider community over the coming years. As the UK's leading charity and scientific society representing the immune research sector, we are confident that we will fulfil this strategy to lead a positive change towards our vision of better health for all through immunology.



Connected community

Our BSI community is at the heart of all we do. Being a member of the BSI means being a member of one of the largest immunology networks in the world. Immunology is a growing field, and the BSI aims to continually develop our activities and the support we provide to members to enable the discipline to flourish. Immunology intersects with numerous research fields, across different sectors, with the involvement of all career grades. Our goal is to bring this ecosystem together into a cohesive whole that fulfils our mission to take immunology forwards faster and more collaboratively.

Membership of the British Society for Immunology brings many benefits. These include discounts to our training courses, meetings and to our exceptional BSI Congress, access to a diverse range of grants, bursaries and prizes, free access to our journals and much more. The Society provides tailored support for our community through our highly valued Regional and Affinity Groups, but we are also there to represent immunology to the wider world. Members value our strong voice to speak out with influence and impact on behalf of immunology in policy, public engagement and the media.

At the end of June 2025, we had over 5,000 members, our highest ever membership, who join us from all walks of immunology. From students up to senior levels, they contribute to our work through many different routes, including speaking at our conferences, helping with our public engagement activities and advising on our policy work – our grateful thanks go to our whole immunology community.

Following the completion of the merger with the United Kingdom Primary Immunodeficiency Network (UKPIN) in 2022, the BSI Clinical Immunology Professional Network (BSI-CIPN) was created. This is an integrated and impactful professional network for individuals working within clinical immunology. The BSI-CIPN provides a strong voice for clinical immunology in policy, public affairs and supports the immunology community to network and engage with other across many disciplines.

At 30 June 2025, the BSI-CIPN had grown to over 200 members including consultant and trainee medics, healthcare scientists, nurses and pharmacists. The two-day BSI-CIPN conference took place in Birmingham during December 2024. The event attracted over 270 participants from across the UK.

Regional and Affinity Groups

The BSI's Regional and Affinity Groups are a key part of the BSI community and are part of our core activity to bring our membership together. The scientific discussions and networking that take place via these Groups are invaluable for the continued development of immunology. Our 17 Regional Groups bring together immunologists within a local community, boosting local research networks. Our 12 Affinity Groups have all been created to focus meetings and discussions on specific areas of immunology and they continue to evolve as immunology expands its reach and knowledge.

Our Groups ran a full programme of activities this year with a huge amount of enthusiasm, dedication and expertise. Collectively, these events attracted over 2,500 delegates and played an important part in our strategy to develop our Regional and Affinity Groups as community-based expert hubs. Our Groups also ran several other activities including in-house seminar series, careers events and public outreach initiatives.

Highlights of the programme include:

The [BSI London Immunology Group](#) hosting a one-day meeting: Visualising Immunology. This event brought together speakers with expertise in the imaging field in a range of settings of the immune response. The group also held an Early career researchers career meeting. The meeting was designed to promote and facilitate informed decision-making of career options for postgraduate and postdoctoral immunologists. It included a series of panel discussions and 'speed networking' sessions.

The [BSI Teaching affinity Group](#), held its inaugural teaching immunology conference. The conference focused on the theme of 'Teaching immunology to future cohorts' and explored key topics such as curriculum development, assessment strategies and innovative teaching practices.

The fourth [Scottish Immunology Groups Network \(SIGNET\) joint symposium](#) held by the BSI Aberdeen, Edinburgh, Tayside and West of Scotland Immunology Groups. SIGNET was a full-day in-person symposium bringing together immunologists from across Scotland to share research, foster new collaborations and encourage networking. The event featured keynote speakers, Professor Sarina Ravens and Professor David Sansom

In June 2025 the [BSI Bristol Immunology Group](#) held the immunology of long-haul disease event highlighting immunological mechanisms that evolve during the development and progression of disease.

Our Groups also ran several other activities including in-house seminar series, careers events and public outreach initiatives.

BSI Journals



The BSI's original ethos still lies at the heart of our Society – to disseminate research with the aim of promoting and advancing immunology to foster future innovation. This has been an exciting year for our highly respected family of three journals, *Clinical & Experimental Immunology*, *Immunotherapy Advances* and *Discovery Immunology*.

Working with our publishing partner, Oxford University Press, our journals aim to serve the field of immunology through publishing high-quality research articles, reviews, commentaries and short reports from researchers around the globe. We work closely with our Editors-in-Chief and Editorial Boards to take a strategic approach to ensure the continued high-performance of the journals. With our mixed portfolio of both hybrid and fully Open Access journals, the Society is in a strong position to continue to provide for the immunology community's publishing needs for many years to come.

This year we also published a joint virtual FOCIS.



Income generated from our journals provides major financial support for the Society's activities and we are hugely grateful to all our Editorial Board members for their ongoing commitment, and everyone who has contributed to the continued success of our journals, including authors, readers, reviewers and editors.



Our established high quality and translational research journal, *Clinical & Experimental Immunology* (CEI), continues to perform increasing its impact factor to 3.8. After eight years in the role Professor Leonie Taams stepped down as Editor-in-Chief in December 2024, the BSI thanks her for successful leadership of the journal. We were delighted that Professor Claudia Mauri joined as the new Editor-in-Chief.

CEI's most viewed article published in 2024 CEI was titled Disrupting B and T-cell collaboration in autoimmune disease: T-cell engagers versus CAR T-cell therapy? It has over 20,000 views.

Other highlights include the Organoids to study immune cell development and function review series. This included a paper collecting over 12,000 views.





Our first fully Open Access journal, *Immunotherapy Advances*, continues its progress to be a globally recognised title that both serves the immunotherapy community and exposes new developments in the field to a wide and diverse readership. Led by Editor-in-Chief, Tim Elliott, *Immunotherapy Advances* focuses on scientifically rigorous research relating to manipulations of the immune system for the benefit of human and animal health in all disease areas.

This year, the journal increased its impact factor to 4.9 maintaining its position in the top quartile of publications in the field of immunology.

CALL FOR PAPERS



The most read article published in the year was Bispecific T-cell engagers for the recruitment of T cells in solid tumors: a literature review collecting over 8,000 views since January 2025. A review and analysis of COVID-19 mRNA vaccine effectiveness against hospitalisations in adults also performed well with over 7,000 views.



This was the second full year for *Discovery Immunology (DSI)*. This new fully Open Access journal, led by Editor-in-Chief Simon Milling, has a broad scope that focuses on new discoveries in cellular and molecular immunology. Over the course of the year, *Discovery Immunology* has reached several important milestones, including achieving indexing in PubMed Central and Scopus.

DSI continued to publish special collections to increase the journal's profile and increase submissions made to the journal. A highlight was the ecoimmunology special collection.



The most read article published this year was titled Deciphering the relationship between temperature and immunity, it has now collected over 10,000 total views.

Our focus for the next year is to continue building the submissions for the journal together with its reach and impact through publishing high-quality articles describing novel mechanisms of the immune response.

Supporting research consortia

Under our current strategy, a new area of our work has been to support national and topic-specific research consortia efforts relevant to immunology. By championing investment in immunology and a 'team science' approach, we aim to use our skills to support cross-sector collaboration efforts to drive forward immunology research faster and more effectively.

We have built on our initial success this year by providing a variety of services to support several national research consortia including CARINA (Catalyst Reducing ImmuNe Ageing) Network, SIREN (SARS-CoV-2 Immunity and Reinfection EvaluationN) study, PITCH (Protective Immunity from T Cells in Healthcare workers) and STRAVINSKY (Stratification of Clinically Vulnerable People for COVID-19 Risk Using Antibody Testing).



The CARINA (Catalyst Reducing ImmuNe Ageing) Network is a project funded by the Medical Research Council (MRC) and Biotechnology and Biological Sciences Research Council (BBSRC) and supported by the BSI. The network, which consists of over 100 researchers, clinicians and other stakeholders interested in the ageing immune system, aims to establish a UK-wide inclusive platform to enhance collaboration and foster knowledge exchange in the area of immune ageing as well as increasing the profile of the research area.

One of the key activities of CARINA is the annual Network meeting, bringing together over 30 researchers from across the immunology research community, but all with a focus on how the immune system changes as we get older. The event sparked many important and interesting conversations, with breakout discussions addressing cross-discipline collaboration in ageing research, panel discussions on public involvement within ageing research and spotlight talks from CARINA members. The meeting was hugely successful and filled with excellent immune ageing research and many interesting discussions!

Championing careers

The BSI provides several grant schemes to our members to support their work and their career development. These include a variety of activities – from covering the travel costs to conferences, to providing financial support for carers, support for public engagement initiatives and those that promote diversity and inclusion within immunology. We are very proud of the range of support we have been able to provide to members over the last 12 months.

**£126k grants
awarded**

**134
members
supported**

Career Enhancing Grants

Supporting current and future generations of immunologists throughout their careers is a vital part of our mission. This year has seen our Career Enhancing Grants go from strength to strength to support even more BSI members to reach their career goals. The scheme provides flexible financial support of up to £5,000 to allow individuals to build their skill set and advance their professional development.

This year we supported 17 BSI members awarding over £66k of grants to fund projects including the generation of pilot data, training courses and lab visits.


Dr Anna Eleonora Karagianni

Lecturer in Veterinary Clinical Research at the University of Surrey

'My BSI Career Enhancing Grant allowed me to use state-of-the-art spatial transcriptomics to improve our understanding of the aetiopathogenesis of mild to moderate equine asthma (MMEA). This advanced knowledge is vital to improving treatment and prevention of this common, performance-limiting disorder of racehorses. Although a number of risk factors for MMEA have been identified, its precise aetiopathogenesis is still not fully understood, meaning options for intervention are currently limited. By taking an advanced -omics approach, I have been able to make a more holistic assessment of the immunological/tissue remodelling status of the lower airways. The proficiency I have gained in this new technology, and the associated analytical components of pathway analysis, has greatly complemented my existing experience in transcriptomics, and has developed my expertise in advanced methodologies for assessing global gene transcription. My results will be used to inform future research priorities in this area, and will help me secure funding

and establish myself as an independent researcher in the area of lung biology. In August, I joined the University of Surrey as a lecturer in Veterinary Clinical Research at the School of Veterinary Medicine, and I continue to work closely with the Roslin Institute, where I was based when I was awarded the grant.'

We are now into the fifth year of awarding these grants and so decided to carry out some evaluation on the impact that these grants had had on recipients from our first three grant rounds, two years on.



Mentoring scheme

Our highly successful mentoring scheme brings together senior scientists with early career researchers to assist the next generation of immunologist with career development and progression. The popularity of this scheme has stayed strong in recent years with a steady stream of applicants both as mentors and mentees and many stories of successful career progression from past participants. This year, we supported 10 pairs to complete the scheme.

BSI Winter School

Taking place in December in Sheffield, our ever popular Winter School is aimed at Immunology MSc students (and equivalents from industry and other areas) to provide them with an opportunity to hear some of the UK's leading immunologists discussing their latest research findings take part in career panels and network with each other. This sold out event welcomed 135 Masters students. The speakers covered a range of topics from the ageing immune system, to macrophages, to the immune system in space. The event also had panels on traditional and non-traditional careers and an interactive public engagement activity based on the speakers talks. The students were really engaged with some extremely insightful questions for the speakers throughout the event and we had very positive feedback and evaluation responses from students, speakers and course leaders.

Clinical immunology training days

We partner with the Association of Clinical Pathologists (ACP) to run Clinical Immunology Training Days aimed at medical trainees in immunology and allergy, and immunology clinical scientists preparing to sit the Royal College of Pathologists in immunology exams.

By working together, the ACP and BSI ensure the continuous delivery of these highly valued training sessions, helping to create a new generation of immunology-aware and informed clinicians and clinical scientists across the NHS to improve the care and treatment of patients with immune-mediated disease. This year saw four events run in total (three in person and one online), covering the broad spectrum of the immunology curriculum. The training events themselves are consistently ranked as excellent by attendees who value the targeted content.

Training

Our new training function went from strength to strength this year, building on past successes and with some exciting new courses launched and in the pipeline. Through our courses, we aim to provide tailored and innovative training to meet the needs of both immunologists, helping them keep their skills up to date and relevant, and non-immunologists, who want to understand the basics of the discipline to help in their jobs. This year, we had offerings applicable to all our members with courses in both the scientific and clinical spheres.

Bioinformatics

This year, we had pleasure of building on the success of our bioinformatics training programme, which has been developed and is delivered by John Cole and Glasgow Bioinformatic Core. This suite of courses aim to equip wet-lab immunologists, biologists and other life scientists with the skills and confidence to perform their own bioinformatic data analysis. Bioinformatics is now a potent driver of scientific development and is fast becoming an essential skill for life sciences researchers. Particularly within immunology, it is also an area where there is currently a significant skills gap. To upskill our members and others working in relevant fields, we offer a range of high-quality and affordable bioinformatics courses, suitable for complete beginners through to advanced practitioners.

Immunology Nursing Excellence Programme

This is a new course from the BSI, aimed at nurses specialising in both paediatric and adult clinical immunology, as well as practicing nurses with an interest in specialising in clinical immunology. The content of the course is mapped against the BSI-CIPN Competency Framework for Immunology Nursing and is the first professional accreditation available of this type for nurses working in an immunology setting.

The initial phase of this programme comprised two in-person training days which took place in March and June in Birmingham. Training comprised expert-led workshops, delivered by senior nurse practitioners, Clinical Nurse Specialists and clinical immunology professionals, with the aim of providing practical applications to enhance clinical practice. All courses to date have been sold out.

Participants praised a variety of elements about the training, including the opportunity to network with colleagues; the size of the training group; the general content and relevance of the training; the pacing and number of breaks; and the delivery style of the presenters. They reported increasing their confidence levels in all topics covered and gave a rating of 8.79/10 as to the course meeting their expectations.

The BSI Immunology Nursing Excellence Programme is funded through the provision of educational grants from BioCryst, CSL Behring, Pharming and Takeda. These organisations have neither influenced nor contributed to the content of the project or any of its associated activities.



Flow Cytometry

Our new fully online, interactive course is specially tailored to give wet lab life scientists the skills they need to take full advantage of multiparameter flow cytometry, a key skill for many working in immunology. Delivered by expert flow cytometry trainer, Derek Davies, this course aims to help participants build their skills and confidence in designing complex multiparameter experiments to obtain high-quality, reliable and repeatable data from their flow cytometry experiments.

Catalysing change

Public engagement


Public engagement continues to be an important part of our mission, both engaging directly with the public ourselves to increase knowledge of immunology to enable people to make more informed decisions about their health, and through providing our members with skills and resources to assist them in carrying out their own engagement activities. Our public engagement work over the last 12 months has focused primarily on vaccines. We have used a wide variety of methods and routes to engage with different communities to understand and answer their questions around vaccination.

Communication & Engagement Grants

Our Communication & Engagement Grants have been a staple of BSI public engagement efforts over recent years and provide vital funding to allow our members to carry out engagement activities that strengthen understanding about immunology topics. The grants provide opportunities for our members to share their passion and knowledge for immunology and to build their confidence and skills in engaging with the public. We know our members hugely value these grants and we are very proud of all they achieve through their inspirational and innovative engagement plans.

Celebrating vaccines

Over March and April, the BSI embarked on an ambitious communications campaign to 'Celebrate Vaccines' and raise awareness of their impact on public health. The campaign started off on our Vaccine Engagement Day on 26 March, where we shared various vaccine resources demonstrating how vaccines work, who can take them and how to discuss them with the public. We are thrilled with the engagement from our members and supporters that day, with lots of important conversations that took place on social media. Building on the momentum generated by our Vaccine Engagement Day, we then celebrated four vaccine success stories by demonstrating the impact they've had on public health.



Partnerships

Working in partnership is a key part of the British Society for Immunology's strategy to build the impact that we can deliver for immunology. We engage with like-minded organisations to collaborate on areas of interest ranging from autoimmunity to cancer, to vaccines. By using our profile, expertise and reach, we can shine a light on the importance of critical areas of immunology to attract new focus and funding and build new collaborations between different sectors.

Supporting veterinary vaccinology research

Supporting veterinary immunology research is a core part of the BSI's remit. In 2025, the Biotechnology and Biological Sciences Research Council (BBSRC) and Department for Environment, Food and Rural Affairs (Defra) developed a funding call to provide £12.5 million to fund projects that aim to engineer next-generation veterinary vaccine technology platforms, a call which addresses a significant gap in our ability to produce new vaccines at pace.

As this new funding had a focus on bringing together researchers and partners with diverse skills, the BSI agreed to collaborate with the International Veterinary Vaccinology Network (IVVN) to co-host an in-person workshop in Nottingham in June to support potential applicants.

Working with colleagues from the BBSRC and Defra, the workshop aimed to:

- Bring together researchers from across disciplines and sectors to facilitate networking and knowledge exchange and the formation of new interdisciplinary research collaborations
- Allow participants to develop a richer understanding of the vaccine technology platform research in the UK and internationally
- Ensure the readiness of the veterinary vaccinology research and innovation community to generate successful applications for the funding call.

The event saw approximately 80 researchers from around the UK and from many different disciplines come together to learn more about the funding call, network and explore collaboration opportunities. The energy in the room was palpable and we hope that the event helped to build lots of new connections that will result in successful applications to the grant call.

Putting the spotlight on cancer immunotherapy

In March 2025, we ran a high-level Cancer Immunotherapies Summit at the Royal Society in London. Chaired by BSI Clinical Research Secretary, Colin Dayan, this meeting brought together almost 50 senior experts spanning academic research, government, clinical practice, industry and patient focused charities to share insights, challenges and priorities in the field of cancer immunotherapy.

The event was structured around three themed sessions: cancer immunotherapy research; clinical application; and getting treatments to patients, with a combination of keynote talks, themed panels and roundtable group discussions for all attendees. This format allowed participants to explore the whole translational pathway – from early discovery in the lab to the real-world delivery of innovative therapies in the NHS.

As well as informing the BSI's response to the UK Government's consultation on the National Cancer Plan, the quality of the discussions was such that we are now developing a policy report outlining the Summit's key themes and recommendations, alongside an editorial in Immunotherapy Advances. Through this work, we aim to make the case for sustained investment in immunology, stronger translational infrastructure, and more joined-up partnerships across the research, clinical and policy ecosystems. With the right vision and collaboration, the UK can continue to lead in cancer immunotherapy – delivering scientific advances that make a real difference for patients.

Putting the spotlight on cancer immunotherapy

In November 2024, we hosted the first ever BSI Immune Therapies Summit, bringing together senior leaders from industry, academia and clinical spheres to discuss the latest developments in immune therapies. The Summit took place in Cambridge and saw over 140 professionals from across the field come together to discuss challenges in the field, network and hear from leading experts. Cross-disease collaboration that encompasses industry, research and clinical disciplines is rare, and we are proud to have brought together a diverse range of delegates during the Summit. It was a fantastic event, where attendees forged new collaborations, shared intel on challenges and developments in the field, and inspired one another with their stories.



Policy highlights

As always, the Society has continued to use our powerful voice to advocate for immunological science and health, ensuring the voice of immunologists is heard loud and clear in public debates and that policymakers have access to the latest immunological thinking. With our dynamic approach, working in partnership with BSI members and allied organisations, we have played a strong role in ensuring the expert voice of immunologists is represented in public debate.

Championing childhood vaccination in Westminster

In April during World Immunology Week, the BSI was delighted to co-host a successful parliamentary event in Westminster with Results UK, a charity who advocate for immunisations for all, and with UCL Vax-Hub Global, a research programme aiming to improve vaccine equity in low- and middle-income countries (LMICs).

The event centred on childhood vaccination, both in the UK and around the world, focusing on three themes – addressing declining childhood vaccine coverage in the UK, driving forward vaccine research in the UK and supporting vaccine equity in LMICs. The event was sponsored by Martin Rhodes MP and was further attended by several parliamentarians interested in vaccine uptake and research. During the event we encouraged parliamentarians to support their local public health teams, alongside championing the benefits of vaccines and vaccine research. BSI members, Professor Alex Richter and Professor Thushan De Silva, represented the BSI and spoke with parliamentarians on the unique opportunities for vaccine research in the UK, and advocated for the inclusion of immune-vulnerable groups in vaccine clinical trials.

Responses to the Government consultation on the 10 year plan for health

In Autumn 2024, the government launched a major consultation to ensure that the NHS health service meets the changing needs of a changing population in the future, with submissions helping to shape a new 10 Year Health Plan for England.

The BSI submitted two responses. The first focused on our long-term focus concerning the importance of vaccinations as a key preventative measure to improve public health. In this, we advocated that additional focus should be given to vaccine development and deployment as a key tool in preventing illness and improving public health throughout the life course. We also highlighted the importance of ensuring that adequate infrastructure and resources are available to allow for the timely implementation of the NHS Vaccination Strategy for England.

Additionally, we submitted a response on behalf of BSI-CIPN, with a focus on greater national and regional ownership of long-term workforce planning for clinical immunology and allergy, and how rising patient demand within the specialist services, the advancing field of immunogenomics, and the growing pipeline of immune therapies used to treat a growing number of conditions warrant an increased national drive and focus to support this vital area of clinical practice.

Enablers


To deliver our ambitious strategic aims, we need to maintain the BSI as a sector-leading organisation. We will do this by:

- Creating a larger and more diverse engaged membership
- Embedding quality, diversity and inclusion in all our activities
- Ensuring the Society's financial sustainability

Enabler - membership

Our membership is the foundation of our Society. We are ambitious in what we want to deliver for immunology and for our members. As the discipline of immunology continues to grow and evolve, we aim to evolve too to ensure we engage with, support and are relevant to immunologists from across the spectrum of our community. As the largest professional immunology society in Europe and third largest in the world, we aim to stand shoulder to shoulder with our members to support and champion the discipline of immunology to drive scientific discovery and make a positive impact on health.

Membership numbers have consistently risen this year achieving record highs. This remarkable growth underscores the increasing value and appeal of our membership offerings, as more people recognise the benefits of joining the Society. At the end of June 2025 total membership reached 5,225.



Providing the best service for our members

One of our key aims is to ensure that increase our support and engagement with our members from all sectors and at all career stages. To support this work, this year we continued to develop our new membership management system to allow us to provide better, more joined up and holistic support and service for our members.

BSI Clinical Immunology Professional Network

This is the third year of BSI Clinical Immunology Professional Network (BSI-CIPN) activities, following our successful merger with the UK Primary Immunodeficiency Network (UKPIN) in early 2023. Our aim is to run an integrated and impactful professional network, representing individuals working in all professions within clinical immunology.

The activities of the network are overseen by the BSI-CIPN Steering Group, chaired by Dr Sinisa Savic, supported by Deputy Chair Dr Suzanne Elcombe. The network welcomes members from all aspects of clinical immunology including doctors, scientists, nurses, pharmacists and trainees.



Delivering on our BSI-CIPN strategy

June 2025 marked a year since the launch of the BSI-CIPN Strategic Plan 2024–2027. We have successfully delivered on all key projects within that plan. Key successes include:

- Membership increased by 40% from 159 to 224, with increased representation from different professional groups
- Launched Immunology Nursing Excellence Programme to provide bespoke training for specialist immunology nurses.
- Collaborated with Association of Clinical Pathologists to drive forward the Clinical Immunology Training Days
- Enabled BSI-CIPN to provide responses to key government and sector consultations including NHS 10-Year Plan and National School for Healthcare Science
- Commenced development of two new BSI-CIPN guidelines on Good Syndrome and use of Sirolimus for immune dysregulation in clinical immunology.
- Ran a high-level roundtable meeting to discuss provision of MMR vaccine to immunocompromised individuals
- Provided submissions to 8 NICE technology appraisals and scoping exercises, and numerous other consultations across the sector including those from NHS England and DHSC

BSI-CIPN conference

This was the second year of our official BSI-CIPN Conference, which brings the clinical immunology community together to discuss important clinical and research topics related to the healthcare of patients with primary immunodeficiencies, as well as a wide range of other topics relevant to clinical immunology practice, covering the latest thinking around key medical, scientific, educational and management issues relevant to all those working in the field.

Held in Birmingham in December as a standalone event, the conference attracted more than 270 attendees over two days and covered a wide range of important clinical and research topics. Delegates came together to hear expert perspectives on the healthcare of patients with primary immunodeficiencies, as well as a wide range of other topics relevant to clinical immunology practice. The event truly showcased the breadth of the field of clinical immunology, offering attendees a choice of parallel sessions that took a deeper look at topics within medical, nursing and laboratory sciences.



Immunology News

The BSI works hard to ensure good communications channels with our members and the wider world. Our flagship membership magazine, *Immunology News*, is published quarterly and includes regular feature articles from leading immunologists, profiles of individuals from across the breadth of our membership, education and careers updates and more information on the Society's activities. Additionally, our monthly e-newsletter continues to be hugely popular among members and non-members alike and successfully drives readership to our website.



BSI wins staff engagement award

We were delighted that the BSI won an Agenda Employee Engagement Award 2024. Towards the end of 2024, we undertook a staff engagement survey, run on our behalf by independent providers, Agenda Consulting. The award is provided to their clients who received high scores across the survey. Ensuring staff wellbeing and engagement is very important to us at the BSI.

This independent survey provided us with the means to benchmark against other similar organisations how our staff experience their roles, as well as the leadership, communications and culture within the BSI. This not only provided us with good insight into our current effectiveness but also allowed us to identify areas for continual improvement. 100% of our staff completed the survey, an extremely high response rate.

Across all areas, the BSI received very positive feedback from staff with scores significantly above average, including in the areas of team working, communications, engagement, leadership, and Equality, Diversity and Inclusion.

Corporate members

We would like to thank our corporate members whose continuous support enables us to undertake our work



Enabler - Equality, diversity and inclusion

The BSI works hard to ensure that diversity and inclusion is at the heart of the ethos of our community. This year, we have continued to build on the promises laid out in our 'Diversity & Inclusion Framework', which outlines our commitment to how we are going to work with our members and community to ramp up our equity, diversity and inclusion work and respond to members' needs. By building on past and ongoing activities, this framework sets out our long-term plan of action for diversity and inclusion at the BSI.

This year, we have consolidated our progress to date as well as building on our EDI commitment further. As always, listening to and engaging with our members forms an important part of this scheme of work, making sure we understand their views of the BSI's role in supporting EDI in immunology, what we're doing well and what we could do better.

We continue to champion EDI through all our communication and particularly in our membership magazine, Immunology News, where we have run a number of high-profile case studies from different individuals on their experience of working in immunology and from projects funded through our EDI Activity Grant. Our Carers' Grants, that we offer for BSI Congress and for Regional and Affinity Group events, continue to be well received by the community, with impressive uptake, particularly for BSI Congress. We also ran a session at BSI Congress on research culture, with a panel of expert speakers to discuss and get feedback from attendees on good research culture practice and where there is still room for improvement within immunology. Finally, we have been engaging deeply with the wider scientific community to spread best practice on how we developed our framework and to learn from their experiences of similar activities.



Enabler - Financial sustainability

Income diversification

To deliver our ambitious strategic plans, we need to maintain the BSI as a sector-leading organisation, and one of the crucial enablers to do so is our financial sustainability. While traditionally we have relied heavily on our journal income to fund charitable activities, our shift to bring in new long-term and stable income sources is now well under way.

The development of new income streams is never a quick process as there is often a delay between investment and return, requiring the use of reserves. However, our strong reserves have been built up for exactly this purpose – to support the organisation through this transition – and their use is now carefully planned.

Consolidating our approach

This has been a year of consolidation in terms of our income diversification activities as we capitalise and build on the successful launch of new products and activities from previous years. Our new, modernised journals offering continues to go from strength to strength, reducing our financial reliance on the traditional subscription model while meeting the needs of our members and wider immunology community. Our two Open Access journals, *Immunology Advances* and *Discovery Immunology*, continue to prove a popular publication option and are meeting their key milestones. We were delighted that *Immunotherapy Advances* achieved its highest ever impact factor of 4.9 in June 2025. Combined with the success of our well-established journal, *Clinical & Experimental Immunology*, we are well on course to stabilise our future journals income.

Meanwhile, we have built up a strong reputation within the sector for assisting the smooth running, effectiveness and impact of large research consortia. Prestigious projects we have worked on over the last 12 months include SIREN (SARS-CoV-2 immunity and reinfection evaluation) study, the CARINA (Catalyst Reducing ImmuNe Ageing) Network and STRAVINSKY (Stratification of Clinically Vulnerable People for COVID-19 Risk Using Antibody Testing). Our participation in this type of funded project continues to be an important source of income while allowing us to meet our wider goal of supporting the national immunology research effort. We have also maintained a future focus

in this work, looking for upcoming opportunities to collaborate with the immunology research community to drive forward scientific discovery to have a positive impact on health.

We also continue to enhance our partnership and sponsorship areas of work with industry, establishing mutually beneficial routes for collaboration to highlight, celebrate and champion the immunology sector, which has been core to our strategic development of this area of work.

Training achievements

A key success this year has been our BSI training function, which we launched at the start of 2023 with the aim of supporting immunologists and the wider research community to keep their skills up to date and relevant.

This year, we launched several new courses, aimed at different sections of the research and clinical community. This included our much anticipated 'Foundations of Immunology' course, to provide training for non-experts in the fundamentals of how the immune system works. We also launched our 'Immunology Nursing Excellence Programme' to support the professional development of UK based immunology nurses working in both adult and paediatric immunology nursing and practicing nurses with an interest in specialising in immunology.

Our training on bioinformatics, delivered in partnership with Glasgow Bioinformatic Core, has built an exceptional reputation among the research community and courses continue to be highly popular with very positive feedback. Throughout the year, we launched several new and updated modules as part of this training, which have been well received. We are delighted that these courses fulfil such a key training niche for researchers and are an excellent example of how our income diversification activities can align to provide much needed services for our immunology community.

Structure, Governance and Management

Charitable status and administrative details

The Society was registered as a charity in 1966 (Charity number 1043255) and incorporated in England and Wales as a company, limited by guarantee (Company number 03005933). The Society's registered address is 9 Appold Street, London EC2A 2AP. It has no share capital and the liability of its members is limited to a sum not exceeding £1. The Society's governing document is the Memorandum and Articles of Association, which was amended on 7 December 2016.

It is also a registered charity in Scotland (Charity number SC047367).

Board of Trustees

The Trustees are company directors for the purposes of the Companies Act and charity Trustees for the purposes of the Charities Act 2011. The current trustees, and any past Trustees who served during the year are listed on page 55.

The Trustees are responsible for directing the Society's activities and for overseeing the management of the affairs of the Society, they delegate the day-to-day management of the organisation to the chief executive and the senior management team. The Board acts on advice and information from regular meetings with the chief executive and the senior management team.

As part of their induction process, Trustees spend some time with the chief executive and senior management team. They are provided a trustee resource pack containing the history of the Society and key information they require to fulfil their duties as Trustee, they are also offered training for new Trustees.

The success of the Society belongs in part to the large number of people who generously volunteer their time to add their experience to our collection of committees, we thank you all.

Finance Sub Committee

The Finance Sub Committee ensures the system of internal control is satisfactory to deliver regulatory compliance, financial probity, value for money, challenge of financial plans, budgets and financial statements, oversight of the annual financial audit, review of investment policy and performance, review of reserves policy, and CEO and staff remuneration.

Nominations Committee

The BSI's Nominations Committee has general oversight concerning the structures and effectiveness of BSI Board of Trustees, committees, advisers and observers. It is also responsible for nominating individuals to represent the views of the BSI on external committees and to identify BSI members to nominate for external awards.

Member Representative Forum

The Membership Representative Forum represents a diverse mix of immunologists from different career stages, backgrounds and geographic locations, it is the BSI's 'think tank' and the place where issues and ideas that are of importance to the Society and its member are raised, discussed and developed.

Congress Committee

The Congress Committee is responsible for the planning and delivery of the BSI's flagship event, BSI Congress, which takes place two out of every three years. It reviews and approves the scientific programme for Congress.

BSI-CIPN Steering Group

The BSI-CIPN Steering Group directs the activities of the BSI-CIPN. The group consists of both elected (from the BSI-CIPN members) and co-opted immunology professionals (chosen because of their roles in other key organisations).

Group structure

The Society has two wholly owned subsidiaries:

BSI Trading Limited is registered in England and Wales under company registration number 010201739. Its principal activity is to manage the corporate membership, sponsorship, exhibition, training and other trading activities for the Society.


The United Kingdom Primary Immunodeficiency Network (UKPIN) is a registered charity (1164466) and a company registered in England and Wales (09273983). The Activity in this company was wound down during 2023 following the transfer of its activities to the Society's Clinical Immunology Professional Network (BSI-CIPN).

Financial Performance

The BSI continued our transition period following the changes to our publishing portfolio. The annual net deficit increased to £0.63m this year from £0.16m last year.

Publishing income remains the BSI's largest source of income; its share of total income increased during the year because there was no Congress. There were also increases in BSI-CIPN, membership and training income.

The main sources of income are shown below:



The Society continued our success obtaining funding for our work supporting immunology research. The BSI received £0.12m grants, this includes £0.04m received for the immunology nursing excellence programme launched during the year.

Income for BSI-CIPN rose by 20% due to a highly successful standalone two-day conference.

In its third year, the BSI training function continued developing new courses, income for the year rose 73% to £114k. It is anticipated this will grow into significant future income stream for the Society.

With no Congress this year, annual profit of BSI Trading Limited fell to £0.3m (2024: £0.51m). This was gifted to the Society.

No activity went through The United Kingdom Primary Immunodeficiency Network (UKPIN) this year (2024: £2k loss).

The Society is in a transition period following the reduction in journal income. The Society has been and will continue to focus on developing new income streams; however, this will require investment from our reserves. During this period, we are forecasting costs to exceed income over the next few years until the new income streams start generating significant levels of income.

Investment policy and performance

The Society operates an investment policy to provide income and generate capital growth. The Society is a long-term investor and the value of its investments remains significant above its original investment.

As planned the BSI continued our programme of drawdowns from investments as we invest in new sources of sustainable income. During the year £0.25m was withdrawn from our investments to help

meet the BSI's cash requirements (2024: £0.65m). Future drawdowns are now estimated to be lower than originally forecast.

Funds are invested with LGT Wealth (formerly abdrn) with a long-term objective to generate a capital return of 3% more than inflation over a three-year rolling period. The performance of the BSI investment portfolio was buoyed by tech stocks which led to a significant rise in investments values. This produced a loss in the value of investments for the year of £0.05m (2024: £0.34m gain). The value of the portfolio fell by £0.24m (2024: fall of £0.23m) significantly less than the drawdowns due to the rise in investment values. On 30 June 2025 investments were valued at £2.83m (2024: £3.07m).

The Finance Sub Committee is responsible for reviewing investment performance and policy.

Reserves policy

The BSI operates a risk-based approach to reserves to ensure the BSI holds the most appropriate level of reserves to cover potential risks and to fund investment in new income sources securing the BSI's long term financial health.

Free reserves represent unrestricted general funds of the Society and exclude both restricted funds and funds that have been designated by the Board of Trustees. The free reserves also exclude any funds that could only be realised by disposing of fixed assets held for charitable use. Details of restricted funds can be found in note 15 of the accounts with details of designated funds in note 16.

	30 June 2025 £m	30 June 2024 £m
Total reserves	3.11	3.74
Less: Fixed assets	(0.08)	(0.10)
Designated funds	(0.23)	(0.40)
Restricted funds	<u>(0.18)</u>	<u>(0.25)</u>
Free reserves	2.60	2.99

The BSI risk register is reviewed annually with monetary values allocated to specific risks to produce the required 'risk-adjusted' reserves level.

	30 June 2025 £m
Income diversification development costs	0.28
Potential devaluation of investment portfolio	0.61
Three months operating costs	0.59
Risk-adjusted' reserves	1.48

The Society's free reserves are £1.12m (2024: £0.98m) more than the 'risk-adjusted' reserves level. The Society consider this is a sufficient provision for unknown risks (to give cover for those risks which the Society is not yet aware) and to fund future income generation opportunities.

Pay policy

The Society's pay policy aims to ensure that all employees are paid at least the market median for their roles with the ability of high performers to move towards the upper quartile.

Salaries, including the Senior Management Team, are reviewed by the Finance Sub Committee with recommendations for the annual pay rise proposed to the wider Board of Trustees for approval as part of the annual budgeting process. The salary of the Chief Executive is reviewed annually by the Board of Trustees.

To increase transparency the Society's is voluntarily reporting its gender pay gap. Calculated in June 2025 the Society's mean gender pay gap is 7.99% (June 2024: 40.38%). The pay gap indicates that while 78% of employees are women (2024: 80%), a higher proportion of men are in management roles. The Society employs more women in each of the quartile pay bands.

The Society strongly supports equal pay, with individuals with the same responsibilities being paid the same irrespective of gender.

Risk management

Good risk management is fundamental to the continued work and sustainability of the Society. We identify and manage risks that could adversely impact the achievement of our strategic purpose and determine the calculated risks we need to take to succeed.

The Society operates a formal framework for the management of risk, taking the view that risk can be positive (opportunity) or negative (threat). The Society operates a risk register incorporating strategic, operational and compliance risks, which are informed by the Society's strategic objectives, performance, voice of our stakeholders, regulatory environment and analysis of the external environment.

The Board delegates day-to-day responsibility for risk management to the Senior Management Team, who are responsible for identifying and evaluating risks to their areas and activities implementing appropriate controls for ongoing mitigation and monitoring.

The Financial Sub Committee reviews the management of risk in detail at each meeting and the Board reviews the Society's strategic and compliance risks twice a year.

The principal risks and uncertainties facing the society and the mitigations that we have put in place are as follows:

Risk: short term	Risk response
Development of new surplus generating training function	We are doing a thorough review of performance and feedback of launched courses and working closely with tutors/instructors to ensure course material is fully up to date. We are keeping our ear to the ground for additional training opportunities and looking to maximise all sponsor and funding opportunities.

Employee/Team capacity	Watching brief, with line managers ready to help team members when workload issues arise. SMT are committed to regularly proactively discussing reviewing our plan of activities and team capacity. The BSI team is now fully recruited.
Risk: long term	Risk response
Failure to find new sources of long-term sustainable income	The Society is proactively looking for new funding opportunities: ▪ Working with partners and corporate members to develop existing and new sources of income ▪ Developing a programme of training courses including training for nurses and a training course for clinicians. We are working to expand/grow the new activities launched in the last year
Loss of significant devaluation of investments A devaluation in the value of investments would result in a reduction of reserves available to use by the Society. Investments could be impacted by sudden unforeseen global events	The Society ▪ Reviews investment performance during each Financial Sub Committee meeting ▪ Communicates regularly with our investment managers, especially through times of significant volatility

Fundraising statement

Although the Society does not actively fundraise from members, occasional donations are received. The Society applies best practice in the tone of its communications and the accuracy of its data to minimise the pressures on supporters. The Society applies best practice to protect supporters' data, never sells or swaps it and ensures that communication preferences can be changed at any time. The Society commits to react to and investigate any complaints received, to learn from them and improve its service. During the year, the Society received no complaints about its fundraising activities.

Future plans

During 2025-26 the Society will focus on:

Connected community

- Expanding our activities and support to further enable our members to network and engage with each other across the immunology community
- Increasing the number and diversity of interdisciplinary connections with industry as well as between immunology and other relevant research and clinical fields
- Initiating and supporting national and topic-specific research consortia efforts relevant to immunology

Championing careers

- Up-skilling and training more of our members than ever before
- Creating a more inclusive and supportive research culture and community, assisting our members and providing opportunities for a career in immunology

Catalysing change

- Having demonstrable impact on public health, policy, practice and research funding issues important to immunology and our members
- Influencing public opinion and engagement in key immunology matters
- Maintaining the BSI as an internationally respected thought leader

Enabler - membership

- Launching targeted marketing campaigns to drive membership growth
- Grow membership of the BSI-CIPN

Enabler - Equality, diversity and inclusion

- Collecting benchmark EDI data on BSI committees and creating a plan to further embed EDI in BSI activities

Enabler - Financial sustainability

- Income diversification is a key priority: consolidation and expansion of current income generating activities and identifying and developing new sources of income including the launch and delivery of new training courses

The Senior Management Team and the Trustees continue to assess all significant risks, in the immediate, medium and longer term.

Trustees' responsibilities

The Trustees (who are also directors of British Society for Immunology for the purposes of company law) are responsible for preparing the Trustees' report and financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the Group and Society and of the income and expenditure of the Group and Society for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable to the United Kingdom and Republic of Ireland; and
- make judgements and estimates that are reasonable and prudent;
- state whether applicable United Kingdom Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume the charity will continue in operation.

The Trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the Group and Society and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Group and Society and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Each of Trustees confirm that:

- so far as the Trustee is aware, there is no relevant audit information of which the Group and Society's auditor is unaware; and
- the Trustee has taken all steps that he/she ought to have taken as a Trustee in order to make himself/herself aware of any relevant audit information and to establish that the Group and Society's auditor is aware of that information.

This confirmation is given and should be interpreted in accordance with the provisions of s418 of the Companies Act 2006.

The Trustees are responsible for the maintenance and integrity of corporate and financial information included on the Society's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Approved by the Trustees and signed on their behalf by:



Tracy Hussell
BSI President

Date: 5 February 2026

Independent Auditor's Report to the members and trustees of the British Society for Immunology

Opinion

We have audited the financial statements of the British Society for Immunology for the year ended 30 June 2025 which comprise the Group Statement of Financial Activities, the Group and Parent Charitable Company Balance Sheets, the Group Cash Flow Statement and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the group's and the parent charitable company's affairs as at 30 June 2025 and of the group's incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 (as amended), regulations 6 and 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended) and the Charities Act 2011.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs(UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the trustees' annual report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the trustees' annual report have been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the group and parent charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the trustees' annual report.

We have nothing to report in respect of the following matters where the Companies Act 2006, the Charities Accounts (Scotland) Regulations 2006 (as amended) and the Charities Act 2011 require us to report to you if, in our opinion:

- the parent charitable company has not kept adequate and sufficient accounting records, or returns adequate for our audit have not been received from branches not visited by us; or
- the parent charitable company's financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the trustees were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies exemption in preparing the Trustees' Annual Report and from preparing a strategic report.

Responsibilities of trustees

As explained more fully in the trustees' responsibilities statement, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the group and parent charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the group or parent charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

We have been appointed as auditor under Section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005, the Companies Act 2006 and Section 151 of the Charities Act 2011 and report to you in accordance with regulations made under those Acts.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs (UK) we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purposes of expressing an opinion on the effectiveness of the group and parent charitable company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the trustees.
- Conclude on the appropriateness of the trustees' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the group and parent charitable company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the group or parent charitable company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit report.
- We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Explanation as to what extent the audit was considered capable of detecting irregularities, including fraud

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below.

The objectives of our audit in respect of fraud, are; to identify and assess the risks of material misstatement of the financial statements due to fraud; to obtain sufficient appropriate audit evidence regarding the assessed risks of material misstatement due to fraud, through designing and implementing appropriate responses to those assessed risks; and to respond appropriately to instances of fraud or suspected fraud identified during the audit. However, the primary responsibility for the prevention and detection of fraud rests with both management and those charged with governance of the charitable company.

Our approach was as follows:

- We obtained an understanding of the legal and regulatory requirements applicable to the charitable company and considered that the most significant are the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 (as amended), regulations 6 and 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended), the Charities Act 2011, the Charity SORP, and UK financial reporting standards as issued by the Financial Reporting Council
- We obtained an understanding of how the charitable company complies with these requirements by discussions with management and those charged with governance.
- We assessed the risk of material misstatement of the financial statements, including the risk of material misstatement due to fraud and how it might occur, by holding discussions with management and those charged with governance.
- We inquired of management and those charged with governance as to any known instances of non-compliance or suspected non-compliance with laws and regulations.
- Based on this understanding, we designed specific appropriate audit procedures to identify instances of non-compliance with laws and regulations. This included making enquiries of management and those charged with governance and obtaining additional corroborative evidence as required.

Use of our report

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006; and to the charity's trustees, as a body, in accordance with Section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005, and in respect of the consolidated financial statements, in accordance with Chapter 3 of Part 8 of the Charities Act 2011. Our audit work has been undertaken so that we might state to the charitable company's members and trustees those matters which we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to any party other than the charitable company, the charitable company's members, as a body, and the charity's trustees, as a body for our audit work, for this report, or for the opinion we have formed.

Moore Kingston Smith LLP

Date 10 February 2026

Neil Finlayson (Senior Statutory Auditor)
for and on behalf of Moore Kingston Smith LLP, Statutory Auditor

9 Appold Street
London
EC2A 2AP

Moore Kingston Smith LLP is eligible to act as auditor in terms of Section 1212 of the Companies Act 2006.

British Society for Immunology
Consolidated Statement of Financial Activities
Year to 30 June 2025

		Unrestricted funds				
	Note	General funds £'000	Designated funds £'000	Restricted funds £'000	Total 2025 £'000	Total 2024 £'000
Income from:						
Grants and donations	2	-	-	112	112	191
Investments	3	91	-	-	91	115
Charitable activities	4					
Membership		183	-	-	183	172
BSI-CIPN		279	-	-	279	228
Partnership work		23	-	-	23	62
Congress		0	-	-	0	574
Meetings and events		181	-	-	181	79
Journals		795	-	-	795	844
Training		114	-	-	114	66
Total income		1,666	-	112	1,778	2,331
Expenditure on:						
Raising funds						
Investment management fees		26	-	-	26	29
Cost of raising funds		-	-	-	-	1
Charitable activities						
Membership		159	-	-	159	234
BSI-CIPN		274	-	-	274	217
Partnership work		154	-	-	154	136
Congress		-	-	-	-	636
Meetings and events		555	-	-	555	327
Journals		326	-	-	326	331
Training		74	15	102	191	115
Education and Careers		44	52	-	96	141
Diversity and inclusion		3	-	-	3	1
National Research support		-	-	65	65	114
Policy and Public Affairs		129	-	-	129	194
Public engagement		80	-	9	89	90
Communications		256	-	-	256	224
International work		30	-	-	30	40
Total expenditure	5	2,110	67	176	2,353	2,830
Net income (expenditure) before gains (losses) on investments and transfers		(444)	(67)	(64)	(575)	(499)
Net gains/(losses) on investments	12	(54)	-	-	(54)	340
Transfers between funds		98	(98)	-	-	-
Net income/(deficit)		(400)	(165)	(64)	(629)	(159)
Reconciliation of funds:						
Funds brought forward		3,093	399	246	3,738	3,897
Funds carried forward		2,693	234	182	3,109	3,738

There are no recognised gains or losses other than those recognised above. All activities are continuing.

The notes on pages 36 to 54 form part of these financial statements

British Society for Immunology
Balance Sheet
30 June 2025

		Group		Charity	
		2025	2024	2025	2024
Fixed assets					
Tangible fixed assets	10	41	38	41	38
Intangible assets	11	42	61	42	61
Investments	12	2,829	3,071	2,837	3,079
		2,912	3,170	2,920	3,178
Current assets					
Debtors	13	340	406	627	939
Cash at bank and in hand		604	734	140	138
		944	1,140	767	1,077
Liabilities:					
Creditors: amounts falling due					
within one year	14	(747)	(573)	(572)	(510)
Net current assets		197	567	195	567
Net assets		3,109	3,737	3,116	3,745
Funds:					
Unrestricted funds					
General fund		2,693	3,093	2,700	3,100
Designated fund	16	234	399	234	399
		2,927	3,492	2,934	3,499
Restricted funds	15	182	246	182	246
Total		3,109	3,738	3,116	3,745

As permitted by s408 Companies Act 2006, the company has not presented its own income and expenditure statement and related notes. The company's loss for the year was £631k (23/24 FY: £155k).

These financial statements have been prepared in accordance with the provisions applicable to the small companies regime.

These accounts were approved by the Board and authorised for issue on 5 February 2026 and were signed on its behalf by:



Tracy Hussell, President

British Society for Immunology, Company Limited by Guarantee
Company Registration Number 03005933 (England and Wales)

British Society for Immunology
Consolidated Statement of Cash Flows
30 June 2025

	2025	2024
	£'000	£'000
Cash flows from operating activities:		
<i>Net cash provided by operating activities</i>	(387)	(524)
Cash flows from investing activities:		
Income from investments	91	114
Purchase of tangible fixed assets	(22)	-
Proceeds from the disposal of investments	895	1,075
Purchase of investments	(725)	(501)
Net cash used in investing activities	239	689
Change in cash and cash equivalents in the year	(148)	162
Cash and cash equivalents at 1 July 2024	753	591
Cash and cash equivalents at 30 June 2025	605	753
Net income for the period (as per the statement of financial activities)	(629)	(159)
Adjustments for:		
Depreciation charge	38	34
(Gains) losses on investments	54	(340)
Investment income	(91)	(115)
(Increase) decrease in debtors	66	286
Increase (decrease) in creditors	174	(230)
Net cash provided by operating activities	(387)	(524)
Analysis of cash and cash equivalents		
Cash at bank and in hand	604	734
Cash held by investment managers	1	19
Total cash and cash equivalents	605	753

The notes on pages 36 to 54 form part of these financial statements

Notes to the financial statements

1 Accounting policies

The principle accounting policies adopted, judgements and key sources of estimation uncertainty in the preparation of the financial statements are as follows:

Basis of preparation

The financial statements are prepared on a going concern basis, under the historical cost convention modified to include the recognition of listed investments measured at fair value, which is consistent with the prior year. The financial statements have been prepared in accordance with the Statement of Recommended Practice: Accounting and Reporting by Charities ("The SORP"), the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102) and the Charities Act 2011.

The British Society for Immunology ("The Society") meets the definition of a public benefit entity under FRS 102

General information

The Society is a charitable company incorporated in England and Wales (company number 03005933) and is a charity registered in England and Wales (charity number 1043255) and registered as a charity in Scotland (charity number SC047367). The Society's registered address is 9 Appold Street, London EC2A 2AP.

Critical accounting judgements and key sources of estimation uncertainty

The preparation of financial statements requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Group and Society accounting policies. In the application of the accounting policies, Trustees are required to make judgements, estimates and assumptions about the carrying value of assets and liabilities that are not readily apparent from other sources. The estimates and underlying assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision only affects that period, or in the period of revision and future periods if the revision affected current and future periods.

In the view of the Trustees, no assumptions concerning the future or estimation uncertainty affecting assets or liabilities at the balance sheet date are likely to result in a material adjustment to their carrying amounts in the next financial year.

Going concern

The financial statements are prepared on a going concern basis which assumes the Society and Group will continue to meet its liabilities as they fall due for a period of at least twelve months from the date of the approval of these accounts. The Trustees review regular updates on performance against KPIs, rolling forecasts, the risk register and in depth financial reports.

The Society is expanding its activities for its members, including further development and rollout of new training courses and events. This together with the holding of significant levels of cash and investments result in the Trustees considering the Society and the Group to be a going concern.

Notes to the financial statements

Income

All income is recognised once the Society and Group has entitlement to income, it is probable that income will be received and the amount of income receivable can be measured reliably. Income of the Society is, where applicable, included net of Value Added Tax (VAT) and is allocated to the period to which it relates, carrying forward that part of the income relating to future accounting periods.

Investment income is recognised on a receivables basis and when the amount can be measured reliably.

Expenditure

Liabilities are recognised as soon as there is a legal or constructive obligation committing the Society and Group to that expenditure, it is probable that settlement will be required and the amount of obligation can be measured reliably. Expenditure is recognised on an accruals basis as a liability is incurred, inclusive of VAT, which cannot be recovered.

Expenditure is allocated to a particular activity where the cost relates directly to that activity. The cost of overall direction and administration of each activity, known as "support costs" and comprising the salary and overhead costs of the central function is apportioned based on staff time attributable to Support costs also include governance costs, which comprise organisational administration and compliance with constitutional and statutory requirements. The allocation of support and governance costs is analysed in notes 7 and 8.

Employee benefits

Short-term benefits including holiday pay are recognised as an expense in the period in which the service is received.

Termination payments are accounted for on an accruals basis and in line with FRS 102.

The Society contributes to a Group pension scheme, the assets of which are administered by Royal London Plc. They are defined contribution schemes. All contributed costs are accounted for on the basis of charging the cost of providing pensions over the period when the Society and Group benefits from the employees' service. The Society and Group has no further liability under the scheme.

Leasing and hire purchase commitments

Rentals paid under operating leases are charged to the income and expenditure account on a straight line basis over the lease term. The Society holds no assets under finance leases or hire purchase contracts.

Tangible fixed assets

Tangible assets are stated at cost less accumulated depreciation. Cost includes the original purchase price, costs directly attributable to bringing the asset to its working condition for its intended use, dismantling and restoration costs. The minimum threshold is £1,000. Depreciated is provided at 33% in order to write off each asset over its estimated useful life.

Intangible fixed assets

Intangible assets are stated at cost less accumulated amortisation. Cost includes the original purchase price, costs directly attributable to bringing the asset to its working condition for its intended use, dismantling and restoration costs. The minimum threshold is £1,000. Amortisation is provided at 20% in order to write off each asset over its estimated useful life. Assets in the course of construction are not amortised.

Investments

Investments are a form of basic financial instrument and are initially shown in the financial statements at fair value. Movements in the fair value of investments are shown as net gains and losses in the Statement of Financial Activities.

Profits and losses on the realisation of investments are shown as realised gains and losses in the Statement of Financial Activities. Net gains and losses on investments are calculated between sales proceeds and their opening carrying values or their purchase price if acquired subsequent to the first day of the financial year. Unrealised gains and losses are calculated as the difference between the fair value at the year end and their carrying value. Realised and unrealised investment gains and losses are combined in the Statement of Financial Activities.

The investment in the subsidiary undertaking is included at cost with provision being made for any permanent diminution in value.

Financial instruments

I) Financial assets

Basic financial assets, including trade and other receivables, cash and bank balances, are initially recognised at transaction value and subsequently measured at amortised cost. Other financial assets, including investments, are initially measured at fair value. Financial assets are derecognised when:

- a) the contractual rights to the cash flows of the asset expire or are settled, or
- b) substantially all the risks and rewards of the ownership of the asset are transferred to another party or
- c) despite having retained some significant risks and rewards of ownership, control of the asset has been transferred to another party who has the practical ability to unilaterally sell the asset to an unrelated third party without imposing additional restrictions.

Cash at bank and cash in hand includes cash and short-term highly liquid investments with a short maturity of three months or less.

II) Financial liabilities

Basic financial liabilities, including trade and other payables, are initially recognised at transaction price. Trade payables are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Financial liabilities held at amortised cost comprise all creditors except social security and other taxes and provisions.

Provisions

Provisions are recognised where the Society has a present legal or constructive obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Provisions are measured at the present value or the expenditures expected to be required to settle the obligation.

Notes to the financial statements

Fund accounting

Unrestricted funds are those funds available to the Society and Group for general purposes. They include funds designated by the Trustees for particular purposes where their use remains at the discretion of the Trustees. It is the policy of the Trustees to retain in unrestricted funds, amounts which in their judgement, can help to mitigate the short-term effects of income volatility; and retain as long-term investment funds to generate sufficient income to meet current and future operational activities of the Society.

Restricted funds are those funds available to the Society and Group restricted to a specific purpose or are subject to particular donor imposed conditions. Further information is available in the reserves section of the Trustees' report.

2 Income from grants and donations

			2025	2024
	Unrestricted	Restricted	Total	Total
	funds	funds	funds	funds
	£'000	£'000	£'000	£'000
Grants	-	112	112	191
Donations	-	-	-	-
Total	-	112	112	191

3 Income from investments and interest

			2025	2024
	Unrestricted	Restricted	Total	Total
	£'000	£'000	£'000	£'000
Listed investments				
Investment Income	87	-	87	111
Bank deposit interest	4	-	4	4
Total	91	-	91	115

4 Income from charitable activities

	Unrestricted	Restricted	2025	2024
	funds	funds	Total	Total
	£'000	£'000	funds	funds
	£'000	£'000	£'000	£'000
Member subscriptions	183	-	183	172
BSI-CIPN	279	-	279	228
Corporates and partnership income	23	-	23	62
Congress	-	-	-	574
Meetings and events	181	-	181	79
Journals	795	-	795	844
Training	114	-	114	66
Total	1,575	0	1,575	2,025

Notes to the financial statements

5 Total expenditure

	Unrestricted funds £'000	Designated funds £'000	Restricted funds £'000	2025 Total £'000
<i>Raising funds</i>				
Investment management fees	26	-	-	26
<i>Charitable Expenditure:</i>				
Membership	159	-	-	159
BSI-CIPN	274	-	-	274
Partnership work	154	-	-	154
Other meetings and events	555	-	-	555
Journals	326	-	-	326
Training	74	15	102	191
Education and Careers	44	52	-	96
Diversity and inclusion	3	-	-	3
National Research support	-	-	65	65
Policy and Public Affairs	129	-	-	129
Public engagement	80	-	9	89
Communications	256	-	-	256
International Work	30	-	-	30
Total	2,110	67	176	2,353

Allocation of support costs to charitable activities:

	Direct costs £'000	Support costs £'000	2025 Total £'000
<i>Raising funds</i>			
Investment management fees	26	-	26
<i>Charitable activities</i>			
Membership	96	63	159
BSI-CIPN	218	56	274
Partnership work	126	28	154
Other meetings and events	461	94	555
Journals	261	65	326
Training	138	53	191
Education and Careers	82	14	96
Diversity and inclusion	3	-	3
National Research support	65	-	65
Policy and Public Affairs	104	25	129
Public engagement	61	28	89
Communications	163	93	256
International Work	30	-	30
Total	1,834	519	2,353

Notes to the financial statements

5 Total expenditure (continued)

Support costs are as follows:

	2025 £'000	2024 £'000
Staff costs	211	235
Premises costs	24	43
Depreciation	38	22
IT and electronic communications costs	95	81
Other	119	126
Recruitment fees	15	26
Governance costs (note 6)	17	19
Total	519	552

Support costs have been allocated based on time spent by departments supporting the various activities.

	Unrestricted funds £'000	Designated funds £'000	Restricted funds £'000	2024 £'000
<i>Raising funds</i>				
Investment management fees	29	-	-	29
Fundraising	1	-	-	1
<i>Charitable Expenditure:</i>				
Membership	201	-	33	234
BSI-CIPN	217	-	-	217
Partnership work	136	-	-	136
Congress	636	-	-	636
Other meetings and events	327	-	-	327
Journals	331	-	-	331
Training	38	77	-	115
Education and Careers	64	77	-	141
Diversity and inclusion	1	-	-	1
National Research support	-	-	114	114
Policy	144	-	50	194
Public engagement	81	-	9	90
Communications	224	-	-	224
International work	40	-	-	40
Total	2,470	154	206	2,830

Notes to the financial statements

6 Governance costs

	2025 £'000	2024 £'000
Auditor's remuneration - audit	16	18
Auditor's remuneration - other	1	1
Total	17	19

7 Net income before gains (losses) on investments

This is stated after charging:	2025 £'000	2024 £'000
Staff costs (note 9)	1,257	1,224
Depreciation	38	34
Auditor's remuneration - audit	16	18
Auditor's remuneration - other	1	1

Notes to the financial statements

8 Staff costs

Staff costs during the year were as follows:

	2025 £'000	2024 £'000
Wages and salaries	1,080	1,056
Social security costs	119	115
Pension costs	58	53
Total	1,257	1,224

The average monthly number of employees during the year was as follows:

Within wages and salaries there are termination payments of £nil (2024: £39k).

	2025	2024
Direct charitable activities	17	16
Administration of the charity	2	2
	19	18

Number of employees whose annualised emoluments fall within following ranges for the year:

	2025	2024
£70,001 - £80,000	-	1
£80,001 - £90,000	1	1
£90,001 - £100,000	1	1
£100,001 - £110,000	1	-
£140,001 - £150,000	1	1

Pension contributions for these employees were £25,519 (2024 - £24,794).

The number of staff for whom retirement benefits are accruing under money purchase pension schemes amounted to 19 (2024 – 19).

The Society considers its key management personnel comprise the Trustees and the Senior Management Team (SMT).

The Trustees provide their time free of charge. The total remuneration, employer's national insurance contributions, benefits and pensions paid to the SMT was £511,043 (2024 - £513,859).

The relevant staff costs have been included in the costs of charitable activities. The gender split in the society workforce is 77% female 23% male (2024: 78% female 22% male). All roles are evaluated and paid in accordance with external benchmarking irrespective of gender.

9 Trustees' remuneration

No trustees received any remuneration for his or her services during the year (2024 – none). During the year expenses totalling £2,987 (2024 - £3,551) were reimbursed to 6 trustees (2024 – 8). In addition £133 was paid for travel and accommodation costs on behalf of trustees (2024: £3,160).

One trustee was paid £500 for his role in delivering part of the Immunology in Clinical Practice training course.

10 Tangible assets of the Group and charity

	Website £'000	Computer equipment £'000	Total £'000
Cost or valuation			
At 1 July 2024	56	4	60
Additions		22	22
Disposals	-	(1)	(1)
At 30 June 2025	56	25	81
Depreciation			
At 1 July 2024	20	2	22
Charge for the year	11	8	19
Eliminated on disposal	-	(1)	(1)
At 30 June 2025	31	9	40
Net book value			
At 30 June 2025	25	16	41
At 1 July 2024	36	2	38

11 Intangible assets of the Group and charity

	IT software £'000	Total £'000
Cost or valuation		
At 1 July 2024	93	93
Additions	-	-
Disposals	-	-
At 30 June 2025	93	93
Depreciation		
At 1 July 2024	32	32
Charge for the year	19	19
Eliminated on disposal	-	-
At 30 June 2025	51	51
Net book value		
At 30 June 2025	42	42
At 1 July 2024	61	61

Notes to the financial statements

12 Investments

	Group		Charity	
	2025	2024	2025	2024
	£'000	£'000	£'000	£'000
Market value at 1 July 2024	3,052	3,286	3,052	3,286
Disposals proceeds	(895)	(1,075)	(895)	(1,075)
Realised gains/(losses)	(3)	(3)	(3)	(3)
Additions at cost	725	501	725	501
Unrealised gains	(51)	343	(51)	343
Market value at 30 June 2025	2,828	3,052	2,829	3,052
Cash held with investment managers	1	19	1	19
Investment in UKPIN	-	-	7	7
Total investments	2,829	3,071	2,837	3,079

Total Group investments includes £100 investment in subsidiary.

	Group		Charity	
	2025	2024	2025	2024
	£'000	£'000	£'000	£'000
At 30 June 2025 the listed investments comprised the following:				
UK equities	679	715	679	715
Overseas equities	1,631	1,781	1,631	1,781
Investment instruments	519	556	519	556
Total	2,829	3,052	2,829	3,052
Historical cost of listed investments	2,226	2,324	2,226	2,324

Investments representing more than 5% of the total market value of the portfolio of listed investments are as follows:

	Cost	Market value	Portfolio
	2025	2025	%
	£'000	£'000	
Volare Offshore strategy fund Ltd Volare sterling fixed int offshore Z GBP	233	219	7.74%

12 Investments (continued)

Investment in subsidiary undertaking

The Society has two wholly owned trading subsidiaries. A summary of their trading results are shown below.

BSI Trading Limited is incorporated in England and Wales, registered number 010201739. Its registered office is 9 Appold Street London EC2A 2AP. The principal activity of the company is the management of corporate membership, sponsorship, exhibition and other trading activities for the Society.

The Society become sole member of United Kingdom Primary Immunodeficiency Network (UKPIN) on 20 December 2022 and accordingly on that date UKPIN became a subsidiary of the group.

UKPIN is incorporated in England and Wales, registered number 09273983. Its registered office is 9 Appold Street, London EC2A 2AP. The principal activity of the company was the advancement of health among those with primary immunodeficiency disorders and advancing education in PID and related subjects. These activities have been transferred to the Societys' Clinical Immunology Professional Network (BSI-CIPN).

A summary of the results of the subsidiaries is shown below:

	2025			2024		
	BSI Trading Limited	UKPIN	Total	BSI Trading Limited	UKPIN	Total
	£'000	£'000	£'000	£'000	£'000	£'000
Turnover	378	-	378	565	-	565
Operating costs	-	-	-	-	-	-
Operating profit	378	-	378	565	-	565
Administration costs	(82)	-	(82)	(51)	(2)	(52)
Profit(loss) for the financial period	296	-	296	514	(2)	513
Distribution to parent charity	-	-	-	(514)	-	(513)
Retained in subsidiary	-	-	-	-	(2)	-

The assets and liabilities of the subsidiaries were:

Assets	491	-	491	601	-	601
Liabilities	(491)	-	(491)	(601)	-	(601)
Net assets	-	-	-	-	-	-

Notes to the financial statements

13 Debtors

	Group		Charity	
	2025	2024	2025	2024
	£'000	£'000	£'000	£'000
Trade debtors	208	127	99	72
Prepayments and accrued income	132	262	132	262
VAT receivable	-	17	-	17
Amount owed by subsidiary undertaking	-	-	397	588
Total	340	406	627	939

14 Creditors

	Group		Charity	
	2025	2024	2025	2024
	£'000	£'000	£'000	£'000
Trade creditors	209	142	128	92
Other taxes and social security costs	36	30	36	30
VAT payable	34	-	34	-
Other creditors	103	133	103	133
Accruals and deferred income	365	268	271	255
Total	747	573	572	510

Included within the above is deferred income as set out below:

	Group	Charity
	2025	2025
	£'000	£'000
Deferred income brought forward at 1 July	181	169
Additional income deferred during the year	278	185
Brought forward funds released in the year	(181)	(169)
Deferred income carried forward at 30 June	278	185

Deferred income comprises advance payments of journal royalties and memberships fees.

Notes to the financial statements

15 Restricted funds

	At 1 July 2024	Income	Expenditure	At 30 June 2025
BSI-CIPN	178	-	-	178
Ageing and immunity	-	52	(52)	-
SIREN	-	-	-	-
STRAVINSKY	2	6	(8)	-
Visiting Scholar and Jonathan Sherrard Awards	4	-	-	4
mRNA project	-	-	-	-
PITCH	-	5	(5)	-
Nursing training	62	40	(102)	-
Vaccine confidence	-	9	(9)	-
Total	246	112	(176)	182

BSI-CIPN

Funds transferred from UKPIN upon the merger to be used to promote and support clinical immunology through the BSI-CIPN

Ageing and immunity

The CARINA (Catalyst Reducing ImmuNe Ageing) Network is a new collaborative network for researchers working on the immune system throughout the life course. The BSI has a leading role in supporting the network through provision of project management, events support, communications expertise and patient and public involvement (PPI).

SIREN

Recruitment, facilitation and reporting of findings from Patient and Participant Involvement workshops for the SIREN project funded by the UK Health Security Agency.

STRAVINSKY

Funds to support a 2 year study aiming to establish if antibody testing can identify who remains at greatest risk of severe COVID-19 infection after vaccinations.

PITCH

The PITCH (Protective Immunity from T Cells in Healthcare workers) is a project seeking to understand the role of T cell immunity in protection against COVID-19 in healthcare workers. The BSI is supporting the project by leading its participant Involvement Panel to ensure the research is relevant, suitable and valuable.

Nursing training

Project to develop and provide immunology training for nurses. This is funded by CSL Behring UK Limited and Biocryst US Sales Co LLC.

Vaccine confidence

Project to produce a report providing evidence on the impact of all the COVID-19 Taskforce's work in policy and public engagement. The project is run in conjunction with the University of Surrey.

Notes to the financial statements

15 Restricted funds (Continued)

UK-CIC

A grant for the BSI support provided to the UK Coronavirus Immunology Consortium (UK-CIC) to understand the immunology of SARS-CoV-2 and COVID-19.

Vaccine taskforce

Funding from the European Federation of Immunological Societies (EFIS) for the EFIS Vaccine Taskforce work led by the BSI.

Immunogenicity project

Immunogenicity measures in vaccine development and decision making programme funded by Merck Sharp & Dohme (UK) Limited.

UK Covid Vaccines Research Hub

Central co-ordination hub for COVID-19 immunology research investments and outcomes funded by UKRI via the National Core Studies programme.

Visiting Schloar and Jonathan Sherrard Awards

Funds to support members for periods of training in academic or clinical centres to further their knowledge of primary immunodeficiencies.

	At 1 July 2023 £'000	Income £'000	Expenditure £'000	At 30 June 2024 £'000
Meeting funds	34	-	(34)	-
BSI-CIPN	178	-	-	178
Ageing and immunity	28	68	(96)	-
SIREN	-	8	(8)	-
STRAVINSKY	14	-	(12)	2
Visiting Scholar and Jonathan Sherrard Awards	4	-	-	4
mRNA project	-	50	(50)	-
PITCH	-	7	(7)	-
Nurses training	-	62	-	62
Total	258	195	(207)	246

16 Designated funds

	At 1 July 2024	Designated in year	Utilised / released	At 30 June 2025
Long term sustainability	98	-	(98)	-
Training	15	-	(15)	-
Career development programme	286	-	(52)	234
Total	399	0	(165)	234

Notes to the financial statements

16 Designated funds (Continued)

Long term sustainability

The long term sustainability fund provides resources for investing in the financial sustainability of the charity over the next five years.

Training

Funding for the creation and development of a new surplus generating training function within the BSI.

CRM project

The CRM project fund provides resources to develop and implement a new CRM system together with an upgrade to the BSI website

Career development programme

The Career development programme will fund a significant expansion in the careers support the BSI offers to our members. This includes two main streams: our career-enabling activities and our career-enhancing activities.

17 Analysis of net assets between funds

				2025
	Unrestricted	Designated	Restricted	Total funds
Group	funds	funds	funds	
	£'000	£'000	£'000	£'000
Tangible fixed assets	41	-	-	41
Intangible assets	42	-	-	42
Investments	2,829	-	-	2,829
Current assets	528	234	182	944
Current liabilities	(747)	-	-	(747)
Total Funds	2,693	234	182	3,109

				2025
	Unrestricted	Designated	Restricted	Total funds
Charity	funds	funds	funds	
	£'000	£'000	£'000	£'000
Tangible fixed assets	41	-	-	41
Intangible assets	42	-	-	42
Investments	2,837	-	-	2,837
Current assets	351	234	182	767
Current liabilities	(572)	-	-	(572)
Total Funds	2,699	234	182	3,116

Notes to the financial statements

17 Analysis of nets assets between funds (Continued)

The total unrealised gains (losses) as at 30 June 2025 constitutes movements on revaluation and are as follows:

	2025 £'000	2024 £'000
Unrealised gains (losses) included above:		
On investments	1,254	1,305
Total unrealised gains (losses) at 30 June	1,254	1,305
Reconciliation of movements in unrealised gains (losses)		
Unrealised gains at 1 July	1,305	962
Less: in respect to disposals in the year	-	-
	1,305	962
Add: net gains (losses) arising on revaluation arising in the year	(51)	343
Total unrealised gains (losses) at 30 June	1,254	1,305

	Unrestricted funds £'000	Designated funds £'000	Restricted funds £'000	2024 Total funds £'000
Group				
Tangible fixed assets	38	-	-	38
Intangible fixed assets	61	-	-	61
Investments	3,072	-	-	3,072
Current assets	494	399	246	1,139
Current liabilities	(573)	-	-	(573)
Total Funds	3,092	399	246	3,737

	Unrestricted funds £'000	Designated funds £'000	Restricted funds £'000	2024 Total funds £'000
Charity				
Tangible fixed assets	38	-	-	38
Intangible fixed assets	61	-	-	61
Investments	3,079	-	-	3,079
Current assets	432	399	246	1,077
Current liabilities	(510)	-	-	(510)
Total Funds	3,099	399	246	3,745

Notes to the financial statements

18 Share capital

The company is limited by guarantee and therefore has no share capital. Each member's liability is limited to £1.

19 Related party transactions

James Brewer was paid £500 for his role in delivering the immunology in clinical practice training.

Matthew Siggins was awarded a Career enhancing grants of £3,210 in May 2024 for two weeks of highly specialised training in lymphatic immunology.

There were no other related party transactions that required disclosure in the current financial period (2024: none).

Notes to the financial statements

20 Comparative consolidated statement of financial activities

	Unrestricted funds			
	General £'000	Designated £'000	Restricted £'000	2024 £'000
Income from:				
Donations	-	-	191	191
Investments	115	-	-	115
Charitable activities				
Membership	172	-	-	172
BSI-CIPN	228	-	-	228
Partnership work	59	-	3	62
Congress	574	-	-	574
Meetings and events	79	-	-	79
Journals	844	-	-	844
Training	66	-	-	66
Total income	2,137	-	194	2,331
<i>Raising funds</i>				
Investment Management Fees	29	-	-	29
Cost of raising funds	1	-	-	1
<i>Charitable activities</i>				
Membership	201	-	33	234
BSI-CIPN	217	-	-	217
Partnership work	136	-	-	136
Congress	636	-	-	636
Meetings and events	327	-	-	327
Journals	331	-	-	331
Training	38	77	-	115
Education and Careers	64	77	-	141
Diversity and inclusion	1	-	-	1
National Research support	-	-	114	114
Policy and Public Affairs	144	-	50	194
Public engagement	81	-	9	90
Communications	224	-	-	224
International work	40	-	-	40
Total expenditure	2,470	154	206	2,830
Net income (expenditure) before gains (losses) on investments and transfers	(333)	(154)	(12)	(499)
Net gains/(losses) on investments	340	-	-	340
Net income	7	(154)	(12)	(159)
Reconciliation of funds:				
Funds brought forward	3,086	553	258	3,897
Funds carried forward	3,093	399	246	3,738

Notes to the financial statements

21 Charity statement of financial activities

	Unrestricted funds			Total	Total
	General funds	Designated funds	Restricted funds	2025	2024
	£'000	£'000	£'000	£'000	£'000
Income from:					
Grants and donations	-	-	112	112	191
Investments	91	-	-	91	115
Charitable activities					
Membership	183	-	-	183	172
BSI-CIPN	37	-	-	37	44
Partnership work	7	-	-	7	29
Congress	0	-	-	0	335
Meetings and events	115	-	-	115	38
Journals	795	-	-	795	844
Training	59	-	-	59	-
Gift Aid and recharge from BSI Trading Limited	376	-	-	376	564
Total income	1,663	-	112	1,775	2,331
Expenditure on:					
Raising funds					
Investment management fees	26	-	-	26	29
Cost of raising funds	-	-	-	-	1
Charitable activities					
Membership	159	-	-	159	234
BSI-CIPN	274	-	-	274	217
Partnership work	154	-	-	154	136
Congress	-	-	-	-	636
Meetings and events	555	-	-	555	327
Journals	326	-	-	326	331
Training	74	15	102	191	115
Education and Careers	44	52	-	96	141
Diversity and inclusion	3	-	-	3	1
National Research support	-	-	65	65	114
Policy and Public Affairs	129	-	-	129	193
Public engagement	80	-	9	89	89
Communications	256	-	-	256	221
International work	30	-	-	30	40
Total expenditure	2,110	67	176	2,353	2,826
Net income (expenditure) before gains (losses) on investments and transfers	(447)	(67)	(64)	(578)	(495)
Net gains/(losses) on investments	(54)	-	-	(54)	340
Transfer between funds	98	(98)	-	-	-
Net income/(deficit)	(403)	(165)	(64)	(632)	(155)
Reconciliation of funds:					
Funds brought forward	3,101	399	246	3,746	3,901
Funds carried forward	2,698	234	182	3,114	3,746

Board of Trustees

Position	Trustee	Date of appointment / resignation
Previous		
Early Career Trustee	Dr Emma Chambers	Resigned June 2024
Co-opted Trustee	Dr Edith Hessel	Resigned December 2024
Co-opted Trustee	Robert Davies	Resigned December 2024
Clinical Research Secretary	Professor Colin Dayan	Resigned June 2025

Current		
President	Professor Tracy Hussell	Appointed December 2022
Treasurer	Dr Fiona Culley	Re-appointed July 2021
Industry Trustee	Dr Lee Booty	Appointed January 2025
Chair of Forum	Professor James Brewer	Appointed January 2023
Clinical Research Secretary	Professor Siobhan Burns	Appointed July 2025
Trustee	Professor Deborah Dunn-Walters	Re-appointed July 2023
Co-opted Trustee	Nicholas Hartigan	Appointed January 2025
Trustee	Professor Teresa Lambe	Appointed January 2023
Co-opted Trustee	James Lowe	Re-appointed June 2023
Trustee	Dr Carolyn Nielsen	Appointed July 2024
Early Career Trustee	Dr Matthew Siggins	Appointed July 2022
Co-opted Trustee	Dr Sinisa Savic	Appointed July 2022
Trustee	Dr Divya Shah	Re-appointed July 2023
Trustee	Dr Jessica Strid	Appointed July 2023

Leadership

Senior Management Team

Name	Position
Graham Blair	Chief Executive
Otto Balsiger	Director of Finance, Membership and Publishing
Jane Sessenwein	Director of Events & Training

Principal professional advisers

Name	Advisor
Bankers	Bank of Scotland 14/16 Cockspur Street London EC2V 6DL
External auditors	Moore Kingston Smith LLP 9 Appold Street London EC2A 2AP
Investment advisers	LGT Wealth (formerly abrdn) 14th Floor 30 St Mary Axe London EC3A 8BF
Solicitors	Russell Cooke LLP 2 Putney Hill London SW15 6AB

Committees

Nominations Committee

Members	
Professor Tracy Hussell	Chair, BSI President
Professor James Brewer	Trustee
Professor Teresa Lambe	Trustee
Graham Blair	BSI CEO (observer)

Finance Sub Committee

Members	
Dr Fiona Culley	BSI Treasurer
James Lowe	Co-opted Trustee
Nicholas Hartigan	Co-opted Trustee
Graham Blair	BSI Chief Executive
Otto Balsiger	BSI Director of Finance, Membership and Publishing

Membership Representative Forum

Members	
Professor James Brewer	Chair
Professor Tracy Hussell	BSI President
Dr Colin Dayan	Clinical Research Secretary
Dr Sophie Rutschmann	Education & Careers Secretary
Professor Matthias Eberl	Public Engagement Secretary
Graham Blair	BSI Chief Executive
Dr Jennie Evans	BSI Director of External Affairs
Dr Patrick Cao	Regional Representative - Scotland
Dr Julia Makinde	Regional Representative - England
Dr Dessi Malinova	Regional Representative - Northern Ireland
Dr James McLaren	Regional Representative - Wales
Dr Hannah Bradford	Early Career Representative
Dr George Robinson	Early Career Representative
Anna Andrusaite	Early Career Representative
Dr Alexandra Dvorscek	Early Career Representative
Dr Chidi Ubachukwu	PhD Representative
Dr Chloe Pyle	Industry Representative
Dr Gareth-Rhys Jones	Clinical Representative
Dr Winnie Ip	Clinical Representative
Dr Rebecca McLean	Veterinary Representative

Committees

Congress Committee

Name	Position
Professor Cecilia Johansson	BSI Congress Secretary
Professor Tracy Hussell	BSI President
Dr Fiona Culley	BSI Treasurer
Dr Siobhan Burns	BSI Clinical Research Secretary
Dr Edith Hessel	Member
Dr Daniel O'Connor	Early Career Representative
Dr Leo Carlin	Member
Dr Helen McGettrick	Member
Dr Henry McSorley	Member
Dr Yvonne Dombrowski	Member
Dr James Thaventhiran	Clinical member
Dr Laura Rivino	Member
Dr Jane Hope	Member
Dr Joanne Konkell	Member
Dr Mahima Swamy	Member
Dr Claire Bennett	Member
Dr Victor Tybulewicz	Member
Dr Nicholas Provine	Member
Dr Regis Joulia	Early Career Representative
Jane Sessenwein	BSI Director of Events & Training

BSI-CIPN Steering Group

Name	Position
Dr Sinisa Savic	Chair
Dr Suzy Elcombe	Deputy Chair
Dr Catherine Stroud	Membership Lead
Sarah Denman	Pharmacy Representative
Jill Edmonds	Nursing Representative
Rachel Dale	Healthcare Scientist Representative
Professor Alex Ritcher	Guidelines Lead
Dr Patrick Yong	Training & Education Lead
Dr Manisha Ahuja	Postgraduate Doctor in Training Representative
Dr Leman Mutlu	Patitent Group Liaison
Dr James Thaventhiran	Conference Lead (Co-opted member)
Dr Austen Worth	Paediatric Representative and PID Registry Representative (Ex-officio member)
Dr Claire Bethune	CRG Representative (Ex-officio member)
Dr Sarah Goddard	QPIDS Representative (Ex-officio member)
Dr Tomaz Garcez	BSACI Representative (Ex-officio member)
Graham Blair	BSI Chief Executive

Journals

Clinical and Experimental Immunology - Editorial Team

Name	Position
Professor Claudia Mauri	Editor-in-Chief
Professor Angelo Manfredi	Section Editor - autoimmunity
Professor Tanja de Gruij	Section Editor - cancer immunity
Professor Ciriaco Piccirillo	Section Editor - immune-mediated inflammatory diseases
Dr Cindy Ma	Section Editor - immunodeficiency
Dr Daniel Douek	Section Editor - infectious diseases and vaccines
Professor Xiao-Ning Xu	Section Editor - infectious diseases and vaccines
Professor Sandra Amor	Section Editor - neuroimmunology

Immunotherapy Advances - Editorial Team

Name	Position
Professor Tim Elliot	Editor-in-Chief
Associate Professor Marianne Boes	Deputy Editor
Professor Yiwei Chu	Associate Editor
Dr Stephanie K Dougan	Deputy Editor
Associate Professor Menno van Zelm	Associate Editor

Discovery Immunology - Editorial Team

Name	Position
Professor Simon Milling	Editor-in-Chief
Dr Sophie Acton	Senior Editor
Dr Philip Ahern	Senior Editor
Dr Florent Ginhoux	Senior Editor
Dr Emily Gwyer Findlay	Senior Editor
Dr Lai Guan Ng	Senior Editor
Professor Francisco J. Quintana	Senior Editor
Dr Meera Ramanujam	Senior Editor

Regional and Affinity groups

Affinity Groups

Group	Position	Member
Autoimmunity Affinity Group	Chair	Professor Lucy Walker
	Secretary	Dr Kathryn Steel
	Treasurer	Dr James Pearson
Comparative Veterinary Immunology Group	Chair	Wilhelm Gerner
	Secretary	Dr Lindert Benedictus
	Treasurer	Dr Kate Sutton
Immunometabolism Affinity Group	Chair	Dr Laura Pallett
	Secretary	Dr Sarah Dimeloe
	Treasurer	Dr Anna Schurich
Immunosenescence Affinity Group	Chair	Dr Sian Henson
	Secretary	Dr Natalie Riddell
	Treasurer	Dr Catarina Henriques
Infection and Immunity Group		
Inflammation Affinity Group	Chair	Dr Samuel Lara Reyna
	Treasurer	Dr Jack Green
	Secretary	Dr Anna Surace
Leukocyte Migration Group	Chair	Dr Myriam Chimen
	Secretary/Treasurer	Dr Graeme O'Boyle
Mathematical Modelling Group	Chair	Dr Grant Lythe
	Secretary	Professor Mark Coles
	Treasurer	Dr Hashem Koohy
Neuroimmunology Group	Chair	Dr Yvonne Dombrowski
	Secretary	Dr Franze Progatzy
Teaching Affinity Group	Co-chair	Professor John Currow
	Co-chair	Dr Nigel Francis
	Secretary	Dr Owen Kavanagh
	Treasurer	Dr Becky Aicheler
Tumour Immunology Affinity Group	Chair	Professor Benjamin Willcox
	Secretary	Dr Seth B. Coffelt
	Treasurer	Professor Awen Gallimore
Vaccine Affinity Group	Chair	Dr Bernardo Villarreal-Ramos
	Secretary	Dr Julia Tree
	Treasurer	Dr Dirk Werling

Regional and Affinity groups

Regional Groups

Group	Position	Member
Aberdeen Immunology Group	Chair	Dr Michael Morgan
	Treasurer	Dr Janine Coombes
Bristol Immunology Group	Chair	Dr Gareth Jones
	Secretary	Dr Dronwen Burton
	Treasurer	Dr Lindsay Nicholson
Cambridge Immunology Group	Chair	Dr Brian Ferguson
	Secretary/Treasurer	Dr Louise Boyle
East Anglia Immunology Group	Secretary	Dr Anastasia Sobolewski
	Treasurer	Dr Cristina Fanutti
Edinburgh Immunology Group	Co-Chair	Dr Ananda Mirchandani
	Co-Chair	Dr Jason Mooney
	Secretary	Dr Protr Janas
	Secretary	Dr Tovah Shaw
	Treasurer	Dr Sean Wattagedera
Exeter Immunology Group	Co-Chair	Dr Peter Cook
	Co-Chair	Dr William Horsnell
	Co-Treasurer	Dr Emily Plumpton
	Co-Treasurer	Dr Tei Lockett
Greater Manchester Immunology Group	Chair	Dr Doug Dyer
	Treasurer	Dr Madhvi Menon
	Secretary	Dr Andrew Greenhaigh
Immunology North East	Chair	Dr Kevin Marchbank
	Secretary	Dr Antony Antoniou
	Treasurer	Dr Andy Knight
London Immunology Group	Chair	Dr Laura Pallett
	Secretary	Dr Lousia James
	Treasurer	Dr George Finney
Midlands Immunology Group	Chair	Dr Rebecca Drummond
	Secretary	Dr Georgina Hopkins
	Treasurer	Dr Martin Davey

Regional and Affinity groups

Regional Groups

Group	Position	Member
Oxford Immunology Group	Chair	Dr Roel De Maeyer
	Secretary	Dr Elena Mitsi
	Treasurer	Dr Gerda Mickute
South Wales Immunology Group	Chair	Dr You Zhou
	Secretary	Dr Rebecca Aicheler
	Treasurer	Dr Ceri Fielding
Tayside Immunology Group	Chair	Dr Andy Howden
	Secretary	Dr Henry McSprley
	Treasurer	Dr Linda Sinclair
Ulster Immunology Group	Co-Chair	Dr Rebecca Coll
	Co-Chair	Professor Emeir McNulty
	Secretary	Dr Dessi Manilova
	Treasurer	Dr Philip Allsopp
Wessex Immunology Group	Co-Chair	Professor Jessica Teeling
	Secretary	Dr Rachana Yadav
	Treasurer	Dr Bonnie Ng
West of Scotland Immunology Group	Chair	Dr Megan MacLeod
	Secretary	Dr Ed Roberts
	Treasurer	Dr Hannah Scales
Yorkshire Immunology Group	Chair	Dr Gina Doody
	Secretary	Dr Erica Wilson

Accounts



Annual Report 2024

Trustees' Report

For the year ended 30 June 2024

What we do and why it matters

The British Society for Immunology is the UK membership organisation working with scientists and clinicians to forward immunology research and application around the world. Our ambitious and collaborative community consists of over 5,000 immunologists, giving us a powerful voice to advocate on immunological science and health for the benefit of society.

The Society supports its members, students and the wider public to learn more about immunology through disseminating research and providing resources, activities and grants to aid education in this field.

Immunological science underpins many aspects of human and animal health and disease, from communicable disease and vaccination to the management and treatment of many chronic conditions. Through enhancing our knowledge of how the immune system functions for the public benefit, the British Society for Immunology can play a key role in advancing Society's ability to prevent and treat disease.

Our mission

The British Society for Immunology's mission is to support our immunology community in driving scientific discovery and making a positive impact on health.

We accomplish this by:

- Connected community: providing the immunology community with support to establish more connections and enhance collaboration, both within the field, and with other related scientific disciplines and between sectors.
- Championing careers: providing sector leading support to attract and retain talent in immunology.
- Catalysing change: influencing and improving the external environment to enable immunology to thrive and deliver positive outcomes for health.

The Trustees confirm they have referred to the Charity Commission's guidance on public benefit when reviewing the Society's aims and objectives, planning future activities and setting the annual operating plan.

Our strategic objectives

The British Society for Immunology strategy sets our direction and priorities for 2021-2025.

Building on the strong foundations of our past work and guided by our updated vision and mission statements and set of values, this ambitious strategy lays out how we will work with our membership to deliver for the immunology and wider community over the coming years. As the UK's leading charity and scientific society representing the immune research sector, we are confident that we will fulfil this strategy to lead a positive change towards our vision of better health for all through immunology.



Connected community

Our BSI community is at the heart of all we do. Being a member of the BSI means being a member of one of the largest immunology networks in the world. Immunology is a growing field, and the BSI aims to continually develop our activities and the support we provide to members to enable the discipline to flourish. Immunology intersects with numerous research fields, across different sectors, with the involvement of all career grades. Our goal is to bring this ecosystem together into a cohesive whole that fulfils our mission to take immunology forwards faster and more collaboratively.

Membership of the British Society for Immunology brings many benefits. These include discounts to our training courses, meetings and to our exceptional BSI Congress, access to a diverse range of grants, bursaries and prizes, free access to our journals and much more. The Society provides tailored support for our community through our highly valued Regional and Affinity Groups, but we are also there to represent immunology to the wider world. Members value our strong voice to speak out with influence and impact on behalf of immunology in policy, public engagement and the media.

At the end of June 2024, we had over 5,000 members, our highest ever membership, who join us from all walks of immunology. From students up to senior levels, they contribute to our work through many different routes, including speaking at our conferences, helping with our public engagement activities and advising on our policy work – our grateful thanks go to our whole immunology community.

In December 2023, over 1,400 immunologists came together in Belfast and online for our flagship event, BSI Congress 2023. It was an amazing four days of immunology, packed with cutting-edge science, inspiring debates and those all-important opportunities to connect and start new collaborations.

Our outstanding Keynote lecture was given by Professor Ronald Germain from the National Institutes of Health, USA on ‘Visualising immunology – insights from multiplex dynamic and static tissue-scale imaging’.



Following the completion of the merger with the United Kingdom Primary Immunodeficiency Network (UKPIN) in 2022, the BSI Clinical Immunology Professional Network (BSI-CIPN) was created. This is an integrated and impactful professional network for individuals working within clinical immunology. The BSI-CIPN provides a strong voice for clinical immunology in policy, public affairs and supports the immunology community to network and engage with other across many disciplines.

At 30 June 2024, the BSI-CIPN had grown to over 150 members including consultant and trainee medics, healthcare scientists, nurses and pharmacists. The first full two-day BSI-CIPN conference took place at the ICC Belfast alongside the BSI Congress in December 2023. The event attracted over 220 participants from across the UK, including more than 35 people attending online.



Regional and Affinity Groups

The BSI's Regional and Affinity Groups are a key part of the BSI community and are part of our core activity to bring our membership together. The scientific discussions and networking that take place via these Groups are invaluable for the continued development of immunology. Our 17 Regional Groups bring together immunologists within a local community, boosting local research networks. Our 12 Affinity Groups have all been created to focus meetings and discussions on specific areas of immunology and they continue to evolve as immunology expands its reach and knowledge.

Our Groups ran a full programme of activities this year with a huge amount of enthusiasm, dedication and expertise. Collectively, these events attracted over 2,500 delegates and played an important part in our strategy to develop our Regional and Affinity Groups as community-based expert hubs. Our Groups also ran several other activities including in-house seminar series, careers events and public outreach initiatives.

Highlights of the programme include:

The [BSI London Immunology Group](#) hosting a one-day meeting: Tissue Immunology 2023. This event attracted over 150 delegates as responses to infectious and inflammatory challenges within specific tissues were discussed.

The [BSI Neuroimmunology Symposium](#), a two-day meeting covering topics including brain injury, regeneration, peripheral neuroimmune mechanisms, neurodegenerative disease and CNS infection.

The third [Scottish Immunology Groups Network \(SIGNET\) joint symposium](#) held by the BSI Aberdeen, Edinburgh, Tayside and West of Scotland Immunology Groups. SIGNET was a full-day in-person symposium bringing together immunologists from across Scotland to share research, foster new collaborations and encourage networking. The event featured keynote speakers, Professor Leonie Taams and Professor Eduardo Villablanca.

In April 2024 the [BSI Immunometabolism Affinity Group](#) held a two-day event: Fuelling the immune response III. The keynote session on metabolic control of t cell function was given by Professor Russell Jones.

Another well attended event was the [BSI Oxford Immunology Group](#) in collaboration with the University of Oxford Immunology Network one day showcase of the fantastic research happening across Oxford. Topics covered included fundamental biology, infection, imaging to system immunology, therapeutics and AI.

The [BSI Tumour Immunology Group](#) held 'Revealing and tackling the complexities of the tumour microenvironment', a two-day event bringing scientific and clinical researchers alongside industry partners to examine and interrogate the multifaceted role of the immune system in the tumour microenvironment and to discuss how to harness these complexities.

Our Groups also ran several other activities including in-house seminar series, careers events and public outreach initiatives.

BSI Journals




The BSI's original ethos still lies at the heart of our Society – to disseminate research with the aim of promoting and advancing immunology to foster future innovation. This has been a year of consolidation and growth for our highly respected family of three journals, *Clinical & Experimental Immunology*, *Immunotherapy Advances* and *Discovery Immunology*.

Working with our publishing partner, Oxford University Press, our journals aim to serve the field of immunology through publishing high-quality research articles, reviews, commentaries and short reports from researchers around the globe. We work closely with our Editors-in-Chief and Editorial Boards to take a strategic approach to ensure the continued high-performance of the journals. With our mixed portfolio of both hybrid and fully Open Access journals, the Society is in a strong position to continue to provide for the immunology community's publishing needs for many years to come.

In September 2023, the BSI journals hosted a webinar: Advances in Tissue Immunology. The Editors-in-Chief of all three BSI journals were joined by Professor Arnie Akbar and Dr Stephanie Dougan to discuss their recent research that has advanced our understanding of tissue immunology and immunity in health and disease. Over 160 people joined the webinar.

This year we also published a joint collection with articles from each of our family of journals.



Income generated from our journals provides major financial support for the Society's activities and we are hugely grateful to all our Editorial Board members for their ongoing commitment, and everyone who has contributed to the continued success of our journals, including authors, readers, reviewers and editors.




Our established high quality and translational research journal, *Clinical & Experimental Immunology* (*CEI*), continues to perform well with a solid impact factor of 3.4. This has been a busy year for the journal, led by Editor-in-Chief Leonie Taams, with several high-profile review series to take a deep dive into key topics including organoids to study immune cell development and function and unconventional T Cells.

544 submissions

120 accepted articles

The most viewed article published this year in *CEI* was titled Revolutionizing immune research with organoid-based co-culture and chip systems. It achieved approximately 3,000 total views from January to June 2024.

Other highlights include the Human B cells special issue, its top tweet collected 14,900 impressions. and the Unconventional T Cells in health and disease review series.



Other *CEI* articles published in the year topping 2,000 total views include Disrupting B and T-cell collaboration in autoimmune disease: T-cell engagers versus CAR T-cell therapy? and Interleukin-11 and its eminent role in tissue fibrosis: a possible therapeutic target.



Our first fully Open Access journal, *Immunotherapy Advances*, continues its progress to be a globally recognised title that both serves the immunotherapy community and exposes new developments in the field to a wide and diverse readership. Led by Editor-in-Chief, Tim Elliott, *Immunotherapy Advances* focuses on scientifically rigorous research relating to manipulations of the immune system for the benefit of human and animal health in all disease areas.

This year, the journal obtained its inaugural impact factor of 4.1 establishing it as a leading publication in the field of immunology.




The most read articles published in the year were Cancer vaccines: from an immunology perspective, and Strategies to overcome low MHC-I expression in paediatric and adult tumour, both published in December 2023 totalling 3,798 total views between them.

The most viewed article of the year was published in 2022-23. Treg-based immunotherapy for antigen-specific immune suppression and stable tolerance induction: a perspective by Shimon Sakaguchi, Ryoji Kawakami and Norihisa Mikami. This article was viewed over 3,000 times.



This was the first full year for *Discovery Immunology (DSI)*. This new fully Open Access journal, led by Editor-in-Chief Simon Milling, has a broad scope that focuses on new discoveries in cellular and molecular immunology. Over the course of the year, *Discovery Immunology* has reached several important milestones, including achieving indexing in PubMed Central and Scopus.

DSI published its first special collections, these help to increase the journal's profile and increase submissions made to the journal.



The most read article published this year was titled Deciphering the relationship between temperature and immunity, it collected almost 2,700 total views in the first six months since it was published.

Our focus for the next year is to continue building the submissions for the journal together with its reach and impact through publishing high-quality articles describing novel mechanisms of the immune response.

Supporting research consortia

Under our current strategy, a new area of our work has been to support national and topic-specific research consortia efforts relevant to immunology. By championing investment in immunology and a 'team science' approach, we aim to use our skills to support cross-sector collaboration efforts to drive forward immunology research faster and more effectively.

We have built on our initial success this year by providing a variety of services to support several national research consortia including CARINA (Catalyst Reducing ImmuNe Ageing) Network, SIREN (SARS-CoV-2 Immunity and Reinfection Evaluation) study, PITCH (Protective Immunity from T Cells in Healthcare workers) and STRAVINSKY (Stratification of Clinically Vulnerable People for COVID-19 Risk Using Antibody Testing).



The CARINA (Catalyst Reducing ImmuNe Ageing) Network is a project funded by the Medical Research Council (MRC) and Biotechnology and Biological Sciences Research Council (BBSRC) and supported by the BSI. The network, which consists of over 100 researchers, clinicians and other stakeholders interested in the ageing immune system, aims to establish a UK-wide inclusive platform to enhance collaboration and foster knowledge exchange in the area of immune ageing as well as increasing the profile of the research area.

This year, we were delighted to successfully apply for a one-year funding extension for CARINA, allowing us to build the network's capacity and output. We ran CARINA's first ever grant round to provide flexible funding to early career CARINA members to support activities that help them develop their career in immune ageing. We were pleased to fund four grants as a result of this, covering a variety of activities including gathering pilot data, conference trips and external lab visits to learn new skills.

The annual CARINA Network meeting has also become a staple in the diary, bringing the immune ageing community together to gain a shared consensus of key research questions within immune ageing, facilitate cross-sector collaborations and strengthen our community. This year was no different with over 40 CARINA members in attendance. This time, we focused on providing slots for attendees to give 'elevator pitches' of their research to build knowledge of the skills and expertise within the Network.



This year, we have continued to support STRAVINSKY (Stratification of Clinically Vulnerable People for COVID-19 Risk Using Antibody Testing), which is funded by the National Institute for Health and Care Research (NIHR) and led by Professor Alex Richter. STRAVINSKY aims to build our understanding of who is most clinically vulnerable to COVID-19 infection and identify individuals or disease groups at highest risk. The study is investigating whether an antibody test result can predict an individual's risk of severe COVID-19 infection.

For this project, the BSI have recruited and are running their patient and public involvement (PPI) panel as well as assisting with external communications. The PPI Panel now meets regularly with the STRAVINSKY research team to ensure the expertise and viewpoints of the public contributors are fed directly into the research agenda. The PPI Panel's contributions are vital to ensuring the study's success.

Keeping members informed

The BSI works hard to ensure good communication channels with our members, the wider immunology community and the public informed about our activities and about developments in immunology in the wider world.

BiteSized Immunology, our online resource designed to form a comprehensive guide to the immune system continues to be popular with some of the website's most visited pages.

Our social media channels continue to provide an important mode of engaging with our membership and the wider world at a more immediate level, to interact with our supporters and spread the word about our work and the wonders of immunology.

Championing careers

The BSI provides several grant schemes to our members to support their work and their career development. These include a variety of activities – from covering the travel costs to conferences, to providing financial support for carers, support for public engagement initiatives and those that promote diversity and inclusion within immunology. We are very proud of the range of support we have been able to provide to members over the last 12 months.

**£192k grants
awarded**

**286
members
supported**

Career Enhancing Grants

Supporting current and future generations of immunologists throughout their careers is a vital part of our mission. This year has seen our Career Enhancing Grants go from strength to strength to support even more BSI members to reach their career goals. The scheme provides flexible financial support of up to £5,000 to allow individuals to build their skill set and advance their professional development.

**£79k
Grants
funded**

**21 members
supported**

**Generate pilot data
Training courses
Lab visits**

Mentoring scheme

Our highly successful mentoring scheme brings together senior scientists with early career researchers to assist the next generation of immunologist with career development and progression. The popularity of this scheme has flourished in recent years with a steady stream of applicants both mentors and mentees and many stories of successful career progression from past participants. This year, we have 23 pairs took part.

Bright Sparks in Immunology

Our highly popular and prestigious 'Bright Sparks in Immunology' sessions at the BSI Congress aim to showcase the work of early career researchers as well as providing them with valuable experience talking about their work in front of a large audience. There are two categories (PhD and postdoc) with ten talks each, with the top three in each category winning a prize and being designated our 'Bright Sparks'.

Our judges are always astounded by the quality of talks and this year was no different. The future of immunology is certainly in good hands if the excellence within our Bright Sparks session is anything to go by and we were pleased to award the following winners.

Clinical immunology training days

We partner with the Association of Clinical Pathologists (ACP) to run Clinical Immunology Training Days aimed at medical trainees in immunology and allergy, and immunology clinical scientists preparing to sit the Royal College of Pathologists in immunology exams.

By working together, the ACP and BSI ensure the continuous delivery of these highly valued training sessions, helping to create a new generation of immunology-aware and informed clinicians and clinical scientists across the NHS to improve the care and treatment of patients with immune-mediated disease. This year saw four events run in total (three in person and one online), covering the broad spectrum of the immunology curriculum. The training events themselves are consistently ranked as excellent by attendees who value the targeted content.

Training

Our new training function went from strength to strength this year, building on past successes and with some exciting new courses launched and in the pipeline. Through our courses, we aim to provide tailored and innovative training to meet the needs of both immunologists, helping them keep their skills up to date and relevant, and non-immunologists, who want to understand the basics of the discipline to help in their jobs. This year, we had offerings applicable to all our members with courses in both the scientific and clinical spheres.

Bioinformatics

This year, we had pleasure of building on the success of our bioinformatics training programme, which has been developed and is delivered by John Cole and Glasgow Bioinformatic Core. This suite of courses aim to equip wet-lab immunologists, biologists and other life scientists with the skills and confidence to perform their own bioinformatic data analysis. Bioinformatics is now a potent driver of scientific development and is fast becoming an essential skill for life sciences researchers. Particularly within immunology, it is also an area where there is currently a significant skills gap. To upskill our members and others working in relevant fields, we offer a range of high-quality and affordable bioinformatics courses, suitable for complete beginners through to advanced practitioners.

Across one entry level and two advanced courses, we trained a total of 324 scientists this year, with extremely positive feedback on the quality of the courses and how gaining these skills has helped to drive forward participants' careers.

**324 people
trained**

Immunotherapy in clinical practice

The last 15 years have seen new forms of immunotherapy introduced into almost every area of clinical practice. Following demand from within our community, we developed and delivered this new interactive training programme for individuals who are involved in the care of patients receiving immunotherapy. The modular online course provides essential immunology knowledge to demystify the science behind immunotherapy and explain the application of these therapies in the clinic.

This year, we piloted our first two modules, gastroenterology and rheumatology, both underpinned by an 'Immunology and immunotherapies 101' introductory module. During the courses, participants used problem-based learning to build their knowledge of how the basic science of the immune system relates to clinical practice, how immunotherapy drugs work, the pros and cons of different treatment options and the safety profile of the drugs and why treatment resistance and immune-related toxicities can occur. We had 16 people attend the gastroenterology course and 17 people on the rheumatology course, with positive feedback. We are taking the learnings from this pilot to develop further modules to launch in the coming year.

Training in Patient & Public Involvement

As part of our work supporting the CARINA Network, we worked with the project's public contributors to update and re-run our online course for researchers on how to involve the public and patients in their research, and how to better understand the mindset and approach needed for effective and inclusive involvement. During the course, researchers were able to hear directly from PPI representatives as well as allowing for peer-to-peer learning through sharing experiences and case studies of successful involvement. The course was fully booked with 25 participants.

Honorary members

Our honorary membership scheme recognises individuals who have made an outstanding contribution to immunology and/or to the Society. At BSI Congress 2023, we were delighted to award Lifetime Honorary Membership to two members:

- Professor Arne Akbar (University College London)
- Professor Allan Mowat (University of Glasgow)
- Professor Brigitta Stockinger (Francis Crick Institute)

Catalysing change

Public engagement

Our public engagement work over the last 12 months has focused primarily on vaccines. We have used a wide variety of methods and routes to engage with different communities to understand and answer their questions around vaccination.

Resources for engagement

We have continued to develop a range of engagement resources around vaccines, including updating our highly rated comprehensive 'Guide to COVID-19 vaccinations' and creating an infographic to how the MMR vaccines works and why it is important that we are all vaccinated to protect against measles.

Measles

British Society for
immunology
www.immunology.org

What is measles?

Measles is a serious illness. It usually starts with cold-like symptoms then a rash. 1 in 5 children who catch measles need a hospital visit.

There is also the risk of very serious complications if it spreads to the lungs and brain.

The MMR (Measles, Mumps and Rubella) vaccine is offered to young children to help protect against illness and to stop the spread of measles.



Who should get the MMR vaccine?

Measles is very infectious. In the UK, we aim for 95% of people to have the MMR vaccine. This stops the diseases spreading in our communities and protects those who can't have the vaccine (e.g. babies under 12 months).

Young children will be offered their first dose at 12 months and second dose at 3 years and 4 months, but adults can also have the vaccine if they weren't vaccinated as a child.

Does the vaccine have side effects?

There can sometimes be mild side effects to the vaccine, like a rash or fever, but these only last a few days. More severe side effects are very rare and are monitored constantly.

The chance of complications from catching measles is a lot higher than any side effects you might experience from the vaccine.

If you aren't sure if you've had the vaccine, get in touch with your GP.



Is there a link between the MMR vaccine and autism?

No. There has been lots of research and there is overwhelming evidence that there is no link.



Why does my child need two doses of the MMR vaccine?

The first dose is to protect your child, and the second dose tops up that protection and helps to stop them spreading it.



I'm worried about my child's immune system being overloaded.

Children's immune systems are exposed to lots of things in their everyday environment. The vaccinations they receive are only a small fraction of this and they help to protect against the most serious illnesses.

Sources: NHS, UKHSA, Green Book – Immunisation against infectious disease. Information correct as of March 2024

Find out more

- BSI Guide to Childhood Vaccinations
- Talk to your GP or health visitor
- Look on the NHS websites
- Always use trusted sources



www.immunology.org

#VaccineConversations

Empowering our members to engage with family, friends and communities to have meaningful conversations about vaccines has continued to be a core part of our work.

This year, we ran a stall at Lambeth Country Show, engaging with the public about how vaccines work and why they are important for health. Attendance at this event allows us to reach diverse communities in London. Using our interactive engagement activities and resources to draw people over to our stand, our wonderful volunteers had many interesting conversations and were able to increase the public's knowledge of the science behind vaccines.

Communication & Engagement Grants

Our Communication & Engagement Grants have been a staple of BSI public engagement efforts over recent years and provide vital funding to allow our members to carry out engagement activities that strengthen understanding about immunology topics. The grants provide opportunities for our members to share their passion and knowledge for immunology and to build their confidence and skills in engaging with the public. We know our members hugely value these grants and we are very proud of all they achieve through their inspirational and innovative engagement plans.

Partnerships

Working in partnership is a key part of the British Society for Immunology's strategy to build the impact that we can deliver for immunology. We engage with like-minded organisations to collaborate on areas of interest ranging from autoimmunity to cancer, to vaccines. By using our profile, expertise and reach, we can shine a light on the importance of critical areas of immunology to attract new focus and funding and build new collaborations between different sectors.

Policy highlights

As always, the Society has continued to use our powerful voice to advocate for immunological science and health, ensuring the voice of immunologists is heard loud and clear in public debates and that policymakers have access to the latest immunological thinking. With our dynamic approach, working in partnership with BSI members and allied organisations, we have played a strong role in ensuring the expert voice of immunologists is represented in public debate.

Enablers


To deliver our ambitious strategic aims, we need to maintain the BSI as a sector-leading organisation. We will do this by:

- Creating a larger and more diverse engaged membership
- Embedding quality, diversity and inclusion in all our activities
- Ensuring the Society's financial sustainability

Enabler - membership

Our membership is the foundation of our Society. We are ambitious in what we want to deliver for immunology and for our members. As the discipline of immunology continues to grow and evolve, we aim to evolve too to ensure we engage with, support and are relevant to immunologists from across the spectrum of our community. As the largest professional immunology society in Europe and third largest in the world, we aim to stand shoulder to shoulder with our members to support and champion the discipline of immunology to drive scientific discovery and make a positive impact on health.

Membership numbers have consistently risen this year achieving record highs each month. This remarkable growth underscores the increasing value and appeal of our membership offerings, as more people recognise the benefits of joining the Society. In a significant milestone, we broke through the **5,000-member** mark for the first time in June 2024. Each month, we celebrate not just an increase in numbers, but a testament to our commitment to excellence and member satisfaction.



Providing the best service for our members

One of our key aims is to ensure that increase our support and engagement with our members from all sectors and at all career stages. To support this work, this year we continued to develop our new membership management system to allow us to provide better, more joined up and holistic support and service for our members.

BSI Clinical Immunology Professional Network

This is the second year of BSI Clinical Immunology Professional Network (BSI-CIPN) activities, following our successful merger with the UK Primary Immunodeficiency Network (UKPIN) in early 2023. Our aim is to run an integrated and impactful professional network, representing individuals working in all professions within clinical immunology.

The activities of the network are overseen by the BSI-CIPN Steering Group, chaired by Dr Sinisa Savic, supported by Deputy Chair Dr Suzanne Elcombe. The network welcomes members from all aspects of clinical immunology including doctors, scientists, nurses, pharmacists and trainees.



The network aims to foster closer links between clinical practitioners and basic scientists and strengthen the voice of clinical immunology in policy and public arenas. The BSI-CIPN will also share best practice through a range of resources and activities, including dedicated events, clinical sessions at BSI Congress, development of clinical guidelines, training provision and much more. By providing this strong platform for UK clinical immunology, our aim is to improve care for patients.

The activities of the network are overseen by the BSI-CIPN Steering Group, chaired by Dr Sinisa Savic, supported by Deputy Chair Dr Suzanne Elcombe. The network welcomes members from all aspects of clinical immunology including clinicians and trainees, nurses, healthcare scientists and pharmacists.

Developing the first strategy for BSI-CIPN

This was a year of focusing on the future for the BSI-CIPN Steering Group, with the development of a new three-year strategy for BSI-CIPN, which lays out how we plan to support our members, and the wider professional and patient community, to be a strong voice and advocate for clinical immunology. The mission of the BSI-CIPN is to lead the delivery of excellence in patient care in clinical immunology, through three themes: education & training, advocacy & engagement, and research. This is an exciting step forward for the network and provides a roadmap to follow our ambition to be the 'go to' organisation for matters relating to clinical immunology in the UK. The strategy will be launched in 2024-25.

BSI-CIPN conference

This was the first year of our official BSI-CIPN Conference, which brings the clinical immunology community together to discuss important clinical and research topics related to the healthcare of patients with primary immunodeficiencies, as well as a wide range of other topics relevant to clinical immunology practice, covering the latest thinking around key medical, scientific, educational and management issues relevant to all those working in the field.

Held alongside the BSI Congress in Belfast, this hugely successful event attracted over 240 participants from six countries, including more than 39 people attending online.

Immunology News

Members in the UK can receive a printed copy of our quarterly membership magazine, *Immunology News*, with online access around the world. Immunology News amplifies the voice of our membership and highlights how we're supporting our members and representing immunology on a wider stage.



Over the last year editions featured, women in immunology, the scientific potential of immunogenicity, the CARINA (immunity for life) project, the Edinburgh Immunology EDI Summer School, highlights from the Parliamentary Links Day 2023, celebration of recent recipients of the BSI's teaching awards, the journey of a deaf immunologist, public engagement, HAE UK and we celebrated our new trustees, secretaries and committee members.

The March issue included an introduction to the fascinating field of ecoimmunology, which draws from both ecology and immunology to explore how the immune system functions in the real world.

This year also included a recap of highlights from BSI Congress 2023 and the 2023 BSI-CIPN conference.

Corporate members

We would like to thank our corporate members whose continuous support enables us to undertake our work



Enabler - Equality, diversity and inclusion

The BSI works hard to ensure that diversity and inclusion is at the heart of the ethos of our community. This year, we have continued to build on the promises laid out in our 'Diversity and Inclusion Framework', which outlines our commitment to how we are going to work with our members and community to ramp up our equity, diversity and inclusion work and respond to members' needs. By building on past and ongoing activities, this framework sets out our long-term plan of action for diversity and inclusion at the BSI.

This year, we have consolidated our progress to date as well as building on our EDI commitment further. As always, listening to and engaging with our members forms an important part of this scheme of work, making sure we understand their views of the BSI's role in supporting EDI in immunology, what we're doing well and what we could do better.

We continue to champion EDI through all our communication and particularly in our membership magazine, Immunology News, where we have run several high-profile case studies from different individuals on their experience of working in immunology and from projects funded through our EDI Activity Grant. Our Carers' Grants, that we offer for BSI Congress and for Regional and Affinity Group events, continue to be well received by the community, with impressive uptake, particularly for BSI Congress. We also ran a session at BSI Congress on research culture, with a panel of expert speakers to discuss and get feedback from attendees on good research culture practice and where there is still room for improvement within immunology. Finally, we have been engaging deeply with the wider scientific community to spread best practice on how we developed our framework and to learn from their experiences of similar activities.

Income diversification

To deliver our ambitious strategic plans, we need to maintain the BSI as a sector-leading organisation, and one of the crucial enablers to do so is our financial sustainability. While traditionally we have relied heavily on our journal income to fund charitable activities, our shift to bring in new long-term and stable income sources is now well under way. The development of new income streams is never a quick process as there is often a delay between investment and return, requiring the use of reserves. However, our strong reserves have been built up for exactly this purpose – to support the organisation through this transition – and their use is now carefully planned.

Consolidating our approach

This has been a year of consolidation in terms of our income diversification activities as we capitalise and build on the successful launch of new products and activities from previous years. Our new, modernised journals offering continues to go from strength to strength, reducing our financial reliance on the traditional subscription model while meeting the needs of our members and wider immunology community. Our two Open Access journals, *Immunology Advances* and *Discovery Immunology*, continue to prove a popular publication option and are meeting their key milestones. We were delighted that *Immunotherapy Advances* achieved its first ever impact factor of 4.1 in June 2024. Combined with the success of our well-established journal, *Clinical & Experimental Immunology*, we are well on course to stabilise our future journals income.

Meanwhile, we have built up a strong reputation within the sector for assisting the smooth running, effectiveness and impact of large research consortia. Prestigious projects we have worked on over the last 12 months include SIREN (SARS-CoV-2 immunity and reinfection evaluation) study, the CARINA (Catalyst Reducing ImmuNe Ageing) Network and STRAVINSKY (Stratification of Clinically Vulnerable People for COVID-19 Risk Using Antibody Testing) – see page 10 for more details. Our participation in this type of funded project continues to be an important source of income while allowing us to meet our wider goal of supporting the national immunology research effort. We have also maintained a future focus in this work, looking for upcoming opportunities to collaborate with the immunology research community to drive forward scientific discovery to have a positive impact on health.

We also continue to enhance our partnership and sponsorship areas of work with industry, establishing mutually beneficial routes for collaboration to highlight, celebrate and champion the immunology sector, which has been core to our strategic development of this area of work.

Training achievements

A key success this year has been our BSI training function, which we launched at the start of 2023 with the aim of supporting immunologists and the wider research community keep their skills up-to-date and relevant.

This year, we launched several new courses, aimed at different sections of the research and clinical community. This included our much anticipated ‘Immunotherapy in clinical practice’ course, with modules focused on rheumatology and gastroenterology, and our collaboration with University of Birmingham on training on immune checkpoint blockade therapy.

Our training on bioinformatics, delivered in partnership with Glasgow Bioinformatic Core, has built an exceptional reputation amongst the research community and courses continue to be highly popular with very positive feedback. Throughout the year, we launched a number of new and/or updated modules as part of this training, which have been well received. We are delighted that these courses fulfil such a key training niche for researchers and are an excellent example of how our income diversification activities can align to provide much needed services for our immunology community.

Structure, Governance and Management

Charitable status and administrative details

The Society was registered as a charity in 1966 (Charity number 1043255) and incorporated in England and Wales as a company, limited by guarantee (Company number 03005933). The Society's registered address is 9 Appold Street, London EC2A 2AP. It has no share capital and the liability of its members is limited to a sum not exceeding £1. The Society's governing document is the Memorandum and Articles of Association, which was amended on 7 December 2016.

It is also a registered charity in Scotland (Charity number SC047367).

Board of Trustees

The Trustees are company directors for the purposes of the Companies Act and charity Trustees for the purposes of the Charities Act 2011. The current trustees, and any past Trustees who served during the year are listed on page 55.

The Trustees are responsible for directing the Society's activities and for overseeing the management of the affairs of the Society, they delegate the day-to-day management of the organisation to the chief executive and the senior management team. The Board acts on advice and information from regular meetings with the chief executive and the senior management team.

As part of their induction process, Trustees spend some time with the chief executive and senior management team. They are provided a trustee resource pack containing the history of the Society and key information they require to fulfil their duties as Trustee, they are also offered training for new Trustees.

The success of the Society belongs in part to the large number of people who generously volunteer their time to add their experience to our collection of committees, we thank you all.

Finance Sub Committee

The Finance Sub Committee ensures the system of internal control is satisfactory to deliver regulatory compliance, financial probity, value for money, challenge of financial plans, budgets and financial statements, oversight of the annual financial audit, review of investment policy and performance, review of reserves policy, and CEO and staff remuneration.

Nominations Committee

The BSI's Nominations Committee has general oversight concerning the structures and effectiveness of BSI Board of Trustees, committees, advisers and observers. It is also responsible for nominating individuals to represent the views of the BSI on external committees and to identify BSI members to nominate for external awards.

Member Representative Forum

The Membership Representative Forum represents a diverse mix of immunologists from different career stages, backgrounds and geographic locations, it is the BSI's 'think tank' and the place where issues and ideas that are of importance to the Society and its member are raised, discussed and developed.

Congress Committee

The Congress Committee is responsible for the planning and delivery of the BSI's flagship event, BSI Congress, which takes place two out of every three years. It reviews and approves the scientific programme for Congress.

BSI-CIPN Steering Group

The BSI-CIPN Steering Group directs the activities of the BSI-CIPN. The group consists of both elected (from the BSI-CIPN members) and co-opted immunology professionals (chosen because of their roles in other key organisations).

Group structure

The Society has two wholly owned subsidiaries:

BSI Trading Limited is registered in England and Wales under company registration number 010201739. Its principal activity is to manage the corporate membership, sponsorship, exhibition, training and other trading activities for the Society.


The United Kingdom Primary Immunodeficiency Network (UKPIN) is a registered charity (1164466) and a company registered in England and Wales (09273983). The Activity in this company was wound down during the year following the transfer of its activities to the Society's Clinical Immunology Professional Network (BSI-CIPN).

Financial Performance

The BSI continued our transition period following the changes to our publishing portfolio. The annual net deficit reduced by 62% from £0.41m last year to £0.16m this year. The operating deficit before movements in investment valuations was better than budget.

Publishing income remains the BSI's largest source of income, however after two years of reductions, it increased to 36% of total BSI income this year from 31% in 2022. This is the result of better performance of *CEI*.

The main sources of income are shown below:



The Society continued our success obtaining funding for our work supporting immunology research. Grants and donations fell 55% to £0.19m as a result of the £0.18m one-off donation received last year following the merger with UKPIN.

Income for BSI-CIPN more than doubled as it held its first two-day conference together with the BSI Congress.

In its second year, the BSI training function continued developing new courses, income for the year rose 138% to £66k. It is anticipated this will grow into significant future income stream for the Society.

Increased sales of exhibition space and sponsorship at Congress, the BSI-CIPN Conference and a rollout of more training courses pushed BSI Trading Limited to an annual profit of £0.56m (2023: £0.49m). This was gifted to the Society.

The United Kingdom Primary Immunodeficiency Network (UKPIN) posted a loss of £2k for the year (2023: £5k).

The Society is in a transition period following the reduction in journal income. The Society has been and will continue to focus on developing new income streams; however, this will require investment from our reserves. During this period, we are forecasting costs to exceed income over the next few years until the new income streams start generating significant levels of income.

Investment policy and performance

The Society operates an investment policy to provide income and generate capital growth. The Society is a long-term investor and the value of its investments remains significant above its original investment.

As planned the BSI commenced our programme of drawdowns from investments as we invest in new sources of sustainable income. During the year £0.65m was withdrawn from our investments to help meet the BSI's cash requirements (2023: £1m). Future drawdowns are now estimated to be lower than originally forecast.

Funds are invested with LGT Wealth (formerly abdrn) with a long-term objective to generate a capital return of 3% more than inflation over a three-year rolling period. The performance of the BSI investment portfolio was buoyed by tech stocks which led to a significant rise in investments values. This produced a gain on investments for the year of £0.34m (2023: £0.007m loss). The value of the portfolio fell by £0.23m (2021: fall of £0.94m) significantly less than the drawdowns due to the rise in investment values. On 30 June 2024 investments were valued at £3.07m (2023: £3.30m).

The Finance Sub Committee is responsible for reviewing investment performance and policy.

Reserves policy

The BSI operates a risk-based approach to reserves to ensure the BSI holds the most appropriate level of reserves to cover potential risks and to fund investment in new income sources securing the BSI's long term financial health.

Free reserves represent unrestricted general funds of the Society and exclude both restricted funds and funds that have been designated by the Board of Trustees. The free reserves also exclude any funds that could only be realised by disposing of fixed assets held for charitable use. Details of restricted funds can be found in note 15 of the accounts with details of designated funds in note 16.

	30 June 2024	30 June 2023
	£m	£m
Total reserves	3.74	3.90
Less: Fixed assets	(0.10)	(0.13)
Designated funds	(0.40)	(0.55)
Restricted funds	(0.25)	(0.26)
Free reserves	2.99	2.95

The BSI risk register is reviewed annually with monetary values allocated to specific risks to produce the required 'risk-adjusted' reserves level.

	30 June 2024
	£m
Income diversification development costs	0.77
Potential devluation of investment portfolio	0.65
Three momths operating costs	0.59
Risk-adjusted' reserves	2.01

The Society's free reserves are £0.98m more than the 'risk-adjusted' reserves level. The Society consider this is a sufficient provision for unknown risks (to give cover for those risks which the Society is not yet aware) and to fund future income generation opportunities.

Pay policy

The Society's pay policy aims to ensure that all employees are paid at least the market median for their roles with the ability of high performers to move towards the upper quartile.

Salaries, including the Senior Management Team, are reviewed by the Finance Sub Committee with recommendations for the annual pay rise proposed to the wider Board of Trustees for approval as part of the annual budgeting process. The salary of the Chief Executive is reviewed annually by the Board of Trustees.

To increase transparency the Society's is voluntarily reporting its gender pay gap. Calculated in June 2024 the Society's mean gender pay gap is 40.38% (June 2023: 35.19%). The pay gap indicates that while 80% of employees are women (2023: 75%), most men are in management roles. The Society employs more women in each of the quartile pay bands.

The Society strongly supports equal pay, with individuals with the same responsibilities being paid the same irrespective of gender.

Risk management

Good risk management is fundamental to the continued work and sustainability of the Society. We identify and manage risks that could adversely impact the achievement of our strategic purpose and determine the calculated risks we need to take to succeed.

The Society operates a formal framework for the management of risk, taking the view that risk can be positive (opportunity) or negative (threat). The Society operates a risk register incorporating strategic, operational and compliance risks, which are informed by the Society's strategic objectives, performance, voice of our stakeholders, regulatory environment and analysis of the external environment.

The Board delegates day-to-day responsibility for risk management to the Senior Management Team, who are responsible for identifying and evaluating risks to their areas and activities implementing appropriate controls for ongoing mitigation and monitoring.

The Financial Sub Committee reviews the management of risk in detail at each meeting and the Board reviews the Society's strategic and compliance risks twice a year.

The principal risks and uncertainties facing the society and the mitigations that we have put in place are as follows:

Risk: short term	Risk response
Development of new surplus generating training function	Several courses are in development with some scheduled to be delivered in the coming months including the immunology nurses' training course. Additional modules are being developed for our successful Bioinformatics training programme. We will perform a thorough review of performance and feedback of launched courses.
Employee/Team capacity	Watching brief, with line managers ready to help team members when workload issues arise. SMT are committed to regularly proactively discussing reviewing our plan of activities and team capacity. The BSI team is now fully recruited.

Risk: long term	Risk response
Failure to find new sources of long-term sustainable income	The Society is proactively looking for new funding opportunities: ▪ Working with partners and corporate members to develop existing and new sources of income ▪ Developing a programme of training courses including training for nurses and a training course for clinicians. We are working to expand/grow the new activities launched in the last year
Loss of significant devaluation of investments A devaluation in the value of investments would result in a reduction of reserves available to use by the Society. Investments could be impacted by sudden unforeseen global events	The Society ▪ Reviews investment performance during each Financial Sub Committee meeting ▪ Communicates regularly with our investment managers, especially through times of significant volatility

Fundraising statement

Although the Society does not actively fundraise from members, occasional donations are received. The Society applies best practice in the tone of its communications and the accuracy of its data to minimise the pressures on supporters. The Society applies best practice to protect supporters' data, never sells or swaps it and ensures that communication preferences can be changed at any time. The Society commits to react to and investigate any complaints received, to learn from them and improve its service. During the year, the Society received no complaints about its fundraising activities.

Future plans

During 2024-25 the Society will focus on:

Connected community

- Launch and commence delivery of the first strategy for the BSI-CIPN
- Delivering a successful inaugural immune therapies summit

Championing careers

- Successfully increase the careers support the BSI provides to members

Catalysing change

- Continue and expand the BSI's successful partnership work
- Expanding the BSI's PPI activities through support of and inclusion in national research consortia

Enabler - membership

- Launching targeted marketing campaigns to drive membership growth
- Grow membership of the BSI-CIPN

Enabler - Equality, diversity and inclusion

- Collecting benchmark EDI data on BSI committees and creating a plan to further embed EDI in BSI activities

Enabler - Financial sustainability

- Income diversification is a key priority: consolidation and expansion of current income generating activities and identifying and developing new sources of income including the launch and delivery of new training courses

The Senior Management Team and the Trustees continue to assess all significant risks, in the immediate, medium and longer term.

Trustees' responsibilities

The Trustees (who are also directors of British Society for Immunology for the purposes of company law) are responsible for preparing the Trustees' report and financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the Group and Society and of the income and expenditure of the Group and Society for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable to the United Kingdom and Republic of Ireland; and
- make judgements and estimates that are reasonable and prudent;
- state whether applicable United Kingdom Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume the charity will continue in operation.

The Trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the Group and Society and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Group and Society and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Each of Trustees confirm that:

- so far as the Trustee is aware, there is no relevant audit information of which the Group and Society's auditor is unaware; and
- the Trustee has taken all steps that he/she ought to have taken as a Trustee in order to make himself/herself aware of any relevant audit information and to establish that the Group and Society's auditor is aware of that information.

This confirmation is given and should be interpreted in accordance with the provisions of s418 of the Companies Act 2006.

The Trustees are responsible for the maintenance and integrity of corporate and financial information included on the Society's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Approved by the Trustees and signed on their behalf by:



Tracy Hussell
BSI President

Date: 16 October 2024

Independent Auditor's Report to the members and trustees of the British Society for Immunology

Opinion

We have audited the financial statements of the British Society for Immunology for the year ended 30 June 2024 which comprise the Group Statement of Financial Activities, the Group and Parent Charitable Company Balance Sheets, the Group Cash Flow Statement and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

give a true and fair view of the state of the group's and the parent charitable company's affairs as at 30 June 2024 and of the group's incoming resources and application of resources, including its income and expenditure, for the year then ended;

have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and have been prepared in accordance with the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 (as amended), regulations 6 and 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended) and the Charities Act 2011.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs(UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

the information given in the trustees' annual report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
the trustees' annual report have been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the group and parent charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the trustees' annual report.

We have nothing to report in respect of the following matters where the Companies Act 2006, the Charities Accounts (Scotland) Regulations 2006 (as amended) and the Charities Act 2011 require us to report to you if, in our opinion:

the parent charitable company has not kept adequate and sufficient accounting records, or returns adequate for our audit have not been received from branches not visited by us; or
the parent charitable company's financial statements are not in agreement with the accounting records and returns; or
certain disclosures of trustees' remuneration specified by law are not made; or
we have not received all the information and explanations we require for our audit; or
the trustees were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies exemption in preparing the Trustees' Annual Report and from preparing a strategic report.

Responsibilities of trustees

As explained more fully in the trustees' responsibilities statement, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the group and parent charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the group or parent charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

We have been appointed as auditor under Section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005, the Companies Act 2006 and Section 151 of the Charities Act 2011 and report to you in accordance with regulations made under those Acts.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below.

Explanation as to what extent the audit was considered capable of detecting irregularities, including fraud

The objectives of our audit in respect of fraud, are; to identify and assess the risks of material misstatement of the financial statements due to fraud; to obtain sufficient appropriate audit evidence regarding the assessed risks of material misstatement due to fraud, through designing and implementing appropriate responses to those assessed risks; and to respond appropriately to instances of fraud or suspected fraud identified during the audit. However, the primary responsibility for the prevention and detection of fraud rests with both management and those charged with governance of the charitable company.

Our approach was as follows:

We obtained an understanding of the legal and regulatory requirements applicable to the charitable company and considered that the most significant are the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 (as amended), regulations 6 and 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended), the Charities Act 2011, the Charity SORP, and UK financial reporting standards as issued by the Financial Reporting Council

We obtained an understanding of how the charitable company complies with these requirements by discussions with management and those charged with governance.

We assessed the risk of material misstatement of the financial statements, including the risk of material misstatement due to fraud and how it might occur, by holding discussions with management and those charged with governance.

We inquired of management and those charged with governance as to any known instances of non-compliance or suspected non-compliance with laws and regulations.

Based on this understanding, we designed specific appropriate audit procedures to identify instances of non-compliance with laws and regulations. This included making enquiries of management and those charged with governance and obtaining additional corroborative evidence as required.

As part of an audit in accordance with ISAs (UK) we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purposes of expressing an opinion on the effectiveness of the group and parent charitable company's internal control.

Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the trustees.

Conclude on the appropriateness of the trustees' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the group and parent charitable company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the group or parent charitable company to cease to continue as a going concern.

Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit report.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Use of our report

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006; and to the charity's trustees, as a body, in accordance with Section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005, and in respect of the consolidated financial statements, in accordance with Chapter 3 of Part 8 of the Charities Act 2011. Our audit work has been undertaken so that we might state to the charitable company's members and trustees those matters which we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to any party other than the charitable company, the charitable company's members, as a body, and the charity's trustees, as a body for our audit work, for this report, or for the opinion we have formed.

Moore Kingston Smith LLP

Date: 9 December 2024

Neil Finlayson (Senior Statutory Auditor)
for and on behalf of Moore Kingston Smith LLP, Statutory Auditor

9 Appold Street
London
EC2A 2AP

Moore Kingston Smith LLP is eligible to act as auditor in terms of Section 1212 of the Companies Act 2006.

British Society for Immunology
Consolidated Statement of Financial Activities
Year to 30 June 2024

		Unrestricted funds				
	Note	General funds £'000	Designated funds £'000	Restricted funds £'000	Total 2024 £'000	Total 2023 £'000
Income from:						
Grants and donations	2	-	-	191	191	425
Investments	3	115	-	-	115	132
Charitable activities	4					
Membership		172	-	-	172	162
BSI-CIPN		228			228	105
Partnership work		59	-	3	62	120
Congress		574	-	-	574	643
Meetings and events		79	-	-	79	83
Journals		844	-	-	844	749
Training		66	-	-	66	28
Total income		2,137	-	194	2,331	2,447
Expenditure on:						
Raising funds						
Investment management fees		29	-	-	29	35
Cost of raising funds		1	-	-	1	12
Charitable activities						
Membership		201	-	33	234	241
BSI-CIPN		217	-	-	217	80
Partnership work		136	-	-	136	147
Congress		636	-	-	636	720
Meetings and events		327	-	-	327	289
Journals		331	-	-	331	370
Training		38	77	-	115	94
Education and Careers		64	77	-	141	200
Diversity and inclusion		1	-	-	1	2
National Research support		-	-	114	114	129
Policy and Public Affairs		144	-	50	194	179
Public engagement		81	-	9	90	111
Communications		224	-	-	224	221
International work		40	-	-	40	23
Total expenditure	5	2,470	154	206	2,830	2,853
Net income (expenditure) before gains (losses) on investments and transfers						
		(333)	(154)	(12)	(499)	(406)
Net gains/(losses) on investments	12	340	-	-	340	(7)
Net income/(deficit)		7	(154)	(12)	(159)	(413)
Reconciliation of funds:						
Funds brought forward		3,086	553	258	3,897	4,310
Funds carried forward		3,093	399	246	3,738	3,897

There are no recognised gains or losses other than those recognised above. All activities are continuing.

The notes on pages 36 to 54 form part of these financial statements

		Group		Charity	
		2024	2023	2024	2023
Fixed assets					
Tangible fixed assets	10	38	53	38	53
Intangible assets	11	61	79	61	79
Investments	12	3,072	3,299	3,079	3,306
		3,171	3,431	3,178	3,438
Current assets					
Debtors	13	406	692	939	1,225
Cash at bank and in hand		734	578	138	25
		1,140	1,270	1,077	1,250
Liabilities:					
Creditors: amounts falling due					
within one year	14	(573)	(804)	(510)	(788)
Net current assets		568	466	567	463
Net assets		3,738	3,897	3,745	3,900
Funds:					
Unrestricted funds					
General fund		3,093	3,086	3,100	3,089
Designated fund	16	399	553	399	553
		3,492	3,639	3,499	3,642
Restricted funds	15	246	258	246	258
Total		3,738	3,897	3,745	3,900

As permitted by s408 Companies Act 1948, the company has not presented its own income and expenditure statement and related notes. The company's loss for the year was £156,238 (22/23 FY: £409,171).

These financial statements have been prepared in accordance with the provisions applicable to the small companies regime.

These accounts were approved by the Board and authorised for issue on 16 October 2024 and were signed on its behalf by:



Tracy Hussell, President

British Society for Immunology, Company Limited by Guarantee
Company Registration Number 03005933 (England and Wales)

British Society for Immunology
Consolidated Statement of Cash Flows
30 June 2024

	2024	2023
	£'000	£'000
Cash flows from operating activities:		
<i>Net cash provided by operating activities</i>	(524)	(893)
Cash flows from investing activities:		
Income from investments	115	132
Purchase of tangible fixed assets	0	(21)
Proceeds from the disposal of investments	1,075	1,669
Purchase of investments	(501)	(933)
Net cash used in investing activities	689	847
Change in cash and cash equivalents in the year	162	(46)
Cash and cash equivalents at 1 July 2023	591	637
Cash and cash equivalents at 30 June 2024	753	591
Net income for the period (as per the statement of financial activities)	(159)	(413)
Adjustments for:		
Depreciation charge	34	30
(Gains) losses on investments	(340)	7
Investment income	(115)	(132)
(Increase) decrease in debtors	286	(140)
Increase (decrease) in creditors	(230)	(245)
Net cash provided by operating activities	(524)	(893)
Analysis of cash and cash equivalents		
Cash at bank and in hand	734	578
Cash held by investment managers	19	13
Total cash and cash equivalents	753	591

The notes on pages 37 to 55 form part of these financial statements

Notes to the financial statements

1 Accounting policies

The principle accounting policies adopted, judgements and key sources of estimation uncertainty in the preparation of the financial statements are as follows:

Basis of preparation

The financial statements are prepared on a going concern basis, under the historical cost convention modified to include the recognition of listed investments measured at fair value, which is consistent with the prior year. The financial statements have been prepared in accordance with the Statement of Recommended Practice: Accounting and Reporting by Charities ("The SORP"), the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102) and the Charities Act 2011.

The British Society for Immunology ("The Society") meets the definition of a public benefit entity under FRS 102

General information

The Society is a charitable company incorporated in England and Wales (company number 03005933) and is a charity registered in England and Wales (charity number 1043255) and registered as a charity in Scotland (charity number SC047367). The Society's registered address is 9 Appold Street, London EC2A 2AP.

Critical accounting judgements and key sources of estimation uncertainty

The preparation of financial statements requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Group and Society accounting policies. In the application of the accounting policies, Trustees are required to make judgements, estimates and assumptions about the carrying value of assets and liabilities that are not readily apparent from other sources. The estimates and underlying assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision only affects that period, or in the period of revision and future periods if the revision affected current and future periods.

In the view of the Trustees, no assumptions concerning the future or estimation uncertainty affecting assets or liabilities at the balance sheet date are likely to result in a material adjustment to their carrying amounts in the next financial year.

Going concern

The financial statements are prepared on a going concern basis which assumes the Society and Group will continue to meet its liabilities as they fall due for a period of at least twelve months from the date of the approval of these accounts. The Trustees are monitoring the post pandemic impact on the Society and Group. This includes regular review of the impact on our members and resulting changes in focus of our activities to support them. Trustees review regular updates on performance against KPIs, rolling forecasts, the risk register and in depth financial reports.

The Society is expanding its activities for its members, including further development and rollout of new training courses and events. This together with the holding of significant levels of cash and investments result in the Trustees considering the Society and the Group to be a going concern.

Notes to the financial statements

Income

All income is recognised once the Society and Group has entitlement to income, it is probable that income will be received and the amount of income receivable can be measured reliably. Income of the Society is, where applicable, included net of Value Added Tax (VAT) and is allocated to the period to which it relates, carrying forward that part of the income relating to future accounting periods.

Investment income is recognised on a receivables basis and when the amount can be measured reliably.

Expenditure

Liabilities are recognised as soon as there is a legal or constructive obligation committing the Society and Group to that expenditure, it is probable that settlement will be required and the amount of obligation can be measured reliably. Expenditure is recognised on an accruals basis as a liability is incurred, inclusive of VAT, which cannot be recovered.

Expenditure is allocated to a particular activity where the cost relates directly to that activity. The cost of overall direction and administration of each activity, known as "support costs" and comprising the salary and overhead costs of the central function is apportioned based on staff time attributable to Support costs also include governance costs, which comprise organisational administration and compliance with constitutional and statutory requirements. The allocation of support and governance costs is analysed in notes 7 and 8.

Employee benefits

Short-term benefits including holiday pay are recognised as an expense in the period in which the service is received.

Termination payments are accounted for on an accruals basis and in line with FRS 102.

The Society contributes to a Group pension scheme, the assets of which are administered by Royal London Plc. They are defined contribution schemes. All contributed costs are accounted for on the basis of charging the cost of providing pensions over the period when the Society and Group benefits from the employees' service. The Society and Group has no further liability under the scheme.

Leasing and hire purchase commitments

Rentals paid under operating leases are charged to the income and expenditure account on a straight line basis over the lease term. The Society holds no assets under finance leases or hire purchase contracts.

Tangible fixed assets

Tangible assets are stated at cost less accumulated depreciation. Cost includes the original purchase price, costs directly attributable to bringing the asset to its working condition for its intended use, dismantling and restoration costs. The minimum threshold is £1,000. Depreciated is provided at 33% in order to write off each asset over its estimated useful life.

Intangible fixed assets

Intangible assets are stated at cost less accumulated amortisation. Cost includes the original purchase price, costs directly attributable to bringing the asset to its working condition for its intended use, dismantling and restoration costs. The minimum threshold is £1,000. Amortisation is provided at 20% in order to write off each asset over its estimated useful life. Assets in the course of construction are not amortised.

Notes to the financial statements

Investments

Investments are a form of basic financial instrument and are initially shown in the financial statements at fair value. Movements in the fair value of investments are shown as net gains and losses in the Statement of Financial Activities.

Profits and losses on the realisation of investments are shown as realised gains and losses in the Statement of Financial Activities. Net gains and losses on investments are calculated between sales proceeds and their opening carrying values or their purchase price if acquired subsequent to the first day of the financial year. Unrealised gains and losses are calculated as the difference between the fair value at the year end and their carrying value. Realised and unrealised investment gains and losses are combined in the Statement of Financial Activities.

The investment in the subsidiary undertaking is included at cost with provision being made for any permanent diminution in value.

Financial instruments

I) Financial assets

Basic financial assets, including trade and other receivables, cash and bank balances, are initially recognised at transaction value and subsequently measured at amortised cost. Other financial assets, including investments, are initially measured at fair value. Financial assets are derecognised when:

- a) the contractual rights to the cash flows of the asset expire or are settled, or
- b) substantially all the risks and rewards of the ownership of the asset are transferred to another party or
- c) despite having retained some significant risks and rewards of ownership, control of the asset has been transferred to another party who has the practical ability to unilaterally sell the asset to an unrelated third party without imposing additional restrictions.

Cash at bank and cash in hand includes cash and short-term highly liquid investments with a short maturity of three months or less.

II) Financial liabilities

Basic financial liabilities, including trade and other payables, are initially recognised at transaction price. Trade payables are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Financial liabilities held at amortised cost comprise all creditors except social security and other taxes and provisions.

Provisions

Provisions are recognised where the Society has a present legal or constructive obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Provisions are measured at the present value or the expenditures expected to be required to settle the obligation.

Notes to the financial statements

Fund accounting

Unrestricted funds are those funds available to the Society and Group for general purposes. They include funds designated by the Trustees for particular purposes where their use remains at the discretion of the Trustees. It is the policy of the Trustees to retain in unrestricted funds, amounts which in their judgement, can help to mitigate the short-term effects of income volatility; and retain as long-term investment funds to generate sufficient income to meet current and future operational activities of the Society.

Restricted funds are those funds available to the Society and Group restricted to a specific purpose or are subject to particular donor imposed conditions. Further information is available in the reserves section of the Trustees' report.

2 Income from grants and donations

			2024	2023
	Unrestricted	Restricted	Total	Total
	funds	funds	funds	funds
	£'000	£'000	£'000	£'000
Grants	-	191	191	217
Donations	-	-	-	208
Total	-	191	191	425

3 Income from investments and interest

			2024	2023
	Unrestricted	Restricted	Total	Total
	£'000	£'000	£'000	£'000
Listed investments				
Investment Income	111	-	111	131
Bank deposit interest	4	-	4	-
Total	115	-	115	131

4 Income from charitable activities

	Unrestricted	Restricted	2024	2023
	funds	funds	Total	Total
	£'000	£'000	funds	funds
	£'000	£'000	£'000	£'000
Member subscriptions	172	-	172	162
BSI-CIPN	228	-	228	105
Corporates and partnership income	59	3	62	120
Congress	574	-	574	643
Meetings and events	79	-	79	83
Journals	844	-	844	749
Training	66	-	66	28
Total	2,021	3	2,024	1,890

Notes to the financial statements

5 Total expenditure

	Unrestricted funds £'000	Designated funds £'000	Restricted funds £'000	2024 Total £'000
<i>Raising funds</i>				
Investment management fees	29	-	-	29
Fundraising	1	-	-	1
<i>Charitable Expenditure:</i>				
Membership	201	-	33	234
BSI-CIPN	217	-	-	217
Partnership work	136	-	-	136
Congress	636	-	-	636
Other meetings and events	327	-	-	327
Journals	331	-	-	331
Training	38	77	-	115
Education and Careers	64	77	-	141
Diversity and inclusion	1	-	-	1
National Research support	-	-	114	114
Policy and Public Affairs	144	-	50	194
Public engagement	81	-	9	90
Communications	224	-	-	224
International Work	40	-	-	40
Total	2,470	154	206	2,830

Allocation of support costs to charitable activities:

	Direct costs £'000	Support costs £'000	2024 Total £'000
<i>Raising funds</i>			
Investment management fees	29	-	29
Cost of raising funds	1	-	1
<i>Charitable activities</i>			
Membership	171	63	234
BSI-CIPN	170	47	217
Partnership work	89	47	136
Congress	576	59	636
Other meetings and events	265	63	327
Journals	260	70	331
Training	76	39	115
Education and Careers	126	16	141
Diversity and inclusion	1	-	1
National Research support	114	-	114
Policy and Public Affairs	162	31	194
Public engagement	59	31	90
Communications	138	86	224
International Work	40	-	40
Total	2,278	552	2,830

Notes to the financial statements

5 Total expenditure (continued)

Support costs are as follows:

	2024 £'000	2023 £'000
Staff costs	235	220
Premises costs	43	38
Depreciation	22	22
IT and electronic communications costs	81	90
Other	126	108
Recruitment fees	25	11
Governance costs (note 6)	19	18
Total	552	507

Support costs have been allocated based on time spent by departments supporting the various activities.

	Unrestricted funds £'000	Designated funds £'000	Restricted funds £'000	2023 £'000
<i>Raising funds</i>				
Investment management fees	35	-	-	35
Fundraising	12	-	-	12
<i>Charitable Expenditure:</i>				
Membership	241	-	-	241
BSI-CIPN	80	-	-	80
Partnership work	147	-	-	147
Congress	720	-	-	720
Other meetings and events	289	-	-	289
Journals	370	-	-	370
Training	35	59	-	94
Education and Careers	64	136	-	200
Diversity and inclusion	2	-	-	2
National Research support	-	-	129	129
Policy	21	-	158	179
Public engagement	73	-	38	111
Communications	221	-	-	221
International work	23	-	-	23
Total	2,333	195	325	2,853

Notes to the financial statements

6 Governance costs

	2024	2023
	£'000	£'000
Auditor's remuneration - audit	18	14
Auditor's remuneration - other	1	4
Total	19	18

7 Net income before gains (losses) on investments

	2024	2023
	£'000	£'000
This is stated after charging:		
Staff costs (note 9)	1,224	1,229
Depreciation	34	30
Auditor's remuneration - audit	18	14
Auditor's remuneration - other	1	4

Notes to the financial statements

8 Staff costs

Staff costs during the year were as follows:

	2024 £'000	2023 £'000
Wages and salaries	1,056	1,054
Social security costs	115	122
Pension costs	53	53
Total	1,224	1,229

The average monthly number of employees during the year was as follows:

Within wages and salaries there are termination payments of £39k (2023: £nil).

	2024	2023
Direct charitable activities	16	15
Administration of the charity	2	3
	18	18

Number of employees whose annualised emoluments fall within following ranges for the year:

	2024	2023
£60,001 - £70,000	-	1
£70,001 - £80,000	1	-
£80,001 - £90,000	1	2
£90,001 - £100,000	1	-
£140,001 - £150,000	1	1

Pension contributions for these employees were £24,794 (2023 - £22,601).

The number of staff for whom retirement benefits are accruing under money purchase pension schemes amounted to 19 (2023 – 19).

The Society considers its key management personnel comprise the Trustees and the Senior Management Team (SMT). The Trustees provide their time free of charge. The total remuneration, employer's national insurance contributions, benefits and pensions paid to the SMT was £513,859 (2023 - £524,335).

The relevant staff costs have been included in the costs of charitable activities. The gender split in the society workforce is 78% female 22% male (2023: 67% female 33% male). All roles are evaluated and paid in accordance with external benchmarking irrespective of gender.

9 Trustees' remuneration

No trustees received any remuneration for his or her services during the year (2023 – none). During the year expenses totalling £3,551 (2023 - £6,933) were reimbursed to 8 trustees (2023 – 14). In addition £3,160 was paid for travel and accommodation costs on behalf of trustees (2023: £9,293).

In May 2024 one trustee was awarded a career enhancing grant of £3,210. One trustee was paid £500 for his role in delivering part of the Immunology in Clinical Practice training course.

Notes to the financial statements

10 Tangible assets of the Group and charity

	Website £'000	Computer equipment £'000	Total £'000
Cost or valuation			
At 1 July 2023	56	33	89
Additions	-	-	-
Disposals	-	(29)	(29)
At 30 June 2024	56	4	60
Depreciation			
At 1 July 2022	9	27	36
Charge for the year	11	4	15
Eliminated on disposal	-	(29)	(29)
At 30 June 2024	20	2	22
Net book value			
At 30 June 2024	36	2	38
At 1 July 2023	47	6	53

11 Intangible assets of the Group and charity

	IT software £'000	Total £'000
Cost or valuation		
At 1 July 2023	93	93
Additions	-	-
Disposals	-	-
At 30 June 2024	93	93
Depreciation		
At 1 July 2023	14	14
Charge for the year	18	18
Eliminated on disposal	-	-
At 30 June 2024	32	32
Net book value		
At 30 June 2024	61	61
At 1 July 2023	93	93

Construction of a new CRM system was completed during the year.

Notes to the financial statements

12 Investments

	Group		Charity	
	2024	2023	2024	2023
	£'000	£'000	£'000	£'000
Market value at 1 July 2023	3,286	4,029	3,286	4,029
Disposals proceeds	(1,075)	(1,669)	(1,075)	(1,669)
Realised gains/(losses)	(3)	14	(3)	14
Additions at cost	501	933	501	933
Unrealised gains	343	(21)	343	(21)
Market value at 30 June 2024	3,052	3,286	3,052	3,286
Cash held with investment managers	19	13	19	13
Investment in UKPIN	-	-	7	7
Total investments	3,072	3,299	3,079	3,306

Total Group investments includes £100 investment in subsidiary.

	Group		Charity	
	2024	2023	2024	2023
	£'000	£'000	£'000	£'000
At 30 June 2024 the listed investments comprised the following:				
UK equities	715	816	715	816
Overseas equities	1,781	1,779	1,781	1,779
Investment instruments	556	691	556	691
Total	3,052	3,286	3,052	3,286
Historical cost of listed investments	2,324	3,317	2,324	3,317

Investments representing more than 5% of the total market value of the portfolio of listed investments are as follows:

	Cost	Market value	Portfolio
	2024	2024	%
	£'000	£'000	
Volare Offshore sterling fixed interest fund Z GBP (formerly Aberdeen Standard Capital Offshore Fixed Interest Fund Institutional)	210	191	6.19%

12 Investments (continued)

Investment in subsidiary undertaking

The Society has two wholly owned trading subsidiaries. A summary of their trading results are shown below.

BSI Trading Limited is incorporated in England and Wales, registered number 01021739. Its registered office is 9 Appold Street London EC2A 2AP. The principal activity of the company is the management of corporate membership, sponsorship, exhibition and other trading activities for the Society.

The Society become sole member of United Kingdom Primary Immunodeficiency Network (UKPIN) on 20 December 2022 and accordingly on that date UKPIN became a subsidiary of the group. During the year UKPIN transferred £175k to the Society being most of its net assets on the acquisition date.

UKPIN is incorporated in England and Wales, registered number 09273983. Its registered office is 9 Appold Street, London EC2A 2AP. The principal activity of the company was the advancement of health among those with primary immunodeficiency disorders and advancing education in PID and related subjects. These activities have been transferred to the Society's Clinical Immunology Professional Network (BSI-CIPN).

A summary of the results of the subsidiaries is shown below:

	2024			2023		
	BSI Trading Limited £'000	UKPIN £'000	Total £'000	BSI Trading Limited £'000	UKPIN £'000	Total £'000
Turnover	565	-	565	576	-	576
Operating costs	-	-	-	-	-	-
Operating profit	565	-	565	576	-	576
Administration costs	(51)	(2)	(53)	(87)	(5)	(92)
Profit(loss) for the financial period	514	(2)	512	489	(5)	484
Distribution to parent charity	(514)	-	(514)	(489)	(175)	(484)
Retained in subsidiary	-	(2)	-	-	(180)	-

The assets and liabilities of the subsidiaries were:

Assets	601	-	601	600	2	602
Liabilities	(601)	-	(601)	(600)	-	(600)
Net assets	-	-	-	-	2	2

Notes to the financial statements

13 Debtors

	Group		Charity	
	2024	2023	2024	2023
	£'000	£'000	£'000	£'000
Trade debtors	127	389	72	425
Prepayments and accrued income	262	303	262	303
VAT receivable	17	-	17	-
Amount owed by subsidiary undertaking	-	-	588	497
Total	406	692	939	1,225

14 Creditors

	Group		Charity	
	2024	2023	2024	2023
	£'000	£'000	£'000	£'000
Trade creditors	142	74	92	74
Other taxes and social security costs	30	40	30	40
VAT payable	-	9	-	9
Other creditors	133	177	133	177
Accruals and deferred income	268	504	255	488
Total	573	804	510	788

Included within the above is deferred income as set out below:

	Group	Charity
	2024	2024
	£'000	£'000
Deferred income brought forward at 1 July	459	422
Additional income deferred during the year	181	169
Brought forward funds released in the year	(459)	(422)
Deferred income carried forward at 30 June	181	169

Deferred income comprises advance payments of journal royalties and memberships fees.

Notes to the financial statements

15 Restricted funds

	At 1 July 2023	Income	Expenditure	At 30 June 2024
Meeting funds	34	-	(34)	-
BSI-CIPN	178	-	-	178
Ageing and immunity	28	68	(96)	-
SIREN	-	8	(8)	-
STRAVINSKY	14	-	(12)	2
Visiting Scholar and Jonathan Sherrard Awards	4	-	-	4
mRNA project	-	50	(50)	-
PITCH	-	7	(7)	-
Nursing training	-	62	-	62
Total	258	194	(206)	246

Meeting funds

Donations to the Society by individuals to promote certain immunological issues.

BSI-CIPN

Funds transferred from UKPIN upon the merger to be used to promote and support clinical immunology through the BSI-CIPN

Ageing and immunity

The CARINA (Catalyst Reducing ImmuNe Ageing) Network is a new collaborative network for researchers working on the immune system throughout the life course. The BSI has a leading role in supporting the network through provision of project management, events support, communications expertise and patient and public involvement (PPI).

SIREN

Recruitment, facilitation and reporting of findings from Patient and Participant Involvement workshops for the SIREN project funded by the UK Health Security Agency.

STRAVINSKY

Funds to support a 2 year study aiming to establish if antibody testing can identify who remains at greatest risk of severe COVID-19 infection after vaccinations.

PITCH

The PITCH (Protective Immunity from T Cells in Healthcare workers) is a project seeking to understand the role of T cell immunity in protection against COVID-19 in healthcare workers. The BSI is supporting the project by leading its participant Involvement Panel to ensure the research is relevant, suitable and valuable.

Nursing training

Project to develop and provide immunology training for nurses. This is funded by CSL Behring UK Limited and Biocryst US Sales Co LLC.

Notes to the financial statements

15 Restricted funds (Continued)

UK-CIC

A grant for the BSI support provided to the UK Coronavirus Immunology Consortium (UK-CIC) to understand the immunology of SARS-CoV-2 and COVID-19.

Vaccine taskforce

Funding from the European Federation of Immunological Societies (EFIS) for the EFIS Vaccine Taskforce work led by the BSI.

Immunogenicity project

Immunogenicity measures in vaccine development and decision making programme funded by Merck Sharp & Dohme (UK) Limited.

UK Covid Vaccines Research Hub

Central co-ordination hub for COVID-19 immunology research investments and outcomes funded by UKRI via the National Core Studies programme.

Visiting Schloar and Jonathan Sherrard Awards

Funds to support members for periods of training in academic or clinical centres to further their knowledge of primary immunodeficiencies.

	At 1 July 2022 £'000	Income £'000	Expenditure £'000	At 30 June 2023 £'000
Meeting funds	34	-	-	34
BSI-CIPN	-	178	-	178
Autoimmunity	12	-	(12)	-
UK-CIC	-	63	(63)	-
Vaccine taskforce	1	25	(26)	-
UK Covid Vaccines research	61	63	(124)	-
Ageing and immunity	-	68	(40)	28
SIREN	8	9	(17)	-
Immunogenicity project	27	15	(42)	-
STRAVINSKY	-	15	(1)	14
Visiting Scholar and Jonathan Sherrard Awards	-	4	-	4
Total	143	440	(325)	258

16 Designated funds

	At 1 July 2023	Designated in year	Utilised / released	At 30 June 2024
Long term sustainability	98	-	-	98
Training	91	-	(76)	15
Career development programme	364	-	(77)	287
Total	553	0	(154)	399

Notes to the financial statements

16 Designated funds (Continued)

Long term sustainability

The long term sustainability fund provides resources for investing in the financial sustainability of the charity over the next five years.

Training

Funding for the creation and development of a new surplus generating training function within the BSI.

CRM project

The CRM project fund provides resources to develop and implement a new CRM system together with an upgrade to the BSI website

Career development programme

The Career development programme will fund a significant expansion in the careers support the BSI offers to our members. This includes two main streams: our career-enabling activities and our career-enhancing activities.

17 Analysis of net assets between funds

				2024
	Unrestricted funds	Designated funds	Restricted funds	Total funds
Group	£'000	£'000	£'000	£'000
Tangible fixed assets	38	-	-	38
Intangible assets	61	-	-	61
Investments	3,072	-	-	3,072
Current assets	494	399	246	1,139
Current liabilities	(573)	-	-	(573)
Total Funds	3,091	399	246	3,737

				2024
	Unrestricted funds	Designated funds	Restricted funds	Total funds
Charity	£'000	£'000	£'000	£'000
Tangible fixed assets	38	-	-	38
Intangible assets	61	-	-	61
Investments	3,079	-	-	3,079
Current assets	432	399	246	1,077
Current liabilities	(510)	-	-	(510)
Total Funds	3,099	399	246	3,745

Notes to the financial statements

17 Analysis of nets assets between funds (Continued)

The total unrealised gains (losses) as at 30 June 2023 constitutes movements on revaluation and are as follows:

	2024 £'000	2023 £'000
Unrealised gains (losses) included above:		
On investments	1,305	962
Total unrealised gains (losses) at 30 June	1,305	962
Reconciliation of movements in unrealised gains (losses)		
Unrealised gains at 1 July	962	983
Less: in respect to disposals in the year	-	-
	962	983
Add: net gains (losses) arising on revaluation arising in the year	343	(21)
Total unrealised gains (losses) at 30 June	1,305	962

	Unrestricted funds £'000	Designated funds £'000	Restricted funds £'000	2023 Total funds £'000
Group				
Tangible fixed assets	53	-	-	53
Intangible fixed assets	79	-	-	79
Investments	3,299	-	-	3,299
Current assets	458	553	258	1,269
Current liabilities	(804)	-	-	(804)
Total Funds	3,085	553	258	3,896

	Unrestricted funds £'000	Designated funds £'000	Restricted funds £'000	2023 Total funds £'000
Charity				
Tangible fixed assets	53	-	-	53
Intangible fixed assets	79	-	-	79
Investments	3,306	-	-	3,306
Current assets	440	553	258	1,251
Current liabilities	(788)	-	-	(788)
Total Funds	3,090	553	258	3,901

Notes to the financial statements

18 Share capital

The company is limited by guarantee and therefore has no share capital. Each member's liability is limited to £1.

19 Related party transactions

Matthew Siggins was awarded a Career enhancing grants of £3,210 in May 2024 for two weeks of highly specialised training in lymphatic immunology.

James Brewer was paid £500 for his role in delivering the immunology in clinical practice training.

In 2022 The Kennedy Trust for Rheumatology Research (charity No. 260059) provided £5,000 sponsorship for the BSI awards. Professor Tracy Hussell is a trustee of this charity.

There were no other related party transactions that required disclosure in the current financial period (2023: none).

Notes to the financial statements

20 Comparative consolidated statement of financial activities

	Unrestricted funds			
	General £'000	Designated £'000	Restricted £'000	2023 £'000
Income from:				
Donations	-	-	425	425
Investments	132	-	-	132
Charitable activities				
Membership	162	-	-	162
BSI-CIPN	105	-	-	105
Partnership work	105	-	15	120
Congress	643	-	-	643
Meetings and events	83	-	-	83
Journals	749	-	-	749
Training	28	-	-	28
Total income	2,007	-	440	2,447
<i>Raising funds</i>				
Investment Management Fees	35	-	-	35
Cost of raising funds	12	-	-	12
<i>Charitable activities</i>				
Membership	241	-	-	241
BSI-CIPN	80	-	-	80
Partnership work	147	-	-	147
Congress	720	-	-	720
Meetings and events	289	-	-	289
Journals	370	-	-	370
Training	35	59	-	94
Education and Careers	64	136	-	200
Diversity and inclusion	2	-	-	2
National Research support	-	-	129	129
Policy and Public Affairs	21	-	158	179
Public engagement	72	-	38	110
Communications	221	-	-	221
International work	23	-	-	23
Total expenditure	2,333	195	325	2,853
Net income (expenditure) before gains (losses) on investments and transfers	(326)	(195)	115	(406)
Net gains/(losses) on investments	(7)	-	-	(7)
Transfers between funds	23	(23)	-	-
Net income	(310)	(218)	115	(413)
Reconciliation of funds:				
Funds brought forward	3,396	771	143	4,310
Funds carried forward	3,086	553	258	3,897

Notes to the financial statements

21 Charity statement of financial activities

	Unrestricted funds			Total	Total
	General funds	Designated funds	Restricted funds	2024	2023
	£'000	£'000	£'000	£'000	£'000
Income from:					
Grants and donations	-	-	191	191	425
Investments	115	-	-	115	132
Charitable activities					
Membership	172	-	-	172	162
BSI-CIPN	44	-	-	44	3
Partnership work	29	-	-	29	38
Congress	332	-	3	335	300
Meetings and events	38	-	-	38	49
Journals	844	-	-	844	749
Training	-	-	-	0	12
Gift Aid and recharge from BSI Trading Limited	564	-	-	564	575
Total income	2,137	-	194	2,331	2,445
Expenditure on:					
Raising funds					
Investment management fees	29	-	-	29	35
Cost of raising funds	1	-	-	1	12
Charitable activities					
Membership	201	-	33	234	242
BSI-CIPN	217	-	-	217	80
Partnership work	136	-	-	136	147
Congress	636	-	-	636	720
Meetings and events	327	-	-	327	289
Journals	331	-	-	331	720
Training	38	77	-	115	94
Education and Careers	64	77	-	141	200
Diversity and inclusion	1	-	-	1	2
National Research support	-	-	114	114	129
Policy and Public Affairs	143	-	50	193	171
Public engagement	80	-	9	89	111
Communications	221	-	-	221	221
International work	40	-	-	40	23
Total expenditure	2,466	154	206	2,826	3,197
Net income (expenditure) before gains (losses) on investments and transfers	(329)	(154)	(12)	(495)	(752)
Net gains/(losses) on investments	340	-	-	340	(7)
Net income/(deficit)	11	(154)	(12)	(155)	(759)
Reconciliation of funds:					
Funds brought forward	3,090	553	258	3,901	4,310
Funds carried forward	3,101	399	246	3,746	3,551

Board of Trustees

Position	Trustee	Date of appointment / resignation
Previous		
Early Career Trustee	Dr Emma Chambers	Resigned June 2024
Co-opted Trustee	David Pemberton	Appointed July 2023 Resigned February 2024
Early Career Trustee	Dr Emma Chambers	Resigned July 2022

Current		
President	Professor Tracy Hussell	Appointed December 2022
Treasurer	Dr Fiona Culley	Re-appointed July 2021
Chair of Forum	Professor James Brewer	Appointed January 2023
Clinical Research Secretary	Professor Colin Dayan	Re-appointed June 2024
Co-opted Trustee	Robert Davies	Re-appointed July 2020
Trustee	Professor Deborah Dunn-Walters	Re-appointed July 2023
Co-opted Trustee	Dr Edith Hessel	Appointed January 2020
Trustee	Professor Teresa Lambe	Appointed January 2023
Co-opted Trustee	James Lowe	Re-appointed June 2023
Trustee	Dr Carolyn Nielsen	Appointed July 2024
Early Career Trustee	Dr Matthew Siggins	Appointed July 2022
Co-opted Trustee	Dr Sinisa Savic	Appointed July 2022
Trustee	Dr Divya Shah	Re-appointed July 2023
Trustee	Dr Jessica Strid	Appointed July 2023

Leadership

Board and Committee meetings and attendance

All Trustees are expected to attend each Board meeting and each Committee meeting for which they are members, unless there are exceptional circumstances preventing them from participating. The table below shows the attendance at Board and other BSI committees.

Trustees	Board	BSI-CIPN Steering Group	Congress Committee	Finance Sub Committee	Membership Representative Forum	Nominations Committee
Professor Tracy Hussell	4/4	-	3/3	-	3/4	1/1
Dr Fiona Culley	4/4	-	1/4	4/4	-	-
Professor James Brewer	3/4	-	-	-	4/4	1/1
Professor Colin Dayan	2/4	-	1/4	-	-	-
Dr Emma Chambers	3/4	-	-	-	-	-
Robert Davies	4/4	-	-	-	-	1/1
Professor Deborah Dunn-Walters	4/4	-	-	-	-	-
Dr Edith Hessel	4/4	-	1/1	-	-	1/1
Professor Teresa Lambe	2/4	-	-	-	-	1/1
James Lowe	4/4	-	-	4/4	-	-
David Pemberton	2/2	-	-	2/2	-	-
Dr Matthew Siggins	4/4	-	-	-	-	-
Dr Sinisa Savic	3/4	4/4	-	-	-	-
Dr Divya Shah	4/4	-	-	-	-	-
Dr Jessica Strid	3/4	-	-	-	-	-

Senior Management Team

Name	Position
Dr Doug Brown	Chief Executive
Otto Balsiger	Director of Finance, Membership and Publishing
Dr Jennie Evans	Director of External Affairs
Jane Sessenwein	Director of Events & Training

Principal professional advisers

Name	Advisor
Bankers	Bank of Scotland 14/16 Cockspur Street London EC2V 6DL
External auditors	Moore Kingston Smith LLP 9 Appold Street London EC2A 2AP
Investment advisers	LGT Wealth (formerly abrdn) 14th Floor 30 St Mary Axe London EC3A 8BF
Solicitors	Russell Cooke LLP 2 Putney Hill London SW15 6AB

Committees

Nominations Committee

Members	
Professor Tracy Hussell	Chair, BSI President
Robert Davies	BSI Co-opted Trustee
Professor James Brewer	Trustee
Dr Edith Hessel	Trustee
Professor Teresa Lambe	Trustee
Dr Doug Brown	BSI CEO (observer)

Finance Sub Committee

Members	
Dr Fiona Culley	BSI Treasurer
James Lowe	Co-opted Trustee
Dr Doug Brown	BSI Chief Executive
Otto Balsiger	BSI Director of Finance, Membership and Publishing

Membership Representative Forum

Members	
Professor James Brewer	Chair
Professor Tracy Hussell	BSI President
Dr Colin Dayan	Clinical Research Secretary
Dr Sophie Rutschmann	Education & Careers Secretary
Professor Matthias Eberl	Public Engagement Secretary
Dr Doug Brown	BSI Chief Executive
Dr Jennie Evans	BSI Director of External Affairs
Dr Patrick Cao	Regional Representative - Scotland
Dr Julia Makinde	Regional Representative - England
Dr Dessi Malinova	Regional Representative - Northern Ireland
Dr Simone Cuff	Regional Representative - Wales
Dr Hannah Bradford	Early Career Representative
Dr George Robinson	Early Career Representative
Anna Andrusaite	Early Career Representative
Dr Edoardo Prediletto	Early Career Representative
Dr Chidi Ubachukwu	PhD Representative
Dr Jhanna Kryukova	PhD Representative
Dr Chloe Pyle	Industry Representative
Dr Gareth-Rhys Jones	Clinical Representative
Dr Winnie Ip	Clinical Representative
Dr Rebecca McLean	Veterinary Representative

Committees

Congress Committee

Name	Position
Professor Mark Coles	BSI Congress Secretary
Professor Tracy Hussell	BSI President
Dr Fiona Culley	BSI Treasurer
Dr Colin Dayan	BSI Clinical Research Secretary
Dr Edith Hessel	Member
Dr Daniel O'Connor	Early Career Representative
Dr Graham Cook	Member
Dr Helen McGettrick	Member
Dr Henry McSorley	Member
Dr James Harker	Member
Dr James Thaventhiran	Clinical member
Dr Laura Rivino	Member
Dr Margarita Dominguez	Member
Dr Sandra Sacre	Member
Jane Sessenwein	BSI Director of Events & Training

BSI-CIPN Steering Group

Name	Position
Dr Sinisa Savic	Chair
Dr Suzy Elcombe	Deputy Chair
Dr Catherine Stroud	Membership Lead
Sarah Denman	Pharmacy Representative
Dr Lisa Devlin	Industry Liaison
Jill Edmonds	Nursing Representative
Dr Emma Callery	Healthcare Scientist Representative
Professor Alex Ritcher	Guidelines Lead
Dr Patrick Yong	Training & Education Lead
Dr Manisha Ahuja	Postgraduate Doctor in Training Representative
Dr Leman Mutlu	Patitent Group Liaison
Dr James Thaventhiran	Conference Lead (Co-opted member)
Dr Austen Worth	Paediatric Representative and PID Registry Representative (Ex-officio member)
Dr Claire Bethune	CRG Representative (Ex-officio member)
Dr Sarah Goddard	QPIDS Representative (Ex-officio member)
Dr Tomaz Garcez	BSACI Representative (Ex-officio member)
Dr Doug Brown	BSI Chief Executive

Journals

Clinical and Experimental Immunology - Editorial Team

Name	Position
Professor Leonie Taams	Editor-in-Chief
Professor Angelo Manfredi	Section Editor - autoimmunity
Professor Tanja de Gruij	Section Editor - cancer immunity
Professor Ciriaco Piccirillo	Section Editor - immune-mediated inflammatory diseases
Dr Cindy Ma	Section Editor - immunodeficiency
Dr Daniel Douek	Section Editor - infectious diseases and vaccines
Professor Xiao-Ning Xu	Section Editor - infectious diseases and vaccines
Professor Sandra Amor	Section Editor - neuroimmunology

Immunotherapy Advances - Editorial Team

Name	Position
Professor Tim Elliot	Editor-in-Chief
Associate Professor Marianne Boes	Deputy Editor
Professor Yiwei Chu	Associate Editor
Dr Stephanie K Dougan	Deputy Editor
Associate Professor Menno van Zelm	Associate Editor

Discovery Immunology - Editorial Team

Name	Position
Professor Simon Milling	Editor-in-Chief
Dr Sophie Acton	Senior Editor
Dr Philip Ahern	Senior Editor
Dr Florent Ginhoux	Senior Editor
Dr Emily Gwyer Findlay	Senior Editor
Dr Lai Guan Ng	Senior Editor
Professor Francisco J. Quintana	Senior Editor
Dr Meera Ramanujam	Senior Editor

Regional and Affinity groups

Affinity Groups

Group	Position	Member
Autoimmunity Affinity Group	Chair	Professor Lucy Walker
	Secretary	Dr Kathryn Steel
	Treasurer	Dr James Pearson
Comparative Veterinary Immunology Group	Chair	Wilhelm Gerner
	Secretary	Dr Lindert Benedictus
	Treasurer	Dr Kate Sutton
Immunometabolism Affinity Group	Co-Chair	Dr Laura Pallett
	Co-Chair	Dr Linda Sinclair
	Secretary	Dr Sarah Dimeloe
	Treasurer	Dr Anna Schurich
Immunosenescence Affinity Group	Chair	Dr Sian Henson
	Secretary	Dr Natalie Riddell
	Treasurer	Dr Catarina Henriques
Infection and Immunity Group		
Inflammation Affinity Group	Chair	Professor Peter Barlow
	Treasurer	Dr Joanne Konkel
	Communications	Dr Jack Rivers-Auty
Leukocyte Migration Group	Chair	Dr Myriam Chimen
	Secretary/Treasurer	Dr Graeme O'Boyle
Mathematical Modelling Group	Chair	Dr Grant Lythe
	Secretary	Professor Mark Coles
	Treasurer	Dr Hashem Koohy
Neuroimmunology Group	Chair	Dr Yvonne Dombrowski
	Secretary	Dr Sarosh Irani
Teaching Affinity Group	Co-chair	Professor John Currow
	Co-chair	Dr Nigel Francis
	Secretary	Dr Owen Kavanagh
	Treasurer	Dr Becky Aicheler
Tumour Immunology Affinity Group	Chair	Professor Benjamin Willcox
	Secretary	Dr Seth B. Coffelt
	Treasurer	Professor Awen Gallimore
Vaccine Affinity Group	Chair	Dr Bernardo Villarreal-Ramos
	Secretary	Dr Julia Tree
	Treasurer	Dr Dirk Werling

Regional and Affinity groups

Regional Groups

Group	Position	Member
Aberdeen Immunology Group	Chair	Dr Isabel Crane
	Treasurer	Dr Janine Coombes
Bristol Immunology Group	Chair	Dr Gareth Jones
	Secretary	Dr Dronwen Burton
	Treasurer	Dr Lindsay Nicholson
Cambridge Immunology Group	Chair	Dr Brian Ferguson
	Secretary/Treasurer	Dr Louise Boyle
East Anglia Immunology Group	Secretary	Dr Anastasia Sobolewski
	Treasurer	Dr Cristina Fanutti
Edinburgh Immunology Group	Co-Chair	Dr Rebecca Gentek
	Co-Chair	Dr Laura McCulloch
	Secretary	Dr Matthew Burgess
	Secretary	Dr Tovah Shaw
	Treasurer	Dr Sean Wattagedera
Greater Manchester Immunology Group	Chair	Dr Doug Dyer
	Secretary	Dr Andrew Greenhaigh
Immunology North East	Chair	Dr Kevin Marchbank
	Secretary	Dr Antony Antoniou
	Treasurer	Dr Andy Knight
London Immunology Group	Chair	Dr Laura Pallett
	Secretary	Dr Franze Progatezky
	Treasurer	Dr George Finney
Midlands Immunology Group	Chair	Dr Rebecca Drummond
	Treasurer	Dr Martin Davey
Oxford Immunology Group	Chair	Dr Roel De Maeyer
	Secretary	Dr Elena Mitsi
South Wales Immunology Group	Chair	Dr You Zhou
	Secretary	Dr Rebecca Aicheler
	Treasurer	Dr Ceri Fielding

Regional and Affinity groups

Regional Groups

Group	Position	Member
Tayside Immunology Group	Chair	Professor Simon Arthur
	Secretary	Dr Mahima Swamy
	Treasurer	Dr Shalini Pathak
Ulster Immunology Group	President	Dr Yvonne Dombrowski
	Secretary	Dr Karim Dib
	Treasurer	Dr Rebecca Coll
Wessex Immunology Group	Co-Chair	Professor Jessica Teeling
	Co-Chair	Dr Sarah Buchan
	Secretary	Dr Alison Hill
	Treasurer	Dr Diogo Silva
West of Scotland Immunology Group	Chair	Dr Megan MacLeod
	Secretary	Dr Ed Roberts
	Treasurer	Dr Hannah Scales
Yorkshire Immunology Group	Chair	Dr Gina Doody
	Secretary	Dr Erica Wilson

Accounts



Annual Report 2023

Trustees' Report

For the year ended 30 June 2023

What we do and why it matters

The British Society for Immunology is the UK membership organisation working with scientists and clinicians to forward immunology research and application around the world. Our ambitious and collaborative community consists of over 4,300 immunologists, giving us a powerful voice to advocate on immunological science and health for the benefit of society.

The Society supports its members, students and the wider public to learn more about immunology through disseminating research and providing resources, activities and grants to aid education in this field.

Immunological science underpins many aspects of human and animal health and disease, from communicable disease and vaccination to the management and treatment of many chronic conditions. Through enhancing our knowledge of how the immune system functions for the public benefit, the British Society for Immunology can play a key role in advancing Society's ability to prevent and treat disease.

Our mission

The British Society for Immunology's mission is to support our immunology community in driving scientific discovery and making a positive impact on health.

We accomplish this by:

- Connected community: providing the immunology community with support to establish more connections and enhance collaboration, both within the field, and with other related scientific disciplines and between sectors.
- Championing careers: providing sector leading support to attract and retain talent in immunology.
- Catalysing change: influencing and improving the external environment to enable immunology to thrive and deliver positive outcomes for health.

The Trustees confirm they have referred to the Charity Commission's guidance on public benefit when reviewing the Society's aims and objectives, planning future activities and setting the annual operating plan.

Our strategic objectives

The British Society for Immunology strategy sets our direction and priorities for 2021-2025.

Building on the strong foundations of our past work and guided by our updated vision and mission statements and set of values, this ambitious strategy lays out how we will work with our membership to deliver for the immunology and wider community over the coming years. As the UK's leading charity and scientific society representing the immune research sector, we are confident that we will fulfil this strategy to lead a positive change towards our vision of better health for all through immunology.



Connected community

Our BSI community is at the heart of all we do. Being a member of the BSI means being a member of one of the largest immunology networks in the world. Immunology is a growing field, and the BSI aims to continually develop our activities and the support we provide to members to enable the discipline to flourish. Immunology intersects with numerous research fields, across different sectors, with the involvement of all career grades. Our goal is to bring this ecosystem together into a cohesive whole that fulfils our mission to take immunology forwards faster and more collaboratively.

Membership of the British Society for Immunology brings many benefits. These include discounts to our meetings and to our exceptional BSI Congress, access to a diverse range of grants, bursaries and prizes, free access to our journals and much more. The Society provides tailored support for our community through our highly valued Regional and Affinity Groups, but we are also there to represent immunology to the wider world. Members value our strong voice to speak out with influence and impact on behalf of immunology in policy, public engagement and the media.

At the end of June 2023, we had over 4,300 members who join us from all walks of immunology. From students up to senior levels, they contribute to our work through many different routes, including speaking at our conferences, helping with our public engagement activities and advising on our policy work – our grateful thanks go to our whole immunology community.

In December 2022, over 1,700 immunologists came together in Liverpool and online for our flagship event, BSI Congress 2022. It was an amazing four days of immunology, packed with cutting-edge science, inspiring debates and those all-important opportunities to connect and start new collaborations.



We look forward to welcoming the immunology community to Belfast in December for the 2023 BSI Congress.

Regional and Affinity Groups

The BSI's Regional and Affinity Groups are a key part of the BSI community and are part of our core activity to bring our membership together. The scientific discussions and networking that take place via these Groups are invaluable for the continued development of immunology. Our 17 Regional Groups bring together immunologists within a local community, boosting local research networks. Our 14 Affinity Groups have all been created to focus meetings and discussions on specific areas of immunology and they continue to evolve as immunology expands its reach and knowledge.

Our Groups ran a full programme of activities this year with a huge amount of enthusiasm, dedication and expertise. In total, our Groups hosted 12 in-person conferences and two online events, covering a whole host of topics from the ageing immune system to comparative immunology to inflammation at barrier sites. Collectively, these events attracted over 1,500 delegates and played an important part in our strategy to develop our Regional and Affinity Groups as community-based expert hubs. Our Groups also ran several other activities including in-house seminar series, careers events and public outreach initiatives.

BSI Journals

The BSI's original ethos still lies at the heart of our Society – to disseminate research with the aim of promoting and advancing immunology to foster future innovation. This has been a year of consolidation and growth for our highly respected family of three journals, *Clinical & Experimental Immunology*, *Immunotherapy Advances* and *Discovery Immunology*.

Working with our publishing partner, Oxford University Press, our journals aim to serve the field of immunology through publishing high-quality research articles, reviews, commentaries and short reports from researchers around the globe. We work closely with our Editors-in-Chief and Editorial Boards to take a strategic approach to ensure the continued high-performance of the journals. With our mixed portfolio of both hybrid and fully Open Access journals, the Society is in a strong position to continue to provide for the immunology community's publishing needs for many years to come.

Income generated from our journals provides major financial support for the Society's activities and we are hugely grateful to all our Editorial Board members for their ongoing commitment, and everyone who has contributed to the continued success of our journals, including authors, readers, reviewers and editors.



Our established high quality and translational research journal, *Clinical & Experimental Immunology* (CEI), continues to go from strength to strength, with a robust impact factor of 4.6. This has been a busy year for the journal, led by Editor-in-Chief Leonie Taams, with several high-profile review series to take a deep dive into key topics including human B cells, inborn errors of immunity and therapeutic options for regulatory T cell enhancing approaches. Additionally, CEI's collaboration with the Federation of Clinical Immunology Societies (FOCIS) continues to strengthen with the publication of our series on unconventional T cells in health and disease.

Impact factor

4.6

(2022: 5.732)

Submissions

546

(2022: 537)

9.57

Avg citations
per article

(2022: 10.95)

*Citations are based on articles for previous two years.



Our first fully Open Access journal, *Immunotherapy Advances*, continues its progress to be a globally recognised title that both serves the immunotherapy community and exposes new developments in the field to a wide and diverse readership. Led by Editor-in-Chief, Tim Elliott, Immunotherapy Advances focuses on scientifically rigorous research relating to manipulations of the immune system for the benefit of human and animal health in all disease areas.

This year, the journal has passed the milestones of being accepted for inclusion in both PubMed Central and Scopus, which is a positive step forward as it means that the journal's content is more discoverable and searchable. The journal has also kept its foot on the pedal, publishing several special collections covering topics including immune-related adverse events, adoptive cellular therapies and T cell targeted approaches.



It's been a busy year for *Discovery Immunology* as we officially launched the content in October 2022 with six research and review articles. This new fully Open Access journal, led by Editor-in-Chief Simon Milling, has a broad scope that focuses on new discoveries in cellular and molecular immunology. Over the course of the year, Discovery Immunology has reached several important milestones, including achieving indexing with the Directory of Open Access Journals (DOAJ). We also launched the journal's first special collection, focused on checkpoint blockade.

Our focus for the next year is to continue building the reach and impact of the journal through publishing high-quality articles describing novel mechanisms of the immune response.

Supporting research consortia

Under our updated strategy, a new area of our work has been to support national and topic-specific research consortia efforts relevant to immunology. By championing investment in immunology and a 'team science' approach, we aim to use our skills to support cross-sector collaboration efforts to drive forward immunology research faster and more effectively. We have built on our initial success this year by providing a variety of services to support five national research consortia – National Core Studies Immunity, UK Coronavirus Immunology Consortium, CARINA (Catalyst Reducing ImmuNe Ageing) Network, SIREN (SARS-CoV-2 Immunity and Reinfection EvaluationN) study and STRAVINSKY (Stratification of Clinically Vulnerable People for COVID-19 Risk Using Antibody Testing).



The National Core Studies (NCS) programme was established by the Government Office for Science in summer 2020 to ensure critical questions around COVID-19 could be answered quickly and effectively. The Immunity programme, led by Professor Paul Moss and funded by UK Research and Innovation (UKRI), funded studies that increase our understanding of immunity against COVID-19 and the role that vaccines play in this.

Building on our successful support through the previous 12 months, the BSI continued to run the UK COVID Vaccine Research Hub (www.covidvaccineresearch.org), a highly successful website set up for the public, policymakers and researchers to provide the latest information on COVID-19 vaccine research in the UK. We also ran the Patient and Public Involvement Panel for the consortia, which as well as ensuring the expertise and viewpoints of the public contributors were fed into the research agenda, also included developing a training programme for NCSi researchers and sharing best practice on how to successfully embed PPI in immunology research. Finally, we also supported NCSi researchers in communicating their work to policymakers, the media and the public in an accessible manner to maximise its impact and reach.



The CARINA (Catalyst Reducing ImmuNe Ageing) Network is a project funded by the Medical Research Council and Biotechnology and Biological Sciences Research Council (BBSRC) and supported by the BSI. The network aims to establish a UK-wide inclusive platform to enhance collaboration and foster knowledge exchange around immune ageing as well as increasing the profile of the research area.

This has been a year of growth for the CARINA network, which now has over 90 members and has delivered a number of initiatives to build the network's capacity and output. We have run several in person and virtual all full network meetings, with a particular focus on facilitating cross-sector collaborations and gaining a shared consensus of the key research questions within immune ageing. CARINA's Early Career Forum is at the heart of their activity and have met regularly for spotlight and talks and development discussions. In addition, ECRs have been able to access free training in bioinformatics. CARINA has also successfully brought network members together to formulate innovative collaborative grant proposals focusing on developing biomarkers for immune frailty.

Keeping members informed

The BSI works hard to ensure good communication channels with our members, the wider immunology community and the public informed about our activities and about developments in immunology in the wider world. The popularity of our website continues with 2.11 million page views this year and 1.10 million unique users.

2.11m
page views

1.10m
unique users

BiteSized Immunology, our online resource designed to form a comprehensive guide to the immune system continues to be popular with six of the top ten most read pages. The BiteSized Immunology: Experimental Techniques: Enzyme-linked immunosorbent assay (ELISA) beat the BSI homepage to become the most visited website page of the year attracting 106,422 page views.

Our social media channels continue to grow in importance as a way of engaging with our membership and the wider world at a more immediate level, to interact with our supporters and spread the word about our work and the wonders of immunology. Across all channels, our social media posts were seen over 5.5 million times.

Championing careers

The BSI provides several grant schemes to our members to support their work and their career development. These include a variety of activities – from covering the travel costs to conferences, to providing financial support for carers, support for public engagement initiatives and those that promote diversity and inclusion within immunology. We are very proud of the range of support we have been able to provide to members over the last 12 months.

£230k grants
awarded

313
members
supported

Projects supported through our Equality, Diversity and Inclusion Activity Grant include:

- An EDI summer school
- A project to celebrate black female scientists
- A workshop exploring sex-based differences in the immune system

Career Enhancing Grants

Supporting current and future generations of immunologists throughout their careers is a vital part of our mission. This year has seen our Career Enhancing Grants go from strength to strength to support even more BSI members to reach their career goals. The scheme provides flexible financial support of up to £5,000 to allow individuals to build their skill set and advance their professional development.

**£121k
Grants
funded**

**34 members
supported**

**Generate pilot data
Training courses
Lab visits**

Mentoring scheme

Our highly successful mentoring scheme brings together senior scientists with early career researchers to assist the next generation of immunologist with career development and progression. The popularity of this scheme has flourished in recent years with a steady stream of applicants both mentors and mentees and many stories of successful career progression from past participants.

Clinical immunology training days

We partner with the Association of Clinical Pathologists (ACP) to run clinical immunology training days aimed at medical trainees in immunology and allergy, and immunology clinical scientists preparing to sit the Royal College of Pathologists in immunology exams.

By working together, the ACP and BSI ensure the continuous delivery of these highly valued training sessions, helping to create a new generation of immunology-aware and informed clinicians and clinical scientists across the NHS to improve the care and treatment of patients with immune-mediated disease. This year saw a return to in person training events around the country, complimented with additional online sessions to cover the broad spectrum of the curriculum. The training events themselves are consistently ranked as excellent by attendees who value the targeted content.

Training

This year, as part of our strategy to increase our careers offering, we launched a new training function to provide tailored and innovative training to meet the needs of both immunologists, helping them keep their skills up to date and relevant, and non-immunologists, who want to understand the basics of the discipline to help in their jobs. This year, we launched two training offerings in bioinformatics and PPI training; however, we have lots of plans in the pipeline for additional courses – watch this space for more information!

Bioinformatics

This year, we launched a new training programme in bioinformatics, which has been developed and is delivered by Glasgow Bioinformatic Core. It aims to equip wet-lab immunologists, biologists and other life scientists with the skills and confidence to perform their own bioinformatic data analysis. Bioinformatics is now a potent driver of scientific development and an area where there is currently a significant skills gap within immunology. We offer a range of courses, suitable for complete beginners through to advanced practitioners. Through these highly rated courses, our aim is to provide affordable access and high-quality training in this essential skill to the current and future generations of immunologists.

**95 people
trained**

**Lecture delivery
9.63/10**

**Session content
9.63/10**

Training in Patient & Public Involvement

As part of our work on National Core Studies Immunity, we teamed up with five of our public contributors from that project to co-design an online course for researchers on how to involve the public and patients in their research, and how to better understand the mindset and approach needed for effective and inclusive involvement. During the course, researchers were able to hear directly from PPI representatives as well as allowing for peer-to-peer learning through sharing experiences and case studies of successful involvement.

Confidence in building rapport and relationships with public contributors increased from 48% before the course to 92% afterwards. Similarly, confidence in giving value to patient and public contributors increased from 9% before the course to 93% after the training.

Honorary members

Our honorary membership scheme recognises individuals who have made an outstanding contribution to immunology and/or to the Society. At BSI Congress 2022, we were delighted to award Lifetime Honorary Membership to two members:

- Professor Faith Osier (Imperial College London)
- Professor Ian MacLennan (University of Birmingham)

BSI Immunology Awards 2023

In April 2023, we revealed the winners of our inaugural BSI Immunology Awards. These awards were created to champion the remarkable achievements of individuals and teams working across the spectrum of immunology to drive excellence in our discipline.

We celebrated the awards at our 'Transforming the immunology landscape' event, which was an opportunity for the immunology community to come together to hear about the extraordinary work being undertaken by their peers and discuss future challenges and opportunities across the sector.

Eleven winners in eight categories were announced at a ceremony as part of our 'Transforming the immunology landscape' event. The event was an opportunity for the immunology community to come together to hear about the extraordinary work being undertaken by their peers and discuss the future challenges and opportunities across the spectrum of immunology research and application.



Congratulations to our Winners!

BSI Outstanding Ambassador for Immunology Award –
Professor Danny Altmann, Imperial College London
Dr Victoria Male, Imperial College London

Outstanding Contribution to the BSI Award –
Professor Gary Entrican, University of Edinburgh

BSI Research Excellence Award –
Professor Lucy Walker, University College London

BSI Early Career Research Excellence Award –
Dr George Robinson, University College London

BSI Outstanding Team Award –
Northern Ireland Multiple Sclerosis Research Network,
Queen's University Belfast / Belfast Health and Social Care Trust

BSI Diversity and Inclusion Award –
Tomi Akingbade, University of Cambridge
Dr Donald Palmer, Royal Veterinary College

BSI Public Engagement Award –
Professor Sheena Cruickshank, University of Manchester

BSI Immunology Teaching Excellence Award –
Dr Sophie Rutschmann, Imperial College London
Dr Tom Wilkinson, Swansea University

Catalysing change

Public engagement

Our public engagement work over the last 12 months has focused primarily on vaccines. We have used a wide variety of methods and routes to engage with different communities to understand and answer their questions around vaccination.

Resources for engagement

We have continued to develop a range of engagement resources around vaccines, including updating our highly rated comprehensive 'Guide to COVID-19 vaccinations' and creating an infographic to explain the importance of booster COVID-19 vaccines.

We also significantly updated our 'Guide to childhood vaccinations' which explains how vaccines work and provides latest information on the UK immunisation schedule, along with developing a new infographic about the polio vaccination campaign in London to encourage parents to catch up on their child's vaccines.

We launched a new 'Guide to vaccinations for adults over 65' to inform adults aged 65 and over about the different vaccines they are eligible for in the UK and answer common questions. This guide was developed in partnership with the CARINA Network and is sponsored by the UK SPINE Knowledge Exchange Network.



We've been working with the EFIS Vaccine Task Force members to translate some of our infographics about how vaccines work into different languages, including Turkish, to make information accessible to diverse communities across Europe.

Additionally, our cancer immunotherapy darts activity featured in the 2023 British Science Week activity packs that were shared with primary schools and community groups across the country.

#VaccineConversations

Empowering our members to engage with their family, friends and communities to have meaningful conversations about vaccines has continued to be a core part of our public engagement work. We held our annual online vaccine engagement day and encouraged members to use their expert voices for a day of education and celebration to champion the critical role of vaccines. These conversations from trusted individuals are incredibly important in strengthening public understanding and helping people make informed decisions about vaccination.

This year, we were excited to return to events in person on a more regular basis, using our interactive activities and resources to engage with all ages about the different components of the immune system, the importance of vaccination and herd immunity. We participated in the Cambridge Big Biology to engage with school-aged children and families, the Science Museum 'Lates' aimed at adults over 18 and the Lambeth Country Show to reach communities in London who wouldn't normally engage with immunology.

Supporting our members' public engagement activities

Our public engagement grant scheme had a revamp this year and was renamed the Communication & Engagement grant, offering our members financial support to develop and deliver their own public engagement activities. We funded twelve successful applications, including a public engagement stall at Glastonbury festival around the immune system and gut microbiome, showcasing the importance of immunology in health and disease. The stall interacted with an estimated 1,200 people over the weekend and overall, feedback was very positive with visitors expressing their interest in immunology and microbiome research.

Partnership for maximum impact

To build public trust and confidence in vaccines, it's important that we work with a variety of organisations to increase our reach into different communities. We partnered with the London Borough of Bexley to create short videos featuring BSI members answering common questions about different aspects of childhood vaccinations, which are played in GP surgeries, shared across community groups and featured online. We also supported NHS England with their social media 'fact cards' answering common questions about COVID-19 vaccine boosters targeted for Black African, Black African Caribbean and Asian communities. These were also used to engage local and national community groups, for example shared by the British Islamic Medical Association (BIMA) and mosques in their WhatsApp groups. We also collaborated with NHS England to develop a new animation about routine vaccinations aimed at families. The animation is shared widely on YouTube and social media. Furthermore, we joined IUIS to celebrate International Day of Immunology for which our president featured in a short public-facing video around the theme of "Immunology talks to public health".

We recognise the importance of sharing best practice of public engagement around vaccines and were invited to present at the UK Health Security Agency conference in late October. This key event brought together experts from local government and public health and was an excellent opportunity to showcase the impact our work has had to a large audience.

Training community champions to have effective vaccine conversations

There has never been a more important time for immunologists to engage with the public about vaccinations by listening to and addressing questions and concerns. We expanded our public engagement work around training community champions to have effective conversations about vaccinations. This year, we collaborated with Birmingham City Council on a programme to train 'vaccine champions' within local community groups to have effective conversations with their peers about vaccinations, including COVID-19, childhood, HPV and flu vaccines.


The training was co-designed with the local authorities' public health teams and their residents, addressing specific questions and key concerns raised by participants and their communities. The programme consisted of accessible online sessions for one hour each week over four weeks. The sessions were led by BSI members who have specialist knowledge of vaccines and honed skills in engagement and communication.

The sessions focus on building understanding of how vaccines train the immune system, as well as developing skills in listening to and answering common questions and sometimes complex worries. Sessions are also supported by our public-friendly resources about vaccines that participants can use and signpost people to.

After completing the training, 100% of community champions in Birmingham strongly agreed or agreed that they felt informed and knowledgeable about vaccines as well as confident to have effective conversations about vaccines. Encouragingly, all community champions reported an increase in the number of people they regularly talk to about vaccinations.

Patient and public involvement

Following our delivery of patient and public involvement (PPI) within the UK Coronavirus Immunology Consortium (UK-CIC), we published our experiences as a paper in the journal Research Engagement & Involvement detailing the positive impact of PPI in the UK-CIC. The paper was co-authored with public contributors who worked with us in the PPI panel within UK-CIC and shared our experiences of running the project and lessons learnt. UK-CIC brought together laboratory-based scientists and clinicians with the experience and unique perspectives of patient and public contributors. The PPI panel within UK-CIC provided a platform for regular two-way conversations with researchers to address key questions about the implications of the research as well as discussions about what was important to the public and patient groups.



This year, we continued to support the National Core Studies Immunity programme and led on the PPI element of the project. We hosted a free public webinar about the research being undertaken to study the immune response to COVID-19 boosters, which included opportunity for the public to submit questions they had around COVID-19 vaccines.

We were proud to launch a new report in association with National Core Studies Immunity entitled 'Patient and public involvement in COVID-19 research: bridging the gap between theory and practice'. The report explored the impact of PPI in COVID-19 research with the aim of encouraging more research teams to consider involving patients and the public in their work, and to provide practical examples of how this can be done to great effect. It was produced with substantial contribution from a group of patients, carers and members of the public and described how research teams working as part of National Core Studies Immunity involved patients and the public in their work, as well as what it means to involve public contributors in research more generally.

Policy highlights

This year, the Society has continued to use our powerful voice to advocate for immunological science and health, ensuring the voice of immunologists is heard loud and clear in public debates and that policymakers have access to the latest immunological thinking. With our dynamic approach, working in partnership with BSI members and with our COVID-19 Taskforce, we have played a strong role in both ensuring the expert voice of immunologists is represented in public debate and how the lessons learnt from the COVID-19 pandemic response can be brought to wider areas of health research.

Engaging with stakeholders

Through our policy and public affairs work, we aim to engage with policymakers and stakeholders to ensure the viewpoint and interests of immunologists are represented in public debate. Over the past year, we have:

- Responded to a number of policy consultations on topics including the future of cancer therapies, prevention strategies in healthcare, misinformation and trusted voices, NHS vaccination strategy consultation, and people and skills in STEM
- Participated in a number of Parliamentary events run by the Royal Society of Biology including Voice of Young Science and Parliamentary Links Day
- Seen several of our response themes adopted in the publication of the Cabinet Office's new national biosecurity strategy document, including stepping up surveillance efforts, continuing investment in vaccines and therapeutics, and building and strengthening links with our international partners.
- Seen the House of Commons' Health and Social Care Select Committee's Inquiry on Prevention choose our proposal 'Vaccinations' as a workstream for this inquiry to determine and advise the Government on how the UK can remain at the forefront of global vaccination policy
- Seen the BSI's community vaccine engagement work highlighted in the oral evidence sessions of the House of Commons Digital, Culture, Media and Sport Select Committee's enquiry on 'Misinformation and trusted voices' as an exemplar of why learned societies are valuable partners in the fight against misinformation.
- Had almost 50 parliamentary questions answered on a wide range of topics including Horizon Europe, barriers to pursuing careers in scientific research and support for predictive vaccinology research.
- Our proposal to the National Screening Committee on the benefits of screening for human T-lymphotropic virus type 1 (HTLV) in high-risk populations has led to a wider consultation to explore this proposal further.
- Took part in two roundtable events on MMR vaccination and Horizon Europe

Enablers

To deliver our ambitious strategic aims, we need to maintain the BSI as a sector-leading organisation. We will do this by:


- Creating a larger and more diverse engaged membership
- Embedding quality, diversity and inclusion in all our activities
- Ensuring the Society's financial sustainability

Enabler - membership

Our membership is the foundation of our Society. We are ambitious in what we want to deliver for immunology and for our members. As the discipline of immunology continues to grow and evolve, we aim to evolve too to ensure we engage with, support and are relevant to immunologists from across the spectrum of our community. As the largest professional immunology society in Europe and third largest in the world, we aim to stand shoulder to shoulder with our members to support and champion the discipline of immunology to drive scientific discovery and make a positive impact on health.

To continue supporting our diverse and ever-growing community, we revamped our membership categories in July 2022. Five categories grouping some of the most common areas in which our members work were introduced. We will continue to provide tailored benefits for each career stage of each category.

Our new membership categories showcase the different sectors that encompass our vibrant community. We also expanded the criteria for the Early Career Membership to include anyone in the first seven years from receipt of their PhD. A new category for those retired from full-time employment was also introduced. The BSI continues to offer concessionary discounts and free membership to various groups.



Providing the best service for our members

One of our key aims is to ensure that increase our support and engagement with our members from all sectors and at all career stages. To support this work, this year we carried out a major project to embed a new membership management system to allow us to provide better, more joined up and holistic support and service for our members. Alongside this, we also upgraded our website to increase functionality and accessibility as well as making it easier to navigate. Both projects have now been successfully implemented resulting in a seamless experience for our members to better interaction with our services.

BSI Clinical Immunology Professional Network

Following the successful merger between the British Society for Immunology (BSI) and the UK Primary Immunodeficiency Network (UKPIN) in early 2023, we have established the BSI Clinical Immunology Professional Network (BSI-CIPN) – a new network championing clinical immunology within the BSI.



In combining the expertise of the BSI and UKPIN, the network aims to foster closer links between clinical practitioners and basic scientists and strengthen the voice of clinical immunology in policy and public arenas. The BSI-CIPN will also share best practice through a range of resources and activities, including dedicated events, clinical sessions at BSI Congress, development of clinical guidelines, training provision and much more. By providing this strong platform for UK clinical immunology, our aim is to improve care for patients.

The activities of the network are overseen by the BSI-CIPN Steering Group, chaired by Dr Sinisa Savic, supported by Deputy Chair Dr Suzanne Elcombe. The network welcomes members from all aspects of clinical immunology including clinicians and trainees, nurses, healthcare scientists and pharmacists.

Having spent this year embedding the network within wider BSI activities, we now have an eye on the future and an exciting programme of activities planned for the next 12 months. Watch this space for more details.

Immunology Nursing Competency Framework

In May, we were delighted to publish the first ever competency framework for immunology nursing in the UK to advance patient care and nursing practice. Immunology nursing plays a vital role in the healthcare system, providing essential support to individuals with complex and diverse immune-related conditions, and demanding a highly skilled and competent nursing workforce. By combining underlying immunology knowledge with clinical best practices and the latest therapeutic advances, this framework provides a comprehensive roadmap for mastering the skills and knowledge required in immunology nursing, covering all career grades from newly entering into the speciality to undertaking nurse-led clinics. Our aim is for this framework to be flexible and to empower immunology nurses to stay abreast of advancements while working innovatively to improve standards of care for patients.

BSI-CIPN meeting

To celebrate the launch of the BSI-CIPN, we held a one-day conference in tandem with the BSI Congress to bring together the clinical immunology community on the topic of 'Expanding horizons within clinical immunology: Redefining the scope of clinical practice'. The successful event brought together over 100 professionals working in clinical immunology to discuss diverse topics such as COVID-19 and primary immunodeficiencies, the new UK perioperative anaphylaxis network as well as learning more about the aims and ambitions of the BSI-CIPN.

Immunology News

Members in the UK can receive a printed copy of our quarterly membership magazine, *Immunology News*, with online access around the world. Immunology News amplifies the voice of our membership and highlights how we're supporting our members and representing immunology on a wider stage.



Over the last year editions featured new BSI membership categories, women in immunology, the BSI's new Bioinformatics training courses, BSI and UKPIN merger and the creation of the BSI-CIPN, training community vaccine champions, an international BSI's member's perspective, the 2022 BSI Summer School and the launch of our new journal *Discovery Immunology*.

There were also interviews with the outgoing and new Presidents, Prof Arnie Akbar and Prof Tracy Hussell.

This year also included a recap of highlights from BSI Congress 2022 and highlights from the celebration of the immunology community at the inaugural BSI Immunology Awards.

Corporate members

We would like to thank our corporate members whose continuous support enables us to undertake our work



Enabler - Equality, diversity and inclusion

The BSI wants diversity and inclusion to be at the heart of the ethos of our community. This year, we have continued to build on the promises laid out in our 'Diversity and Inclusion Framework', which outlines our commitment to how we are going to work with our members and community to ramp up our equity, diversity and inclusion work and respond to members' needs. By building on past and ongoing activities, this framework set out our long-term plan of action for diversity and inclusion at the BSI.

This year, we have made significant steps forward in our EDI commitment, carrying out an organisational wide review of how EDI is embedded within our activities and how are staff are supported in delivering these and developing their knowledge of best practice in EDI. We have also engaged much more deeply with our wider membership around understanding their views of the BSI's role in supporting EDI within immunology, what we are doing well and what we could do better. In September, we held two focus groups with a wide cross section of our membership and received some incredibly useful feedback as well as ideas and suggestions for future activities that we are taking forward. Watch this space! We also ran a session at BSI Congress on EDI, highlighting some successful case studies from our Equality, Diversity and Inclusion Activity Grant scheme as well as getting members' feedback on the implementation of our Diversity and Inclusion Framework.

Finally, we have been engaging deeply with the wider scientific community to spread best practice on how we developed our framework and to learn from their experiences of similar activities.

Enabler - Financial sustainability

Income diversification

To deliver our ambitious strategic plans, we need to maintain the BSI as a sector-leading organisation, and one of the crucial enablers to do so is our financial sustainability. While traditionally we have relied heavily on our journal income to fund charitable activities, our shift to bring in new long-term and stable income sources is now well under way. The development of new income streams is never a quick process as there is often a delay between investment and return, requiring the use of reserves. However, our strong reserves have been built up for exactly this purpose – to support the organisation through this transition – and their use is now carefully planned

Consolidating our approach

Last year, we reported on changes to our journals with the aim of moving our financial reliance away from traditional subscription journals to develop a modern publishing portfolio that also meets the needs of our members and wider immunology community. This work is now well underway, and this year saw the growth of our two new Open Access journals, Immunotherapy Advances and Discovery Immunology, which are proving popular additions to the BSI portfolio. Both journals have met key milestones this year on their journey towards gaining an impact factor and stabilising our future journals income.

Our new activity to provide support to wider immunology research efforts is also paying dividends and we have built up a strong reputation within the sector for assisting the smooth running, effectiveness and impact of large research consortia. Prestigious projects we have worked on over the last 12 months include UK Coronavirus Immunology Consortium, SIREN (SARS-CoV-2 immunity and reinfection evaluation) study, National Core Studies Immunity, the CARINA (CATalyst Reducing ImmuNe Ageing) Network and STRAVINSKY (Stratification of Clinically Vulnerable People for COVID-19 Risk Using Antibody Testing). Our participation in this type of funded project continues to be an important source of income while allowing us to meet our wider goal of supporting the national immunology research effort.

New endeavours

This year has seen the launch of several new projects, which fulfil our goals of making a positive contribution to the immunology sector while also diversifying the BSI's income. Chief among these has been the launch of a BSI training function to support immunologists and the wider research community to keep their skills up to date and relevant. Our first training offering on bioinformatics, delivered in partnership with Glasgow Bioinformatic Core, has proved hugely popular, with exceptionally positive feedback, and provides vital training in a growth area for immunology. We also piloted a training course for researchers in public and patient involvement, which we hope to role out further next year. These courses, along with several new offerings in pipeline which particularly focus on the clinical sector, mean the BSI is well on our way to establishing ourselves as a leading training provider in the immunology sector.

We are also enhancing our partnership and sponsorship areas of work with industry, establishing mutually beneficial routes for collaboration to highlight, celebrate and champion the immunology sector, which has been core to our strategic development of this area of work. Notably among these is the launch of our new Immunology Awards ceremony which brings together leaders from across the immunology sector to celebrate the potential of immunology to make positive contributions to wider society and public health.

Structure, Governance and Management

Charitable status and administrative details

The Society was registered as a charity in 1966 (Charity number 1043255) and incorporated in England and Wales as a company, limited by guarantee (Company number 03005933). The Society's registered address is 9 Appold Street, London EC2A 2AP. It has no share capital and the liability of its members is limited to a sum not exceeding £1. The Society's governing document is the Memorandum and Articles of Association, which was amended on 7 December 2016.

It is also a registered charity in Scotland (Charity number SC047367).

Board of Trustees

The Trustees are company directors for the purposes of the Companies Act and charity Trustees for the purposes of the Charities Act 2011. The current trustees, and any past Trustees who served during the year are listed on page 56.

The Trustees are responsible for directing the Society's activities and for overseeing the management of the affairs of the Society, they delegate the day to day management of the organisation to the chief executive and the senior management team. The Board acts on advice and information from regular meetings with the chief executive and the senior management team.

As part of their induction process, Trustees spend some time with the chief executive and senior management team. They are provided a trustee resource pack containing the history of the Society and key information they require to fulfil their duties as Trustee, they are also offered training for new Trustees.

The success of the Society belongs in part to the large number of people who generously volunteer their time to add their experience to our collection of committees, we thank you all.

Finance Sub Committee

The Finance Sub Committee ensures the system of internal control is satisfactory to deliver regulatory compliance, financial probity, value for money, challenge of financial plans, budgets and financial statements, oversight of the annual financial audit, review of investment policy and performance, review of reserves policy, and CEO and staff remuneration.

Nominations Committee

The BSI's Nominations Committee has general oversight concerning the structures and effectiveness of BSI Board of Trustees, committees, advisers and observers. It is also responsible for nominating individuals to represent the views of the BSI on external committees and to identify BSI members to nominate for external awards.

Member Representative Forum

The Membership Representative Forum represents a diverse mix of immunologists from different career stages, backgrounds and geographic locations, it is the BSI's 'think tank' and the place where issues and ideas that are of importance to the Society and its member are raised, discussed and developed.

Congress Committee

The Congress Committee is responsible for the planning and delivery of the BSI's flagship event, BSI Congress, which takes place two out of every three years. It reviews and approves the scientific programme for Congress.

BSI-CIPN Steering Group

The BSI-CIPN Steering Group directs the activities of the BSI-CIPN. The group consists of both elected (from the BSI-CIPN members) and co-opted immunology professionals (chosen because of their roles in other key organisations).

Group structure

The Society has two wholly owned subsidiaries:

BSI Trading Limited is registered in England and Wales under company registration number 010201739. Its principal activity is to manage the corporate membership, sponsorship, exhibition and other trading activities for the Society.

The United Kingdom Primary Immunodeficiency Network (UKPIN) is a registered charity (1164466) and a company registered in England and Wales (09273983). The principal activity is the advancement and support of clinical immunology, especially the health among those with primary immunology deficiency disorders and advancing education in PID and related subjects. These activities have been transferred to the Society's Clinical Immunology Professional Network (BSI-CIPN).

Financial Performance


The BSI continued our transition period following the changes to our publishing portfolio. The annual net deficit reduced by 35% from £0.63m last year to £0.41m this year. The operating deficit before investments were better than budget.

The BSI recorded its highest ever income reaching £2.45m, 11% higher than 2022.

Income



Publishing income remains the BSI's largest source of income, however it continued to fall from 41% of total BSI income in 2022 to 31% this year. This fall was offset by increases in income from Congress and grants and donations.



Congress 2022 attracted a record number of delegates and increased income from exhibition space hire and sponsorship.

The Society continued our success obtaining funding for our work supporting immunology research. Total grants received were over £0.2m for the second consecutive year. Total donations of £0.21m were received in 2023. This includes £0.18m from UKPIN following the merger with the BSI during the year.

The newly launched BSI-CIPN held its first meeting in December 2022, this attracted over £100k of sponsorship income. It is anticipated that the BSI-CIPN will assist in creating partnerships with industry leading to exciting projects in future years.

In their second year, the BSI funded career enhancing grants of £121k. This continues to be an important source of career support to our members.

Increased sales of exhibition space and sponsorship at Congress helped push BSI Trading Limited to an annual profit of £0.49m (2022: £0.34m). This was gifted to the society.

The United Kingdom Primary Immunodeficiency Network (UKPIN) posted a loss of £5k for the period.

The Society is in a transition period following the reduction in journal income. The Society is focusing on developing new income streams; however, this will require investment from our reserves. During this period, we are forecasting costs to exceed income over the next few years until the new income streams start generating significant levels of income.

Investment policy and performance

The Society operates an investment policy to provide income and generate capital growth. The Society is a long-term investor and the value of its investments remains significant above its original investment.

UK events including the 2022 mini budget, the high level of inflation together with global events such as the Russian invasion of Ukraine created another challenging year for investments.

As planned the BSI commenced our programme of drawdowns from investments as we invest in new sources of sustainable income. During the year £1m was withdrawn from our investments to help meet the BSI's cash requirements.

Funds are invested with abrdn (formerly Aberdeen Standard Chartered) with a long-term objective to generate a capital return of 3% more than inflation over a three year rolling period. As noted above performance was challenging this year resulting in a small net loss of £0.007m (2022: £0.51m gain). The value of the portfolio fell by £0.94m (2021: fall of £0.31m) because of the drawdowns. On 30 June 2023 investments were valued at £3.30m (2022: £4.26m).

The Finance Sub Committee is responsible for reviewing investment performance and policy.

Reserves policy

The BSI operates a risk-based approach to reserves to ensure the BSI holds the most appropriate level of reserves to cover potential risks and to fund invest in new income sources securing the BSI's long term financial health.

The risk register is reviewed annually with monetary values allocated to specific risks. This value is added to the total of restricted and designated funds. A provision for unknown risks (to give cover for those risks of which the society is not yet aware) is then added to produce the required reserves level. The calculation of the required reserves level is performed on an annual basis.

The latest review resulted in total required reserves of £3.78m (2022: £3.76m). On 30 June 2023 total reserves were £3.90m, (2022: £4.31m), this was £0.12m more than the total required reserves. The charity held free reserves (unrestricted reserves less fixed assets) of £2.95m (2022: £3.25m). Details of restricted funds can be found in note 15 of the accounts with details of designated funds in note 16.

Pay policy

The Society's pay policy aims to ensure that all employees are paid at least the market median for their roles with the ability of high performers to move towards the upper quartile.

Salaries, including the Senior Management Team, are reviewed by the Finance Sub Committee with recommendations for the annual pay rise proposed to the wider Board of Trustees for approval as part of the annual budgeting process. The salary of the Chief Executive is reviewed annually by the Board of Trustees.

To increase transparency the Society's is voluntarily reporting its gender pay gap. Calculated in June 2023 the Society's mean gender pay gap is 23% (June 2022: 32%). The pay gap indicates that while 75% of employees are women (2022: 72%), most men are in management roles. The Society employs more women in each of the quartile pay bands.

The Society strongly supports equal pay, with individuals with the same responsibilities being paid the same irrespective of gender.

Risk management

Good risk management is fundamental to the continued work and sustainability of the Society. We identify and manage risks that could adversely impact the achievement of our strategic purpose and determine the calculated risks we need to take to succeed.

The Society operates a formal framework for the management of risk, taking the view that risk can be positive (opportunity) or negative (threat). The Society operates a risk register incorporating strategic, operational and compliance risks, which are informed by the Society's strategic objectives, performance, voice of our stakeholders, regulatory environment and analysis of the external environment.

The Board delegates day-to-day responsibility for risk management to the Senior Management Team, who are responsible for identifying and evaluating risks to their areas and activities implementing appropriate controls for ongoing mitigation and monitoring.

The Financial Sub Committee reviews the management of risk in detail at each meeting and the Board reviews the Society's strategic and compliance risks twice a year.

The principal risks and uncertainties facing the society and the mitigations that we have put in place are as follows:

Risk: short term	Risk response
Development of new surplus generating training function	The Society has performed detailed market analysis and is focussing development of training in areas where demand has been identified. The BSI are working with partners to develop and market courses. Regular review of delegates numbers and experiences are performed to ensure courses are relevant.
Unable to recruit the right people	Upon coming vacant all roles are reviewed to ensure they are relevant, job descriptions are reviewed and updated to ensure they are clear. Roles are benchmarked to market rates and we conduct a transparent and inclusive recruitment process.
Risk: long term	Risk response
Inflation – rising costs	The Society regularly reviews value for money from our suppliers and potential impacts on future sustainability, proposing action as required.
Failure to find new sources of long term sustainable income	The Society is proactively looking for new funding opportunities: ▪ Working with partners and corporate members to develop existing and new sources of income ▪ Developing a programme of training courses with partners including University of Glasgow
Loss of significant devaluation of investments A devaluation in the value of investments would result in a reduction of reserves available to use by the Society. Investments could be impacted by sudden unforeseen global events	The Society ▪ Reviews investment performance during each Financial Sub Committee meeting ▪ Communicates regularly with our investment managers, especially through times of significant volatility

Fundraising statement

Although the Society does not actively fundraise from members, occasional donations are received. The Society applies best practice in the tone of its communications and the accuracy of its data to minimise the pressures on supporters. The Society applies best practice to protect supporters' data, never sells or swaps it and ensures that communication preferences can be changed at any time. The Society commits to react to and investigate any complaints received, to learn from them and improve its service. During the year, the Society received no complaints about its fundraising activities.

Future plans

During 2023-24 the Society will focus on:

Connected community

- Delivering a successful Congress 2023
- Delivering the first two-day BSI-CIPN conference

Championing careers

- Successfully increase the careers support the BSI provides to members

Catalysing change

- Continue and expand the BSI's successful partnership work
- Expanding the BSI's PPI activities through support of and inclusion in national research consortia

Enabler - membership

- Launching targeted marketing campaigns to drive membership growth
- Grow membership of the BSI-CIPN

Enabler - Equality, diversity and inclusion

- Collecting benchmark EDI data on BSI committees and creating a plan to further embed EDI in BSI activities

Enabler - Financial sustainability

- Income diversification is a key priority: expanding current income generating activities and identifying and developing new sources of income

The Senior Management Team and the Trustees continue to assess all significant risks, in the immediate, medium and longer term.

Trustees' responsibilities

The Trustees (who are also directors of British Society for Immunology for the purposes of company law) are responsible for preparing the Trustees' report and financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the Group and Society and of the income and expenditure of the Group and Society for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable to the United Kingdom and Republic of Ireland; and
- make judgements and estimates that are reasonable and prudent;
- state whether applicable United Kingdom Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume the charity will continue in operation.

The Trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the Group and Society and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Group and Society and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.


Each of Trustees confirm that:

- so far as the Trustee is aware, there is no relevant audit information of which the Group and Society's auditor is unaware; and
- the Trustee has taken all steps that he/she ought to have taken as a Trustee in order to make himself/herself aware of any relevant audit information and to establish that the Group and Society's auditor is aware of that information.

This confirmation is given and should be interpreted in accordance with the provisions of s418 of the Companies Act 2006.

The Trustees are responsible for the maintenance and integrity of corporate and financial information included on the Society's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Approved by the Trustees and signed on their behalf by:



Tracy Hussell
BSI President

Date: 18 October 2023

Independent Auditor's Report to the members and trustees of the British Society for Immunology

Opinion

We have audited the financial statements of the British Society for Immunology for the year ended 30 June 2023 which comprise the Group Statement of Financial Activities, the Group and Parent Charitable Company Balance Sheets, the Group Cash Flow Statement and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

give a true and fair view of the state of the group's and the parent charitable company's affairs as at 30 June 2023 and of the group's incoming resources and application of resources, including its income and expenditure, for the year then ended;

have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and have been prepared in accordance with the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 (as amended), regulations 6 and 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended) and the Charities Act 2011.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs(UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

the information given in the trustees' annual report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
the trustees' annual report have been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the group and parent charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the trustees' annual report.

We have nothing to report in respect of the following matters where the Companies Act 2006, the Charities Accounts (Scotland) Regulations 2006 (as amended) and the Charities Act 2011 require us to report to you if, in our opinion:

the parent charitable company has not kept adequate and sufficient accounting records, or returns adequate for our audit have not been received from branches not visited by us; or
the parent charitable company's financial statements are not in agreement with the accounting records and returns; or
certain disclosures of trustees' remuneration specified by law are not made; or
we have not received all the information and explanations we require for our audit; or
the trustees were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies exemption in preparing the Trustees' Annual Report and from preparing a strategic report.

Responsibilities of trustees

As explained more fully in the trustees' responsibilities statement, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the group and parent charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the group or parent charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

We have been appointed as auditor under Section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005, the Companies Act 2006 and Section 151 of the Charities Act 2011 and report to you in accordance with regulations made under those Acts.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below.

Explanation as to what extent the audit was considered capable of detecting irregularities, including fraud

The objectives of our audit in respect of fraud, are; to identify and assess the risks of material misstatement of the financial statements due to fraud; to obtain sufficient appropriate audit evidence regarding the assessed risks of material misstatement due to fraud, through designing and implementing appropriate responses to those assessed risks; and to respond appropriately to instances of fraud or suspected fraud identified during the audit. However, the primary responsibility for the prevention and detection of fraud rests with both management and those charged with governance of the charitable company.

Our approach was as follows:

We obtained an understanding of the legal and regulatory requirements applicable to the charitable company and considered that the most significant are the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 (as amended), regulations 6 and 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended), the Charities Act 2011, the Charity SORP, and UK financial reporting standards as issued by the Financial Reporting Council

We obtained an understanding of how the charitable company complies with these requirements by discussions with management and those charged with governance.

We assessed the risk of material misstatement of the financial statements, including the risk of material misstatement due to fraud and how it might occur, by holding discussions with management and those charged with governance.

We inquired of management and those charged with governance as to any known instances of non-compliance or suspected non-compliance with laws and regulations.

Based on this understanding, we designed specific appropriate audit procedures to identify instances of non-compliance with laws and regulations. This included making enquiries of management and those charged with governance and obtaining additional corroborative evidence as required.

As part of an audit in accordance with ISAs (UK) we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purposes of expressing an opinion on the effectiveness of the group and parent charitable company's internal control.

Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the trustees.

Conclude on the appropriateness of the trustees' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the group and parent charitable company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the group or parent charitable company to cease to continue as a going concern.

Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit report.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Use of our report

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006; and to the charity's trustees, as a body, in accordance with Section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005, and in respect of the consolidated financial statements, in accordance with Chapter 3 of Part 8 of the Charities Act 2011. Our audit work has been undertaken so that we might state to the charitable company's members and trustees those matters which we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to any party other than the charitable company, the charitable company's members, as a body, and the charity's trustees, as a body for our audit work, for this report, or for the opinion we have formed.

Moore Kingston Smith LLP

Date 7 December 2023

Neil Finlayson (Senior Statutory Auditor)
for and on behalf of Moore Kingston Smith LLP, Statutory Auditor

9 Appold Street
London
EC2A 2AP

Moore Kingston Smith LLP is eligible to act as auditor in terms of Section 1212 of the Companies Act 2006.

British Society for Immunology
Consolidated Statement of Financial Activities
Year to 30 June 2023

		Unrestricted funds				
	Note	General funds £'000	Designated funds £'000	Restricted funds £'000	Total 2023 £'000	Total 2022 £'000
Income from:						
Grants and donations	2	-	-	425	425	280
Investments	3	132	-	-	132	151
Charitable activities	4					
Membership		162	-	-	162	160
BSI-CIPN		105	-	-	105	-
Partnership work		105	-	15	120	136
Congress		643	-	-	643	512
Meetings and events		83	-	-	83	59
Journals		749	-	-	749	913
Training		28	-	-	28	-
Total income		2,007	-	440	2,447	2,211
Expenditure on:						
Raising funds						
Investment management fees		35	-	-	35	41
Cost of raising funds		12	-	-	12	30
Charitable activities						
Membership		241	-	-	241	240
BSI-CIPN		80	-	-	80	-
Partnership work		147	-	-	147	133
Congress		720	-	-	720	642
Meetings and events		289	-	-	289	184
Journals		370	-	-	370	370
Training		35	59	-	94	-
Education and Careers		64	136	-	200	198
Diversity and inclusion		2	-	-	2	4
National Research support		-	-	129	129	149
Policy and Public Affairs		21	-	158	179	175
Public engagement		72	-	38	111	118
Communications		221	-	-	221	228
International work		23	-	-	23	28
Total expenditure	5	2,333	195	325	2,853	2,540
Net income (expenditure) before gains (losses) on investments and transfers		(326)	(195)	115	(406)	(330)
Net gains/(losses) on investments	12	(7)	-	-	(7)	(305)
Transfers between funds		23	(23)	-	-	-
Net income/(deficit)		(310)	(218)	115	(413)	(635)
Reconciliation of funds:						
Funds brought forward		3,396	771	143	4,310	4,944
Funds carried forward		3,086	553	258	3,897	4,310

There are no recognised gains or losses other than those recognised above. All activities are continuing.

The notes on pages 37 to 55 form part of these financial statements

British Society for Immunology
Balance Sheet
30 June 2023

		Group		Charity	
		2023	2022	2023	2022
Fixed assets					
Tangible fixed assets	10	53	49	53	49
Intangible assets	11	79	93	79	93
Investments	12	3,299	4,259	3,306	4,259
		3,431	4,401	3,438	4,401
Current assets					
Debtors	13	692	552	1,225	875
Cash at bank and in hand		578	407	25	37
		1,270	959	1,250	912
Liabilities:					
Creditors: amounts falling due within one year	14	(804)	(1,050)	(788)	(1,003)
Net current assets		466	(91)	462	(91)
Net assets		3,897	4,310	3,900	4,310
Funds:					
Unrestricted funds					
General fund		3,086	3,396	3,089	3,423
Designated fund	16	553	771	553	771
		3,639	4,167	3,642	4,194
Restricted funds	15	258	143	258	116
Total		3,897	4,310	3,900	4,310

As permitted by s408 Companies Act 2006, the company has not presented its own income and expenditure statement and related notes. The company's loss for the year was £409,171 (21/22 FY: £631,850).

These financial statements have been prepared in accordance with the provisions applicable to the small companies regime.

These accounts were approved by the Board and authorised for issue on 18 October 2023 and were signed on its behalf by:



Tracy Hussell, President

British Society for Immunology
Consolidated Statement of Cash Flows
30 June 2023

2023 2022
£'000 £'000

Cash flows from operating activities:

Net cash provided by operating activities **(893)** **(765)**

Cash flows from investing activities:

Income from investments	132	151
Purchase of tangible fixed assets	(21)	(40)
Purchase of intangible fixed assets	-	(57)
Proceeds from the disposal of investments	1,669	521
Purchase of investments	(933)	(659)
Net cash used in investing activities	847	(83)

Change in cash and cash equivalents in the year **(46)** **(848)**

Cash and cash equivalents at 1 July 2022 637 1,485

Cash and cash equivalents at 30 June 2023 **591** **637**

Net income for the period (as per the statement of financial activities) **(413)** **(635)**

Adjustments for:

Depreciation charge	30	9
(Gains) losses on investments	7	305
Investment income	(132)	(151)
(Increase) decrease in debtors	(140)	(422)
Increase (decrease) in creditors	(245)	129
Net cash provided by operating activities	(893)	(765)

Analysis of cash and cash equivalents

Cash at bank and in hand	578	407
Cash held by investment managers	13	230
Total cash and cash equivalents	591	637

The notes on pages 37 to 55 form part of these financial statements

Notes to the financial statements

1 Accounting policies

The principle accounting policies adopted, judgements and key sources of estimation uncertainty in the preparation of the financial statements are as follows:

Basis of preparation

The financial statements are prepared on a going concern basis, under the historical cost convention modified to include the recognition of listed investments measured at fair value, which is consistent with the prior year. The financial statements have been prepared in accordance with the Statement of Recommended Practice: Accounting and Reporting by Charities ("The SORP"), the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102) and the Charities Act 2011.

The British Society for Immunology ("The Society") meets the definition of a public benefit entity under FRS 102.

General information

The Society is a charitable company incorporated in England and Wales (company number 03005933) and is a charity registered in England and Wales (charity number 1043255) and registered as a charity in Scotland (charity number SC047367). The Society's registered address is 9 Appold Street, London EC2A 2AP.

Critical accounting judgements and key sources of estimation uncertainty

The preparation of financial statements requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Group and Society accounting policies. In the application of the accounting policies, Trustees are required to make judgements, estimates and assumptions about the carrying value of assets and liabilities that are not readily apparent from other sources. The estimates and underlying assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision only affects that period, or in the period of revision and future periods if the revision affected current and future periods.

In the view of the Trustees, no assumptions concerning the future or estimation uncertainty affecting assets or liabilities at the balance sheet date are likely to result in a material adjustment to their carrying amounts in the next financial year.

Going concern

The financial statements are prepared on a going concern basis which assumes the Society and Group will continue to meet its liabilities as they fall due for a period of at least twelve months from the date of the approval of these accounts. The Trustees are monitoring the post pandemic impact on the Society and Group. This includes regular review of the impact on our members and resulting changes in focus of our activities to support them. Trustees review regular updates on performance against KPIs, rolling forecasts, the risk register and in depth financial reports.

Following the pandemic, the immunology community is busier than ever, attracting new funding to support its essential work to improve public health. This together with the holding of significant levels of cash and investments result in the Trustees considering the Society and the Group to be a going concern.

Notes to the financial statements

Income

All income is recognised once the Society and Group has entitlement to income, it is probable that income will be received and the amount of income receivable can be measured reliably. Income of the Society is, where applicable, included net of Value Added Tax (VAT) and is allocated to the period to which it relates, carrying forward that part of the income relating to future accounting periods.

Investment income is recognised on a receivables basis and when the amount can be measured reliably.

Expenditure

Liabilities are recognised as soon as there is a legal or constructive obligation committing the Society and Group to that expenditure, it is probable that settlement will be required and the amount of obligation can be measured reliably. Expenditure is recognised on an accruals basis as a liability is incurred, inclusive of VAT, which cannot be recovered.

Expenditure is allocated to a particular activity where the cost relates directly to that activity. The cost of overall direction and administration of each activity, known as "support costs" and comprising the salary and overhead costs of the central function is apportioned based on staff time attributable to Support costs also include governance costs, which comprise organisational administration and compliance with constitutional and statutory requirements. The allocation of support and governance costs is analysed in notes 7 and 8.

Employee benefits

Short-term benefits including holiday pay are recognised as an expense in the period in which the service is received.

Termination payments are accounted for on an accruals basis and in line with FRS 102.

The Society contributes to a Group pension scheme, the assets of which are administered by Royal London Plc. They are defined contribution schemes. All contributed costs are accounted for on the basis of charging the cost of providing pensions over the period when the Society and Group benefits from the employees' service. The Society and Group has no further liability under the scheme.

Leasing and hire purchase commitments

Rentals paid under operating leases are charged to the income and expenditure account on a straight line basis over the lease term. The Society holds no assets under finance leases or hire purchase contracts.

Tangible fixed assets

Tangible assets are stated at cost less accumulated depreciation. Cost includes the original purchase price, costs directly attributable to bringing the asset to its working condition for its intended use, dismantling and restoration costs. The minimum threshold is £1,000. Depreciated is provided at 33% in order to write off each asset over its estimated useful life.

Intangible fixed assets

Intangible assets are stated at cost less accumulated amortisation. Cost includes the original purchase price, costs directly attributable to bringing the asset to its working condition for its intended use, dismantling and restoration costs. The minimum threshold is £1,000. Amortisation is provided at 20% in order to write off each asset over its estimated useful life. Assets in the course of construction are not amortised.

Notes to the financial statements

Investments

Investments are a form of basic financial instrument and are initially shown in the financial statements at fair value. Movements in the fair value of investments are shown as net gains and losses in the Statement of Financial Activities.

Profits and losses on the realisation of investments are shown as realised gains and losses in the Statement of Financial Activities. Net gains and losses on investments are calculated between sales proceeds and their opening carrying values or their purchase price if acquired subsequent to the first day of the financial year. Unrealised gains and losses are calculated as the difference between the fair value at the year end and their carrying value. Realised and unrealised investment gains and losses are combined in the Statement of Financial Activities.

The investment in the subsidiary undertaking is included at cost with provision being made for any permanent diminution in value.

Financial instruments

I) Financial assets

Basic financial assets, including trade and other receivables, cash and bank balances, are initially recognised at transaction value and subsequently measured at amortised cost. Other financial assets, including investments, are initially measured at fair value. Financial assets are derecognised when:

- a) the contractual rights to the cash flows of the asset expire or are settled, or
- b) substantially all the risks and rewards of the ownership of the asset are transferred to another party or
- c) despite having retained some significant risks and rewards of ownership, control of the asset has been transferred to another party who has the practical ability to unilaterally sell the asset to an unrelated third party without imposing additional restrictions.

Cash at bank and cash in hand includes cash and short-term highly liquid investments with a short maturity of three months or less.

II) Financial liabilities

Basic financial liabilities, including trade and other payables, are initially recognised at transaction price. Trade payables are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Financial liabilities held at amortised cost comprise all creditors except social security and other taxes and provisions.

Provisions

Provisions are recognised where the Society has a present legal or constructive obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Provisions are measured at the present value or the expenditures expected to be required to settle the obligation.

Notes to the financial statements

Fund accounting

Unrestricted funds are those funds available to the Society and Group for general purposes. They include funds designated by the Trustees for particular purposes where their use remains at the discretion of the Trustees. It is the policy of the Trustees to retain in unrestricted funds, amounts which in their judgement, can help to mitigate the short-term effects of income volatility; and retain as long-term investment funds to generate sufficient income to meet current and future operational activities of the Society.

Restricted funds are those funds available to the Society and Group restricted to a specific purpose or are subject to particular donor imposed conditions. Further information is available in the reserves section of the Trustees' report.

2 Income from grants and donations

	Unrestricted funds £'000	Restricted funds £'000	2023 Total funds £'000	2022 Total funds £'000
Grants	-	217	217	249
Donations	-	208	208	31
Total	-	425	425	280

3 Income from investments and interest

	Unrestricted £'000	Restricted £'000	2023 Total £'000	2022 Total £'000
Listed investments				
Investment Income	131	-	131	151
Bank deposit interest	1	-	1	-
Total	132	-	132	151

4 Income from charitable activities

	Unrestricted funds £'000	Restricted funds £'000	2023 Total funds £'000	2022 Total funds £'000
Member subscriptions	162	-	162	160
BSI-CIPN	105	-	105	-
Corporates and partnership income	105	15	120	136
Congress	643	-	643	512
Meetings and events	83	-	83	59
Journals	749	-	749	913
Training	28	-	28	-
Total	1,874	15	1,889	1,780

Notes to the financial statements

5 Total expenditure

	Unrestricted funds £'000	Designated funds £'000	Restricted funds £'000	2023 Total £'000
<i>Raising funds</i>				
Investment management fees	35	-	-	35
Fundraising	12	-	-	12
<i>Charitable Expenditure:</i>				
Membership	241	-	-	241
BSI-CIPN	80	-	-	80
Partnership work	147	-	-	147
Congress	720	-	-	720
Other meetings and events	289	-	-	289
Journals	370	-	-	370
Training	35	59	-	94
Education and Careers	64	136	-	200
Diversity and inclusion	2	-	-	2
National Research support	-	-	129	129
Policy and Public Affairs	21	-	158	179
Public engagement	73	-	38	111
Communications	221	-	-	221
International Work	23	-	-	23
Total	2,333	195	325	2,853

Allocation of support costs to charitable activities:

	Direct costs £'000	Support costs £'000	2023 Total £'000
<i>Raising funds</i>			
Investment management fees	35	-	35
Cost of raising funds	12	-	12
<i>Charitable activities</i>			
Membership	185	56	241
BSI-CIPN	52	28	80
Partnership work	119	28	147
Congress	664	56	720
Other meetings and events	261	28	289
Journals	290	80	370
Training	66	28	94
Education and Careers	173	27	200
Diversity and inclusion	2	-	2
National Research support	129	-	129
Policy and Public Affairs	135	44	179
Public engagement	83	28	111
Communications	117	104	221
International Work	23	-	23
Total	2,346	507	2,853

Notes to the financial statements

5 Total expenditure (continued)

Support costs are as follows:

	2023 £'000	2022 £'000
Staff costs	220	198
Premises costs	38	30
Depreciation	22	9
IT and electronic communications costs	90	67
Other	108	81
Recruitment fees	11	0
Governance costs (note 6)	18	13
Total	507	398

Support costs have been allocated based on time spent by departments supporting the various activities.

	Unrestricted funds £'000	Designated funds £'000	Restricted funds £'000	2022 £'000
<i>Raising funds</i>				
Investment management fees	41	-	-	41
Fundraising	30	-	-	30
<i>Charitable Expenditure:</i>				
Membership	240	-	-	240
Congress	642	-	-	642
Other meetings and events	184	-	-	184
Publications and journals	370	-	-	370
Policy and public affairs	130	-	45	175
National Research support	-	-	149	149
Partnership work	133	-	-	133
Education and careers	68	125	5	198
Diversity and inclusion	4	-	-	4
Public engagement	116	-	2	118
Communications	228	-	-	228
International work	28	-	-	28
Total	2,214	125	201	2,540

Notes to the financial statements

6 Governance costs

	2023 £'000	2022 £'000
Auditor's remuneration - audit	14	12
Auditor's remuneration - other	4	1
Total	18	13

7 Net income before gains (losses) on investments

This is stated after charging:	2023 £'000	2022 £'000
Staff costs (note 9)	1,229	1,182
Depreciation	30	9
Auditor's remuneration - audit	14	12
Auditor's remuneration - other	4	1

Notes to the financial statements

8 Staff costs

Staff costs during the year were as follows:

	2023 £'000	2022 £'000
Wages and salaries	1,054	1,009
Social security costs	122	118
Pension costs	53	55
Total	1,229	1,182

The average monthly number of employees during the year was as follows:

	2023	2022
Direct charitable activities	15	16
Administration of the charity	3	3
	18	19

Number of employees whose annualised emoluments fall within following ranges for the year:

	2023	2022
£60,001 - £70,000	1	1
£80,001 - £90,000	2	2
£140,001 - £150,000	1	1

Pension contributions for these employees were £22,601 (2022 - £21,848).

The number of staff for whom retirement benefits are accruing under money purchase pension schemes amounted to 19 (2022 - 19).

The Society considers its key management personnel comprise the Trustees and the Senior Management Team (SMT). The Trustees provide their time free of charge. The total remuneration, employer's national insurance contributions, benefits and pensions paid to the SMT was £524,335 (2022 - £516,095).

The relevant staff costs have been included in the costs of charitable activities. The gender split in the society workforce is 67% female 33% male (2022: 74% female 26% male). All roles are evaluated and paid in accordance with external benchmarking irrespective of gender.

9 Trustees' remuneration

No trustees received any remuneration for his or her services during the year (2022 - none). During the year expenses totalling £6,933 (2022 - £4,783) were reimbursed to 14 trustees (2022 - 7). In addition £9,293 was paid for travel and accommodation costs on behalf of trustees (2022: £5,483).

In 2022 one trustee received a £250 BSI Congress 2021 Education and Public poster prize for best presentation and a Communicating Immunology grant of £1,000 for his project entitled 'Superbugs'.

Notes to the financial statements

10 Tangible assets of the Group and charity

	Website £'000	Computer equipment £'000	Total £'000
Cost or valuation			
At 1 July 2022	38	30	68
Additions	18	3	21
Disposals	-	-	-
At 30 June 2023	56	33	89
Depreciation			
At 1 July 2022	-	20	20
Charge for the year	9	7	16
Eliminated on disposal	-	-	-
At 30 June 2023	9	27	36
Net book value			
At 30 June 2023	47	6	53
At 1 July 2022	38	10	48

11 Intangible assets of the Group and charity

	IT software £'000	Total £'000
Cost or valuation		
At 1 July 2022	93	93
Additions	-	-
Disposals	-	-
At 30 June 2023	93	93
Depreciation		
At 1 July 2022	-	-
Charge for the year	14	14
Eliminated on disposal	-	-
At 30 June 2023	14	14
Net book value		
At 30 June 2023	79	79
At 1 July 2022	93	93

Construction of a new CRM system was completed during the year.

Notes to the financial statements

12 Investments

	Group		Charity	
	2023	2022	2023	2022
	£'000	£'000	£'000	£'000
Market value at 1 July 2022	4,029	4,196	4,029	4,196
Disposals proceeds	(1,669)	(521)	(1,669)	(521)
Realised gains/(losses)	14	(57)	14	(57)
Additions at cost	933	659	933	659
Unrealised gains	(21)	(248)	(21)	(248)
Market value at 30 June 2023	3,286	4,029	3,286	4,029
Cash held with investment managers	13	230	13	230
Investment in UKPIN	-	-	7	-
Total investments	3,299	4,259	3,306	4,259

Total Group investments includes £100 investment in subsidiary.

	Group		Charity	
	2023	2022	2023	2022
	£'000	£'000	£'000	£'000
At 30 June 2023 the listed investments comprised the following:				
UK equities	816	1,244	816	1,244
Overseas equities	1,779	2,270	1,779	2,270
Investment instruments	691	515	691	515
Total	3,286	4,029	3,286	4,029
Historical cost of listed investments	2,805	3,317	2,805	3,317

Investments representing more than 5% of the total market value of the portfolio of listed investments are as follows:

	Cost 2023 £'000	Market value 2023 £'000	Portfolio %
Aberdeen Standard Capital Offshore Fixed Interest Fund Institutional Income Z GBP	240	209	6.35%

12 Investments (continued)

Investment in subsidiary undertaking

The Society has two wholly owned trading subsidiaries. A summary of their trading results are shown below.

BSI Trading Limited is incorporated in England and Wales, registered number 01021739. Its registered office is 9 Appold Street London EC2A 2AP. The principal activity of the company is the management of corporate membership, sponsorship, exhibition and other trading activities for the Society.

The Society become sole member of United Kingdom Primary Immunodeficiency Network (UKPIN) on 20 December 2022 and accordingly on that date UKPIN became a subsidiary of the group. During the year UKPIN transferred £175k to the Society being most of its net assets on the acquisition date.

UKPIN is incorporated in England and Wales, registered number 09273983. Its registered office is 9 Appold Street, London EC2A 2AP. The principal activity of the company was the advancement of health among those with primary immunodeficiency disorders and advancing education in PID and related subjects. These activities have been transferred to the Society's Clinical Immunology Professional Network (BSI-CIPN).

A summary of the results of the subsidiaries is shown below:

	2023			2022		
	BSI Trading Limited £'000	UKPIN £'000	Total £'000	BSI Trading Limited £'000	UKPIN £'000	Total £'000
Turnover	576	-	576	354	-	354
Operating costs	-	-	-	-	-	-
Operating profit	576	-	576	354	-	354
Administration costs	(87)	(5)	(92)	(19)	-	(19)
Profit(loss) for the financial period	489	(5)	484	335	-	335
Distribution to parent charity	(489)	(175)	(664)	(335)	-	(335)
Retained in subsidiary	-	(180)	-	-	-	-

The assets and liabilities of the subsidiaries were:

Assets	600	2	602	388	-	388
Liabilities	(600)	-	(600)	(388)	-	(388)
Net assets	-	2	2	-	-	-

Notes to the financial statements

13 Debtors

	Group		Charity	
	2023	2022	2023	2022
	£'000	£'000	£'000	£'000
Trade debtors	389	358	425	341
Prepayments and accrued income	303	194	303	194
Amount owed by subsidiary undertaking	-	-	497	340
Total	692	552	1,225	875

14 Creditors

	Group		Charity	
	2023	2022	2023	2022
	£'000	£'000	£'000	£'000
Trade creditors	74	355	74	345
Other taxes and social security costs	40	39	40	39
VAT payable	9	5	9	5
Other creditors	177	124	177	124
Accruals and deferred income	504	527	488	490
Total	804	1,050	788	1,003

Included within the above is deferred income as set out below:

	Group	Charity
	2023	2023
	£'000	£'000
Deferred income brought forward at 1 July	459	422
Additional income deferred during the year	437	422
Brought forward funds released in the year	(459)	(422)
Deferred income carried forward at 30 June	437	422

Deferred income comprises advance payments of journal royalties and memberships fees.

Notes to the financial statements

15 Restricted funds

	At 1 July 2022	Income	Expenditure	At 30 June 2023
Meeting funds	34	-	-	34
BSI-CIPN	-	178	-	178
Autoimmunity	12	-	(12)	-
UK-CIC	-	63	(63)	-
Vaccine taskforce	1	25	(26)	-
UK Covid Vaccines Research	61	63	(124)	-
Ageing and immunity	-	68	(40)	28
SIREN	8	9	(17)	-
Immunogenicity project	27	15	(42)	-
STRAVINSKY	-	15	(1)	14
Visiting Scholar and Jonathan Sherrard Awards	-	4	-	4
Total	143	440	(325)	258

Meeting funds

Donations to the Society by individuals to promote certain immunological issues.

BSI-CIPN

Funds transferred from UKPIN upon the merger to be used to promote and support clinical immunology through the BSI-CIPN

Autoimmunity

A grant from the Lorna and Yuti Chernajovsky Biomedical Research Foundation for administrative support for the development and management of the autoimmune research initiative.

UK-CIC

A grant for the BSI support provided to the UK Coronavirus Immunology Consortium (UK-CIC) to understand the immunology of SARS-CoV-2 and COVID-19.

Vaccine taskforce

Funding from the European Federation of Immunological Societies (EFIS) for the EFIS Vaccine Taskforce work led by the BSI.

UK Covid Vaccines Research Hub

Central co-ordination hub for COVID-19 immunology research investments and outcomes funded by UKRI via the National Core Studies programme.

Notes to the financial statements

15 Restricted funds (Continued)

Ageing and immunity

The CARINA (Catalyst Reducing ImmuNe Ageing) Network is a new collaborative network for researchers working on the immune system throughout the life course. The BSI has a leading role in supporting the network through provision of project management, events support, communications expertise and patient and public involvement (PPI).

SIREN

Recruitment, facilitation and reporting of findings from Patient and Participant Involvement workshops for the SIREN project funded by the UK Health Security Agency.

Immunogenicity project

Immunogenicity measures in vaccine development and decision making programme funded by Merck Sharp & Dohme (UK) Limited.

STRAVINSKY

Funds to support a 2 year study aiming to establish if antibody testing can identify who remains at greatest risk of severe COVID-19 infection after vaccinations.

Visiting Scholar and Jonathan Sherrard Awards

Funds to support members for periods of training in academic or clinical centres to further their knowledge of primary immunodeficiencies.

	At 1 July 2021 £'000	Income £'000	Expenditure £'000	At 30 June 2022 £'000
Meeting funds	34	-	-	34
Autoimmunity	10	15	(13)	12
UK-CIC	(24)	53	(29)	-
Vaccine taskforce	-	25	(24)	1
BiteSized immunology	5	-	(5)	-
UK Covid Vaccines research	-	157	(96)	61
Ageing and immunity	-	24	(24)	-
SIREN	-	10	(2)	8
Immunogenicity project	-	35	(8)	27
Total	25	319	(201)	143

16 Designated funds

	At 1 July 2022	Designated in year	Utilised / released	At 30 June 2023
Long term sustainability	248	-	(150)	98
Training	-	150	(59)	91
CRM project	23	-	(23)	-
Career development programme	500	-	(136)	364
Total	771	150	(368)	553

Notes to the financial statements

16 Designated funds (Continued)

Long term sustainability

The long term sustainability fund provides resources for investing in the financial sustainability of the charity over the next five years.

Training

Funding for the creation and development of a new surplus generating training function within the BSI.

CRM project

The CRM project fund provides resources to develop and implement a new CRM system together with an upgrade to the BSI website

Career development programme

The Career development programme will fund a significant expansion in the careers support the BSI offers to our members. This includes two main streams: our career-enabling activities and our career-enhancing activities.

17 Analysis of net assets between funds

				2023
Group	Unrestricted funds £'000	Designated funds £'000	Restricted funds £'000	Total funds £'000
Tangible fixed assets	53	-	-	53
Intangible assets	79	-	-	79
Investments	3,299	-	-	3,299
Current assets	458	553	258	1,269
Current liabilities	(804)	-	-	(804)
Total Funds	3,086	553	258	3,897

				2023
Charity	Unrestricted funds £'000	Designated funds £'000	Restricted funds £'000	Total funds £'000
Tangible fixed assets	53	-	-	53
Intangible assets	79	-	-	79
Investments	3,306	-	-	3,306
Current assets	439	553	258	1,250
Current liabilities	(788)	-	-	(788)
Total Funds	3,090	553	258	3,901

Notes to the financial statements

17 Analysis of nets assets between funds (Continued)

The total unrealised gains (losses) as at 30 June 2023 constitutes movements on revaluation and are as follows:

	2023 £'000	2022 £'000
Unrealised gains (losses) included above:		
On investments	962	983
Total unrealised gains (losses) at 30 June	962	983
Reconciliation of movements in unrealised gains (losses)		
Unrealised gains at 1 July	983	522
Less: in respect to disposals in the year	-	-
	983	522
Add: net gains (losses) arising on revaluation arising in the year	(21)	461
Total unrealised gains (losses) at 30 June	962	983

				2022
Group	Unrestricted funds £'000	Designated funds £'000	Restricted funds £'000	Total funds £'000
Tangible fixed assets	49	-	-	49
Intangible fixed assets	93	-	-	93
Investments	4,259	-	-	4,259
Current assets	45	771	143	959
Current liabilities	(1,050)	-	-	(1,050)
Total Funds	3,396	771	143	4,310

				2022
Charity	Unrestricted funds £'000	Designated funds £'000	Restricted funds £'000	Total funds £'000
Tangible fixed assets	49	-	-	49
Intangible fixed assets	93	-	-	93
Investments	4,259	-	-	4,259
Current assets	25	771	116	912
Current liabilities	(1,003)	-	-	(1,003)
Total Funds	3,423	771	116	4,310

Notes to the financial statements

18 Share capital

The company is limited by guarantee and therefore has no share capital. Each member's liability is limited to £1.

19 Related party transactions

The Kennedy Trust for Rheumatology Research (charity No. 260059) provided £5,000 sponsorship for the BSI awards. Professor Tracy Hussell is a trustee of this charity.

Matthias Eberl received a £250 BSI Congress 2021 Education and Public poster prize and a Communicating Immunology grant of £1,000.

There were no other related party transactions that required disclosure in the current financial period (2022: none).

Notes to the financial statements

20 Comparative consolidated statement of financial activities

	Unrestricted funds			
	General	Designated	Restricted	2022
	£'000	£'000	£'000	£'000
Income from:				
Donations	6	-	274	280
Investments	151	-	-	151
Charitable activities				
Membership	160	-	-	160
Partnership work	91	-	45	136
Congress	512	-	-	512
Meetings and events	59	-	-	59
Journals	913	-	-	913
Total income	1,892	-	319	2,211
<i>Raising funds</i>				
Investment Management Fees	41	-	-	41
Cost of raising funds	30	-	-	30
<i>Charitable activities</i>				
Membership	240	-	-	240
Congress	642	-	-	642
Meetings and events	184	-	-	184
Publications and journals	370	-	-	370
Policy and Public Affairs	130	-	45	175
National Research support	-	-	149	149
Partnership work	133	-	-	133
Education and Careers	68	125	5	198
Diversity and inclusion	4	-	-	4
Public engagement	116	-	2	118
Communications	228	-	-	228
International work	28	-	-	28
Total expenditure	2,214	125	201	2,540
Net income (expenditure) before gains (losses) on investments and transfers	(322)	(125)	118	(329)
Net gains/(losses) on investments	(305)	-	-	(305)
Transfers between funds	90	(90)	-	-
Net income	(537)	(215)	118	(634)
Reconciliation of funds:				
Funds brought forward	3,933	986	25	4,944
Funds carried forward	3,396	771	143	4,310

Notes to the financial statements

21 Charity statement of financial activities

	Unrestricted funds				
	General funds £'000	Designated funds £'000	Restricted funds £'000	Total 2023 £'000	Total 2022 £'000
Income from:					
Grants and donations	-	-	425	425	290
Investments	132	-	-	132	151
Charitable activities					
Membership	162	-	-	162	160
BSI-CIPN	3	-	-	3	-
Partnership work	38	-	-	38	40
Congress	300	-	-	300	293
Meetings and events	49	-	-	49	11
Journals	749	-	-	749	913
Training	12	-	-	12	-
Gift Aid and recharge from BSI	575	-	-	575	353
Trading Limited					
Total income	2,020	-	425	2,445	2,211
Expenditure on:					
Raising funds					
Investment management fees	35	-	-	35	41
Cost of raising funds	12	-	-	12	30
Charitable activities					
Membership	242	-	-	242	240
BSI-CIPN	80	-	-	80	-
Partnership work	147	-	-	147	133
Congress	720	-	-	720	642
Meetings and events	289	-	-	289	184
Journals	370	-	-	370	370
Training	35	59	-	94	-
Education and Careers	64	136	-	200	198
Diversity and inclusion	2	-	-	2	4
National Research support	-	-	129	129	149
Policy and Public Affairs	56	-	115	171	175
Public engagement	73	-	38	111	118
Communications	221	-	-	221	228
International work	23	-	-	23	28
Total expenditure	2,369	195	283	2,847	2,537
Net income (expenditure) before gains (losses) on investments and transfers	(349)	(195)	142	(402)	(326)
Net gains/(losses) on investments	(7)	-	-	(7)	(305)
Transfers between funds	23	(23)	-	-	-
Net income/(deficit)	(333)	(218)	142	(409)	(632)
Reconciliation of funds:					
Funds brought forward	3,423	771	116	4,310	4,944
Funds carried forward	3,089	553	258	3,900	4,312

Board of Trustees

Position	Trustee	Date of appointment / resignation
Previous		
Past President	Professor Arne Akbar	Resigned December 2022
Past Chair of Forum	Professor Ann Ager	Resigned December 2022
Early Career Trustee	Dr Calum Bain	Resigned July 2022
Trustee	Professor Matthias Eberl	Resigned June 2023
Co-opted Trustee	Dr Paul Harding	Resigned June 2023
Trustee	Professor Allan Mowat	Resigned June 2023

Current		
President	Professor Tracy Hussell	Appointed December 2022
Treasurer	Dr Fiona Culley	Re-appointed July 2022
Chair of Forum	Professor James Brewer	Appointed December 2022
Clinical Secretary	Professor Colin Dayan	Appointed October 2019
Early Career Trustee	Dr Emma Chambers	Appointed December 2018
Co-opted Trustee	Robert Davies	Re-appointed July 2023
Trustee	Professor Deborah Dunn-Walters	Re-appointed July 2023
Co-opted Trustee	Dr Edith Hessel	Appointed January 2017
Trustee	Professor Teresa Lambe	Appointed December 2022
Co-opted Trustee	James Lowe	Appointed July 2019
Co-opted Trustee	David Pemberton	Appointed July 2023
Early Career Trustee	Dr Matthew Siggins	Appointed July 2022
Co-opted Trustee	Dr Sinisa Savic	Appointed July 2022
Trustee	Dr Divya Shah	Re-appointed July 2023
Trustee	Dr Jessica Strid	Appointed July 2023

Board composition



Gender (%)

Female	53
Male	47



Length of tenure (%)

< 1 year	40
1-3 years	27
> 4 years	33

Leadership

Board and Committee meetings and attendance

All Trustees are expected to attend each Board meeting and each Committee meeting for which they are members, unless there are exceptional circumstances preventing them from participating. The table below shows the attendance at Board and other BSI committees.

	BSI-CIPN		Membership			
		Steering	Congress	Finance Sub	Representative	Nominations
Trustees	Board	Group	Committee	Committee	Forum	Committee
Professor Tracy Hussell	4/4	-	3/3	-	3/3	1/1
Dr Fiona Culley	4/4	-	1/4	5/5	-	-
Professor James Brewer	1/2	-	-	-	3/3	1/1
Professor Colin Dayan	4/4	-	1/4	-	1/4	-
Dr Emma Chambers	4/4	-	-	-	-	-
Robert Davies	4/4	-	-	-	-	1/1
Professor Deborah Dunn-Walters	3/4	-	-	-	-	-
Dr Edith Hessel	3/4	-	1/1	-	-	1/1
Professor Teresa Lambe	2/2	-	-	-	-	1/1
James Lowe	3/4	-	-	5/5	-	-
David Pemberton	0/0	-	-	0/0	-	-
Dr Matthew Siggins	4/4	-	-	-	-	-
Dr Sinisa Savic	2/4	2/2	-	-	-	-
Dr Divya Shah	2/2	-	-	-	-	-
Dr Jessica Strid	0/0	-	-	-	-	-

Senior Management Team

Name	Position
Dr Doug Brown	Chief Executive
Otto Balsiger	Finance Director
Dr Jennie Evans	Director of External Affairs
Jane Sessenwein	Head of Events & Conferences
Lucy McIver	Head of Publishing

Principal professional advisers

Name	Advisor
Bankers	Bank of Scotland 14/16 Cockspur Street London EC2V 6DL
External auditors	Moore Kingston Smith LLP 9 Appold Street London EC2A 2AP
Investment advisers	Abrdn (formerly Aberdeen Standard Chartered) 14th Floor 30 St Mary Axe London EC3A 8BF
Solicitors	Russell Cooke LLP 2 Putney Hill London SW15 6AB

Committees

Nominations Committee

Members	
Professor Tracy Hussell	Chair, BSI President
Robert Davies	BSI Co-opted Trustee
Professor James Brewer	Trustee
Professor Teresa Lambe	Trustee
Dr Doug Brown	BSI CEO (observer)

Finance Sub Committee

Members	
Dr Fiona Culley	BSI Treasurer
James Lowe	Co-opted Trustee
David Pemberton	Co-opted Trustee
Dr Doug Brown	BSI Chief Executive
Otto Balsiger	BSI Finance Director

Forum

Members	
Professor James Brewer	Chair
Professor Tracy Hussell	BSI President
Dr Colin Dayan	Clinical Secretary
Dr Donald Palmer	Education & Careers Secretary
Professor Matthias Eberl	Public Engagement Secretary
Dr Doug Brown	BSI Chief Executive
Dr Jennie Evans	BSI Director of External Affairs
Dr Patrick Cao	Regional Representative - Scotland
Dr Julia Makinde	Regional Representative - England
Dr Karim Dib	Regional Representative - Northern Ireland
Dr Simone Cuff	Regional Representative - Wales
Dr Louise Topping	Early Career Representative
Dr George Robinson	Early Career Representative
Dr George Robinson	Early Career Representative
Dr Edoardo Prediletto	Early Career Representative
Dr Lauren Campbell	PhD Representative
Dr Jhanna Kryukova	PhD Representative
Dr Chloe Pyle	Industry Representative
Dr Gareth-Rhys Jones	Clinical Representative
Dr Tomaz Garcez	Clinical Representative
Dr Rebecca McLean	Veterinary Representative

Committees

Congress Committee

Name	Position
Professor Mark Coles	BSI Congress Secretary
Professor Tracy Hussell	BSI President
Dr Fiona Culley	BSI Treasurer
Dr Colin Dayan	BSI Clinical Secretary
Dr Edith Hessel	Member
Dr Daniel O'Connor	Early Career Representative
Dr Graham Cook	Member
Dr Helen McGettrick	Member
Dr Henry McSorley	Member
Dr James Harker	Member
Dr James Thaventhiran	Clinical member
Dr Laura Rivino	Member
Dr Margarita Dominguez	Member
Dr Sandra Sacre	Member
Jane Sessenwein	BSI Head of Events & Conferences

BSI-CIPN Steering Group

Name	Position
Dr Sinisa Savic	Chair
Dr Suzy Elcombe	Deputy Chair
Dr Catherine Stroud	Membership Lead
Sarah Denman	Pharmacy Representative
Dr Lisa Devlin	Industry Liaison
Jull Edmonds	Nursing Representative
Dr Kimberly Gilmour	Clinical/Biomedical Scientist Representative
Professor Alex Ritcher	Guidelines Lead
Dr Ravishnkar Sargur	Member
Dr Patrick Yong	Training & Education Lead
Dr Manisha Ahuja	Postgraduate Doctor in Training Representative
Position vacant	Patitent Group Liaison
Dr James Thaventhiran	Conference Lead (Co-opted member)
Dr Austen Worth	Paediatric Representative and PID Registry Representative (Ex-officio member)
Dr Claire Bethune	CRG Representative (Ex-officio member)
Dr Sarah Goddard	QPIDS Representative (Ex-officio member)
Dr Doug Brown	BSI Chief Executive

Journals

Clinical and Experimental Immunology - Editorial Team

Name	Position
Professor Leonie Taams	Editor-in-Chief
Professor Angelo Manfredi	Section Editor - autoimmunity
Professor Tanja de Gruij	Section Editor - cancer immunity
Professor Ciriaco Piccirillo	Section Editor - immune-mediated inflammatory diseases
Dr Cindy Ma	Section Editor - immunodeficiency
Dr daniel Douek	Section Editor - infectious diseases and vaccines
Professor Xiao-Ning Xu	Section Editor - infectious diseases and vaccines
Professor Sandra Amor	Section Editor - neuroimmunology

Immunotherapy Advances - Editorial Team

Name	Position
Professor Tim Elliot	Editor-in-Chief
Professor Stefan Barth	Regional Editor: Africa
Associate Professor Marianne Boes	Regional Editor: Europe
Professor Adrianna Bonomo	Regional Editor: South America
Professor Tao Dong	Regional Editor: Asia
Dr Stephanie K Dougan	Regional Editor: North America
Associate Professor Menno van Zelm	Regional Editor: Australasia

Discovery Immunology - Editorial Team

Name	Position
Professor Simon Milling	Editor-in-Chief
Dr Philip Ahern	Senior Editor
Dr Awen Gallimore	Senior Editor
Dr Florent Ginhoux	Senior Editor
Dr Emily Gwyer Findlay	Senior Editor
Dr Lai Guan Ng	Senior Editor
Professor Francisco J. Quintana	Senior Editor
Dr Meera Ramanujam	Senior Editor

Regional and Affinity groups

Affinity Groups

Group	Position	Member
Autoimmunity Affinity Group	Chair	Professor Lucy Walker
	Secretary	Dr Kathryn Steel
	Treasurer	Dr James Pearson
Comparative Veterinary Immunology Group	Chair	Wilhelm Gerner
	Secretary	Dr Lindert Benedictus
	Treasurer	Dr Kate Sutton
Immunometabolism Affinity Group	Co-Chair	Dr Laura Pallett
	Co-Chair	Dr Linda Sinclair
	Secretary	Dr Sarah Dimeloe
	Treasurer	Dr Anna Schurich
Immunosenescence Affinity Group	Chair	Dr Sian Henson
	Secretary	Dr Natalie Riddell
	Treasurer	Dr Catarina Henriques
Infection and Immunity Group		
Inflammation Affinity Group	Chair	Professor Peter Barlow
	Treasurer	Dr Joanne Konkel
	Communications	Dr Jack Rivers-Auty
Leukocyte Migration Group	Chair	Dr Myriam Chimen
	Secretary/Treasurer	Dr Graeme O'Boyle
Mathematical Modelling Group	Chair	Dr Grant Lythe
	Secretary	Professor Mark Coles
	Treasurer	Dr Hashem Koohy
Neuroimmunology Group	Chair	Dr Yvonne Dombrowski
	Secretary	Dr Sarosh Irani
Teaching Affinity Group	Co-chair	Professor John Currow
	Co-chair	Dr Nigel Francis
	Secretary	Dr Owen Kavanagh
	Treasurer	Dr Becky Aicheler
Tumour Immunology Affinity Group	Chair	Professor Benjamin Willcox
	Secretary	Dr Seth B. Coffelt
	Treasurer	Professor Awen Gallimore
Vaccine Affinity Group	Chair	Dr Bernardo Villarreal-Ramos
	Secretary	Dr Julia Tree
	Treasurer	Dr Dirk Werling

Regional and Affinity groups

Regional Groups

Group	Position	Member
Aberdeen Immunology Group	Chair	Dr Isabel Crane
	Treasurer	Dr Janine Coombes
Bristol Immunology Group	Chair	Dr Gareth Jones
	Secretary	Dr Dronwen Burton
	Treasurer	Dr Lindsay Nicholson
Cambridge Immunology Group	Chair	Dr Brian Ferguson
	Secretary/Treasurer	Dr Louise Boyle
East Anglia Immunology Group	Secretary	Dr Anastasia Sobolewski
	Treasurer	Dr Cristina Fanutti
Edinburgh Immunology Group	Co-Chair	Dr Rebecca Gentek
	Co-Chair	Dr Laura McCulloch
	Secretary	Dr Matthew Burgess
	Secretary	Dr Tovah Shaw
	Treasurer	Dr Sean Wattagedera
Greater Manchester Immunology Group	Chair	Dr Doug Dyer
	Secretary	Dr Andrew Greenhaigh
Immunology North East	Chair	Dr Kevin Marchbank
	Secretary	Dr Antony Antoniou
	Treasurer	Dr Andy Knight
London Immunology Group	Chair	Dr Laura Pallett
	Secretary	Dr Franze Progatzy
	Treasurer	Dr George Finney
Midlands Immunology Group	Chair	Dr Rebecca Drummond
	Treasurer	Dr Martin Davey
Oxford Immunology Group	Chair	Dr Roel De Maeyer
	Secretary	Dr Elena Mitsi
South Wales Immunology Group	Chair	Dr You Zhou
	Secretary	Dr Rebecca Aicheler
	Treasurer	Dr Ceri Fielding

Regional and Affinity groups

Regional Groups

Group	Position	Member
Tayside Immunology Group	Chair	Professor Simon Arthur
	Secretary	Dr Mahima Swamy
	Treasurer	Dr Shalini Pathak
Ulster Immunology Group	President	Dr Yvonne Dombrowski
	Secretary	Dr Karim Dib
	Treasurer	Dr Rebecca Coll
Wessex Immunology Group	Co-Chair	Professor Jessica Teeling
	Co-Chair	Dr Sarah Buchan
	Secretary	Dr Alison Hill
	Treasurer	Dr Diogo Silva
West of Scotland Immunology Group	Chair	Dr Megan MacLeod
	Secretary	Dr Ed Roberts
	Treasurer	Dr Hannah Scales
Yorkshire Immunology Group	Chair	Dr Gina Doody
	Secretary	Dr Erica Wilson

Accounts



Annual Report 2022

Trustees' Report

For the year ended 30 June 2022

What we do and why it matters

The British Society for Immunology is the award winning (Best Overall Association 2020, The Association Awards) and leading UK membership organisation working with scientists and clinicians from academia and industry to forward immunology research and application around the world. Our friendly, accessible community consists of over 4,300 immunologists, giving us a powerful voice to advocate on immunological science and health for the benefit of society.

The Society supports its members, students and the wider public to learn more about immunology through disseminating research and providing resources, activities and grants to aid education in this field.

Immunological science underpins many aspects of human and animal health and disease, from communicable disease and vaccination to the management and treatment of many chronic conditions. Through enhancing our knowledge of how the immune system functions for the public benefit, the British Society for Immunology can play a key role in advancing Society's ability to prevent and treat disease.

Our mission

The British Society for Immunology's mission is to promote excellence in immunological research, scholarship and clinical practice in order to improve human and animal health.

We accomplish this by:


- Working with our members to support current and future generations of immunologists.
- Sharing our passion for immunology through meetings, publications and the media.
- Building up an understanding of our work by engaging with the public and those working in the research and health environments.
- Working with partners in pursuit of our mission, building on common interests

The Trustees confirm they have referred to the Charity Commission's guidance on public benefit when reviewing the Society's aims and objectives, planning future activities and setting the annual operating plan.

Our strategic objectives

The British Society for Immunology strategy sets our direction and priorities for 2021-2025.

Building on the strong foundations of our past work and guided by our updated vision and mission statements and set of values, this ambitious strategy lays out how we will work with our membership to deliver for the immunology and wider community over the coming years. As the UK's leading charity and scientific society representing the immune research sector, we are confident that we will fulfil this strategy to lead a positive change towards our vision of better health for all through immunology.



Connected community

Our BSI community is at the heart of all we do. Being a member of the BSI means being a member of one of the largest immunology networks in the world. Immunology is a growing field, and the BSI aims to continually develop our activities and the support we provide to members to enable the discipline to flourish. Immunology intersects with numerous research fields, across different sectors, with the involvement of all career grades. Our goal is to bring this ecosystem together into a cohesive whole that fulfils our mission to take immunology forwards faster and more collaboratively.

Membership of the British Society for Immunology brings many benefits. These include discounts to our meetings and to our exceptional BSI Congress, access to a diverse range of grants, bursaries and prizes, free access to our journals and much more. The Society provides tailored support for our community through our highly valued Regional and Affinity Groups, but we are also there to represent immunology to the wider world. Members value our strong voice to speak out with influence and impact on behalf of immunology in policy, public engagement and the media.

At the end of June 2022, we had over 4,300 members who join us from all walks of immunology. From students up to senior levels, they contribute to our work through many different routes, including speaking at our conferences, helping with our public engagement activities and advising on our policy work – our grateful thanks go to our whole immunology community.

In December 2021, over 1,600 immunologists came together in Edinburgh and online for our flagship event, BSI Congress. It was an amazing four days of immunology, packed with cutting-edge science, inspiring debates and those much-missed opportunities to connect and start new collaborations. This year, we kept our online attendance option which proved popular with those who did not feel comfortable attending in person or who couldn't get time away from work. Feedback from delegates was very positive, with many praising the scientific content, the networking opportunities afforded to attendees and the inclusive nature of the event.



An amazing 97% of delegates stating they would recommend the BSI Congress to colleagues.

We look forward to welcoming the immunology community back to Liverpool for the 2022 BSI Congress.

Regional and Affinity Groups

The BSI's Regional and Affinity Groups are a key part of the BSI community and carry out much of the core activity of bringing our membership together. The scientific discussions and networking that take place at these meetings are invaluable for the continued development of immunology. The strengths of our 17 Regional Groups are to bring together immunologists within a local community, boosting local research networks. The 12 Affinity Groups have all been created to focus meetings and discussions on specific areas of immunology and they continue to evolve as immunology expands its reach and knowledge.

While the activities of our Groups have been somewhat curtailed during the pandemic, they approached this year with renewed enthusiasm and ideas. In total, our Groups hosted nine in person conferences, two online conferences and three webinars, covering a whole host of topics from B cells to tumour checkpoint blockade to avian immunology flow cytometry. These events played an important part in our strategy to develop our Regional and Affinity Groups as community-based expert hubs. Our Groups also ran several other activities including in house seminar series, careers events and public outreach initiatives.

Our programme of events continued to be disrupted by COVID-19 restrictions. Groups turned to online and hybrid events to keep members engaged and up to date with over 4,900 people attending events this year, over 1,000 more than last year. A full calendar of group events is planned for next year.

BSI Journals

The BSI's original ethos still lies at the heart of our Society – to disseminate research with the aim of promoting and advancing immunology to foster future innovation. This has been a busy and exciting year for our journals and one full of change.

After a strategic review of our portfolio, the BSI decided to focus on developing journals that are fully owned by the Society to give us greater control over our publishing portfolio's future and to allow us to continue to support future generations of immunologists. This meant that our long-standing association with the Wiley-owned journal *Immunology* came to an end.

However, we were delighted to cement our relationship with Oxford University Press, who became our new publishing partner for *Clinical & Experimental Immunology*, where it joined our Open Access journal *Immunotherapy Advances*. January 2022 also saw the exciting move of launching our second fully Open Access journal, *Discovery Immunology*. This launch completes our highly respected family of three journals serving the field of immunology, publishing high-quality research articles, reviews, commentaries and short reports from researchers across the globe.

Income generated from our journals provides major financial support for the Society's activities and we are hugely grateful to all our Editorial Board members for their ongoing commitment, and everyone who has contributed to the continued success of our journals, including authors, readers, reviewers and editors.



Clinical & Experimental IMMUNOLOGY

Our established translational research journal, *Clinical & Experimental Immunology* (CEI), continues to go from strength to strength, and this year reached its highest-ever impact factor of 5.732 (28% increase from last year). We're incredibly proud of this achievement and our thanks go to Editor-in-Chief Leonie Taams and the journal's editorial board for their hard work in bringing about this success.

It's been a busy year for CEI all round, publishing a number of high impact virtual issues and taking part in a number of collaborations including highlighting primary research and review articles that complemented the scientific programme of FOCIS 2022.



*Citations are based on articles for previous two years.



Immunotherapy ADVANCES

It's been another successful year for our first fully Open Access journal, *Immunotherapy Advances*, as it continues its journey to be a globally recognised title that both serves the immunotherapy community and exposes new developments in the field to a wide and diverse readership. Led by Editor-in-Chief, Tim Elliott, *Immunotherapy Advances* publishes scientifically rigorous research relating to manipulations of the immune system for the benefit of human and animal health in all disease areas. A highlight this year has been the recruitment of an Early Career Editorial Board who gain the opportunity to develop their skills as peer reviewers, learn more about the editorial process and contribute to the growth and development of the journal.





This year, the BSI launched *Discovery Immunology*, a fully Open Access journal whose broad scope focuses on new discoveries in cellular and molecular immunology. Led by Editor-in-Chief Simon Milling and supported by six prestigious senior editors and a growing international Editorial Board from academia and industry, *Discovery Immunology* aims to publish high-quality articles describing novel mechanisms controlling the immune response. After a successful launch, we are now focused on building the reach and impact of the journal over the coming months.

"Our vision is for Discovery Immunology to become an invaluable resource to the immunology community, providing trusted new insights into the workings of the immune system." Professor Simon Milling, Editor-in-Chief, *Discovery Immunology*.

Supporting research consortia

Under our updated strategy, a new facet of our work has been to support national and topic-specific research consortia efforts relevant to immunology. By championing investment in immunology and a 'team science' approach, we aim to use our skills to support cross-sector collaboration efforts to drive forwards immunology research faster and more effectively. This work has got off to a fast-paced start with the BSI providing a variety of services to support two national research consortia detailed below. In addition, we are also continuing our support of the UK Coronavirus Immunology Consortium (UK-CIC) to ensure the legacy of this project and are currently supporting the SIREN (SARS-CoV-2 immunity and reinfection evaluation) study to deliver their participant involvement panel.



The CARINA (Catalyst Reducing ImmuNe Ageing) Network is an initiative funded by the Medical Research Council (MRC) and the Biotechnology and Biological Sciences Research Council (BBSRC) and supported by the BSI. The network was established to create a UK-wide, inclusive platform to enhance collaboration and foster knowledge exchange in the area of immune ageing.

Involving over 70 researchers and experts from a range of disciplines and career levels, the network is identifying the priority areas for a better understanding of immunity and ageing and how to address them through an interdisciplinary approach.

The Management Group, led by BSI President Professor Arne Akbar, provides important oversight of the CARINA Network and directs network activities by identifying novel research strategies. The BSI has a leading role in providing the project support that enables these activities. This includes the delivery of involved project management to ensure important milestones are met, events support to bring network members together for essential interactions, communication of the progress of the network with key audiences through management of an online presence and embedding a patient and public involvement component in the project.



The National Core Studies (NCS) programme was established by the Government Office for Science in summer 2020 to ensure critical questions around COVID-19 could be answered quickly and effectively. The Immunity programme, led by Professor Paul Moss and funded by UKRI, funds studies that deepen our understanding of immunity against COVID-19 by predicting individual risk, preventing reinfection, understanding the vaccine responses by different groups in more depth and preparing for future pandemic challenges.

As part of National Core Studies Immunity (NCSi) work, the BSI has developed and runs the UK COVID Vaccine Research Hub (www.covidvaccineresearch.org), a highly successful website set up for the public, policymakers and researchers to provide the latest information on COVID-19 vaccine research being conducted in the UK. We also run the Patient and Public Involvement Panel for the consortia, ensuring that the expertise and viewpoints of public contributors are fed into the various research studies that the initiative funds. Finally, we support NCSi researchers in communicating their work to policymakers, the media and the public in an accessible manner to maximise its impact and reach.

Keeping members informed

The BSI works hard to ensure good communication channels with our members, the wider immunology community and the public informed about our activities and about developments in immunology in the wider world. This has been a particularly important part of our activities this year with the COVID-19 pandemic. The popularity of our website continues with 4.18 million page views this year and 2.36 million unique users.

Our infographics on COVID vaccines continue to be the most viewed pages on the site, with our comparison of 'COVID-19 immunity: Infection compared with vaccination' the most read page during the year.

4.18m
page views

2.36m
unique users

BiteSized Immunology, our online resource designed to form a comprehensive guide to the immune system continues to be popular with five of the top ten most read pages.

Our social media channels continue to grow in importance as a way of engaging with our membership and the wider world at a more immediate level, to interact with our supporters and spread the word about our work and the wonders of immunology. Across all channels, our social media posts were seen over 5.5 million times.

Championing careers

The BSI provides several grant schemes to our members to support their work and their career development. These include a variety of activities – from covering the travel costs to conferences, to providing financial support for carers, support for public engagement initiatives and those that promote diversity and inclusion within immunology. We are very proud of the range of support we've provided to members over the last 12 months.

**£225k grants
awarded**

**339
members
supported**

In 2021 we launched new Regional and Affinity Group Travel Grants and Carers Grants – to support our members to attend in person meetings run by the BSI.

18 Communication and Engagement Grant were awarded to support public engagement projects run by our members

8 Carers' Grants were provided to support attendance at BSI conferences

Projects supported through our Equality, Diversity and Inclusion Activity Grant include:

- Staff workshop to raise awareness of race-related issues in the workplace
- Work experience scheme for year 11 and 12 students from backgrounds that are underrepresented in science
- Diversity episodes of popular science podcast

Career Enhancing Grants

Supporting current and future generations of immunologists throughout their careers is a vital part of our mission. This year, we launched a new grant scheme, our Career Enhancing Grants, to invest significant funds to provide flexible financial support to help our members reach their career goals. This scheme was developed in response to feedback from our membership about the difficulties many were encountering in accessing this type of funding, particularly in the wake of the COVID-19 pandemic.

**£125k
Career
Enhancing
Grants**

**36 members
supported**

**Generate pilot data
Training courses
Lab visits**

Mentoring scheme

Our highly successful mentoring scheme brings together senior scientists with early career researchers to assist the next generation of immunologists with career development and progression. The popularity of this scheme has flourished in recent years with 50 pairs matched up in this year's cycle. Over the last full cycle of the scheme, 90% reported the scheme met all or most of their goals, with all participants saying they were either very or fairly well matched.

Clinical immunology training days

We partner with the Association of Clinical Pathologists (ACP) to run clinical immunology training days aimed at medical trainees in immunology and allergy, and immunology clinical scientists preparing to sit the Royal College of Pathologists in Immunology exams.

By working together, the ACP and BSI ensure the continuous delivery of these highly valued training sessions, helping to create a new generation of immunology-aware and informed clinicians and clinical scientists across the NHS to improve the care and treatment of patients with immune-mediated disease. The training events themselves are consistently ranked as excellent by attendees who value the targeted content.

"A really inspiring talk and overview of a potentially difficult subject for clinicians. Very relevant and an area I often feel under confident with" Training session attendee.

Celebrating excellence

Our members use their skills to work in many different sectors and drive excellence in immunology in a plethora of ways. It's the BSI's honour to recognise the outstanding achievements of our members in all spheres of work that make up immunology.

Honorary members

Our honorary membership scheme recognises individuals who have made an outstanding contribution to immunology and/or to the Society. At BSI Congress 2021, we were delighted to award Lifetime Honorary Membership to six members:

- Professor Danny Altmann (Imperial College London)
- Professor Dame Sarah Gilbert (University of Oxford)
- Professor Teresa Lambe OBE (University of Oxford)
- Professor Paul Moss OBE (University of Birmingham)
- Professor Sir Andrew Pollard (University of Oxford)
- Professor Dame Fiona Powrie (University of Oxford)

BSI Global Impact and Innovation Award

This year, we presented this special one-off award to all those involved in the design and development of the Oxford/AstraZeneca COVID-19 vaccine to recognise the huge achievement in developing this vaccine in such a short time period. This award recognises the contributions of the researchers in the lab and the clinics who designed and tested the vaccine, but also their support networks – legal, technical, admin, IT support, housekeeping, childminding – and the volunteers from the public who stepped forwards to take part in the clinical trials. At time of writing, more than 3 billion doses of this vaccine have been supplied to 183 countries around the world. It's estimated that this vaccine has saved 6.3 million lives in its first year of rollout, more than any other COVID-19 vaccine. This truly is an unprecedented achievement.

Bright Sparks in Immunology

Our 'Bright Sparks' sessions at BSI Congress aim to highlight exceptional work from PhD students and postdoctoral researchers. The standards of presentations this year were incredibly high and we were pleased to award the following winners.

Postdoctoral category winners

- First: Dr Johanna Kabbert (Lund University) – High microbiota reactivity of human intestinal IgA requires somatic mutations
- Second: Dr Lucy McShane (University of Glasgow) – TAM receptor Axl loss accelerates atherosclerosis in mice
- Third: Dr Andrew McLean (University of Oxford) – Alveolar macrophages coordinate early migration and differentiation of lung resident memory B cells at infected sites after influenza rechallenge

PhD category winners

- First: Lucia Labeur Iurman (Imperial College London) – An enriched IL-2 environment in early life limits T follicular helper cell development and protective immunity after respiratory virus infection
- Second: Julie M Mazet (University of Oxford) – Interferon-gamma regulates anti-tumour response by restricting cytotoxic T cell potential in melanoma
- Third: Harry Horsnell (University College London) – Lymph node homeostasis and adaptation to immune challenge resolved by fibroblast network mechanics

Immunology Teaching Excellence Award

This award recognises exceptional immunology teaching in a higher education setting in the UK. Our winner this year was Dr Nicholas Barnes (University of Manchester). He was particularly praised by the judges for his creative approach to pilot use of a web-based resource of patient cases, allowing students to formatively develop their clinical and scientific interpretative skills in an interactive, safe environment and encouraging peer-discussion, learning and reflection.

We plan to ramp up our efforts over the coming year to recognise excellence in immunology. Keep an eye on our website for more details!

Catalysing change

Partnerships

Working in partnership is a key part of the British Society for Immunology's strategy to build the impact that we can deliver for immunology. We engage with like-minded organisations to collaborate on areas of common interest and perspective, with areas of interest ranging from autoimmunity, to cancer and vaccines. By using our profile, expertise and reach, we can shine a light on the importance of critical areas of immunology to attract new focus and funding.

New funding for autoimmune research

Through our Connect Immune Research alliance, we partnered with The Lorna and Yuti Chernajovsky Biomedical Research Foundation, to award grants totalling £1 million to ten 12-month pilot research projects to identify the underlying causes of autoimmune diseases and generate new treatments. The studies examine a variety of areas including the genetics of autoimmunity, potential new immunotherapy treatments and how different immune cell types are involved in the development of autoimmune conditions. On completion, the most promising projects will be invited to apply for follow-on funding to take their work forward.

This initiative has shined a spotlight on the importance of this research area and provided important new funding for this important work. Our ultimate aim is to deliver significant new investment to confront the UK's high prevalence of autoimmunity and develop new treatments for multiple autoimmune conditions, faster.

The value of veterinary vaccines

We partnered with the International Veterinary Vaccinology Network to publish a joint report on value of veterinary vaccinology research, which reviews the current state of the veterinary vaccinology landscape and sets out the key recommendations to maintain the UK's leading role in this area.

Supporting efforts to improve animal health is a key area of work for the BSI. This report aims to help funders and policymakers better understand the vital need to invest in animal vaccine development to secure our food, economy and health for the future. The UK is a world leader in the field of veterinary vaccinology, but lack of investment and further funding cuts threatens this excellence, food security and our ability to respond to global health challenges. The report lays out immediate measures that can be taken to remove known barriers and ensure the numerous benefits of veterinary vaccines are reaped by millions around the world. It is only by investing in veterinary vaccine research, career development, collaborations and infrastructure that we can secure our future.

EFIS Vaccine Task Force

The BSI chairs Vaccine Task Force of the European Federation of Immunological Societies (EFIS) to bring together immunologists from across Europe to pool resources and expertise to encourage the vaccine uptake by providing a strong, engaging, evidence-based and collective voice. Although the Task Force was established to tackle general vaccine uptake across Europe, due to the pandemic, focus recently has been on increasing public confidence in COVID-19 vaccines across Europe.




Over the last year, the Task Force has delivered several major projects including both policy reports providing the latest updates on the COVID-19 vaccines and public engagement work. For the latter, we have produced infographics for the public describing how vaccines work and why they are important, with a particular focus on COVID-19 vaccines. Languages covered so far include French, German, Greek, Irish, Lithuanian, Polish, Spanish and Ukrainian.

Public engagement

Our public engagement work over the last 12 months has focused primarily on COVID-19 and vaccines. We have used a wide variety of methods and routes to engage with different communities to understand and answer their questions around COVID-19 vaccines.


#VaccineConversations

Empowering our members to engage with their family, friends and communities to have meaningful conversations about vaccines, and in particular COVID-19 vaccines, has been a core facet of our public engagement work. These conversations from trusted individuals are incredibly important in strengthening public understanding and helping people make informed decisions about vaccination.



We have continued to work with our members to help them have these conversations by providing a range of resources to build communication skills and aid these conversations, including sharing expert tips on having constructive conversations about vaccinations. We have also continued to develop a range of engagement resources around COVID-19 vaccines, including an updated version of our highly rated comprehensive “Guide to COVID-19 vaccinations” and a number of infographics to explain key facets of our understanding of how vaccines work and how they increase immunity to SARS-CoV-2.

We have also continued to run our very popular Instagram Q&A sessions on COVID-19 vaccines where members of the public can send in their questions for an immunology expert to answer. We also branched out into the arts sphere to encourage hands on learning through a new origami to create paper viruses and antibodies.



Partnership for maximum impact

To build public trust and confidence in COVID-19 vaccines, it's important that we work with a variety of organisations to increase our reach into different communities. Throughout the pandemic, the BSI has partnered with a wide variety of organisations to make sure our information is getting out to those who need it. As well as our work with several local councils (see below), we worked with the Cabinet Office to help find immunologists to speak at their 'Keeping communities safe' webinars, targeted at an audience of community leaders nationwide. We also presented our own engagement work at this webinar series, gaining lots of praise for our initiatives and leads for new collaborations with local authorities, charities and community groups.

We also partnered with NHS England, NHS Improvement and the COVID Vaccine Connect and Research Hub on several projects, including producing flashcards targeted at different communities providing answers to key questions around COVID-19 vaccines and providing speakers for webinars on the topic aimed at healthcare professionals.

Throughout this work, we have not lost focus of the importance of continued engagement around childhood vaccinations to encourage uptake and answer any questions parents have. A major project we undertook this year on this was to partner with the Department of Health and Social Care to create engaging short videos about the importance of childhood vaccinations, featuring BSI members answering common questions. These videos have been shared widely on social media channels, including Twitter and Facebook, throughout the year, and have been viewed by many thousands of people, helping to increase awareness of the importance of these vital vaccinations.

Effective conversations on COVID-19 vaccines

There has never been a more important time for immunologists to engage with the public about vaccinations by listening to and addressing questions and concerns. While the BSI and our members are ideally placed to be expert sources of knowledge in these dialogues, working in partnership with organisations that support local communities is powerful in reaching wider audiences. This year, the BSI collaborated with the London Borough of Bexley and Bexley Voluntary Services Council, and later with Birmingham and Newcastle City Councils, on programmes to train 'vaccine champions' within local community groups to have effective conversations with their peers about COVID-19 vaccines.


The programme was developed to train people who hold social capital in communities by combining our expertise in immunology with the expertise of the local area and people. Sessions were led primarily by BSI members, who were skilled communicators, with appearances from local community leaders. The sessions were user-led, meaning that participants shared key questions they and their communities had on COVID-19 vaccines and the course content was adapted to address these.

Participants were very positive about the training, with 100% of the community leaders feeling better informed, more knowledgeable and more confident about having effective conversations about COVID-19 vaccinations. All community leaders reported having increased the number of people they talked to about COVID-19 vaccines.

Patient and public involvement

Following our delivery of patient and public involvement (PPI) within the UK Coronavirus Immunology Consortium (UK-CIC), we partnered with them to publish a report to celebrate and showcase the positive impact of involving patients and the public in immunology research.

UK-CIC brought together laboratory-based scientists and clinicians with the experience and unique perspectives of patient and public contributors. The PPI panel within UK-CIC provided a platform for regular two-way conversations with researchers to address key questions about the implications of the research as well as discussions about what was important to the public and patient groups.



This report provides a guide to our experiences of running that project and practical suggestions of how to bridge the gap between basic research and the lived experiences of patients and the public. By sharing learning and knowledge from UK-CIC and presenting the beneficial influence that PPI brings to science, we hope this report acts as a guide on how to include more PPI in immunology research.

Policy highlights

The COVID-19 pandemic has dominated the BSI's policy work over the past 12 months. The Society has continued to use our powerful voice to advocate for immunological science and health throughout this time, ensuring the voice of immunologists is heard loud and clear in public debates, and that policy-makers have access to the latest immunological thinking. With our dynamic approach, working through our COVID-19 Taskforce, we have played a strong role in both ensuring the expert voice of immunologists is represented in public debate and how the lessons learnt from the COVID-19 pandemic response can be brought to wider areas of health research.

BSI COVID-19 Taskforce

Our expert taskforce has continued to work hard this year ensure that we can respond quickly to the developments of the COVID-19 pandemic as and when they arise. Our huge thanks to the taskforce members who have contributed to this work. Important highlights from this work include:

- Publishing a FAQ style briefing paper on 'What we know about COVID-19 immunity' in winter 2021 aimed at MPs, members of the House of Lords and policymakers. The goal of this was to provide an easy-to-understand summary of this fast-moving area of scientific understanding to facilitate more evidence-based policymaking.
- At the request of Sir Patrick Vallance and the BEIS Vaccine Taskforce in winter 2021, our group prepared a list of what it believed to be the pressing immunological research questions that affect public health in relation to the Omicron variant.
- Responded to several Parliamentary consultations including on the idea of vaccine mandates for healthcare workers, biological security strategy and UK science and technology strategy.
- Met with a number of high profile politicians including Maggie Throup MP, Vaccines Minister, to discuss next generation vaccines and learning lessons of the COVID-19 vaccine deployment.

Westminster Hall debate

The BSI has worked tirelessly to raise the ongoing importance of immunology research to the pandemic response. Following the efforts of our COVID-19 Taskforce, we worked closely with Jim Shannon MP, DUP Spokesperson for Health, to secure a Westminster Hall debate on 'Immunology Research and COVID-19'. We provided Mr Shannon with a briefing on important issues to raise in the debate and he was able to discuss most of these in presenting the case to the Minister, highlighting the important gains in knowledge that immunology research into COVID-19 has delivered to build our understanding and deliver treatments and vaccines against the disease. This is an important step forward in our policy work and in raising the profile of immunology and the BSI – debates such as these allow us to get issues on the radar of the relevant Minister, and elicit an official response.

Enablers

To deliver our ambitious strategic aims, we need to maintain the BSI as a sector-leading organisation. We will do this by:

- Creating a larger and more diverse engaged membership
- Embedding quality, diversity and inclusion in all our activities
- Ensuring the Society's financial sustainability

Enabler - membership

Our membership is the foundation of our Society. We are ambitious in what we want to deliver for immunology and for our members. As the discipline of immunology grows and evolves, we aim to evolve too to ensure we engage with, support and are relevant to immunologists from across the spectrum of our discipline. As the largest professional immunology society in Europe and third largest in the world, we aim to stand shoulder to shoulder with our members to support and champion the discipline of immunology to drive scientific discovery and make a positive impact on health.

New support and engagement opportunities for members this year

One of our key aims to increase membership engagement opportunities has been well and truly met this year with a plethora of new activities and support to enable increased involvement and support for our members across the spectrum of BSI's work. This included:

- New Career Enhancing Grant to provide up to £5,000 of flexible career funding
- Travel and carers grants to support attendance at BSI Regional and Affinity Group conferences
- Additional opportunities to get involved in our public engagement programme on vaccines
- Established Early Career Editorial Boards for two of our journals, Clinical & Experimental Immunology and Immunotherapy Advances
- Both in person and online options to attend BSI Congress

- New Diversity and Inclusion Framework launched with increased opportunities to get involved in our EDI activities
- Increased investment in autoimmune research through our Connect Immune Research and Chernajovsky Foundation partnership

Immunology News

Members in the UK have the opportunity to receive a printed copy of our quarterly membership magazine, *Immunology News*, with online access around the world. Immunology News amplifies the voice of our membership and highlights how we're supporting our members and representing immunology on a wider stage.



Over the last year editions featured the BSI 2021-2025 strategy, the launch of our brand-new Open Access journal, *Discovery Immunology*, a recap of highlights from BSO Congress 2021. The 2022 summer issue was a special edition marking the launch of our new Diversity & Inclusion framework where we lay out how we are going to work with our members and community to progress equity, diversity and inclusion (EDI) work and showcasing the amazing EDI activities being carried out by our members.

Corporate members

We would like to thank our corporate members whose continuous support enables us to undertake our work

20Scientific

10X GENOMICS

InvivoGen

abbvie

BECKMAN
COULTER

MABTECH

MERCK

Miltenyi Biotec

nanoString

STANDARD
BIOTOOLS

Takeda

abcam

BIO-RAD

PEPROTECH.
OUR SUPPORT. YOUR DISCOVERY
Part of Thermo Fisher Scientific

STEMCELL
TECHNOLOGIES

absolute
antibody

BioLegend®
Enabling Legendary Discovery™

CURIOX

pe
peptides&elephants

Enabler - Equality, diversity and inclusion

The BSI wants diversity and inclusion to be at the heart of the ethos of our community. We took a big step forward in our endeavours this year by publishing our new 'Diversity and Inclusion Framework'. This brings together all the BSI's activities in this space to outline our commitment to how we are going to work with our members and community to ramp up our equity, diversity and inclusion work and respond to members' needs. Developed in consultation with our Board of Trustees and Forum members, our aim is to foster a culture within immunology that ensures fair treatment and opportunity for all. By building on past and ongoing activities, this framework set out our long-term plan of action for diversity and inclusion at the BSI.



Enabler - Financial sustainability

Income diversification

To deliver our ambitious strategic plans, we need to maintain the BSI as a sector-leading organisation, and one of the crucial enablers to do so is our financial sustainability. Traditionally, the BSI has heavily relied on journal income to fund our charitable activities. With current changes within the scholarly publishing landscape, we need to secure new income streams which will provide funding for our activities and maintain the long-term financial security of the Society, while also allowing us to make a positive contribution to the immunology sector. The development of new income streams is not a quick process as there is often a delay between investment and return requiring the use of reserves. However, our strong reserves have been built up for exactly this purpose to support us through this transition and their use is now carefully planned. The key areas of our current work are discussed below.

Widening our journals portfolio

Changes to our publishing portfolio (as discussed on page 5) in tandem with the global move towards Open Access publishing have seen the BSI significantly evolve our journals strategy. The overall aim behind this is for the Society to reduce our reliance on journal income, particularly that from traditional subscription journals, while making sure we develop a modern publishing portfolio that meets the needs of our members and wider immunology community.

The initial launch of our first Open Access journal, *Immunotherapy Advances*, was swiftly followed this year by the debut of a new Open Access journal for the BSI, *Discovery Immunology*. This, partnered with our moves this year to secure the future of *Clinical & Experimental Immunology*, mean that the Society is now in strong position to stabilise our future journals income, whilst reducing our overall reliance on this.

Supporting immunology research

We have recently expanded our activities to include providing support to wider immunology research efforts. Within the BSI staff, we have many specialist skills – such as communications, public engagement and involvement, governance – that we can bring to large research consortia and networks to support their smooth running, effectiveness and impact.

Prestigious projects we have worked with over the last 12 months include the UK Coronavirus Immunology Consortium, a nationally targeted effort to understand the immunology of SARS-CoV-2 and COVID-19, the SIREN (SARS-CoV-2 immunity and reinfection evaluation) study, National Core Studies Immunity and the CARINA (CATalyst Reducing ImmuNe Ageing) Network (see page 7 for more details). This type of funded project, through which we support the delivery of existing and new immunology consortia, is an important new source of income for the organisation, and which is expected to contribute over 10% of our income next year.

Future direction

We have several additional new projects under development, which all fulfil our goals of making a positive contribution to the immunology sector whilst also diversifying the BSI's income. Key amongst these is to develop a training programme within the Society to meet the needs of both immunologists, helping them keep their skills up to date and relevant, as well as non-immunologists who want to understand the basics to help them in their jobs.

Structure, Governance and Management

Charitable status and administrative details

The Society was registered as a charity in 1966 (Charity number 1043255) and incorporated in England and Wales as a company, limited by guarantee (Company number 03005933). The Society's registered address is 9 Appold Street, London EC2A 2AP. It has no share capital and the liability of its members is limited to a sum not exceeding £1. The Society's governing document is the Memorandum and Articles of Association, which was amended on 7 December 2016.

It is also a registered charity in Scotland (Charity number SC047367).

Board of Trustees

The Trustees are company directors for the purposes of the Companies Act and charity Trustees for the purposes of the Charities Act 2011. The current trustees, and any past Trustees who served during the year are listed on page 54.

The Trustees are responsible for directing the Society's activities and for overseeing the management of the affairs of the Society, they delegate the day to day management of the organisation to the chief executive and the senior management team. The Board acts on advice and information from regular meetings with the chief executive and the senior management team.

As part of their induction process, Trustees spend some time with the chief executive and senior management team. They are provided a trustee resource pack containing the history of the Society and key information they require to fulfil their duties as Trustee, they are also offered training for new Trustees.

The success of the Society belongs in part to the large number of people who generously volunteer their time to add their experience to our collection of committees, we thank you all.

Finance Sub Committee

The Finance Sub Committee ensures the system of internal control is satisfactory to deliver regulatory compliance, financial probity, value for money, challenge of financial plans, budgets and financial statements, oversight of the annual financial audit, review of investment policy and performance, review of reserves policy, and CEO and staff remuneration.

Nominations Committee

The BSI's Nominations Committee has general oversight concerning the structures and effectiveness of BSI Board of Trustees, committees, advisers and observers. It is also responsible for nominating individuals to represent the views of the BSI on external committees and to identify BSI members to nominate for external awards.

Forum

The Forum represents a diverse mix of immunologists from different career stages, backgrounds and geographic locations, it is the BSI's 'think tank' and the place where issues and ideas that are of importance to the Society and its member are raised, discussed and developed.

Congress Committee

The Congress Committee is responsible for the planning and delivery of the BSI's flagship event, BSI Congress, which takes place two out of every three years. It reviews and approves the scientific programme for Congress.

Clinical Committee

The Clinical Committee represents the wider clinical immunology and allergy community and aims to enhance communication between scientific and clinical immunology communities.

Group structure

The Society has one wholly owned subsidiary:

BSI Trading Limited is registered in the UK under company registration number 010201739. Its principal activity is to manage the corporate membership, sponsorship, exhibition and other trading activities for the Society. This primarily comprises exhibition and sponsorship for the BSI Congress.

Financial Performance

This year the BSI entered our transition period following the changes to our publishing portfolio. The Society moved to a net deficit of £0.63m from net income of £0.87m last year. The operating deficit before investments were better than budget, however losses on the value of our investment portfolio pushed the net deficit for the year higher.

The BSI team rose to the challenge again this year posting total income slightly higher than 2021, however the income mix changed significantly.

Total income	2022 	£2.21m
	2021 	£2.19m


Publishing income remains the BSI's largest source of income, however this fell by 41%, the BSI received six months income for *Immunology* following the return of the journal to Wiley, the Society's previous publisher.

We welcomed Congress back in December 2021 with a record level of attendees. This together with a strong demand for exhibition space and sponsorship pushed the event to its highest ever income for a BSI-only Congress.

The Society continued its recent success obtaining funding our work supporting the immunology community's work on COVID-19 projects. Total grants received were £0.25m an increase of 66% from last year. A grant for £157k was received for creating a central co-ordination hub for COVID-19 immunology research investments and outcomes. Moving away from COVID the Society started a two-year project to provide admin support to the new 'Ageing Across the Life Course' interdisciplinary research network.

Demand for the Society to provide Patient and Public Involvement (PPI) in projects is growing following the success of providing these services as part of our work in the above projects. Although relatively small this is an area for potential growth.

COVID-19 continued to have a significant impact on the society's activities during the year; travel restrictions reduced our programme of physical events leading to reduced costs, although the Society was delighted to re-start our Conference travel grants in 2022. The launch of our new Career Enhancing Grants was successful with £125k of grants awarded in its first year.



BSI Trading Limited posted an annual profit of £0.34m (2021: £0.12m) following the return of Congress. This was gifted to the society.

The Society is in a transition period following the reduction in journal income. The Society is focusing on developing new income streams; however, this will require investment from our reserves. During this period, we are forecasting costs to exceed income over the next few years until the new income streams start generating funds.

Investment policy and performance

The Society operates an investment policy to provide income and generate capital growth. The Society is a long-term investor and the value of its investments remains significant above its original investment.

It has been a challenging year for investments. In the first half of the year our investment portfolio rose; however, the invasion of Ukraine triggered a sharp decline. During the spring the portfolio slowly regained some lost ground however it never made its way back to its highpoint at the end of December. The worsening cost of living crisis produced falls in investment values in June.

Funds are invested with abrdn (formerly Aberdeen Standard Chartered) with a long-term objective to generate a capital return of 3% more than inflation over a three year rolling period. As note above performance was challenging this year resulting in net losses of £0.31m (2021: £0.51m gain). The value of the portfolio fell by £0.31m (2021: rise of £0.51m). On 30 June 2021 investments were valued at £4.26m (2021: £4.45m).

The Finance Sub Committee is responsible for reviewing investment performance and policy.

Reserves policy

The BSI operates a risk-based approach to reserves to ensure the BSI holds the most appropriate level of reserves to cover potential risks and to fund invest in new income sources securing the BSI's long term financial health.

The risk register is reviewed annually with monetary values allocated to specific risks, restricted and designated funds. A provision for unknown risks (to give cover for those risks of which the society is not yet aware) is calculated based as a percentage of the risk adjusted fund.

The latest review resulted in total required allocated reserves of £3.71m (2021: £2.75m). On 30 June 2022 total reserves were £4.31m, including free reserves (unrestricted reserves less fixed assets) of £4.03m giving an excess over the target of £0.32m (2021: £2.11m) available for use by the Society to further its strategic aims. Details of restricted funds can be found in note 17 of the accounts with details of designated funds in note 18.

The calculation of the total required allocated reserves is performed on an annual basis.

Pay policy

The Society's pay policy aims to ensure that all employees are paid at least the market median for their roles with the ability of high performers to move towards the upper quartile.

Salaries, including Key Management Personnel, are reviewed by the Finance Sub Committee with recommendations for the annual pay rise proposed to the wider Board of Trustees for approval as part of the annual budgeting process. The salary of the Chief Executive is reviewed annually by the Board of Trustees.

To increase transparency the Society's is voluntarily reporting its gender pay gap. Calculated in June 2022 the Society's mean gender pay gap is 32% (June 2021: 26%). The pay gap indicates that while 72% of employees are women (2021: 68%), most men are in management roles. The Society employs more women in each of the quartile pay bands.

The Society strongly supports equal pay, with individuals with the same responsibilities being paid the same irrespective of gender.

Risk management

Good risk management is fundamental to the continued work and sustainability of the Society. We identify and manage risks that could adversely impact the achievement of our strategic purpose and determine the calculated risks we need to take to succeed.

The Society operates a formal framework for the management of risk, taking the view that risk can be positive (opportunity) or negative (threat). The Society operates a risk register incorporating strategic, operational and compliance risks, which are informed by the Society's strategic objectives, performance, voice of our stakeholders, regulatory environment and analysis of the external environment.

The Board delegates day-to-day responsibility for risk management to the Senior Management Team, who are responsible for identifying and evaluating risks to their areas and activities implementing appropriate controls for ongoing mitigation and monitoring.

The Financial Sub Committee reviews the management of risk in detail at each meeting and the Board reviews the Society's strategic and compliance risks twice a year.

The major risks facing the society and the mitigation that we have put in place are as follows:

Risk	Risk response
Failure to diversify our income The Society is heavily reliant on a single source of income: journals.	The Society is proactively looking for new funding: ▪ Working with partners to develop important relationships with funders delivering increased grants and donations ▪ Implementing a fundraising strategy to develop new income streams
Loss of significant devaluation of investments A devaluation in the value of investments would result in a reduction of reserves available to use by the Society. Investments could be impacted by sudden unforeseen global events	The Society ▪ Reviews investment performance during each Financial Sub Committee meeting ▪ Communicates regularly with our investment managers, especially through times of significant volatility

Fundraising statement

Although the Society does not actively fundraise from members, occasional donations are received. The Society applies best practice in the tone of its communications and the accuracy of its data to minimise the pressures on supporters. The Society applies best practice to protect supporters' data, never sells or swaps it and ensures that communication preferences can be changed at any time. The Society commits to react to and investigate any complaints received, to learn from them and improve its service. During the year, the Society received no complaints about its fundraising activities.

Future plans

During 2022-23 the Society will focus on:

Connected community

- Delivering a successful Congress 2022
- Delivering a new BSI awards ceremony

Championing careers

- Successfully increase the careers support the BSI provides to members

Catalysing change

- Continuing the BSI's successful partnership work
- Expanding the BSI's PPI activities

Enabler - membership

- Launching a refreshed membership offer
- Launching a new website

Enabler - Equality, diversity and inclusion

- Collecting benchmark EDI data on BSI activities

Enabler - Financial sustainability

- A smooth transition to long-term hybrid working
- Launching new income generating activities

The Senior Management Team and the Trustees continue to assess the impact of COVID-19 on the Society, together with all other significant risks, in the immediate, medium and longer term.

Trustees' responsibilities

The Trustees (who are also directors of British Society for Immunology for the purposes of company law) are responsible for preparing the Trustees' report and financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the Group and Society and of the income and expenditure of the Group and Society for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable to the United Kingdom and Republic of Ireland; and
- make judgements and estimates that are reasonable and prudent;
- state whether applicable United Kingdom Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume the charity will continue in operation.

The Trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the Group and Society and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Group and Society and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Each of Trustees confirm that:

- so far as the Trustee is aware, there is no relevant audit information of which the Group and Society's auditor is unaware; and
- the Trustee has taken all steps that he/she ought to have taken as a Trustee in order to make himself/herself aware of any relevant audit information and to establish that the Group and Society's auditor is aware of that information.

This confirmation is given and should be interpreted in accordance with the provisions of s418 of the Companies Act 2006.

The Trustees are responsible for the maintenance and integrity of corporate and financial information included on the Society's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Approved by the Trustees and signed on their behalf by:

Arne Akbar
BSI President



Date:

19/10/22

Independent Auditor's Report to the members and trustees of the British Society for Immunology

Opinion

We have audited the financial statements of the British Society for Immunology for the year ended 30 June 2022 which comprise the Group Statement of Financial Activities, the Group and Parent Charitable Company Balance Sheets, the Group Cash Flow Statement and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

give a true and fair view of the state of the group's and the parent charitable company's affairs as at 30 June 2022 and of the group's incoming resources and application of resources, including its income and expenditure, for the year then ended;

have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and have been prepared in accordance with the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 (as amended), regulations 6 and 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended) and the Charities Act 2011.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs(UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

the information given in the trustees' annual report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
the trustees' annual report have been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the group and parent charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the trustees' annual report.

We have nothing to report in respect of the following matters where the Companies Act 2006, the Charities Accounts (Scotland) Regulations 2006 (as amended) and the Charities Act 2011 require us to report to you if, in our opinion:

the parent charitable company has not kept adequate and sufficient accounting records, or returns adequate for our audit have not been received from branches not visited by us; or
the parent charitable company's financial statements are not in agreement with the accounting records and returns; or
certain disclosures of trustees' remuneration specified by law are not made; or
we have not received all the information and explanations we require for our audit; or
the trustees were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies exemption in preparing the Trustees' Annual Report and from preparing a strategic report.

Responsibilities of trustees

As explained more fully in the trustees' responsibilities statement, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the group and parent charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the group or parent charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

We have been appointed as auditor under Section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005, the Companies Act 2006 and Section 151 of the Charities Act 2011 and report to you in accordance with regulations made under those Acts.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below.

Explanation as to what extent the audit was considered capable of detecting irregularities, including fraud

The objectives of our audit in respect of fraud, are; to identify and assess the risks of material misstatement of the financial statements due to fraud; to obtain sufficient appropriate audit evidence regarding the assessed risks of material misstatement due to fraud, through designing and implementing appropriate responses to those assessed risks; and to respond appropriately to instances of fraud or suspected fraud identified during the audit. However, the primary responsibility for the prevention and detection of fraud rests with both management and those charged with governance of the charitable company.

Our approach was as follows:

We obtained an understanding of the legal and regulatory requirements applicable to the charitable company and considered that the most significant are the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 (as amended), regulations 6 and 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended), the Charities Act 2011, the Charity SORP, and UK financial reporting standards as issued by the Financial Reporting Council

We obtained an understanding of how the charitable company complies with these requirements by discussions with management and those charged with governance.

We assessed the risk of material misstatement of the financial statements, including the risk of material misstatement due to fraud and how it might occur, by holding discussions with management and those charged with governance.

We inquired of management and those charged with governance as to any known instances of non-compliance or suspected non-compliance with laws and regulations.

Based on this understanding, we designed specific appropriate audit procedures to identify instances of non-compliance with laws and regulations. This included making enquiries of management and those charged with governance and obtaining additional corroborative evidence as required.

As part of an audit in accordance with ISAs (UK) we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purposes of expressing an opinion on the effectiveness of the group and parent charitable company's internal control.

Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the trustees.

Conclude on the appropriateness of the trustees' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the group and parent charitable company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the group or parent charitable company to cease to continue as a going concern.

Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit report.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Use of our report

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006; and to the charity's trustees, as a body, in accordance with Section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005, and in respect of the consolidated financial statements, in accordance with Chapter 3 of Part 8 of the Charities Act 2011. Our audit work has been undertaken so that we might state to the charitable company's members and trustees those matters which we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to any party other than the charitable company, the charitable company's members, as a body, and the charity's trustees, as a body for our audit work, for this report, or for the opinion we have formed.

Moore Kingston Smith LLP

Neil Finlayson (Senior Statutory Auditor)
for and on behalf of Moore Kingston Smith LLP, Statutory Auditor

Date 2 November 2022

9 Appold Street
London
EC2A 2AP

Moore Kingston Smith LLP is eligible to act as auditor in terms of Section 1212 of the Companies Act 2006.

British Society for Immunology
Consolidated Statement of Financial Activities
Year to 30 June 2022

		Unrestricted funds				
	Note	General funds £'000	Designated funds £'000	Restricted funds £'000	Total 2022 £'000	Total 2021 £'000
Income from:						
Grants and donations	2	6	-	274	280	190
Investments	3	151	-	-	151	113
Charitable activities	4					
Membership		160	-	-	160	145
Partnership work		91	-	45	136	78
Congress		512	-	-	512	-
Meetings and events		59	-	-	59	108
Journals		913	-	-	913	1,552
Total income		1,892	-	319	2,211	2,186
Expenditure on:						
Raising funds						
Investment management fees		41	-	-	41	36
Cost of raising funds		30	-	-	30	13
Charitable activities						
Membership		240	-	-	240	181
Congress		642	-	-	642	166
Meetings and events		184	-	-	184	253
Publications and journals		370	-	-	370	377
Policy and Public Affairs		130	-	45	175	181
National Research support		-	-	149	149	161
Partnership work		133	-	-	133	117
Education and Careers		68	125	5	198	67
Diversity and inclusion		4	-	-	4	-
Public engagement		116	-	2	118	73
Communications		228	-	-	228	169
International work		28	-	-	28	32
Total expenditure	6	2,214	125	201	2,540	1,827
Net income (expenditure) before gains (losses) on investments and transfers		(322)	(125)	118	(329)	359
Net gains/(losses) on investments	12	(305)	-	-	(305)	507
Transfers between funds		90	(90)	-	-	-
Net income/(deficit)		(537)	(215)	118	(634)	866
Reconciliation of funds:						
Funds brought forward		3,933	986	25	4,944	4,078
Funds carried forward		3,396	771	143	4,310	4,944

There are no recognised gains or losses other than those recognised above. All activities are continuing.

The notes on pages 35 to 53 form part of these financial statements

British Society for Immunology
Balance Sheet
30 June 2022

		Group		Charity	
		2022	2021	2022	2021
Fixed assets					
Tangible fixed assets	10	49	18	49	18
Intangible assets	11	93	37	93	37
Investments	12	4,259	4,454	4,259	4,454
		4,401	4,509	4,401	4,509
Current assets					
Debtors	13	552	130	875	264
Cash at bank and in hand		407	1,227	37	1,079
		959	1,357	912	1,343
Liabilities:					
Creditors: amounts falling due within one year	14	(1,050)	(922)	(1,003)	(908)
Net current assets		(91)	435	(90)	436
Net assets		4,310	4,944	4,310	4,944
Funds:					
Unrestricted funds					
General fund		3,396	3,933	3,423	3,933
Designated fund	16	771	986	771	986
		4,167	4,919	4,194	4,919
Restricted funds	15	143	25	116	25
Total		4,310	4,944	4,310	4,944

These financial statements have been prepared in accordance with the provisions applicable to the small companies regime.

These accounts were approved by the Board and authorised for issue on
signed on its behalf by:

and were

Arne Akbar, President



19/12/22

British Society for Immunology, Company Limited by Guarantee
Company Registration Number 03005933 (England and Wales)

The notes on pages 35 to 53 form part of these financial statements

British Society for Immunology
Consolidated Statement of Cash Flows
30 June 2022

	2022 £'000	2021 £'000
Cash flows from operating activities:		
<i>Net cash provided by operating activities</i>	(765)	203
Cash flows from investing activities:		
Income from investments	151	113
Purchase of tangible fixed assets	(40)	(11)
Purchase of intangible fixed assets	(57)	(37)
Proceeds from the disposal of investments	521	599
Purchase of investments	(659)	(595)
Net cash used in investing activities	(83)	69
Change in cash and cash equivalents in the year	(848)	270
Cash and cash equivalents at 1 July 2021	1,485	1,215
Cash and cash equivalents at 30 June 2022	637	1,485
Net income for the period (as per the statement of financial activities)	(634)	866
Adjustments for:		
Depreciation charge	9	9
(Gains) losses on investments	305	(507)
Investment income	(151)	(113)
(Increase) decrease in debtors	(422)	(8)
Increase (decrease) in creditors	129	(44)
Net cash provided by operating activities	(765)	203
Analysis of cash and cash equivalents		
Cash at bank and in hand	407	1,227
Cash held by investment managers	230	258
Total cash and cash equivalents	637	1,485

The notes on pages 32 to 50 form part of these financial statements

Notes to the financial statements

1 Accounting policies

The principle accounting policies adopted, judgements and key sources of estimation uncertainty in the preparation of the financial statements are as follows:

Basis of preparation

The financial statements are prepared on a going concern basis, under the historical cost convention modified to include the recognition of listed investments measured at fair value, which is consistent with the prior year. The financial statements have been prepared in accordance with the Statement of Recommended Practice: Accounting and Reporting by Charities ("The SORP"), the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102) and the Charities Act 2011.

The British Society for Immunology ("The Society") meets the definition of a public benefit entity under FRS 102.

General information

The Society is a charitable company incorporated in England and Wales (company number 03005933) and is a charity registered in England and Wales (charity number 1043255) and registered as a charity in Scotland (charity number SC047367). The Society's registered address is 9 Appold Street, London EC2A 2AP.

Critical accounting judgements and key sources of estimation uncertainty

The preparation of financial statements requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Group and Society accounting policies. In the application of the accounting policies, Trustees are required to make judgements, estimates and assumptions about the carrying value of assets and liabilities that are not readily apparent from other sources. The estimates and underlying assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision only affects that period, or in the period of revision and future periods if the revision affected current and future periods.

In the view of the Trustees, no assumptions concerning the future or estimation uncertainty affecting assets or liabilities at the balance sheet date are likely to result in a material adjustment to their carrying amounts in the next financial year.

Going concern

The financial statements are prepared on a going concern basis which assumes the Society and Group will continue to meet its liabilities as they fall due for a period of at least twelve months from the date of the approval of these accounts. The Trustees are monitoring the impact of Covid-19 on the Society and Group. This includes regular review of the pandemic's impact on our members and our ability to deliver our activities a flexible approach to our annual plan, rolling forecasts and in depth review of actual financial results.

The immunology community is at the heart of work on Covid-19 leading to the Society being busier than ever and attracting new funding to support this work. This together with the holding of significant levels of cash and investments result in the Trustees considering the Society and the Group to be a going concern.

Notes to the financial statements

Income

All income is recognised once the Society and Group has entitlement to income, it is probable that income will be received and the amount of income receivable can be measured reliably. Income of the Society is, where applicable, included net of Value Added Tax (VAT) and is allocated to the period to which it relates, carrying forward that part of the income relating to future accounting periods.

Investment income is recognised on a receivables basis and when the amount can be measured reliably.

Expenditure

Liabilities are recognised as soon as there is a legal or constructive obligation committing the Society and Group to that expenditure, it is probable that settlement will be required and the amount of obligation can be measured reliably. Expenditure is recognised on an accruals basis as a liability is incurred, inclusive of VAT, which cannot be recovered.

Expenditure is allocated to a particular activity where the cost relates directly to that activity. The cost of overall direction and administration of each activity, known as "support costs" and comprising the salary and overhead costs of the central function is apportioned based on staff time attributable to Support costs also include governance costs, which comprise organisational administration and compliance with constitutional and statutory requirements. The allocation of support and governance costs is analysed in notes 7 and 8.

Employee benefits

Short-term benefits including holiday pay are recognised as an expense in the period in which the service is received.

Termination payments are accounted for on an accruals basis and in line with FRS 102.

The Society contributes to a Group pension scheme, the assets of which are administered by Royal London Plc. They are defined contribution schemes. All contributed costs are accounted for on the basis of charging the cost of providing pensions over the period when the Society and Group benefits from the employees' service. The Society and Group has no further liability under the scheme.

Leasing and hire purchase commitments

Rentals paid under operating leases are charged to the income and expenditure account on a straight line basis over the lease term. The Society holds no assets under finance leases or hire purchase contracts.

Tangible fixed assets

Tangible assets are stated at cost less accumulated depreciation. Cost includes the original purchase price, costs directly attributable to bringing the asset to its working condition for its intended use, dismantling and restoration costs. The minimum threshold is £1,000. Depreciated is provided at 33% in order to write off each asset over its estimated useful life.

Intangible fixed assets

Intangible assets are stated at cost less accumulated amortisation. Cost includes the original purchase price, costs directly attributable to bringing the asset to its working condition for its intended use, dismantling and restoration costs. The minimum threshold is £1,000. Amortisation is provided at 20% in order to write off each asset over its estimated useful life. Assets in the course of construction are not amortised.

Notes to the financial statements

Investments

Investments are a form of basic financial instrument and are initially shown in the financial statements at fair value. Movements in the fair value of investments are shown as net gains and losses in the Statement of Financial Activities.

Profits and losses on the realisation of investments are shown as realised gains and losses in the Statement of Financial Activities. Net gains and losses on investments are calculated between sales proceeds and their opening carrying values or their purchase price if acquired subsequent to the first day of the financial year. Unrealised gains and losses are calculated as the difference between the fair value at the year end and their carrying value. Realised and unrealised investment gains and losses are combined in the Statement of Financial Activities.

The investment in the subsidiary undertaking is included at cost with provision being made for any permanent diminution in value.

Financial instruments

I) Financial assets

Basic financial assets, including trade and other receivables, cash and bank balances, are initially recognised at transaction value and subsequently measured at amortised cost. Other financial assets, including investments, are initially measured at fair value. Financial assets are derecognised when:

- a) the contractual rights to the cash flows of the asset expire or are settled, or
- b) substantially all the risks and rewards of the ownership of the asset are transferred to another party or
- c) despite having retained some significant risks and rewards of ownership, control of the asset has been transferred to another party who has the practical ability to unilaterally sell the asset to an unrelated third party without imposing additional restrictions.

Cash at bank and cash in hand includes cash and short-term highly liquid investments with a short maturity of three months or less.

II) Financial liabilities

Basic financial liabilities, including trade and other payables, are initially recognised at transaction price. Trade payables are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Financial liabilities held at amortised cost comprise all creditors except social security and other taxes and provisions.

Provisions

Provisions are recognised where the Society has a present legal or constructive obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Provisions are measured at the present value or the expenditures expected to be required to settle the obligation.

Notes to the financial statements

Fund accounting

Unrestricted funds are those funds available to the Society and Group for general purposes. They include funds designated by the Trustees for particular purposes where their use remains at the discretion of the Trustees. It is the policy of the Trustees to retain in unrestricted funds, amounts which in their judgement, can help to mitigate the short-term effects of income volatility; and retain as long-term investment funds to generate sufficient income to meet current and future operational activities of the Society.

Restricted funds are those funds available to the Society and Group restricted to a specific purpose or are subject to particular donor imposed conditions. Further information is available in the reserves section of the Trustees' report.

Notes to the financial statements

2 Income from grants and donations

	Unrestricted funds £'000	Restricted funds £'000	2022 Total funds £'000	2021 Total funds £'000
Grants	-	249	249	149
Donations	6	25	31	41
Total	6	274	280	190

3 Income from investments and interest

	Unrestricted £'000	Restricted £'000	2022 Total £'000	2021 Total £'000
Listed investments				
Investment Income	151	-	151	113
Bank deposit interest	-	-	-	-
Total	151	-	151	113

4 Income from charitable activities

	Unrestricted funds £'000	Restricted funds £'000	2022 Total funds £'000	2021 Total funds £'000
Member subscriptions	160	-	160	145
Corporates and partnership income	91	45	136	78
Congress	512	-	512	-
Meetings and events	59	-	59	108
Journals	913	-	913	1,552
Total	1,735	45	1,780	1,883

Notes to the financial statements

5 Total expenditure

	Unrestricted funds £'000	Designated funds £'000	Restricted funds £'000	2022 Total £'000
<i>Raising funds</i>				
Investment management fees	41	-	-	41
Fundraising	30	-	-	30
<i>Charitable Expenditure:</i>				
Membership	240	-	-	240
Congress	642	-	-	642
Other meetings and events	184	-	-	184
Publications and journals	370	-	-	370
Policy and Public Affairs	130	-	45	175
National Research support	-	-	149	149
Partnership work	133	-	-	133
Education and Careers	68	125	5	198
Diversity and inclusion	4	-	-	4
Public engagement	116	-	2	118
Communications	228	-	-	228
International Work	28	-	-	28
Total	2,214	125	201	2,540

Allocation of support costs to charitable activities:

	Direct costs £'000	Support costs £'000	2022 Total £'000
<i>Raising funds</i>			
Investment management fees	41	-	41
Cost of raising funds	30	-	30
<i>Charitable activities</i>			
Membership	169	71	240
Congress	596	46	642
Other meetings and events	163	21	184
Publications and journals	309	61	370
Policy and Public Affairs	125	50	175
National Research support	149	-	149
Partnership work	112	21	133
Education and Careers	177	21	198
Diversity and inclusion	4	-	4
Public engagement	97	21	118
Communications	142	86	228
International Work	28	-	28
Total	2,142	398	2,540

Notes to the financial statements

5 Total expenditure (continued)

Support costs are as follows:

	2022 £'000	2021 £'000
Staff costs	198	185
Premises costs	30	71
Depreciation	9	9
IT and electronic communications costs	67	65
Other	81	50
Recruitment fees	0	9
Governance costs (note 6)	13	12
Total	398	401

Support costs have been allocated based on time spent by departments supporting the various activities.

	Unrestricted funds £'000	Designated funds £'000	Restricted funds £'000	2021 £'000
<i>Raising funds</i>				
Investment management fees	36	-	-	36
Fundraising	13	-	-	13
<i>Charitable Expenditure:</i>				
Membership	181	-	-	181
Congress	166	-	-	166
Other meetings and events	253	-	-	253
Publications and journals	377	-	-	377
Policy and public affairs	176	-	5	181
National Research support	-	-	161	161
Partnership work	87	-	31	118
Education and careers	62	2	3	67
Public engagement	73	-	-	73
Communications	146	-	23	169
International work	32	-	-	32
Total	1,602	2	223	1,827

Notes to the financial statements

6 Governance costs

	2022	2021
	£'000	£'000
Auditor's remuneration - audit	12	11
Auditor's remuneration - other	1	1
Total	13	12

7 Net income before gains (losses) on investments

This is stated after charging:	2022	2021
	£'000	£'000
Staff costs (note 9)	1,182	1,103
Operating lease rental	0	90
Depreciation	9	8
Auditor's remuneration - audit	12	11
Auditor's remuneration - other	1	1

Notes to the financial statements

8 Staff costs

Staff costs during the year were as follows:

	2022 £'000	2021 £'000
Wages and salaries	1,009	962
Social security costs	118	97
Pension costs	55	44
Total	1,182	1,103

The average monthly number of employees during the year was as follows:

	2022	2021
Direct charitable activities	16	17
Administration of the charity	3	3
	19	20

Number of employees whose annualised emoluments fall within following ranges for the year:

	2022	2021
£60,001 - £70,000	1	2
£70,001 - £80,000	-	1
£80,001 - £90,000	2	-
£130,001 - £140,000	-	1
£140,001 - £150,000	1	-

Pension contributions for these employees were £21,848 (2021 - £19,625).

The number of staff for whom retirement benefits are accruing under money purchase pension schemes amounted to 19 (2021 - 21).

The Society considers its key management personnel comprise the Trustees and the Senior Management Team (SMT). The Trustees provide their time free of charge. The total remuneration, employer's national insurance contributions, benefits and pensions paid to the SMT was £516,095 (2021 - £484,192).

The relevant staff costs have been included in the costs of charitable activities. The gender split in the society workforce is 67% female 33% male (2021: 74% female 26% male). All roles are evaluated and paid in accordance with external benchmarking irrespective of gender.

9 Trustees' remuneration

No trustees received any remuneration for his or her services during the year (2021 - none). During the year expenses totalling £4,783 (2021 - £nil) were reimbursed to 7 trustees (2021 - nil). In addition £5,483 was paid for travel and accommodation costs on behalf of trustees (2021: £nil).

One trustee received a £250 BSI Congress 2021 Education and Public poster prize for best presentation and a Communicating Immunology grant of £1,000 for his project entitled 'Superbugs'. (2021 - One trustee received a prize of £25 for best presentation as voted by attendees of a regional meeting).

Notes to the financial statements

10 Tangible assets of the Group and charity

	Website £'000	Computer equipment £'000	Total £'000
Cost or valuation			
At 1 July 2021	-	29	29
Additions	38	1	40
Disposals	-	-	-
At 30 June 2022	38	30	69
Depreciation			
At 1 July 2021	-	11	11
Charge for the year	-	9	9
Eliminated on disposal	-	-	-
At 30 June 2022	-	20	20
Net book value			
At 30 June 2022	38	10	49
At 1 July 2021	-	18	18

11 Intangible assets of the Group and charity

	IT software £'000	Total £'000
Cost or valuation		
At 1 July 2021	37	37
Additions	57	57
Disposals	-	-
At 30 June 2022	93	93
Depreciation		
At 1 July 2021	-	-
Charge for the year	-	-
Eliminated on disposal	-	-
At 30 June 2022	-	-
Net book value		
At 30 June 2022	93	93
At 1 July 2021	37	37

Construction of a new CRM system started in the year and is expected to be completed next year.

Notes to the financial statements

12 Investments

	Group		Charity	
	2022 £'000	2021 £'000	2022 £'000	2021 £'000
Market value at 1 July 2021	4,196	3,693	4,196	3,693
Disposals proceeds	(521)	(599)	(521)	(599)
Realised gains/(losses)	(57)	46	(57)	46
Additions at cost	659	595	659	595
Unrealised gains	(248)	461	(248)	461
Market value at 30 June 2022	4,029	4,196	4,028	4,196
Cash held with investment managers	230	258	230	258
Total investments	4,259	4,454	4,259	4,454

Total Group investments includes £100 investment in subsidiary.

	Group		Charity	
	2022 £'000	2021 £'000	2022 £'000	2021 £'000
At 30 June 2022 the listed investments comprised the following:				
UK equities	1,244	1,157	1,244	1,157
Overseas equities	2,270	1,944	2,270	1,944
Investment instruments	515	1,353	515	1,353
Total	4,029	4,454	4,029	4,454
Historical cost of listed investments	3,317	3,470	3,317	3,470

At 30 June 2022 no holdings held represents more than 5% of the total market value of the portfolio of listed investments.

Notes to the financial statements

12 Investments (continued)

Investment in subsidiary undertaking

The Society owns 100% of the ordinary issued share capital of BSI Trading Limited, a company registered in England and Wales (Company number 01021739). Its registered address is 9 Appold Street, London EC2A 2AP. The principal activity of the company is the management of corporate membership, sponsorship, exhibition and other trading activities for the Society.

A summary of the results of the subsidiary is shown below:

	2022 £'000	2021 £'000
Turnover	354	133
Operating costs	-	-
Operating profit	354	133
Administration costs	(19)	(10)
Profit(loss) for the financial period	335	123
Distribution to parent charity	(335)	(123)
Retained in subsidiary	-	-

The company's assets and liabilities at 30 June 2022 were as follows:

Assets	388	148
Liabilities	(388)	(148)
Net assets	-	-

13 Debtors

	Group		Charity	
	2022 £'000	2021 £'000	2022 £'000	2021 £'000
Trade debtors	358	14	341	14
Prepayments and accrued income	194	92	194	92
Amount owed by subsidiary undertaking	-	-	340	134
VAT receivable	-	24	-	24
Total	552	130	875	264

Notes to the financial statements

14 Creditors

	Group		Charity	
	2022	2021	2022	2021
	£'000	£'000	£'000	£'000
Trade creditors	355	60	345	60
Other taxes and social security costs	39	49	39	49
VAT payable	5	-	5	-
Other creditors	124	13	124	13
Accruals and deferred income	527	800	490	786
Total	1,050	922	1,003	908

Included within the above is deferred income as set out below:

	Group	Charity
	2022	2022
	£'000	£'000
Deferred income brought forward at 1 July	800	786
Additional income deferred during the year	459	422
Brought forward funds released in the year	(800)	(786)
Deferred income carried forward at 30 June	459	422

Deferred income comprises advance payments of journal royalties and memberships fees.

Notes to the financial statements

15 Restricted funds

	At 1 July 2021	Income	Expenditure	At 30 June 2022
Meeting funds	34	-	-	34
Autoimmunity	10	15	(13)	12
UK-CIC	(24)	53	(29)	-
Vaccine taskforce	-	25	(24)	1
BiteSized immunology	5	-	(5)	-
UK Covid Vaccines Research	-	157	(96)	61
Ageing and immunity	-	24	(24)	-
SIREN	-	10	(2)	8
Immunogenicity project	-	35	(8)	27
Total	25	319	(201)	143

Meeting funds

Donations to the Society by individuals to promote certain immunological issues.

Autoimmunity

A grant from the Lorna and Yuti Chernajovsky Biomedical Research Foundation for administrative support for the development and management of the autoimmune research initiative.

UK-CIC

A grant for the BSI support provided to the UK Coronavirus Immunology Consortium (UK-CIC) to understand the immunology of SARS-CoV-2 and COVID-19.

Vaccine taskforce

Funding from the European Federation of Immunological Societies (EFIS) for the EFIS Vaccine Taskforce work led by the BSI.

BiteSized Immunology

Donations received to update the BSI's online resource, BiteSized Immunology, which provides a comprehensive guide to the immune system especially suitable for biomedical undergraduates and those new to immunology.

UK Covid Vaccines Research Hub

Central co-ordination hub for COVID-19 immunology research investments and outcomes funded by UKRI via the National Core Studies programme.

Ageing and immunity

The CARINA (Catalyst Reducing ImmuNe Ageing) Network is a new collaborative network for researchers working on the immune system throughout the life course. The BSI has a leading role in supporting the network through provision of project management, events support, communications expertise and patient and public involvement (PPI).

Notes to the financial statements

15 Restricted funds (Continued)

SIREN

Recruitment, facilitation and reporting of findings from Patient and Participant Involvement workshops for the SIREN project funded by the UK Health Security Agency.

Immunogenicity project

Immunogenicity measures in vaccine development and decision making programme funded by Merck Sharp & Dohme (UK) Limited.

	At 1 July 2020 £'000	Income £'000	Expenditure £'000	At 30 June 2021 £'000
Meeting funds	34	-	-	34
Celebrate vaccines	10	-	(10)	-
Covid-19	13	-	(13)	-
Connect on coronavirus	-	5	(5)	-
Autoimmunity	-	15	(5)	10
UK-CIC	-	137	(161)	(24)
Vaccine taskforce	-	26	(26)	-
BiteSized immunology	-	8	(3)	5
Total	57	191	(223)	25

16 Designated funds

	At 1 July 2021	Designated in year	Utilised / released	At 30 June 2022
Long term sustainability	248	-	-	248
CRM project	113	-	(90)	23
Career development programme	625	-	(125)	500
Total	986	-	(215)	771

Long term sustainability

The long term sustainability fund provides resources for investing in the financial sustainability of the charity over the next five years.

CRM project

The CRM project fund provides resources to develop and implement a new CRM system together with an upgrade to the BSI website

Career development programme

The Career development programme will fund a significant expansion in the careers support the BSI offers to our members. This includes two main streams: our career-enabling activities and our career-enhancing activities.

Notes to the financial statements

17 Analysis of nets assets between funds

				2022
Group	Unrestricted funds £'000	Designated funds £'000	Restricted funds £'000	Total funds £'000
Tangible fixed assets	49	-	-	49
Intangible assets	93	-	-	93
Investments	4,259	-	-	4,259
Current assets	45	771	143	959
Current liabilities	(1,050)	-	-	(1,050)
Total Funds	3,396	771	143	4,310

				2022
Charity	Unrestricted funds £'000	Designated funds £'000	Restricted funds £'000	Total funds £'000
Tangible fixed assets	49	-	-	49
Intangible assets	93	-	-	93
Investments	4,259	-	-	4,259
Current assets	25	771	116	912
Current liabilities	(1,003)	-	-	(1,003)
Total Funds	3,423	771	116	4,310

The total unrealised gains (losses) as at 30 June 2022 constitutes movements on revaluation and are as follows:

	2022 £'000	2021 £'000
Unrealised gains (losses) included above:		
On investments	734	983
Total unrealised gains (losses) at 30 June	734	983
Reconciliation of movements in unrealised gains (losses)		
Unrealised gains at 1 July	983	522
Less: in respect to disposals in the year	-	-
	983	522
Add: net gains (losses) arising on revaluation arising in the year	(248)	461
Total unrealised gains (losses) at 30 June	734	983

Notes to the financial statements

17 Analysis of nets assets between funds (Continued)

				2021
	Unrestricted	Designated	Restricted	Total funds
Group	funds	funds	funds	
	£'000	£'000	£'000	£'000
Tangible fixed assets	18	-	-	18
Intangible fixed assets	37	-	-	37
Investments	4,454	-	-	4,454
Current assets	346	986	25	1,357
Current liabilities	(922)	-	-	(922)
Total Funds	3,933	986	25	4,944

				2021
	Unrestricted	Designated	Restricted	Total funds
Charity	funds	funds	funds	
	£'000	£'000	£'000	£'000
Tangible fixed assets	18	-	-	18
Intangible fixed assets	37	-	-	37
Investments	4,454	-	-	4,454
Current assets	332	986	25	1,343
Current liabilities	(908)	-	-	(908)
Total Funds	3,933	986	25	4,944

18 Share capital

The company is limited by guarantee and therefore has no share capital. Each member's liability is limited to £1.

19 Related party transactions

Matthias Eberl received a £250 BSI Congress 2021 Education and Public poster prize and a Communicating Immunology grant of £1,000.

Calum Bain is a member of the Editorial Board of *Immunology*, no payments were made in relation to this.

There were no other related party transactions that required disclosure in the current financial period (2021: none).

Notes to the financial statements

20 Comparative consolidated statement of financial activities

	Unrestricted funds			
	General £'000	Designated £'000	Restricted £'000	2021 £'000
Income from:				
Donations	2	-	188	190
Investments	113	-	-	113
Charitable activities				
Membership	145	-	-	145
Partnership work	78	-	-	78
Congress	0	-	-	0
Meetings and events	105	-	3	108
Journals	1,552	-	-	1,552
Total income	1,995	-	191	2,186
Raising funds				
Investment Management Fees	36	-	-	36
Cost of raising funds	13	-	-	13
Charitable activities				
Membership	181	-	-	181
Congress	166	-	-	166
Meetings and events	253	-	-	253
Publications and Journals	377	-	-	377
Policy and Public Affairs	176	-	5	181
National Research support	0	-	161	161
Partnership work	87	-	31	118
Education and Careers	62	2	3	67
Public engagement	73	-	-	73
Communications	146	-	23	169
International work	32	-	-	32
Total expenditure	1,602	2	223	1,827
Net income (expenditure) before gains (losses) on investments and transfers	393	(2)	(32)	359
Net gains/(losses) on investments	507	-	-	507
Transfers between funds	(738)	738	-	-
Net income	162	736	(32)	866
Reconciliation of funds:				
Funds brought forward	3,771	250	57	4,078
Funds carried forward	3,933	986	25	4,944

Notes to the financial statements

21 Charity statement of financial activities

	Unrestricted funds			Total	Total
	General funds £'000	Designated funds £'000	Restricted funds £'000	2022 £'000	2021 £'000
Income from:					
Grants and donations	6	-	284	290	190
Investments	151	-	-	151	113
Charitable activities					
Membership	160	-	-	160	145
Partnership work	40	-	-	40	10
Congress	293	-	-	293	-
Meetings and events	11	-	-	11	44
Journals	913	-	-	913	1,552
Gift Aid and recharge from BSI Trading Limited	353	-	-	353	132
Total income	1,927	-	284	2,211	2,186
Expenditure on:					
Raising funds					
Investment management fees	41	-	-	41	36
Cost of raising funds	30	-	-	30	13
Charitable activities					
Membership	240	-	-	240	181
Congress	642	-	-	642	166
Meetings and events	184	-	-	184	253
Publications and journals	370	-	-	370	377
Policy and Public Affairs	138	-	37	175	181
National Research support	-	-	149	149	161
Partnership work	133	-	-	133	118
Education and Careers	68	125	5	198	67
Diversity and inclusion	4	-	-	4	-
Public engagement	115	-	2	117	73
Communications	227	-	-	227	169
International work	28	-	-	28	32
Total expenditure	2,219	125	193	2,537	1,827
Net income (expenditure) before gains (losses) on investments and transfers	(292)	(125)	91	(326)	359
Net gains/(losses) on investments	(305)	-	-	(305)	507
Transfers between funds	90	(90)	-	-	-
Net income/(deficit)	(508)	(215)	91	(632)	866
Reconciliation of funds:					
Funds brought forward	3,933	986	25	4,944	4,078
Funds carried forward	3,425	771	116	4,312	4,944

Board of Trustees

Position	Current office holder	Date of appointment / resignation	2021-22 Board attendance	2021-22 committees	2021-22 Committee attendance
President	Professor Arne Akbar	Appointed December 2018	4/4	Forum, Nominations & Congress Committees	0/4 1/1 1/2
Treasurer	Dr Fiona Culley	Re-appointed July 2022	4/4	Finance Sub Committee & Congress Committee	4/4 4/4
Chair of Forum	Professor Ann Ager	Appointed December 2018	4/4	Forum & Nominations Committee	4/4 1/1
Clinical Secretary	Professor Colin Dayan	Appointed October 2019	3/4	Forum, Clinical & Congress Committees	4/4 2/2 1/2
Early Career Trustee	Dr Calum Bain	Resigned July 2022	3/4		
Early Career Trustee	Dr Emma Chambers	Appointed December 2018	0/2		
Co-opted Trustee	Robert Davies	Appointed October 2016	4/4	Nominations Committee	1/1
Trustee	Professor Deborah Dunn-Walters	Appointed July 2019	3/4		
Trustee	Professor Matthias Eberl	Appointed January 2017	4/4	Nominations Committee	1/1
Co-opted Trustee	Dr Paul Harding	Re-appointed July 2019	3/4	Finance Sub Committee	4/4
Co-opted Trustee	Dr Edith Hessel	Appointed January 2017	4/4		
Co-opted Trustee	James Lowe	Appointed July 2019	3/4	Finance Sub Committee	4/4
Trustee	Professor Allan Mowat	Re-appointed May 2019	4/4		
Early Career Trustee	Dr Matthew Siggins	Appointed July 2022			
Co-opted Trustee	Dr Sinisa Savic	Appointed July 2022			
Trustee	Dr Divya Shah	Appointed December 2018	4/4	Nominations Committee	1/1

Key management personnel

Name	Position
Dr Doug Brown	Chief Executive
Otto Balsiger	Finance Director
Dr Jennie Evans	Director of External Affairs
Jane Sessenwein	Head of Events & Conferences
Lucy McIver	Head of Publishing

Principal professional advisers

Name	Position
Bankers	Bank of Scotland
	14/16 Cockspur Street
	London
	EC2V 6DL
External auditors	Moore Kingston Smith LLP
	9 Appold Street
	London
	EC2A 2AP
Investment advisers	Abrdn (formerly Aberdeen Standard Chartered)
	14th Floor
	30 St Mary Axe
	London
Solicitors	EC3A 8BF
	Russell Cooke LLP
	2 Putney Hill
	London
	SW15 6AB

Committees

Nominations Committee

Name	Position
Professor Arne Akbar	Chair, BSI President
Professor Ann Ager	Forum Chair and Trustee
Robert Davies	BSI Co-opted Trustee
Professor Matthias Eberl	Trustee
Dr Divya Shah	Trustee
Dr Doug Brown	BSI CEO (observer)

Finance Sub Committee

Name	Position
Dr Fiona Culley	BSI Treasurer
James Lowe	Co-opted Trustee
Paul Harding	Co-opted Trustee
Dr Doug Brown	BSI Chief executive
Otto Balsiger	BSI Finance Director

Forum

Name	Position
Professor Ann Ager	Chair
Professor Arne Akbar	BSI President
Dr Colin Dayan	Clinical Secretary
Dr Donald Palmer	Education & Careers Secretary
Professor Donald Davidson	Public Engagement Secretary
Dr Doug Brown	BSI Chief Executive
Dr Jennie Evans	BSI Director of External Affairs
Dr Megan Macleod	Regional Representative - Scotland
Dr Julia Makinde	Regional Representative - England
Dr Karim Dib	Regional Representative - Northern Ireland
Dr Simone Cuff	Regional Representative - Wales
Dr Louise Topping	Early Career Representative
Dr George Robinson	Early Career Representative
Dr Faith Uwadiae	Early Career Representative
Dr Edoardo Prediletto	Early Career Representative
Dr Lauren Campbell	PhD Representative
Dr Niamh Richmond	PhD Representative
Dr Federica Villanova	Industry Representative
Dr Matthew Buckland	Clinical Representative
Dr Tomaz Garcez	Clinical Representative
Dr Elma Tchilian	Veterinary Representative

Committees

Congress Committee

Name	Position
Professor Mark Coles	BSI Congress Secretary
Professor Arne Akbar	BSI President
Dr Fiona Culley	BSI Treasurer
Dr Colin Dayan	BSI Clinical Secretary
Professor Linda Wooldridge	Member
Dr Helen McGettrick	Member
Dr Daniel O'Connor	Early Career Representative
Dr Alexandra Spencer	Member
Dr Henry McSorley	Member
Dr John Tregoning	Member
Dr James Thaventhiran	Clinical member
Dr Margarita Dominguez	Member
Dr James Harker	Member
Dr Graham Cook	Member
Dr Sandra Sacre	Member
Jane Sessenwein	BSI Head of Events & Conferences

Clinical Committee

Name	Position
Dr Adrian Heaps	Association for Clinical Biochemistry
Dr Richard Herriot	Association of Clinical Pathologists
Dr Chris Scott	Institute of Biomedical Science
Dr Tariq El-Shanawany	British Society for Allergy & Clinical Immunology
Dr Stephen Hughes	British Paediatric Allergy Immunology & Infections Group
Dr Siraj Misbah	Special Advisory Committee on Immunology (RCPATH SAC)
Dorothea Grosse-Kreul	Immunology & Allergy Nurses group
Dr Kavitha Sooriyakumar	Trainee Rep
Dr Shuaib Nasser	Joint Committee on Immunology & Allergy (JCIA)
Dr Sinisa Savic	UK Primary Immunodeficiency Network (UKPIN)
Dr Colin Dayan	Chair/Clinical Secretary
Dr Doug Brown	BSI Chief Executive

Journals

Clinical and Experimental Immunology - Editorial Team

Name	Position
Professor Leonie Taams	Editor-in-Chief
Professor Angelo Manfredi	Section Editor - autoimmunity
Professor Tanja de Gruij	Section Editor - cancer immunity
Professor Ciriaco Piccirillo	Section Editor - immune-mediated inflammatory diseases
Dr Cindy Ma	Section Editor - immunodeficiency
Dr daniel Douek	Section Editor - infectious diseases and vaccines
Professor Xiao-Ning Xu	Section Editor - infectious diseases and vaccines
Professor Sandra Amor	Section Editor - neuroimmunology

Immunotherapy Advances - Editorial Team

Name	Position
Professor Tim Elliot	Editor-in-Chief
Professor Stefan Barth	Regional Editor: Africa
Associate Professor Marianne Boes	Regional Editor: Europe
Professor Adrianna Bonomo	Regional Editor: South America
Professor Tao Dong	Regional Editor: Asia
Dr Stephanie K Dougan	Regional Editor: North America
Associate Professor Menno van Zelm	Regional Editor: Australasia

Discovery Immunology - Editorial Team

Name	Position
Professor Simon Milling	Editor-in-Chief
Dr Awen Gallimore	Senior Editor
Dr Florent Ginhoux	Senior Editor
Dr Emily Gwyer Findlay	Senior Editor
Professor Kathleen McCoy	Senior Editor
Dr Lai Guan Ng	Senior Editor
Professor Francisco J. Quintana	Senior Editor
Dr Meera Ramanujam	Senior Editor

Regional and Affinity groups

Affinity Groups

Group	Position	
Autoimmunity Affinity Group	Chair	Professor Lucy Walker
	Secretary	Dr Kathryn Steel
	Treasurer	Dr James Pearson
Comparative Veterinary Immunology Group	Chair	Wilhelm Gerner
	Secretary	Dr Lindert Benedictus
	Treasurer	Dr Kate Sutton
Histocompatibility & Immunogenetics Group	Chair	Professor David Briggs
	Secretary	Dr Luke Foster
Immunometabolism Affinity Group	Co-Chair	Dr Laura Pallett
	Co-Chair	Dr Linda Sinclair
	Secretary	Dr Sarah Dimeloe
	Treasurer	Dr Anna Schurich
Immunosenescence Affinity Group	Chair	Dr Sian Henson
	Secretary	Dr Natalie Riddell
	Treasurer	Dr Catarina Henriques
Infection and Immunity Group		
Inflammation Affinity Group	Chair	Professor Peter Barlow
	Treasurer	Dr Joanne Konkel
	Communications	Dr Jack Rivers-Auty
Leukocyte Migration Group	Chair	Dr Myriam Chimen
	Secretary/Treasurer	Dr Graeme O'Boyle
Mathematical Modelling Group	Chair	Professor Carmen-Molina Paris
	Secretary	Professor Mark Coles
	Treasurer	Professor Grant Lythe
Neuroimmunology Group	Chair	Dr Sarosh Irani
	Secretary	Dr Yvonne Dombrowski
Vaccine Affinity Group	Chair	Dr Phil Hogarth
	Secretary	Dr Julia Tree
	Treasurer	Dr Bernardo Villarreal-Ramos
Tumour Immunology Affinity Group	Chair	Professor Benjamin Willcox
	Secretary	Dr Seth B. Coffelt
	Treasurer	Professor Awen Gallimore
Teaching Affinity Group	Co-chair	Professor John Currow
	Co-chair	Dr Nigel Francis

Regional and Affinity groups

Regional Groups

Group	Position	
Aberdeen Immunology Group	Chair	Dr Isabel Crane
	Treasurer	Dr Soumya Palliyil
Bristol Immunology Group	Chair	Dr Laura Rivino
	Secretary	Dr Dronwen Burton
	Treasurer	Dr Lindsay Nicholson
Cambridge Immunology Group	Chair	Dr Brian Ferguson
	Secretary/Treasurer	Dr Louise Boyle
East Anglia Immunology Group	Secretary	Dr Maria O'Connell
	Treasurer	Dr Cristina Fanutti
Edinburgh Immunology Group	Co-Chair	De Cecile Benezech
	Co-Chair	Dr Laura McCulloch
	Secretary	Dr Matthew Burgess
	Secretary	Dr Tovah Shaw
	Treasurer	Dr David Donaldson
Greater Manchester Immunology Group	Chair	Professor Richard Grencis
	Secretary	Dr Ana Villegas-Mendez
	Treasurer	Dr Joanne Konkel
Immunology North East	Chair	Dr Kevin Marchbank
	Secretary	Dr Antony Antoniou
	Treasurer	Dr Andy Knight
London Immunology Group	Chair	Dr James Harker
	Secretary	Dr Laura Pallett
	Treasurer	Dr Alice Burton
Merseyside Immunology Group	Secretary	Dr Qibo Zhang
	Treasurer	Dr Steve Christmas
Oxford Immunology Group	Chair	Dr Alexandra Spencer
	Co-Secretary	Dr Louise Johnson
	Co-Secretary	Dr Anita Milicic
	Treasurer	Dr Philipp Kruger

Regional and Affinity groups

Regional Groups

Group	Position	
South Wales Immunology Group	Chair	Dr You Zhou
	Secretary	Dr Rebecca Aicheler
	Treasurer	Dr Ceri Fielding
Tayside Immunology Group	Chair	Professor Simon Arthur
	Secretary	Dr Mahima Swamy
	Treasurer	Dr Stephen Matthews
Ulster Immunology Group	President	Dr Yvonne Dombrowski
	Secretary	Dr Karim Dib
Wessex Immunology Group	Chair	Dr Emma Reeves
	Secretary	Dr Alison Hill
	Treasurer	Dr Diogo Silva
West Midlands Immunology Group	Co-Chair	Dr David Bending
	Co-Chair	Dr Kendle Maslowski
	Secretary	Dr Lia Liaskou
	Treasurer	Dr Zhi Li
West of Scotland Immunology Group	Chair	Dr Megan MacLeod
	Secretary	Dr Ed Roberts
	Treasurer	Dr Hannah Scales
Yorkshire Immunology Group	Chair	Dr Gina Doody
	Secretary	Dr Erica Wilson

Accounts



Annual Report 2021

Trustees' Report

For the year ended 30 June 2021

What we do and why it matters

The British Society for Immunology is the award winning (Best Overall Association 2020, The Association Awards) and leading UK membership organisation working with scientists and clinicians from academia and industry to forward immunology research and application around the world. Our friendly, accessible community consists of over 4,000 immunologists, giving us a powerful voice to advocate on immunological science and health for the benefit of society.

The Society supports its members, students and the wider public to learn more about immunology through disseminating research and providing resources, activities and grants to aid education in this field.

Immunological science underpins many aspects of human and animal health and disease, from communicable disease and vaccination to the management and treatment of many chronic conditions. Through enhancing our knowledge of how the immune system functions for the public benefit, the British Society for Immunology can play a key role in advancing Society's ability to prevent and treat disease.

Our mission

The British Society for Immunology's mission is to promote excellence in immunological research, scholarship and clinical practice in order to improve human and animal health.

We accomplish this by:

- Working with our members to support current and future generations of immunologists.
- Sharing our passion for immunology through meetings, publications and the media.
- Building up an understanding of our work by engaging with the public and those working in the research and health environments.
- Working with partners in pursuit of our mission, building on common interests

The Trustees confirm they have referred to the Charity Commission's guidance on public benefit when reviewing the Society's aims and objectives, planning future activities and setting the annual operating plan.

Our strategic objectives


1. Grow membership
2. Promote the internationalism of Immunology
3. Develop an integrated publications strategy
4. Extend our relevance and impact through our policy and external affairs activities
5. Diversify our income

1 Membership

Our members are at the heart of everything we do. The United Kingdom is a world leader in immunological research, and immunology underpins many aspects of recent advances in our knowledge of human and animal health and disease. As the largest professional immunology society in Europe and third largest in the world, we are a friendly, accessible community for immunologists from all disciplines, which supports diversity and works across different sectors and national borders. We work with members from across the spectrum of the discipline, from basic science through to clinical application, and from different sectors, to support current and future generations of immunologists.

Membership of the British Society for Immunology brings many benefits. These include discounts to our meetings and to our exceptional BSI Congress, access to a diverse range of grants, bursaries and prizes, free access to our journals and much more. The Society provides tailored support for our community through our highly valued Regional and Affinity Groups, but we are also there to represent immunology to the wider world. Members value our strong voice to speak out with influence and impact on behalf of immunology in policy, public engagement and the media.

At the end of June 2021, we had over 4,000 members who join us from all walks of immunology. From students up to senior levels, they contribute to our work through many different routes, including speaking at our conferences, helping with our public engagement activities and advising on our policy work – our grateful thanks go to our whole immunology community.



The BSI's first ever virtual conference, '**Connecting immunology in the time of COVID-19**', took place on 1-2 December 2020. We welcomed over 780 attendees and connected with people from 31 countries. We were honoured to welcome Sir Patrick Vallance, the UK Government's Chief Scientific Advisor, to join the 'Immunology and COVID-19' plenary session which also featured a presentation from Professor Paul Moss and Dr John Grainger on behalf of the UK Coronavirus Immunology Consortium (UK-CIC). Speaking on the day that the Pfizer-BioNTech COVID-19 vaccine was approved for UK use, Sir Patrick reflected on his role of Chief Scientific Advisor during the pandemic and the huge advances that we have made in our understanding of the disease's biology, treatments, and vaccines.

We hope to reunite in person in November 2021 for the return of the BSI Congress in the beautiful city of Edinburgh.

Regional and Affinity Groups

The BSI's Regional and Affinity Groups are a key part of the BSI community and carry out much of the core activity of bringing our membership together. The scientific discussions and networking that take place at these meetings are invaluable for the continued development of immunology. The strengths of our 17 Regional Groups are to bring together immunologists within a local community, boosting local research networks. The 12 Affinity Groups have all been created to focus meetings and discussions on specific areas of immunology and they continue to evolve as immunology expands its reach and knowledge.

Our programme of events was disrupted by COVID-19; however, many of the groups switched their events online and were able to keep members engaged and up to date with almost 3,500 people attending. It is planned to reintroduce physical events when restrictions allow.

Keeping members informed

The BSI works hard to ensure good communication channels with our members to keep them informed about our activities and about developments in immunology in the wider world. This has been a particularly important part of our activities this year with the COVID-19 pandemic. The popularity of our website continues to grow with over 4.22 million page views this year and 2.38 million unique users. This is an increase of 59% and 92% respectively compared with last year's figures. The BiteSized Immunology section continues to be popular along with our new Coronavirus information hub, which collects the BSI's activities on COVID-19 with useful resources for our members and the wider public. Our infographics on COVID vaccines are the most viewed pages on the site.

4.22m
page views

2.38m
unique users

BSI email communications to members and additional subscribers have become a mainstay for keeping the immunology community informed and connected, with audience numbers growing considerably over the course of the year. Our flagship membership magazine **Immunology News** is published quarterly and continues to be a popular way of engaging with our members. The magazine includes feature articles from leading immunologists, an education and careers section and more information on our activities. As it contains many articles likely to be of interest to a broad audience range, it is an important part of our work to increase exposure of the BSI to the immunology community and beyond.

Our social media channels continue to grow in importance as a way of engaging with our membership and the wider world at a more immediate level, to interact with our supporters and spread the word about our work and the wonders of immunology. This year has been a success story for our social media channels with touchpoints such as BSI virtual conference, our **Vaccine Engagement Starts at Home** campaign and our coronavirus work being especially influential in driving our engagement figures. We have also run several campaigns to highlight the diversity of our membership, including supporting Women in Science Day and #BlackInImmunology week. Twitter has seen an increase in followers of 31% compared with last year, while our LinkedIn audience has grown by 44%. We've also seen a significant increase in our Instagram following and engagement, particularly amongst non-immunologist followers driven by our interactive COVID-19 vaccines Q&As. Our posts on Twitter were seen almost 4 million times. Across all channels, our social media posts were seen over 3.6 million times, with LinkedIn at 580k and Facebook at almost 700k.

31%
More Twitter
followers

44%
More LinkedIn
followers

3.6 million
Social media post
views

Supporting members throughout their career

The BSI is a hub of expertise to support our members in forging strong careers in the many sectors in which immunologists are employed. It is essential that our members feel supported at all stages of their careers, from undergraduate through to retirement, and beyond. One of our core responsibilities is to offer careers and educational support to current and future generations of immunologists. We do this through ongoing initiatives, such as our grants schemes, our education website BiteSized Immunology and our highly rated mentoring scheme.

BiteSized Immunology

BiteSized Immunology is our highly popular online educational resource which provides a comprehensive overview of the immune system, delivered in short self-contained articles that highlight major 'take home' messages. The content is designed for use by bioscience undergraduates, A-level students and anyone with an interest in the subject. This year, we have continued to review current content and commission new articles to ensure we keep up to date with the immunology field.

Each month, BiteSized Immunology receives an average of 192,502 page views, up 70% from last year.

Teaching recognition

Supporting higher education immunology teachers is important to ensure that the next generation are inspired to follow a career in immunology. The BSI runs several initiatives to support this sector of membership. Our Immunology Teaching Excellence Award recognises outstanding immunology teachers at higher education institutes in the UK. Now in its fourth year, we were delighted to present the award to Dr Nigel Francis, a Honorary Associate Professor at the University of Swansea Medical School. The judges felt that Nigel was a dedicated and passionate immunologist who demonstrated commitment, innovation and creativity in his teaching to bring the subject to life to students at all levels. It was clear to the judges that Nigel's teaching skill is valued by students and colleagues alike.

Mentoring scheme

The success of our mentoring scheme has continued apace. This key part of our strategic plan aims to support professional development among the immunology community, bringing together senior scientists with early career researchers to assist the next generation of immunologists with career development and progression.

Our 2020 intake of 8 mentor-mentee pairs all valued the scheme and finished well with positive feedback all round. For 2021, the popularity of the scheme more than quadrupled to 50 mentors and mentees taking part (which does indicate the need for this type of activity within the community). Due to the pandemic, training was switched online but this has increased accessibility of the scheme. Initial feedback indicates the scheme is working well.

Winter School

An important part of our mission is to support future generations of immunologists. This year, we adapted our Winter School event to a virtual setting. This one-day online event gave immunology students at a Master's degree level the opportunity to hear from top immunologists. With over 260 people registered, the delegates heard from 6 leading immunologists giving tailored talks on the latest updates in their area along with the opportunity to ask questions. There was also a career development session and a mental wellbeing session. Feedback on the event was very positive.

Career Development Webinars

Providing access to credible, useful and informative careers resources is a key aim of the BSI. This year, we continued our success in providing webinars on different aspects of career development, providing all members, no matter where they are based, with access to our career's resources.

We completed our initial webinar series which took a wide-ranging look at the different types of skills that BSI members need to be successful in their careers. This included how to manage a lab successfully and how to write a grant application.

This was followed up with a six-part webinar series for BSI members on 'Careers in immunology'. This looked at the different career routes that individuals can take after studying immunology, ranging from publishing, public engagement and lab technician. This has been a particularly important offering to our early career members to allow them to find out more about the opportunities open to them. Feedback has been hugely positive.

Grants to support members

A significant proportion of BSI funds is distributed to its members through our grant schemes to support their research, help them to build their transferable skills and to participate in outreach projects. Although some of our grant schemes were disrupted by the COVID-19 pandemic meaning some activities – such as travel to international conferences – could no longer go ahead, the BSI remains committed to supporting its members through these schemes in the future when circumstances allow.

Travel Awards and Lab Placement Grants

All travel award schemes were paused by the society in line with government guidance. We plan to re-open the awards when the situation allows and physical conferences resume.

Communicating Immunology Grants

We supported 8 projects through this scheme with the aim of stimulating interest, discussion and understanding of immunology among a public audience. Projects ranged from creating animated videos to explain how COVID-19 vaccines work to illustrations about how the immune system fights off pathogens.

Equality, Diversity & Inclusion Activity Grants

This new grant scheme aimed to support BSI members by funding activities and events that promote diversity and inclusion across the immunology community and the wider biomedical sciences. In this pilot year of the scheme, we funded 7 grants. Projects ranged from funding a workshop to support researcher mental health to a project to decolonise and diversify some immunology units on the university curriculum.

2 Promoting the internationalism of immunology

As immunological research develops, the international networks that underpin our cutting-edge, cross-disciplinary discoveries become increasingly important. The Society has always been ambitious in terms of our international reach, something we know our members value highly. We understand that it's now more important than ever for us to have a prominent voice on the international stage, speaking up for immunology and the UK research community.

We actively engage with our international counterparts on a regular basis through membership of the European Federation of Immunological Societies (EFIS) and the International Union of Immunological Societies (IUIS).

European Federation of Immunological Societies (EFIS)

The BSI is leading the EFIS taskforce on vaccines. The taskforce aims to work together to promote evidence-based information on vaccines across Europe, looking at how we can influence the policy environment. The taskforce will also be a forum to share information and promote best practice between societies. The taskforce has made good progress this year, publishing a policy document in February on COVID-19 vaccines. This was used by EFIS members to send to their governments to provide evidenced-based information on COVID-19 vaccines. Plans are now underway on the public engagement front too to provide translated information resources for the public on how vaccines work and commonly asked questions around COVID-19 vaccines.

The BSI is taking part in an initiative entitled yEFIS (young EFIS) to create a network of early career researchers across Europe. The group have several plans including hosting sessions at the upcoming European Congress of Immunology.

In June, the UK hosted the world's first Global Vaccine Confidence Summit. Bringing together public and private sector experts from around the world, the summit aimed to drive forward collective action to build global vaccine confidence and increase vaccine uptake in the fight against COVID-19. We ran a campaign calling on the UK Government to make improving global vaccine confidence a specific legacy project of the 2021 G7 conference. As well as writing to the Prime Minister, our members also joined us on social media to raise their voices and amplify this message.

3 Develop an integrated publications strategy

The BSI's original ethos still lies at the heart of our Society – to disseminate research with the aim of promoting and advancing immunology to foster future innovation. The BSI is proud to achieve this aim through the publication of our two well established official journals, *Immunology* and *Clinical & Experimental Immunology*. Working with the publisher Wiley, our journals provide a significant proportion of the Society's income.

It's been a busy year for journals as we work hard to ensure they maintain their competitive edge considering the current changes in the publishing industry. 2020 saw the impact factor for *Immunology* climb from 5 to 7, its highest ever.



7.397
Impact Factor

859,600
downloads
(2020: 650,157)

696
submissions



Clinical & Experimental Immunology had another good year with an increase in submissions and 43% more downloads. It reached its highest impact factor of 4.330 driven by successful review series.



Our new open access journal, *Immunotherapy Advances*, was launched in November. The number of submissions has been encouraging hitting our target with 26 articles accepted in its first eight months.



4 Extend our relevance and impact through our policy and external affairs activities

The BSI's policy and public affairs work have strengthened significantly over the past year to raise our profile and take forward engagements with policymakers to bring about meaningful change for immunology. Achievements last year include:

- Through our Parliamentary Questions programme, we had 61 written questions answered, submitted by MPs from all the main political parties.
- Met with nine MPs and members of the House of Lords, including Shadow Health and Social Care Secretary, Jon Ashworth MP, Vaccines Minister Nadhim Zahawi MP, and Lord Bethell, Parliamentary Under Secretary of State at the Department of Health and Social Care. Also met with many other individuals playing a significant role in the pandemic response including Deputy Chief Medical Officer, Jonathan Van Tam and Susan Hopkins, Strategic Response Director for COVID-19 in Public Health England.

- Responded to 5 consultations on a wide range of topics including COVID-19 pandemic, research funding and diversity and inclusion in science.
- Gave oral evidence to two Select Committee inquiries on vaccine passports.
- Worked with the Mayor of London's office to aware awareness of the importance of COVID vaccines
- We became an official supporter of the All Party Parliamentary Group on Diversity and Inclusion in STEM and sponsored their report on 'Equality in the STEM workforce'
- Participated in stakeholder network meetings with the Royal Society of Biology (including Parliamentary Links Day and Voice of the Future), Association of Medical Research Charities, Campaign for Science and Engineering and the Royal Society.

Focus on Coronavirus and COVID-19

The Coronavirus outbreak has affected our lives in countless ways. From our jobs and research to our wellbeing and the way we connect to our peers, the immunology community has had to rapidly adapt to this new world. At the same time as adjusting to the pandemic ourselves we pivoted rapidly to support our members and wider communities with respect to the science of the pandemic.




Research focus

We continued our webinar series called 'Connect on Coronavirus' which brings expert opinion and emerging science from internationally renowned researchers to our membership and beyond. These webinars have been highly popular with up to 1,500 people viewing live and many hundreds more viewing the recordings afterwards. They are free and open to all and have been lauded as a vital resource for the community to remain up to date on COVID-19 research.

Policy focus

The BSI worked hard to ensure that the Government recognises that proper understanding of immunology is critical to the country's response. Most of this work has been carried out through our COVID-19 expert taskforce, led by BSI Trustee Professor Deborah Dunn-Walters, which brings together 18 of UK's leading immunologists to provide expert advice to input to the BSI's policy work on COVID-19.

The key achievement of the taskforce has been to publish three expert reports throughout the year "Long-term immunological health consequences of COVID-19", "The ageing immune system and COVID-19" and "Immunity and COVID-19". These were widely circulated and made significant impact in increasing knowledge about the immune system and COVID-19 amongst policymakers. The last of these reports was cited by Lord Patel, Chair of the House of Lords Science and Technology Committee, in the House of Lords, which led to a meeting with Lord Bethell, the Parliamentary Under Secretary of State at the Department of Health and Social Care, responsible for life sciences, research and COVID-19 long term health impacts



In January, we issued a statement around the decision to extend the dosing schedules for the COVID vaccines. This had a significant effect as at the time there were few expert voices speaking out on the issue. The statement was referenced by Chief Medical Officer, Chris Whitty, in a live Number 10 press briefing and extensively quoted in the media. From this, we were also invited to provide an expert briefing to the Labour Shadow Cabinet on the issue and to meet with Jonathan Van Tam, Deputy Chief Medical Officer.

Throughout the year, we have engaged extensively with Parliament around COVID-19, providing briefings for individual MPs, giving evidence to the APPG on Coronavirus, providing a background briefing for the APPG on Blood Cancer on immunosuppression and COVID vaccines to name but a few.


When the COVID vaccines were first rolled out, we produced some highly popular Q&A sheets for MPs to help them answer potential questions that their constituents might send them about COVID vaccines. We received lots of positive feedback on how helpful these were and they also led to several face-to-face meetings with MPs.

More recently, several other BSI members have given evidence on behalf of the BSI to different select committee around the immunology underlying the assumptions around vaccine passports. Several of our members have also spoken in policy events including to the Parliamentary and Scientific Committee.

Public engagement

Engaging with the public on immunology is one of the key aims of the BSI and we've been busy working to achieve this, both through running public engagement initiatives ourselves and through providing support to our members to build their engagement skills. Ensuring that the public has access to reliable, evidence-based immunology information has become more important with the coronavirus pandemic and the need for us all to understand the science to make informed choices about our health. Key activities included:

- Developing our highly regarded "Guide to Vaccinations for COVID-19", a guide for the public to explain how vaccines work and provide answers to commonly asked questions. We update this every month to make sure the information contained is accurate. This has received great praise from public and experts alike – the Director for Public Health for Hertfordshire called it "by far the most up to date and accurate guide". TV doctor Chris Van Tulleken said "This guide is a phenomenal piece of work and will answer almost any question about COVID vaccines". Our guide is now linked signposted from government sites including Public Health Scotland.




- Throughout the year, we have run Instagram Q&As to allow members of the public to send in questions about COVID-19 vaccines that are then answered by an expert immunologist. This has proved very popular and we have received lots of engagement from the public.
- We have developed numerous infographics to help explain how vaccines work. This includes infographics on types of COVID-19 vaccine, vaccine ingredients, why have the vaccines been developed so fast, natural versus vaccine induced immunity, and the immune response after COVID vaccination. These are now some of the most accessed pages on our website and are regularly used by BSI members and the public to help explain to others the science behind vaccination.



- We had a particular focus on vaccines, fertility and pregnancy and worked with BSI member Viki Male to produce a video to answer common questions on this topic.
- We worked with the Royal Society of Biology to produce explainer videos aimed at younger adults on why it was important for them to get the COVID vaccines.
- We worked with the University of Edinburgh to produce several animations explaining different aspects of how immune memory works after COVID infection and why you need two doses of the COVID vaccines.
- We have worked with many organisations to help find expert speakers to engage with their communities and answer questions about vaccines. This includes a broad range from working with the Cabinet Office, different local councils, Science Museum etc.
- We worked with the Mayor of London's office to produce videos featuring our members from diverse communities answering common questions around vaccination. These were put out via social media channels and on community hubs for use.
- We collaborated with the London Borough of Bexley and Bexley Voluntary Services Council to develop a course on how to have productive conversations about COVID-19 vaccines (more details below).
- Took part in online events such as Swansea Science Festival and Dr Jenner's House Discovery at Home to increase public understanding around vaccines.
- In November, we took part in I'm a Scientist: an online, student-led STEM enrichment activity, connecting students with scientists through real-time text-based chats. The BSI part-sponsored the 'Health Zone' with a focus on vaccine immunology. Fifteen BSI members took part and had online conversations with school students to answer their questions about vaccines and what it's like to have a career as a scientist.
- We submitted an activity to the British Science Week activity pack for primary school students. We adapted the 'herd immunity Jenga' activity for their 'Innovating for the future' theme. Early evaluation stats are that the pack has been downloaded a total of 52,470 times.

- We are working with a number of individuals and organisations to translate some of our vaccine resources to make them more accessible to other communities. This includes a number of Yiddish translations, undertaken in collaboration with the Contemporary Hasidic Yiddish research team at University College London, funded by the Arts and Humanities Research Council. Other translations are in the pipeline and will be released soon.
- We collaborated with Nature Reviews and the Francis Crick Institute to put on an online event about COVID-19. With high profile speakers including Peter Hotez and Teresa Lambe, this event attracted well over 1,500 registrations and was well received.
- We produced several infographics and accompanying blog to explain how COVID testing works, including information on PCR and antibody tests.



A huge thank you to all the BSI members who have assisted us with these activities.

Engaging with members on COVID-19 vaccines

Our members are all expert immunologists but they are also mothers, fathers, sons, daughters, trusted friends and members of their communities and that puts them in an excellent position of trust within their networks to have conversations about vaccines to improve public understanding. People can sometimes lack the confidence to have these conversations so the BSI ran a series of events and activities aimed at helping our members to build their confidence and engagement skills to have these conversations. We:

- Developed a database of BSI members who wanted to take part in COVID vaccine engagement activities. This has been hugely helpful to us in enabling us to find suitable volunteers for different opportunities.
- Ran two webinars for members “Effective ways of engaging with the public” and “Discovering your path to effective public engagement” to help provide members with training on how to have effective conversations about vaccines. Both webinars had extensive opportunities to ask questions to the speakers.
- Ran our ‘Vaccine Engagement Starts At Home’ campaign to provide helpful tips and advice to members on how to have conversations about vaccines with friends and family
- Developed a series of case studies of different activities that BSI members are carrying out around COVID vaccines to engage and inspire others to get involved.



Media highlights

Through our media work, we aim to promote evidence-based and accurate coverage of immunology in the news and ensure that journalists have access to relevant experts who can provide knowledgeable responses. We do this through providing expert comment to breaking news stories, working with programme researchers to shape TV or radio broadcasts and through providing background briefings.

This year, our media work has again been dominated by two topics which have received very high levels of coverage: vaccination and COVID-19. The BSI has been a strong expert voice on both topics, ensuring that the expert voice of immunologists features prominently in this fast-moving, complex and high-profile story. We have worked closely with the Science Media Centre throughout, including running a number of high profile media briefing for national journalists.

Our coverage has included all major national news outlets such as BBC, ITV News, Sky News, The Times, The Guardian, Daily Mail, Daily Telegraph, Daily Mirror and The Sun. International coverage has included Reuters, CNN, Associated Press, Washington Post amongst many others.

- 40 BSI press release/response statements
- 220 articles in UK national press
- 1,000+ article in worldwide press

Partnerships

Working in partnership is core to how the British Society for Immunology operates. Immunology touches on numerous disease areas and other research disciplines and is a central pillar of the life sciences and medical ecosystem. As such, it's critical to our work that we engage with like-minded organisations to take forward our mission and collaborate on areas of common interest and perspective. Growing our partnership portfolio across all our activities will allow us to achieve our strategic goals and bring increased benefits for our members and the discipline.

Key partnerships this year include:

- Connect Immune Research, working with JDRF, MS Society and Versus Arthritis and others on autoimmune research.
- National Cancer Research Institute, working to move the cancer immunotherapy field forward
- Supporting the UK Coronavirus Immunology Consortium, a UKRI/NIHR funded initiative to bring together 20 of the UK's leading immunology research institute to increase our knowledge of the immune system and COVID-19 to improve public health
- London Borough of Bexley and Bexley Voluntary Service Council to provide a training course for community champions and health and social care workers on how to have productive conversations about COVID-19 vaccines
- Mayor of London's office to produce social media assets answering common questions on COVID-19 vaccines.
- International Day of Immunology, working with Nature Research and the Francis Crick Institute to hold a scientific symposium and public event on COVID-19 vaccines
- Royal Society of Biology, ensuring that the discipline of biology has a strong voice on the national stage
- Association of Clinical Pathologists to run training days for clinical immunology trainees and immunology biomedical and clinical scientists preparing to sit the Royal College of Pathologists Fellowship examinations.

- Science Media Centre, providing evidence-based expert response to immunology news stories of national importance
- Campaign for Science and Engineering, providing a strong voice to Government of the collective views on the science and research sector
- Association of Medical Research Charities, representing the health and medical research charity sector on a wider stage.

Connect Immune Research

Connect Immune Research is a collaboration between several charities that support autoimmune research – JDRF, the MS Society, Versus Arthritis and the British Society for Immunology. Traditionally, autoimmune conditions have been researched and treated in disease-specific silos but underlying common immunological mechanisms have indicated the benefit of a joined-up research approach. Our partnership is designed to bring about a critical change in the way autoimmune conditions are researched, bringing together the different disease areas to facilitate a joined-up approach to grow funding and research infrastructure and speed up clinical discovery.

This year, we have added several new organisations to the coalition including Alopecia UK and Psoriasis and Psoriatic Arthritis Alliance. We have also undertaken a major new stream of work collaborating with the Lorna and Yuti Chernajovsky Biomedical Research Foundation. Our aim is to work together to provide significant funding aimed at quickly developing proof of principle for potential new treatments for multiple immune-mediated inflammatory conditions by targeting pathways common in autoimmunity. An initial scoping day was held with the immunology community in May and plans are underway to launch the grant scheme in 2021-22.

London Borough of Bexley and Bexley Voluntary Service Council

A partnership between the BSI, London Borough of Bexley and Bexley Voluntary Services Council delivered a pilot programme to train champions within local community leaders and health/social care workers to have effective conversations with their networks and peers, answering questions and concerns about COVID-19 vaccines. The training was co-designed with 2 different groups (community leaders and health/social care workers), and consisted of 1-hour online sessions each week for 5 weeks. The sessions were led by immunologists skilled at engagement, with appearances from local faith leaders and healthcare professionals.

The content focused on building understanding of vaccines, as well as developing skills on listening to and answering questions and concerns. Sessions were user-led, addressing topics raised by participants and their communities.

Both groups had positive experiences. 100% of community leaders strongly agreed or agreed that they felt better informed, more knowledgeable, and confident to have effective conversations as well as reporting that they increased the number of people they talked to about COVID-19 vaccines. 92% of healthcare workers strongly agreed or agreed that they felt better informed and more knowledgeable about COVID-19 vaccines, while 85% strongly agreed or agreed that they felt more confident about having effective conversations. 70% of healthcare workers agreed or strongly agreed that they had increased the number of people they talked to about COVID-19 vaccines. Working in partnership was key to success of the project in reaching people on the front line who hold social capital and thus increased the impact of the project.

UK Coronavirus Immunology Consortium

The UK Coronavirus Immunology Consortium (UK-CIC) is a nationally targeted effort to understand the immunology of SARS-CoV-2 and COVID-19. This project has received £6.5 million of funding over 12 months from UK Research and Innovation (UKRI) and the National Institute for Health Research (NIHR), and involves leading immunologists from 20 centres of excellence around the UK.



The British Society for Immunology was a supporting partner of UK-CIC throughout its 12 months of funding. BSI President, Professor Arne Akbar, acted as chair of the UK-CIC Scientific Advisory Board, which delivered independent oversight and input to its strategic priorities. The BSI also provided secretarial services to this board, including organising the agenda, arranging presentations from UK-CIC researchers, and providing minutes after each meeting.

The BSI also implemented the Patient and Public Involvement (PPI) programme, sourcing a panel of representatives that offered unique insights and perspectives on UK-CIC research. The BSI organised regular meetings with the PPI panel, with similar administrative support to the Scientific Advisory Board meetings. We have also worked with the PPI panel on several public engagement activities including research summaries, webinars, videos, and on a formal manuscript on PPI involvement in UK-CIC research.

The BSI ran communications for UK-CIC to engage with researchers, the public, and policy makers. This included internal and external communications, media engagement, the website (uk-cic.org) and social media. This also included the flagship virtual conference for UK-CIC, 'Collaborative Covid Immunology', which the BSI organised, promoted, and delivered.

International Veterinary Vaccinology Network (IVVN)

The BSI published a joint report with the IVVN to review the current state of the veterinary vaccinology landscape and set out the key recommendations to maintain the UK's leading role in this area.

5 Diversify our income

It is essential for the Society's long-term sustainability that we diversify our income through the enhancement of current income generating activities and the creation of new income streams.

In November 2020 the Society launched its first new journal in over sixty years. It has met its initial performance targets and is hoped to grow significantly over the next few years.

The Society increased the number of approaches made to funders resulting in a rise of grants and donations received. This work will continue next year.

The trustees increased the Society's long term sustainability fund to £250k to resource the development of new income sources to ensure the long term sustainability of the Society.

Structure, Governance and Management

Charitable status and administrative details

The Society was registered as a charity in 1966 (Charity number 1043255) and incorporated in England and Wales as a company, limited by guarantee (Company number 03005933). The Society's registered address is Devonshire House, 60 Goswell Road, London EC1M 7AD. It has no share capital and the liability of its members is limited to a sum not exceeding £1. The Society's governing document is the Memorandum and Articles of Association, which was amended on 7 December 2016.

It is also a registered charity in Scotland (Charity number SC047367).

Board of Trustees

The Trustees are company directors for the purposes of the Companies Act and charity Trustees for the purposes of the Charities Act 2011. The current trustees, and any past Trustees who served during the year are listed on page 51.

The Trustees are responsible for directing the Society's activities and for overseeing the management of the affairs of the Society, they delegate the day to day management of the organisation to the chief executive and the senior management team. The Board acts on advice and information from regular meetings with the chief executive and the senior management team.

As part of their induction process, Trustees spend some time at the Society's office, with the chief executive and staff. They are provided a trustee resource pack containing the history of the Society and key information they require to fulfil their duties as Trustee, they are also offered training for new Trustees.

The success of the Society belongs in part to the large number of people who generously volunteer their time to add their experience to our collection of committees, we thank you all.

Finance Sub Committee

The Finance Sub Committee ensures the system of internal control is satisfactory to deliver regulatory compliance, financial probity, value for money, challenge of financial plans, budgets and financial statements, oversight of the annual financial audit, review of investment policy and performance, review of reserves policy, and CEO and staff remuneration.

Nominations Committee

The BSI's Nominations Committee has general oversight concerning the structures and effectiveness of BSI Board of Trustees, committees, advisers and observers. It is also responsible for nominating individuals to represent the views of the BSI on external committees and to identify BSI members to nominate for external awards.

Forum

The Forum represents a diverse mix of immunologists from different career stages, backgrounds and geographic locations, it is responsible for developing policy and advising on communications, education and public engagement work.

Congress Committee

The Congress Committee is responsible for the planning and delivery of the BSI's flagship event, BSI Congress, which takes place two out of every three years. It reviews and approves the scientific programme for Congress.

The Clinical Committee represents the wider clinical immunology and allergy community and aims to enhance communication between scientific and clinical immunology communities.

The Society has one wholly owned subsidiary:

BSI Trading Limited is registered in the UK under company registration number 010201739. Its principal activity is to manage the corporate membership, sponsorship, exhibition and other trading activities for the Society. This primarily comprises exhibition and sponsorship for the BSI Congress.

This year been challenging, however the BSI team worked incredibly hard to deliver a very strong financial performance. Net income climbed to £0.87m from £0.17m last year. Congress was postponed due to COVID-19 restrictions; however, we delivered the BSI's first ever virtual conference. Our journals remain our largest income stream, this was bolstered this year with signing bonuses for our new journal *Immunotherapy Advances* and for the new publishing contract for *Clinical & Experimental Immunology*. The society's diversification of income continued with an increase in grants and donations.

[illegible]

COVID-19 had a significant impact on the society's activities during the year; the postponement of Congress led to a reduction in total costs. Costs in other areas also fell as activities were either postponed or delivered in another form. Travel restrictions also resulted in the withdrawal of our travel grants.

The society spent £161k supporting the UK Coronavirus Immunology Consortium (UK-CIC), a twelve month project to bring together immunology research on COVID-19. This work was funded by a grant from UKRI and NIHR.

The postponement of Congress had an impact on BSI Trading Limited, although the financial success of the virtual conference limited the reduction in income to 57%. The company posted an annual profit of £0.12m (2020: £0.31m). This was gifted to the society.

The society's investment portfolio provided solid income in line with 2020. The value of the portfolio rose by £0.51m producing its best annual performance. On 30 June 2021 investments were valued at £4.45m.

Reserves rose to £4.94m, continuing their rise from £3m five year ago. The BSI also had a year-end cash balance of over £1m for the third consecutive year.



The central role of immunology in uncovering the impact of COVID-19 on the immune system and into research for treatments and a vaccine puts the BSI in a relatively good position to secure future funding to continue the Society's work supporting the immunology community during this pandemic and beyond.

Investment policy and performance

The Society operates an investment policy to generate capital growth.

The high levels of volatility resulting from the COVID-19 pandemic, continuing UK and global political uncertainty creates a challenging environment in which to manage investments. The Society is a long-term investor and the value of its investments remains significant above its original investment.

Funds are invested with Aberdeen with a long-term objective to generate a capital return of 3% more than inflation over a three year rolling period. Performance was exceptional generating net gains of £0.51m for the year (2020: £0.11m).

The Finance Sub Committee is responsible for reviewing investment performance and policy.

Reserves policy

The BSI operates a risk-based approach to reserves to ensure the BSI holds the most appropriate level of reserves to cover potential risks and to fund invest in new income sources securing the BSI's long term financial health.

The risk register is reviewed annually with monetary values allocated to specific risks, restricted and designated funds. A provision for unknown risks (to give cover for those risks of which the society is not yet aware) is calculated based as a percentage of the risk adjusted fund. The latest review resulted in total required allocated reserves of £2.93m (2020: £2.89m). On 30 June 2021 total reserves were £4.94m, including free reserves (general reserves less fixed assets) of £3.82m giving an excess over the target of £0.89m (2020: £0.86m) available for use by the Society to further its strategic aims. Details of restricted funds can be found in note 17 of the accounts with details of designated funds in note 18.

The calculation of the total required allocated reserves is performed on an annual basis.

Pay policy

Salaries, including Key Management Personnel, are reviewed by the Finance Sub Committee with recommendations for the annual pay rise proposed to the wider Board of Trustees for approval as part of the annual budgeting process. The salary of the Chief Executive is reviewed annually by the Board of Trustees.

Risk management

Good risk management is fundamental to the continued work and sustainability of the Society. We identify and manage risks that could adversely impact the achievement of our strategic purpose and determine the calculated risks we need to take to succeed.

The Society operates a formal framework for the management of risk, taking the view that risk can be positive (opportunity) or negative (threat). The Society operates a risk register incorporating strategic, operational and compliance risks, which are informed by the Society's strategic objectives, performance, voice of our stakeholders, regulatory environment and analysis of the external environment.

The Board delegates day-to-day responsibility for risk management to the Senior Management Team, who are responsible for identifying and evaluating risks to their areas and activities implementing appropriate controls for ongoing mitigation and monitoring.

The Financial Sub Committee reviews the management of risk in detail at each meeting and the Board reviews the Society's strategic and compliance risks twice a year.

The major risks facing the society and the mitigation that we have put in place are as follows:

Risk	Risk response
Failure to diversify our income The Society is heavily reliant on a single source of income: journals.	The Society is looking at opportunities to diversify income including: ▪ Working with partners to develop important relationships with funders delivering increased grants and donations ▪ Implementing a fundraising strategy to develop new income streams
Longer-term reduced income from the BSI portfolio of journals The move to open access will impact the income received from the Society's journals. Inflationary price increases may be limited post-pandemic	The Society has ▪ Developed a plan with our publisher to limit any financial loss on the move to Open Access ▪ Worked with a publishing consultant to assist with negotiations with our publisher to secure the best financial outcome in new contracts ▪ Launched new journal
Poor handling of government/funding bodies relations Insensitive handling of issues such as vaccines or animal research could leave BSI with poorer reputation	The Society will continue to: ▪ Ensure good Forum and President oversight of our statements , sign-off of sensitive letters via President or another trustee. ▪ Ensure SMT discuss all significant Policy and Public Affairs issues
Adverse commentary, publicity or action or poor public perception Public do not know much about the BSI but the risk would be twofold: that we do not talk about issues of importance to members, or that we misrepresent their views	The Society will continue to: ▪ All staff, trustees and volunteers who perform media/website/ policy/ public engagement work on behalf of the BSI are properly trained and aware of public's views ▪ CEO oversees and discusses controversial issues with trustees before releasing public statements

Fundraising statement

Although the Society does not actively fundraise from members, occasional donations are received. The Society applies best practice in the tone of its communications and the accuracy of its data to minimise the pressures on supporters. The Society applies best practice to protect supporters' data, never sells or swaps it and ensures that communication preferences can be changed at any time. The Society commits to react to and investigate any complaints received, to learn from them and improve its service. During the year, the Society received no complaints about its fundraising activities.

Future plans

The trustees have approved a new five year strategy commencing July 2021. The new strategy was developed through consultation with staff, trustees, BSI Forum members, Secretaries and editors building on work from the previous six years. The new strategy includes a vision statement:

“Better health for all through immunology”

And an updated mission statement:

“We are committed to supporting our immunology community in driving scientific discovery and to make a positive impact on health”

The strategy is based upon three pillars Connected Community, Careers, Catalysing Change and our underpinning priority: Enablers

<u>Pillar 1: Connected Community</u>	<u>Pillar 2: Careers</u>	<u>Pillar 3: Catalysing Change</u>	<u>Underpinning priority: Enablers</u>
By 2025 we will provide the immunology community the support to establish more connections and to enhance collaboration within the field, with other related scientific disciplines and between sectors. We will do this by: • Expanding our activities and support to further enable our members to network and engage with each other across the immunology community • Increasing the number and diversity of interdisciplinary connections with industry as well as between immunology and other relevant research and clinical fields • Initiating and supporting national and topic specific research consortia efforts relevant to Immunology	By 2025 we will provide sector leading support to attract and retain talent in Immunology. We will do this by: • Up-skilling and training more of our members than ever before • Creating a more inclusive and supportive research culture and community, assisting our members and providing opportunities for a career in Immunology • Recognising and promoting outstanding achievements and performance from BSI members	By 2025 we will influence and improve the environment to enable Immunology to thrive and deliver positive outcomes for health. We will do this by: • Having demonstrable impact on public health, policy, practice and research funding issues important to immunology and our members • Influencing public opinion and engagement in key immunology matters • Maintaining the BSI as an internationally respected thought leader	To deliver these ambitious strategic aims we need to maintain the BSI as a sector leading organisation. We will achieve this by: • Creating a larger and more diverse engaged membership • Embedding equality, diversity and inclusion in all our activities • Ensuring the Society's financial sustainability

As part of our strategy the BSI has developed a set of BSI values which underpin all society activities:

We are:

Ambitious and committed
Evidence-based and responsible
Collaborative and inclusive
Agile and energetic

The activities for 2021-22 will focus on:

Pillar 1: Connected Community

- Deliver a successful Congress 2021
- Deliver a new BSI awards ceremony

Pillar 2: Careers

- To successfully increase the careers support the BSI provides to members

Pillar 3: Catalysing Change

- To build the BSI's partnership portfolio and impact
- To continue the BSI's successful programme of vaccine work.

Underpinning priority: Enablers

- Deliver a journals strategy, ensuring optimal financial performance from existing and new journals
- Launch refreshed membership offer
- Develop and launch new CRM system
- Smooth transition to hybrid working

The majority of BSI income is derived from our journals. To date, the submission of papers and journal subscriptions have not been significantly affected by COVID-19.

The Senior Management Team and the Trustees continue to assess the impact of COVID-19 on the Society, together with all other significant risks, in the immediate, medium and longer term. This includes the BSI team's ways of working, our financial requirements, all income streams and the performance of investments.

Trustees' responsibilities

The Trustees (who are also directors of British Society for Immunology for the purposes of company law) are responsible for preparing the Trustees' report and financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the Group and Society and of the income and expenditure of the Group and Society for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable to the United Kingdom and Republic of Ireland; and
- make judgements and estimates that are reasonable and prudent;
- state whether applicable United Kingdom Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume the charity will continue in operation.

The Trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the Group and Society and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Group and Society and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Each of Trustees confirm that:

- so far as the Trustee is aware, there is no relevant audit information of which the Group and Society's auditor is unaware; and
- the Trustee has taken all steps that he/she ought to have taken as a Trustee in order to make himself/herself aware of any relevant audit information and to establish that the Group and Society's auditor is aware of that information.

This confirmation is given and should be interpreted in accordance with the provisions of s418 of the Companies Act 2006.

The Trustees are responsible for the maintenance and integrity of corporate and financial information included on the Society's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Approved by the Trustees and signed on their behalf by:

Arne Akbar
BSI President



Date:

13/10/21

Independent Auditor's Report to the members and trustees of the British Society for Immunology

Opinion

We have audited the financial statements of the British Society for Immunology for the year ended 30 June 2021 which comprise the Group Statement of Financial Activities, the Group and Parent Charitable Company Balance Sheets, the Group Cash Flow Statement and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

give a true and fair view of the state of the group's and the parent charitable company's affairs as at 30 June 2021 and of the group's incoming resources and application of resources, including its income and expenditure, for the year then ended;

have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and have been prepared in accordance with the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 (as amended), regulations 6 and 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended) and the Charities Act 2011.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs(UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

the information given in the trustees' annual report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
the trustees' annual report have been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the group and parent charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the trustees' annual report.

We have nothing to report in respect of the following matters where the Companies Act 2006, the Charities Accounts (Scotland) Regulations 2006 (as amended) and the Charities Act 2011 require us to report to you if, in our opinion:

the parent charitable company has not kept adequate and sufficient accounting records, or returns adequate for our audit have not been received from branches not visited by us; or
the parent charitable company's financial statements are not in agreement with the accounting records and returns; or
certain disclosures of trustees' remuneration specified by law are not made; or
we have not received all the information and explanations we require for our audit; or
the trustees were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies exemption in preparing the Trustees' Annual Report and from preparing a strategic report.

Responsibilities of trustees

As explained more fully in the trustees' responsibilities statement, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the group and parent charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the group or parent charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

We have been appointed as auditor under Section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005, the Companies Act 2006 and Section 151 of the Charities Act 2011 and report to you in accordance with regulations made under those Acts.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below.

Explanation as to what extent the audit was considered capable of detecting irregularities, including fraud

The objectives of our audit in respect of fraud, are; to identify and assess the risks of material misstatement of the financial statements due to fraud; to obtain sufficient appropriate audit evidence regarding the assessed risks of material misstatement due to fraud, through designing and implementing appropriate responses to those assessed risks; and to respond appropriately to instances of fraud or suspected fraud identified during the audit. However, the primary responsibility for the prevention and detection of fraud rests with both management and those charged with governance of the charitable company.

Our approach was as follows:

We obtained an understanding of the legal and regulatory requirements applicable to the charitable company and considered that the most significant are the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 (as amended), regulations 6 and 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended), the Charities Act 2011, the Charity SORP, and UK financial reporting standards as issued by the Financial Reporting Council

We obtained an understanding of how the charitable company complies with these requirements by discussions with management and those charged with governance.

We assessed the risk of material misstatement of the financial statements, including the risk of material misstatement due to fraud and how it might occur, by holding discussions with management and those charged with governance.

We inquired of management and those charged with governance as to any known instances of non-compliance or suspected non-compliance with laws and regulations.

Based on this understanding, we designed specific appropriate audit procedures to identify instances of non-compliance with laws and regulations. This included making enquiries of management and those charged with governance and obtaining additional corroborative evidence as required.

As part of an audit in accordance with ISAs (UK) we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purposes of expressing an opinion on the effectiveness of the group and parent charitable company's internal control.

Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the trustees.

Conclude on the appropriateness of the trustees' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the group and parent charitable company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the group or parent charitable company to cease to continue as a going concern.

Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit report.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Use of our report

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006; and to the charity's trustees, as a body, in accordance with Section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005, and in respect of the consolidated financial statements, in accordance with Chapter 3 of Part 8 of the Charities Act 2011. Our audit work has been undertaken so that we might state to the charitable company's members and trustees those matters which we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to any party other than the charitable company, the charitable company's members, as a body, and the charity's trustees, as a body for our audit work, for this report, or for the opinion we have formed.

Moore Kingston Smith LLP

Date 19/10/2021

Neil Finlayson (Senior Statutory Auditor)
for and on behalf of Moore Kingston Smith LLP, Statutory Auditor

Devonshire House
60 Goswell Road
London
EC1M 7AD

Moore Kingston Smith LLP is eligible to act as auditor in terms of Section 1212 of the Companies Act 2006.

British Society for Immunology
Consolidated Statement of Financial Activities
Year to 30 June 2021

		Unrestricted funds				
	Note	General funds £'000	Designated funds £'000	Restricted funds £'000	Total 2021 £'000	Total 2020 £'000
Income from:						
Grants and donations	2	2	-	188	190	100
Investments	3	113	-	-	113	112
Charitable activities	4					
Membership		145	-	-	145	170
Partnership work		78	-	-	78	61
Congress		-	-	-	-	464
Meetings and events		105	-	3	108	46
Journals		1,552	-	-	1,552	1,282
Total income		1,995	-	191	2,186	2,235
Expenditure on:						
Raising funds						
Investment management fees		36	-	-	36	33
Cost of raising funds		13	-	-	13	12
Charitable activities						
Membership		156	-	-	156	183
Awards and grants	5	25	-	-	25	136
Congress		166	-	-	166	587
Meetings and events		253	-	-	253	267
Publications and journals		377	-	-	377	358
Policy and Public Affairs		176	-	5	181	190
UK-CIC		-	-	161	161	-
Partnership work		87	-	31	118	-
Education and Careers		62	2	3	67	75
Public engagement		73	-	-	73	86
Communications		146	-	23	169	213
International work		32	-	-	32	36
Total expenditure	6	1,602	2	223	1,827	2,177
Net income (expenditure) before gains (losses) on investments and transfers		393	(2)	(32)	359	57
Net gains/(losses) on investments	12	507	-	-	507	110
Transfers between funds		(738)	738	-	-	-
Net income/(deficit)		162	736	(32)	866	167
Reconciliation of funds:						
Funds brought forward		3,771	250	57	4,078	3,911
Funds carried forward		3,933	986	25	4,944	4,078

There are no recognised gains or losses other than those recognised above. All activities are continuing.

The notes on pages 32 to 50 form part of these financial statements

British Society for Immunology
Balance Sheet
30 June 2021

		Group		Charity	
		2021	2020	2021	2020
Fixed assets					
Tangible fixed assets	11	18	13	18	13
Intangible assets	12	37		37	
Investments	13	4,454	3,871	4,454	3,871
		4,509	3,884	4,509	3,884
Current assets					
Debtors	14	130	122	264	418
Cash at bank and in hand		1,227	1,037	1,079	696
		1,357	1,159	1,343	1,114
Liabilities:					
Creditors: amounts falling due within one year	15	(922)	(965)	(908)	(920)
Net current assets		435	194	435	195
Net assets		4,944	4,078	4,944	4,078
Funds:					
Unrestricted funds					
General fund		3,933	3,771	3,933	3,771
Designated fund	18	986	250	986	250
		4,919	4,021	4,919	4,021
Restricted funds	17	25	57	25	57
Total		4,944	4,078	4,944	4,078

These financial statements have been prepared in accordance with the provisions applicable to the small companies regime.

These accounts were approved by the Board and authorised for issue on 12/10/21 and were signed on its behalf by:



Arne Akbar, President

British Society for Immunology, Company Limited by Guarantee
 Company Registration Number 03005933 (England and Wales)

The notes on pages 32 to 50 form part of these financial statements

British Society for Immunology
Consolidated Statement of Cash Flows
30 June 2021

	2021	2020
	£'000	£'000
Cash flows from operating activities:		
<i>Net cash provided by operating activities</i>	203	(118)
Cash flows from investing activities:		
Income from investments	113	112
Purchase of tangible fixed assets	(11)	(11)
Proceeds from the disposal of investments	599	630
Purchase of investments	(595)	(836)
Net cash used in investing activities	105	(105)
Change in cash and cash equivalents in the year	270	33
Cash and cash equivalents at 1 July 2020	1,215	1,182
Cash and cash equivalents at 30 June 2021	1,485	1,215
Net income for the period (as per the statement of financial activities)	866	167
Adjustments for:		
Depreciation charge	9	8
(Gains) on investments	(507)	(110)
Investment income	(113)	(112)
(Increase) decrease in debtors	(8)	49
Increase in creditors	(44)	(120)
Net cash provided by operating activities	203	(118)
Analysis of cash and cash equivalents		
Cash at bank and in hand	1,227	1,037
Cash held by investment managers	258	178
Total cash and cash equivalents	1,485	1,215

The notes on pages 32 to 50 form part of these financial statements

Notes to the financial statements

1 Accounting policies

The principle accounting policies adopted, judgements and key sources of estimation uncertainty in the preparation of the financial statements are as follows:

Basis of preparation

The financial statements are prepared on a going concern basis, under the historical cost convention modified to include the recognition of listed investments measured at fair value, which is consistent with the prior year. The financial statements have been prepared in accordance with the Statement of Recommended Practice: Accounting and Reporting by Charities ("The SORP"), the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102) and the Charities Act 2011.

The British Society for Immunology ("The Society") meets the definition of a public benefit entity under FRS 102.

General information

The Society is a charitable company incorporated in England and Wales (company number 03005933) and is a charity registered in England and Wales (charity number 1043255) and registered as a charity in Scotland (charity number SC047367). The Society's registered address is Devonshire House 60 Goswell Road, London EC1M 7AD

Critical accounting judgements and key sources of estimation uncertainty

The preparation of financial statements requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Group and Society accounting policies. In the application of the accounting policies, Trustees are required to make judgements, estimates and assumptions about the carrying value of assets and liabilities that are not readily apparent from other sources. The estimates and underlying assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision only affects that period, or in the period of revision and future periods if the revision affected current and future periods.

In the view of the Trustees, no assumptions concerning the future or estimation uncertainty affecting assets or liabilities at the balance sheet date are likely to result in a material adjustment to their carrying amounts in the next financial year.

Going concern

The financial statements are prepared on a going concern basis which assumes the Society and Group will continue to meet its liabilities as they fall due for a period of at least twelve months from the date of the approval of these accounts. The Trustees are monitoring the impact of Covid-19 on the Society and Group. This includes regular review of the pandemic's impact on our members and our ability to deliver our activities a flexible approach to our annual plan, rolling forecasts and in depth review of actual financial results.

The immunology community is at the heart of work on Covid-19 leading to the Society being busier than ever and attracting new funding to support this work. This together with the holding of significant levels of cash and investments result in the Trustees considering the Society and the Group to be a going concern.

Notes to the financial statements

Income

All income is recognised once the Society and Group has entitlement to income, it is probable that income will be received and the amount of income receivable can be measured reliably. Income of the Society is, where applicable, included net of Value Added Tax (VAT) and is allocated to the period to which it relates, carrying forward that part of the income relating to future accounting periods.

Investment income is recognised on a receivables basis and when the amount can be measured reliably.

Expenditure

Liabilities are recognised as soon as there is a legal or constructive obligation committing the Society and Group to that expenditure, it is probable that settlement will be required and the amount of obligation can be measured reliably. Expenditure is recognised on an accruals basis as a liability is incurred, inclusive of VAT, which cannot be recovered.

Expenditure is allocated to a particular activity where the cost relates directly to that activity. The cost of overall direction and administration of each activity, known as "support costs" and comprising the salary and overhead costs of the central function is apportioned based on staff time attributable to Support costs also include governance costs, which comprise organisational administration and compliance with constitutional and statutory requirements. The allocation of support and governance costs is analysed in notes 7 and 8.

Employee benefits

Short-term benefits including holiday pay are recognised as an expense in the period in which the service is received.

Termination payments are accounted for on an accruals basis and in line with FRS 102.

The Society contributes to a Group pension scheme, the assets of which are administered by Royal London Plc. They are defined contribution schemes. All contributed costs are accounted for on the basis of charging the cost of providing pensions over the period when the Society and Group benefits from the employees' service. The Society and Group has no further liability under the scheme.

Leasing and hire purchase commitments

Rentals paid under operating leases are charged to the income and expenditure account on a straight line basis over the lease term. The Society holds no assets under finance leases or hire purchase contracts.

Tangible fixed assets

Tangible assets are stated at cost less accumulated depreciation. Cost includes the original purchase price, costs directly attributable to bringing the asset to its working condition for its intended use, dismantling and restoration costs. The minimum threshold is £1,000. Depreciated is provided at 33% in order to write off each asset over its estimated useful life.

Intangible fixed assets

Intangible assets are stated at cost less accumulated amortisation. Cost includes the original purchase price, costs directly attributable to bringing the asset to its working condition for its intended use, dismantling and restoration costs. The minimum threshold is £1,000. Amortisation is provided at 20% in order to write off each asset over its estimated useful life. Assets in the course of construction are not amortised.

Notes to the financial statements

Investments

Investments are a form of basic financial instrument and are initially shown in the financial statements at fair value. Movements in the fair value of investments are shown as net gains and losses in the Statement of Financial Activities.

Profits and losses on the realisation of investments are shown as realised gains and losses in the Statement of Financial Activities. Net gains and losses on investments are calculated between sales proceeds and their opening carrying values or their purchase price if acquired subsequent to the first day of the financial year. Unrealised gains and losses are calculated as the difference between the fair value at the year end and their carrying value. Realised and unrealised investment gains and losses are combined in the Statement of Financial Activities.

The investment in the subsidiary undertaking is included at cost with provision being made for any permanent diminution in value.

Financial instruments

I) Financial assets

Basic financial assets, including trade and other receivables, cash and bank balances, are initially recognised at transaction value and subsequently measured at amortised cost. Other financial assets, including investments, are initially measured at fair value. Financial assets are derecognised when:

- a) the contractual rights to the cash flows of the asset expire or are settled, or
- b) substantially all the risks and rewards of the ownership of the asset are transferred to another party or
- c) despite having retained some significant risks and rewards of ownership, control of the asset has been transferred to another party who has the practical ability to unilaterally sell the asset to an unrelated third party without imposing additional restrictions.

Cash at bank and cash in hand includes cash and short-term highly liquid investments with a short maturity of three months or less.

II) Financial liabilities

Basic financial liabilities, including trade and other payables, are initially recognised at transaction price. Trade payables are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Financial liabilities held at amortised cost comprise all creditors except social security and other taxes and provisions.

Provisions

Provisions are recognised where the Society has a present legal or constructive obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Provisions are measured at the present value or the expenditures expected to be required to settle the obligation.

Notes to the financial statements

Fund accounting

Unrestricted funds are those funds available to the Society and Group for general purposes. They include funds designated by the Trustees for particular purposes where their use remains at the discretion of the Trustees. It is the policy of the Trustees to retain in unrestricted funds, amounts which in their judgement, can help to mitigate the short-term effects of income volatility; and retain as long-term investment funds to generate sufficient income to meet current and future operational activities of the Society.

Restricted funds are those funds available to the Society and Group restricted to a specific purpose or are subject to particular donor imposed conditions. Further information is available in the reserves section of the Trustees' report.

Notes to the financial statements

2 Income from grants and donations

	Unrestricted funds £'000	Restricted funds £'000	2021 Total funds £'000	2020 Total funds £'000
Grants	-	149	149	-
Donations	2	39	41	100
Total	2	188	190	100

3 Income from investments and interest

	Unrestricted £'000	Restricted £'000	2021 Total £'000	2020 Total £'000
Listed investments				
Investment Income	113	-	113	109
Bank deposit interest	-	-	-	3
Total	113	-	113	112

4 Income from charitable activities

	Unrestricted funds £'000	Restricted funds £'000	2021 Total funds £'000	2020 Total funds £'000
Member subscriptions	145	-	145	170
Corporates and partnership income	78	-	78	61
Congress	-	-	-	464
Meetings and events	105	3	108	45
Journals	1,552	-	1,552	1,282
Total	1,880	3	1,883	2,022

Notes to the financial statements

5 Awards and grants

	2021 Total funds £'000	2020 Total funds £'000
Awards and grants to individuals	5	104
Other Awards and Grants	-	-
Support costs (note 7)	20	32
Total	25	136

Awards and grants were paid to a total of 36 (2020– 248) individuals.

6 Total expenditure

	Unrestricted funds £'000	Designated funds £'000	Restricted funds £'000	2021 Total £'000
<i>Raising funds</i>				
Investment management fees	36	-	-	36
Fundraising	13	-	-	13
<i>Charitable Expenditure:</i>				
Membership	156	-	-	156
Awards and grants	25	-	-	25
Congress	166	-	-	166
Other meetings and events	253	-	-	253
Publications and journals	377	-	-	377
Policy and Public Affairs	176	-	5	181
UK-CIC	-	-	161	161
Partnership work	87	-	31	118
Education and Careers	62	2	3	67
Public engagement	73	-	-	73
Communications	146	-	23	169
International Work	32	-	-	32
Total	1,602	2	223	1,827

Allocation of support costs to charitable activities:

	Direct costs £'000	Support costs £'000	2021 Total £'000
<i>Raising funds</i>			
Investment management fees	36	-	36
Cost of raising funds	13	-	13
<i>Charitable activities</i>			
Membership	91	65	156
Awards and grants	5	20	25
Congress	140	25	166
Other meetings and events	211	42	253
Publications and journals	313	64	377
Policy and Public Affairs	118	63	181
UK-CIC	161	-	161
Partnership work	110	8	118
Education and Careers	47	20	67
Public engagement	52	21	73
Communications	91	78	169
International Work	32	-	32
Total	1,421	406	1,827

Notes to the financial statements

6 Total expenditure (continued)

Support costs are as follows:

	2021 £'000	2020 £'000
Staff costs	185	254
Premises costs	71	91
Depreciation	9	8
IT and electronic communications costs	65	60
Other	50	105
Recruitment fees	9	10
Governance costs (note 7)	12	11
Total	401	538

Support costs have been allocated based on time spent by departments supporting the various activities.

	Unrestricted funds £'000	Designated funds £'000	Restricted funds £'000	2020 £'000
<i>Raising funds</i>				
Investment management fees	33	-	-	33
Fundraising	12	-	-	12
<i>Charitable Expenditure:</i>				
Membership	183	-	-	183
Awards and grants	136	-	-	136
Congress	587	-	-	587
Other meetings and events	267	-	-	267
Publications and journals	358	-	-	358
Policy and public affairs	173	-	18	191
Education and careers	75	-	-	75
Public engagement	63	-	23	86
Communications	183	-	30	213
International work	36	-	-	36
Total	2,106	-	71	2,177

Notes to the financial statements

7 Governance costs

	2021	2020
	£'000	£'000
Auditor's remuneration - audit	11	10
Auditor's remuneration - other	1	1
Total	12	11

8 Net income before gains (losses) on investments

This is stated after charging:	2021	2020
	£'000	£'000
Staff costs (note 9)	1,103	905
Operating lease rental	70	90
Depreciation	9	8
Auditor's remuneration - audit	11	10
Auditor's remuneration - other	1	1

Notes to the financial statements

9 Staff costs

Staff costs during the year were as follows:

	2021 £'000	2020 £'000
Wages and salaries	962	781
Social security costs	97	84
Pension costs	44	41
Total	1,103	905

The average monthly number of employees during the year was as follows:

	2021	2020
Direct charitable activities	17	14
Administration of the charity	3	4
	20	18

Number of employees whose annualised emoluments fall within following ranges for the year:

	2021	2020
£60,001 - £70,000	2	-
£70,001 - £80,000	1	1
£120,001 - £130,000	-	1
£130,001 - £140,000	1	-

Pension contributions for these employees were £19,625 (2020 - £9,481).

The number of staff for whom retirement benefits are accruing under money purchase pension schemes amounted to 21 (2020 - 16).

The Society considers its key management personnel comprise the Trustees and the Senior Management Team (SMT). The Trustees provide their time free of charge. The total remuneration, employer's national insurance contributions, benefits and pensions paid to the SMT was £484,192 (2020 - £436,269).

The relevant staff costs have been included in the costs of charitable activities. The gender split in the society workforce is 74% female 26% male (2020: 74% female 26% male). All roles are evaluated and paid in accordance with external benchmarking irrespective of gender.

10 Trustees' remuneration

No trustee received any remuneration for his or her services during the year (2020 - none). During the year expenses totalling £nil (2020 - £7,984) were reimbursed to nil trustees (2020 - 10).

One trustee received a prize of £25 for best presentation as voted by attendees of a regional meeting (2020 - none).

Notes to the financial statements

11 Tangible assets of the Group and charity

	Computer equipment £'000	Office equipment and furniture £'000	Office refurbishment and improvement £'000	Total £'000
Cost or valuation				
At 1 July 2020	72	6	22	100
Additions	11	-	-	11
Disposals	(54)	(6)	(22)	(82)
At 30 June 2021	29	-	-	29
Depreciation				
At 1 July 2020	59	6	22	87
Charge for the year	9	-	-	9
Eliminated on disposal	(57)	(6)	(22)	(85)
At 30 June 2021	11	-	-	11
Net book value				
At 30 June 2021	18	-	-	18
At 1 July 2020	13	-	-	13

12 Intangible assets of the Group and charity

	IT software £'000	Total £'000
Cost or valuation		
At 1 July 2020	-	-
Additions	37	37
Disposals	-	-
At 30 June 2021	37	37
Depreciation		
At 1 July 2020	-	-
Charge for the year	-	-
Eliminated on disposal	-	-
At 30 June 2021	-	-
Net book value		
At 30 June 2021	37	37
At 1 July 2020	-	-

Construction of a new CRM system started in the year and is expected to be completed next year.

Notes to the financial statements

13 Investments

	Group		Charity	
	2021 £'000	2020 £'000	2021 £'000	2020 £'000
Market value at 1 July 2020	3,693	3,632	3,693	3,632
Disposals proceeds	(599)	(673)	(599)	(673)
Realised losses	46	(21)	46	(21)
Additions at cost	595	622	595	622
Unrealised gains	461	131	461	131
Market value at 30 June 2021	4,196	3,692	4,197	3,693
Cash held with investment managers	258	178	258	178
Total investments	4,454	3,871	4,454	3,871

Total Group investments includes £100 investment in subsidiary

	Group		Charity	
	2021 £'000	2020 £'000	2021 £'000	2020 £'000
At 30 June 2021 the listed investments comprised the following:				
UK equities	1,157	1,510	1,157	1,510
Overseas equities	1,944	1,643	1,944	1,643
Investment instruments	1,353	718	1,353	718
Total	4,454	3,871	4,454	3,871
Historical cost of listed investments	3,470	3,268	3,470	3,268

At 30 June 2021 the holding in ASC (Offshore) Sterling Fixed Interest Fund Z Inc. represents 5.06% of the total market value of the portfolio of listed investments.

Notes to the financial statements

13 Investments (continued)

Investment in subsidiary undertaking

The Society owns 100% of the ordinary issued share capital of BSI Trading Limited, a company registered in England and Wales (Company number 01021739). Its registered address is Devonshire House, 60 Goswell Road, London EC1M 7AD. The principal activity of the company is the management of corporate membership, sponsorship, exhibition and other trading activities for the Society.

A summary of the results of the subsidiary is shown below:

	2021 £'000	2020 £'000
Turnover	133	307
Operating costs	-	-
Operating profit	133	307
Administration costs	(10)	(14)
Profit(loss) for the financial period	123	293
Distribution to parent charity	(123)	(293)
Retained in subsidiary	-	-

The company's assets and liabilities at 30 June 2021 were as follows:

Assets	148	233
Liabilities	(147)	(233)
Net assets	-	-

14 Debtors

	Group		Charity	
	2021 £'000	2020 £'000	2021 £'000	2020 £'000
Trade debtors	14	15	14	1
Other debtors	-	1	-	1
Prepayments and accrued income	92	106	92	106
Amount owed by subsidiary undertaking	-	-	134	310
VAT receivable	24	-	24	-
Total	130	122	264	418

Notes to the financial statements

15 Creditors

	Group		Charity	
	2021	2020	2021	2020
	£'000	£'000	£'000	£'000
Trade creditors	60	40	60	33
Other taxes and social security costs	49	39	49	39
VAT payable	-	40	-	40
Other creditors	13	18	13	18
Accruals and deferred income	800	829	786	790
Total	922	965	908	920

Included within the above is deferred income as set out below:

	Group	Charity
	2021	2021
	£'000	£'000
Deferred income brought forward at 1 July	919	919
Additional income deferred during the year	800	800
Brought forward funds released in the year	(919)	(919)
Deferred income carried forward at 30 June	800	786

Deferred income comprises advance payments of journal royalties and memberships fees.

16 Operating leases

The total future minimum lease payments under non cancellable operating leases is as follows:

	Land and Buildings	
	2021	2020
	£'000	£'000
Payments which fall due:		
Within one year	-	47
Between one and two years	-	-

Notes to the financial statements

17 Restricted funds

	At 1 July 2020	Income	Expenditure	At 30 June 2021
Meeting funds	34	-	-	34
Celebrate vaccines	10	-	(10)	-
Covid-19	13	-	(13)	-
Connect on coronavirus	-	5	(5)	-
Autoimmunity	-	15	(5)	10
UK-CIC	-	137	(161)	(24)
Vaccine taskforce	-	26	(26)	-
BiteSized immunology	-	8	(3)	5
Total	57	191	(223)	25

Meeting funds

Donations to the Society by individuals to promote certain immunological issues.

Celebrate Vaccines

The New Venture Fund grant provided to enhance the success of the Gavi 2020 replenishment, though the BSI's Celebrate Vaccines campaign.

Covid-19

A grant from the Lorna and Yuti Chernajovsky Biomedical Research Foundation for BSI's work on Covid-19.

Connect on Coronavirus

A donation to fund the Society's series of webinars providing information which may contribute to the understanding and treatment of COVID-19.

Autoimmunity

A grant from the Lorna and Yuti Chernajovsky Biomedical Research Foundation for administrative support for the development and management of the autoimmune research initiative.

UK-CIC

A grant for the BSI support provided to the UK Coronavirus Immunology Consortium (UK-CIC). Invoices are raised quarterly for expenses incurred, the final invoice for reimbursement of the remaining costs will be raised after the year end.

Vaccine taskforce

A grant from the European Federation of Immunological Societies (EFIS) for the EFIS Vaccine Taskforce work led by the BSI.

BiteSized Immunology

Donations received to update the BSI's online resource, BiteSized Immunology, which provides a comprehensive guide to the immune system especially suitable for biomedical undergraduates and those new to immunology.

Notes to the financial statements

17 Restricted funds (Continued)

	At 1 July 2019 £'000	Income £'000	Expenditure £'000	At 30 June 2020 £'000
Meeting funds	34	-	-	34
Celebrate vaccines	-	74	(64)	10
Covid-19	-	20	(7)	13
Total	34	94	(71)	57

18 Designated funds

	At 1 July 2020	Designated in year	Utilised / released	At 30 June 2021
Long term sustainability	150	100	(2)	248
Office refurbishment	100	-	(100)	-
CRM project	-	150	(37)	113
Career development programme	-	625	-	625
Total	250	875	(139)	986

Long term sustainability

The long term sustainability fund provides resources for investing in the financial sustainability of the charity over the next five years.

Office refurbishment

Funds designated for office refurbishment were released when the office lease was not renewed

CRM project

The CRM project fund provides resources to develop and implement a new CRM system together with an upgrade to the BSI website

Career development programme

The Career development programme will fund a significant expansion in the careers support the BSI offers to our members. This includes two main streams: our career-enabling activities and our career-enhancing activities.

Notes to the financial statements

19 Analysis of nets assets between funds

				2021
	Unrestricted	Designated	Restricted	Total funds
Group	funds	funds	funds	
	£'000	£'000	£'000	£'000
Tangible fixed assets	18	-	-	18
Intangible assets	37	-	-	37
Investments	4,454	-	-	4,454
Current assets	346	986	25	1,357
Current liabilities	(922)	-	-	(922)
Total Funds	3,933	986	25	4,944

				2021
	Unrestricted	Designated	Restricted	Total funds
Charity	funds	funds	funds	
	£'000	£'000	£'000	£'000
Tangible fixed assets	18	-	-	18
Intangible assets	37	-	-	37
Investments	4,454	-	-	4,454
Current assets	332	986	25	1,343
Current liabilities	(908)	-	-	(908)
Total Funds	3,933	986	25	4,944

The total unrealised gains (losses) as at 30 June 2021 constitutes movements on revaluation and are as follows:

	2021	2020
	£'000	£'000
Unrealised gains (losses) included above:		
On investments	983	391
Total unrealised gains (losses) at 30 June	983	391
Reconciliation of movements in unrealised gains (losses)		
Unrealised gains at 1 July	522	391
Less: in respect to disposals in the year	-	-
	522	391
Add: net gains (losses) arising on revaluation arising in the year	461	131
Total unrealised gains (losses) at 30 June	983	522

Notes to the financial statements

19 Analysis of nets assets between funds (Continued)

Group	£'000	£'000	£'000	2020 £'000
Tangible fixed assets	13	-	-	13
Investments	3,871	-	-	3,871
Current assets	852	250	57	1,159
Current liabilities	(965)	-	-	(965)
Total Funds	3,771	250	57	4,078

	Unrestricted funds £'000	Designated funds £'000	Restricted funds £'000	2020 Total funds £'000
Charity				
Tangible fixed assets	13	-	-	13
Current assets	3,871	250	57	4,178
Current liabilities	807	-	-	807
Current liabilities	(920)	-	-	(920)
Total Funds	3,771	250	57	4,078

20 Share capital

The company is limited by guarantee and therefore has no share capital. Each member's liability is limited to £1.

21 Related party transactions

An oral prize of £25 was made to Emma Chambers at a London Immunology Group meeting.
Calum Bain is a member of the Editorial Board of *Immunology*, no payments were made in relation to this.

There were no other related party transactions that required disclosure in the current financial period (2020: none).

Notes to the financial statements

22 Comparative consolidated statement of financial activities

	Unrestricted funds			
	General £'000	Designated £'000	Restricted £'000	2020 £'000
Income from:				
Donations	6	-	94	100
Investments	112	-	-	112
Charitable activities				
Membership	170	-	-	170
Partnership work	61	-	-	61
Congress	464	-	-	464
Meetings and events	45	-	-	45
Journals	1,282	-	-	1,282
Total income	2,140	-	94	2,234
Raising funds				
Investment Management Fees	33	-	-	33
Cost of raising funds	12	-	-	12
Charitable activities				
Membership	183	-	-	183
Awards and grants	136	-	-	136
Congress	587	-	-	587
Meetings and events	267	-	-	267
Publications and journals	358	-	-	358
Policy and Public Affairs	173	-	18	191
Education and Careers	75	2,000-	-	77
Public engagement	63	-	23	86
Communications	183	-	30	213
International work	36	-	-	36
Total expenditure	2,106	2	71	2,179
Net income before gains (losses) on investments	34	(2)	23	55
Net gains/(losses) on investments	110	-	-	110
Transfers between funds	(144)	144	-	-
Net income	0	142	23	165
Reconciliation of funds:				
Funds brought forward	3,771	106	34	3,911
Funds carried forward	3,771	248	57	4,076

Notes to the financial statements

23 Charity statement of financial activities

	Unrestricted funds			Total	Total
	General funds	Designated funds	Restricted funds	2021	2020
	£'000	£'000	£'000	£'000	£'000
Income from:					
Grants and donations	2	-	188	190	100
Investments	113	-	-	113	112
Charitable activities					
Membership	145	-	-	145	170
Partnership work	10	-	-	10	-
Congress	-	-	-	-	208
Meetings and events	41	-	3	44	57
Journals	1,552	-	-	1,552	1,282
Gift Aid and recharge from BSI	132	-	-	132	305
Trading Limited					
Total income	1,995	-	191	2,186	2,234
Expenditure on:					
Raising funds					
Investment management fees	36	-	-	36	33
Cost of raising funds	13	-	-	13	12
Charitable activities					
Membership	156	-	-	156	183
Awards and grants	25	-	-	25	136
Congress	166	-	-	166	587
Meetings and events	253	-	-	253	267
Publications and journals	377	-	-	377	358
Policy and Public Affairs	176	-	5	181	190
UK-CIC	-	-	161	161	-
Partnership work	87	-	31	118	-
Education and Careers	62	2	3	67	75
Public engagement	73	-	-	73	86
Communications	146	-	23	169	213
International work	32	-	-	32	36
Total expenditure	1,602	2	223	1,827	2,177
Net income (expenditure) before gains (losses) on investments and transfers	393	(2)	(32)	359	57
Net gains/(losses) on investments	507	-	-	507	110
Transfers between funds	(738)	738	-	-	-
Net income/(deficit)	162	736	(32)	866	167
Reconciliation of funds:					
Funds brought forward	3,771	250	57	4,078	3,911
Funds carried forward	3,933	986	25	4,944	4,078

Board of Trustees

Position	Current office holder	Date of appointment / resignation	2020-21 Board attendance	2019-20 committees	2020-21 Committee attendance
President	Professor Arne Akbar	Appointed December 2018	5/5	Forum, Nominations & Congress Committees	4/4 1/1 2/4
Treasurer	Dr Fiona Culley	Appointed July 2017	5/5	Finance Sub Committee & Congress Committee	5/5 4/4
Chair of Forum	Professor Ann Ager	Appointed December 2018	5/5	Forum & Nominations Committee	4/4 1/1
Clinical Secretary	Professor Colin Dayan	Appointed October 2019	5/5	Forum, Clinical & Congress Committees	3/4 2/4
Early Career Trustee	Dr Calum Bain	Appointed July 2018	5/5		
Early Career Trustee	Dr Emma Chambers	Appointed December 2018	5/5		
Co-opted Trustee	Robert Davies	Appointed October 2016	5/5	Nominations Committee	1/1
Trustee	Professor Deborah Dunn-Walters	Appointed July 2019	3/5		
Trustee	Professor Matthias Eberl	Appointed January 2017	5/5	Nominations Committee	1/1
Co-opted Trustee	Dr Paul Harding	Re-appointed July 2019	5/5	Finance Sub Committee	5/5
Co-opted Trustee	Dr Edith Hessel	Appointed January 2017	5/5		
Co-opted Trustee	James Lowe	Appointed July 2019	4/5	Finance Sub Committee	5/5
Trustee	Professor Allan Mowat	Re-appointed May 2019	5/5		
Trustee	Dr Divya Shah	Appointed December 2018	5/5	Nominations Committee	1/1

Key management personnel

Name	Position
Dr Doug Brown	Chief Executive
Otto Balsiger	Finance Director
Dr Jennie Evans	Director of External Affairs
Jane Sessenwein	Head of Events & Conferences
Lucy McIver	Head of Publishing

Principal professional advisers

Name	Position
Bankers	Bank of Scotland 14/16 Cockspur Street London EC2V 6DL
External auditors	Moore Kingston Smith LLP Devonshire House 60 Goswell Road London EC1M 7AD
Investment advisers	Aberdeen Standard Capital 14th Floor 30 St Mary Axe London EC3A 8BF
Solicitors	Russell Cooke LLP 2 Putney Hill London SW15 6AB

Committees

Nominations Committee

Name	Position
Professor Arne Akbar	Chair, BSI President
Professor Ann Ager	Forum Chair and Trustee
Robert Davies	BSI Co-opted Trustee
Professor Matthias Eberl	Trustee
Dr Divya Shah	Trustee
Dr Doug Brown	BSI CEO (observer)

Finance Sub Committee

Name	Position
Dr Fiona Culley	BSI Treasurer
James Lowe	Co-opted Trustee
Paul Harding	Co-opted Trustee
Dr Doug Brown	BSI Chief executive

Forum

Name	Position
Professor Ann Ager	Chair
Professor Arne Akbar	BSI Preseident
Dr Colin Dayan	Clinical Secretary
Dr Donald Palmer	Education & Careers Secretary
Professor Donald Davidson	Public Engagement Secretary
Dr Doug Brown	BSI Chief Executive
Dr Megan Macleod	Regional Representative - Scotland
Dr Helen McGettrick	Regional Representative - England
Dr Karim Dib	Regional Representative - Northern Ireland
Dr Simone Cuff	Regional Representative - Wales
Dr Louise Topping	Early Career Representative
Dr Alice Burton	Early Career Representative
Dr Faith Uwadiae	Early Career Representative
Dr Edoardo Prediletto	Early Career Representative
Dr Lauren Campbell	PhD Representative
Dr Niamh Richmond	PhD Representative
Dr Federica Villanova	Industry Representative
Dr Matthew Buckland	Clinical Representative
Dr Tomaz Garcez	Clinical Representative
Dr Elma Tchilian	Veterinary Representative

Committees

Congress Committee

Name	Position
Professor Gary Entrican	BSI Congress Secretary
Professor Arne Akbar	BSI President
Dr Fiona Culley	BSI Treasurer
Dr Colin Dayan	BSI Clinical Secretary
Professor Mark Coles	BSI Congress Secretary Elect
Professor Linda Wooldridge	Member
Professor James Brewer	Member
Dr Martina Colicchia	Early Career Representative
Dr Alexandra Spencer	Member
Dr Deena Gibbons	Member
Dr John Tregoning	Member
Dr Sinisa Savic	Clinical member
Dr Margarita Dominguez	Member
Dr James Harker	Member
Dr Graham Cook	Member
Dr Sandra Sacre	Member

Clinical Committee

Name	Position
Dr Adrian Heaps	Association for Clinical Biochemistry
Dr Richard Herriot	Association of Clinical Pathologists
Dr Chris Scott	Institute of Biomedical Science
Dr Tariq El-Shanawany	British Society for Allergy & Clinical Immunology
Dr Stephen Hughes	British Paediatric Allergy Immunology & Infections Group
Dr Siraj Misbah	Special Advisory Committee on Immunology (RCPATH SAC)
Dorothea Grosse-Kreul	Immunology & Allergy Nurses group
Dr Kavitha Sooriyakumar	Trainee Rep
Dr Shuaib Nasser	Joint Committee on Immunology & Allergy (JCIA)
Dr Sinisa Savic	UK Primary Immunodeficiency Network (UKPIN)
Dr Colin Dayan	Chair/Clinical Secretary
Dr Doug Brown	BSI Chief Executive

Journals

Immunology - Editorial Team

Name	Position
Professor Simon Milling	Editor-in-Chief
Dr Awen Gallimore	Associate Editor
Dr Florent Ginhoux	Associate Editor
Professor Kathleen McCoy	Associate Editor
Professor Francisco J. Quintana	Associate Editor
Dr Meera Ramanujam	Associate Editor

Clinical and Experimental Immunology - Editorial Team

Name	Position
Professor Leonie Taams	Editor-in-Chief
Professor Angelo Manfredi	Section Editor - autoimmunity
Professor Tanja de Gruiji	Section Editor - cancer immunity
Professor Ciriaco Piccirillo	Section Editor - immune-mediated inflammatory diseases
Dr Cindy Ma	Section Editor - immunodeficiency
Dr daniel Douek	Section Editor - infectious diseases and vaccines
Professor Xiao-Ning Xu	Section Editor - infectious diseases and vaccines
Professor Sandra Amor	Section Editor - neuroimmunology

Immunotherapy Advances - Editorial Team

Name	Position
Professor Tim Elliot	Editor-in-Chief
Professor Stefan Barth	Regional Editor: Africa
Associate Professor Marianne Boes	Regional Editor: Europe
Professor Adrianna Bonomo	Regional Editor: South America
Professor Tao Dong	Regional Editor: Asia
Dr Stephanie K Dougan	Regional Editor: North America
Associate Professor Menno van Zelm	Regional Editor: Australasia

Regional and Affinity groups

Affinity Groups

Group	Position	
Autoimmunity Affinity Group	Chair	Professor Lucy Walker
	Secretary	Dr Kathryn Steel
	Treasurer	Dr James Pearson
Comparative Veterinary Immunology Group	Resigned 2019	Dr Elma Tchilian
	Secretary	Dr Lindert Benedictus
	Treasurer	Dr Kate Sutton
Histocompatibility & Immunogenetics Group	Chair	Professor David Briggs
	Secretary	Dr Luke Foster
Immunometabolism Affinity Group	Co-Chair	Dr Laura Pallett
	Co-Chair	Dr Linda Sinclair
	Secretary	Dr Sarah Dimeloe
	Treasurer	Dr Anna Schurich
Immunosenescence Affinity Group	Chair	Dr Sian Henson
	Secretary	Dr Natalie Riddell
	Treasurer	Dr Catarina Henriques
Infection and Immunity Group		
Inflammation Affinity Group	Chair	Professor Peter Barlow
	Treasurer	Dr Joanne Konkel
	Communications	Dr Jack Rivers-Auty
Leukocyte Migration Group	Chair	Dr Myriam Chimen
	Secretary/Treasurer	Dr Graeme O'Boyle
Mathematical Modelling Group	Chair	Professor Carmen-Molina Paris
	Secretary	Professor Mark Coles
	Treasurer	Professor Grant Lythe
Neuroimmunology Group	Chair	Professor Sandra Amor
	Secretary	Dr Sarosh Irani
Vaccine Affinity Group	Chair	Dr Phil Hogarth
	Secretary	Dr Julia Tree
	Treasurer	Dr Bernardo Villarreal-Ramos
Tumour Immunology Affinity Group	Chair	Professor Benjamin Willcox
	Secretary	Dr Seth B. Coffelt
	Treasurer	Professor Awen Gallimore

Regional and Affinity groups

Regional Groups

Group	Position	
Aberdeen Immunology Group	Chair	Dr Isabel Crane
	Treasurer	Dr Soumya Palliyil
Bristol Immunology Group	Chair	Dr Laura Rivino
	Secretary	Dr Dronwen Burton
	Treasurer	Dr Lindsay Nicholson
Cambridge Immunology Group	Chair	Dr Brian Ferguson
	Secretary/Treasurer	Dr Louise Boyle
East Anglia Immunology Group	Secretary	Dr Maria O'Connell
	Treasurer	Dr Cristina Fanutti
Edinburgh Immunology Group	Co-Chair	De Cecile Benezech
	Co-Chair	Dr Laura McCulloch
	Secretary	Dr Matthew Burgess
	Secretary	Dr Tovah Shaw
	Treasurer	Dr David Donaldson
Greater Manchester Immunology Group	Chair	Professor Richard Grencis
	Secretary	Dr Ana Villegas-Mendez
	Treasurer	Dr Joanne Konkell
Immunology North East	Chair	Dr Kevin Marchbank
	Secretary	Dr Antony Antoniou
	Treasurer	Dr Andy Knight
London Immunology Group	Chair	Dr James Harker
	Secretary	Dr Laura Pallett
	Treasurer	Dr Alice Burton
Merseyside Immunology Group	Secretary	Dr Qibo Zhang
	Treasurer	Dr Steve Christmas
Oxford Immunology Group	Chair	Dr Alexandra Spencer
	Co-Secretary	Dr Louise Johnson
	Co-Secretary	Dr Anita Milicic
	Treasurer	Dr Philipp Kruger

Regional and Affinity groups

Regional Groups

Group	Position	
South Wales Immunology Group	Chair	Dr You Zhou
	Secretary	Dr Rebecca Aicheler
	Treasurer	Dr Ceri Fielding
Tayside Immunology Group	Chair	Professor Simon Arthur
	Secretary	Dr Mahima Swamy
	Treasurer	Dr Stephen Matthews
Ulster Immunology Group	President	Dr Yvonne Dombrowski
	Secretary	Dr Karim Dib
Wessex Immunology Group	Chair	Dr Emma Reeves
	Secretary	Dr Alison Hill
	Treasurer	Dr Diogo Silva
West Midlands Immunology Group	Co-Chair	Dr David Bending
	Co-Chair	Dr Kendle Maslowski
	Secretary	Dr Lia Liaskou
	Treasurer	Dr Zhi Li
West of Scotland Immunology Group	Chair	Dr Megan MacLeod
	Secretary	Dr Ed Roberts
	Treasurer	Dr Hannah Scales
Yorkshire Immunology Group	Chair	Dr Gina Doody
	Secretary	Dr Erica Wilson

